{"PMC7282740": [["IntroductionA novel coronavirus has emerged in human population in the city of Wuhan (China) causing severe respiratory illness that the World Health Organization named 2019 novel coronavirus disease (COVID-19) and the pathogen named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Huang et al., 2020; Li et al., 2020).", [["respiratory", "ANATOMY", 108, 119], ["respiratory illness", "DISEASE", 108, 127], ["coronavirus disease", "DISEASE", 180, 199], ["COVID-19", "CHEMICAL", 201, 209], ["acute respiratory syndrome coronavirus", "DISEASE", 241, 279], ["coronavirus", "ORGANISM", 20, 31], ["human", "ORGANISM", 47, 52], ["coronavirus", "ORGANISM", 180, 191], ["COVID-19", "ORGANISM", 201, 209], ["human", "SPECIES", 47, 52], ["coronavirus", "SPECIES", 180, 191], ["human", "SPECIES", 47, 52], ["severe acute respiratory syndrome coronavirus", "SPECIES", 234, 279], ["SARS-CoV-2", "SPECIES", 283, 293], ["IntroductionA novel coronavirus", "PROBLEM", 0, 31], ["severe respiratory illness", "PROBLEM", 101, 127], ["novel coronavirus disease", "PROBLEM", 174, 199], ["COVID", "TEST", 201, 206], ["the pathogen", "PROBLEM", 215, 227], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 234, 279], ["coronavirus", "OBSERVATION", 20, 31], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["respiratory illness", "OBSERVATION", 108, 127], ["coronavirus disease", "OBSERVATION", 180, 199], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["respiratory syndrome", "OBSERVATION", 247, 267]]], ["Since its emergence in December 2019, the viral infection has already spread in many Chinese cities and several countries, and the World Health Organization has declared it a public health emergency of international concern by the end of January 2020.", [["viral infection", "DISEASE", 42, 57], ["the viral infection", "PROBLEM", 38, 57], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 48, 57]]], ["The situation report 114 of the WHO (May 13th, 2020) indicated that more than 4 million confirmed cases had been reported globally with nearly 32% of the cases in the USA alone; the total deaths caused by the disease reached 287 399 cases, mainly in the Americas and Europe (37% and 55%, respectively) (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200513-covid-19-sitrep-114.pdf?sfvrsn=17ebbbe_4).IntroductionCoronaviruses belong to the family Coronaviridae in the order Nidovirales and can be classified into four genera: Alpha-coronavirus, Beta-coronavirus, Gamma-coronavirus, and Delta-coronavirus (Cui et al., 2019; Perlman and Netland, 2009).", [["deaths", "DISEASE", 188, 194], ["Beta-coronavirus", "DISEASE", 570, 586], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 499, 510], ["Alpha-coronavirus", "ORGANISM", 551, 568], ["Beta-coronavirus", "ORGANISM", 570, 586], ["Gamma-coronavirus", "ORGANISM", 588, 605], ["Delta-coronavirus", "ORGANISM", 611, 628], ["Alpha-coronavirus", "SPECIES", 551, 568], ["Beta-coronavirus", "SPECIES", 570, 586], ["Gamma-coronavirus", "SPECIES", 588, 605], ["Delta-coronavirus", "SPECIES", 611, 628], ["Alpha-coronavirus", "SPECIES", 551, 568], ["Beta-coronavirus", "SPECIES", 570, 586], ["Gamma-coronavirus", "SPECIES", 588, 605], ["Delta-coronavirus", "SPECIES", 611, 628], ["the disease", "PROBLEM", 205, 216], ["Alpha-coronavirus", "PROBLEM", 551, 568], ["Beta-coronavirus", "PROBLEM", 570, 586], ["Gamma", "TEST", 588, 593], ["coronavirus", "PROBLEM", 594, 605]]], ["They are, enveloped, positive-stranded RNA viruses, containing the largest genome among all RNA viruses, ranging from 27 to 32 kb (Fehr and Perlman, 2015).", [["stranded RNA viruses", "PROBLEM", 30, 50], ["stranded RNA viruses", "OBSERVATION", 30, 50], ["largest", "OBSERVATION_MODIFIER", 67, 74], ["genome", "OBSERVATION_MODIFIER", 75, 81], ["RNA viruses", "OBSERVATION", 92, 103]]], ["After the release of the SARS-CoV-2 genome sequence, it has been classified as Beta-coronavirus, closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV) that emerged in 2002-2003 (Ksiazek et al., 2003; Peiris et al., 2003).IntroductionThe coronaviruses spike protein (S) forms large protrusions from the virus surface (spikes) giving the viral particles the appearance of having crowns (hence their name coronavirus) (Cui et al., 2019; Perlman and Netland, 2009; Zumla et al., 2016).", [["surface", "ANATOMY", 334, 341], ["Beta-coronavirus", "DISEASE", 79, 95], ["acute respiratory syndrome coronavirus", "DISEASE", 127, 165], ["SARS-CoV)", "DISEASE", 167, 176], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["Beta-coronavirus", "ORGANISM", 79, 95], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 120, 165], ["SARS-CoV", "ORGANISM", 167, 175], ["coronaviruses spike protein (S)", "GENE_OR_GENE_PRODUCT", 263, 294], ["SARS-CoV-2 genome sequence", "DNA", 25, 51], ["coronaviruses spike protein", "PROTEIN", 263, 290], ["S", "PROTEIN", 292, 293], ["Beta-coronavirus", "SPECIES", 79, 95], ["severe acute respiratory syndrome coronavirus", "SPECIES", 120, 165], ["SARS-CoV", "SPECIES", 167, 175], ["the SARS", "TEST", 21, 29], ["Beta-coronavirus", "PROBLEM", 79, 95], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 116, 165], ["The coronaviruses spike protein", "TEST", 259, 290], ["large protrusions", "PROBLEM", 301, 318], ["the virus surface", "PROBLEM", 324, 341], ["the viral particles", "PROBLEM", 358, 377], ["crowns", "PROBLEM", 403, 409], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["respiratory syndrome coronavirus", "OBSERVATION", 133, 165], ["coronaviruses spike", "OBSERVATION", 263, 282], ["large", "OBSERVATION_MODIFIER", 301, 306], ["protrusions", "OBSERVATION", 307, 318], ["virus surface", "OBSERVATION", 328, 341], ["viral particles", "OBSERVATION", 362, 377]]], ["These spikes represent the first contact with the host and mediate the virus entry into host cells; besides, the S protein has been linked to host and tissue tropism (Du et al., 2009; Li, 2016).", [["cells", "ANATOMY", 93, 98], ["tissue", "ANATOMY", 151, 157], ["host cells", "CELL", 88, 98], ["tissue", "TISSUE", 151, 157], ["host cells", "CELL_TYPE", 88, 98], ["S protein", "PROTEIN", 113, 122], ["These spikes", "PROBLEM", 0, 12], ["the S protein", "PROBLEM", 109, 122], ["host cells", "OBSERVATION", 88, 98]]], ["Structurally, the coronavirus spikes are clove-shaped trimers of the S protein with the asymmetric unit containing a large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail (Kirchdoerfer et al., 2016; Smith et al., 2016).", [["transmembrane", "ANATOMY", 149, 162], ["intracellular", "ANATOMY", 183, 196], ["coronavirus", "ORGANISM", 18, 29], ["intracellular tail", "CELLULAR_COMPONENT", 183, 201], ["clove-shaped trimers", "PROTEIN", 41, 61], ["S protein", "PROTEIN", 69, 78], ["asymmetric unit", "PROTEIN", 88, 103], ["ectodomain", "PROTEIN", 123, 133], ["single-pass transmembrane anchor", "PROTEIN", 137, 169], ["short intracellular tail", "PROTEIN", 177, 201], ["the coronavirus spikes", "PROBLEM", 14, 36], ["a large ectodomain", "PROBLEM", 115, 133], ["coronavirus spikes", "OBSERVATION", 18, 36], ["clove", "OBSERVATION_MODIFIER", 41, 46], ["shaped", "OBSERVATION_MODIFIER", 47, 53], ["trimers", "OBSERVATION_MODIFIER", 54, 61], ["asymmetric", "OBSERVATION_MODIFIER", 88, 98], ["large", "OBSERVATION_MODIFIER", 117, 122], ["ectodomain", "OBSERVATION_MODIFIER", 123, 133], ["transmembrane anchor", "OBSERVATION", 149, 169], ["short", "OBSERVATION_MODIFIER", 177, 182], ["tail", "OBSERVATION_MODIFIER", 197, 201]]], ["The ectodomain consists of a receptor-binding subunit S1 and a membrane-fusion subunit S2, with the S1 subunit containing distinct N-terminal and C-terminal domains (S1-NTD and S1-CTD) (Beniac et al., 2006; Walls et al., 2016).IntroductionOne of the major complexities of coronaviruses is their receptor recognition pattern.", [["membrane", "ANATOMY", 63, 71], ["N-", "CHEMICAL", 131, 133], ["C", "CHEMICAL", 146, 147], ["receptor-binding subunit S1", "GENE_OR_GENE_PRODUCT", 29, 56], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["S2", "GENE_OR_GENE_PRODUCT", 87, 89], ["coronaviruses", "ORGANISM", 272, 285], ["ectodomain", "PROTEIN", 4, 14], ["receptor-binding subunit S1", "PROTEIN", 29, 56], ["membrane-fusion subunit S2", "PROTEIN", 63, 89], ["S1 subunit", "PROTEIN", 100, 110], ["N-terminal and C-terminal domains", "PROTEIN", 131, 164], ["S1", "PROTEIN", 166, 168], ["NTD", "PROTEIN", 169, 172], ["S1", "PROTEIN", 177, 179], ["CTD", "PROTEIN", 180, 183], ["a receptor-binding subunit S1", "TREATMENT", 27, 56], ["a membrane-fusion subunit S2", "TREATMENT", 61, 89], ["the S1 subunit containing distinct N-terminal and C-terminal domains", "PROBLEM", 96, 164], ["coronaviruses", "PROBLEM", 272, 285], ["S1", "ANATOMY", 54, 56], ["terminal", "OBSERVATION_MODIFIER", 133, 141], ["terminal", "ANATOMY_MODIFIER", 148, 156], ["S1", "ANATOMY", 166, 168], ["S1", "ANATOMY", 177, 179], ["coronaviruses", "OBSERVATION", 272, 285]]], ["Among these receptors: zinc peptidases such as angiotensin-converting enzyme 2 (ACE2) (Hofmann et al., 2005; Li et al., 2003) and aminopeptidase N (APN) (Delmas et al., 1993; Li et al., 2007); dipeptidyl peptidase 4 (DPP4) (Raj et al., 2013; Yang et al., 2014); carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) (Dveksler et al., 1991; Williams et al., 1991); and sialic acid-containing receptors (Schwegmann-Wessels and Herrler, 2006).", [["angiotensin", "CHEMICAL", 47, 58], ["zinc", "CHEMICAL", 23, 27], ["zinc peptidases", "GENE_OR_GENE_PRODUCT", 23, 38], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 47, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 130, 146], ["APN", "GENE_OR_GENE_PRODUCT", 148, 151], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 193, 215], ["DPP4", "GENE_OR_GENE_PRODUCT", 217, 221], ["carcinoembryonic antigen-related cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 262, 319], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 321, 328], ["sialic acid-containing receptors", "GENE_OR_GENE_PRODUCT", 382, 414], ["zinc peptidases", "PROTEIN", 23, 38], ["angiotensin-converting enzyme 2", "PROTEIN", 47, 78], ["ACE2", "PROTEIN", 80, 84], ["APN", "PROTEIN", 148, 151], ["dipeptidyl peptidase 4", "PROTEIN", 193, 215], ["DPP4", "PROTEIN", 217, 221], ["carcinoembryonic antigen-related cell adhesion molecule 1", "PROTEIN", 262, 319], ["CEACAM1", "PROTEIN", 321, 328], ["sialic acid-containing receptors", "PROTEIN", 382, 414], ["zinc peptidases", "TREATMENT", 23, 38], ["angiotensin", "TREATMENT", 47, 58], ["aminopeptidase N (APN)", "TREATMENT", 130, 152], ["dipeptidyl peptidase", "TREATMENT", 193, 213], ["carcinoembryonic antigen", "TEST", 262, 286], ["related cell adhesion molecule", "TREATMENT", 287, 317], ["sialic acid-containing receptors", "TREATMENT", 382, 414]]], ["In this report, we compared the composition and the structural features of the S protein receptor-binding domains between the SARS-CoV-2 and related viruses (especially the SARS-CoV) and tried to extrapolate the findings to shed some light on possible functioning of this S protein of the new coronavirus, especially the receptor-binding domains.Primary sequence alignment ::: Results and discussionA total of 1652 sequences of S proteins of SARS-CoV-2 isolates from 29 countries were retrieved.", [["SARS-CoV-2", "ORGANISM", 126, 136], ["SARS-CoV", "ORGANISM", 173, 181], ["coronavirus", "ORGANISM", 293, 304], ["SARS-CoV-2", "ORGANISM", 442, 452], ["S protein receptor-binding domains", "PROTEIN", 79, 113], ["S protein", "PROTEIN", 272, 281], ["receptor-binding domains", "PROTEIN", 321, 345], ["S proteins", "PROTEIN", 428, 438], ["CoV-2", "SPECIES", 447, 452], ["SARS-CoV", "SPECIES", 126, 134], ["SARS-CoV", "SPECIES", 173, 181], ["SARS-CoV", "SPECIES", 442, 450], ["the S protein receptor", "TEST", 75, 97], ["the SARS", "TEST", 122, 130], ["related viruses", "PROBLEM", 141, 156], ["this S protein", "PROBLEM", 267, 281], ["the new coronavirus", "PROBLEM", 285, 304], ["S proteins", "TEST", 428, 438], ["SARS", "TEST", 442, 446], ["CoV", "TEST", 447, 450], ["viruses", "OBSERVATION", 149, 156], ["new", "OBSERVATION_MODIFIER", 289, 292], ["coronavirus", "OBSERVATION", 293, 304]]], ["The sequence identity to the reference sequence (YP_009724390.1) varied from 99.7 to 100%, indicating thus a high degree of conservation.", [["reference sequence", "DNA", 29, 47], ["high degree", "OBSERVATION_MODIFIER", 109, 120]]], ["Nearly 40% of these sequences were identical to the reference sequence, while the other 60% presented mostly single mutations (one mutated position in each sequence).", [["these sequences", "TEST", 14, 29], ["single mutations", "PROBLEM", 109, 125]]], ["The mutated positions (77 in total) are reported in Supplementary file 1.", [["positions", "OBSERVATION_MODIFIER", 12, 21]]], ["However, of these mutated positions, three were shared by several sequences: position 791 where Thr was mutated to Ile in 5 of the Taiwanese sequences; position 829 where Ala was mutated to Thr in 9 sequences from Thailand; and more importantly the apparition of Gly instead of Asp at position 614 in 923 sequences. it is to note that all these three positions are located in the S2 subunit.Primary sequence alignment ::: Results and discussionThe S protein of the SARS-CoV-2 shares 97.41% amino acid similarity with the recently identified bat-CoV RatG13 isolate, 80.32% with a bat SARS-like CoV and only 76.27% identity with the SARS-CoV GZ02 isolate.", [["Gly", "CHEMICAL", 263, 266], ["Asp", "CHEMICAL", 278, 281], ["amino acid", "CHEMICAL", 490, 500], ["Thr", "CHEMICAL", 96, 99], ["Ile", "CHEMICAL", 115, 118], ["Ala", "CHEMICAL", 171, 174], ["Thr", "CHEMICAL", 190, 193], ["Gly", "CHEMICAL", 263, 266], ["Asp", "CHEMICAL", 278, 281], ["amino acid", "CHEMICAL", 490, 500], ["Thr", "AMINO_ACID", 96, 99], ["Ile", "AMINO_ACID", 115, 118], ["Ala", "AMINO_ACID", 171, 174], ["Thr", "AMINO_ACID", 190, 193], ["Gly", "AMINO_ACID", 263, 266], ["Asp", "AMINO_ACID", 278, 281], ["position 614", "AMINO_ACID", 285, 297], ["S2", "GENE_OR_GENE_PRODUCT", 380, 382], ["SARS-CoV-2", "ORGANISM", 465, 475], ["amino acid", "AMINO_ACID", 490, 500], ["bat-CoV RatG13", "ORGANISM", 541, 555], ["bat SARS-like CoV", "ORGANISM", 579, 596], ["SARS-CoV GZ02", "ORGANISM", 631, 644], ["S2 subunit", "PROTEIN", 380, 390], ["S protein", "PROTEIN", 448, 457], ["SARS-CoV", "SPECIES", 465, 473], ["bat-CoV", "SPECIES", 541, 548], ["SARS-CoV", "SPECIES", 631, 639], ["the SARS", "TEST", 461, 469], ["CoV", "TEST", 470, 473], ["amino acid similarity", "TEST", 490, 511], ["CoV RatG13 isolate", "TEST", 545, 563], ["a bat SARS", "TEST", 577, 587], ["the SARS", "TEST", 627, 635], ["CoV GZ02 isolate", "TREATMENT", 636, 652], ["S2", "ANATOMY", 380, 382]]], ["Moreover, compared to the S1 subunit, the S2 subunit of the S proteins was found more conserved in the four strains (Fig. 1and Table 1).", [["S2", "GENE_OR_GENE_PRODUCT", 42, 44], ["S1 subunit", "PROTEIN", 26, 36], ["S2 subunit", "PROTEIN", 42, 52], ["S proteins", "PROTEIN", 60, 70], ["the S proteins", "TEST", 56, 70]]], ["Further, by comparing segments of 100aa of the SARS-CoV-2 S protein to the other three coronaviruses (Fig. 1a), the results indicated that the region spanning aa1-400 of the S protein was more similar to the new bat isolate (>90%) than to the SARS- or the bat SARS-like strains.", [["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 243, 247], ["SARS", "DISEASE", 260, 264], ["S protein", "GENE_OR_GENE_PRODUCT", 174, 183], ["bat", "ORGANISM", 212, 215], ["bat SARS-like strains", "ORGANISM", 256, 277], ["SARS-CoV-2 S protein", "PROTEIN", 47, 67], ["aa1", "DNA", 159, 162], ["S protein", "PROTEIN", 174, 183], ["the SARS", "TEST", 43, 51], ["CoV", "TEST", 52, 55], ["aa1", "TEST", 159, 162], ["the S protein", "TEST", 170, 183], ["the SARS", "PROBLEM", 239, 247], ["the bat SARS-like strains", "PROBLEM", 252, 277], ["bat", "ANATOMY", 256, 259]]], ["A more pronounced dissimilarity was noted at the regions spanning aa401-500 and aa601-700, which correspond to the C-terminal domain of the S1 subunit (S1-CTD).Analysis of the S1-NTD receptor binding domain ::: Results and discussionThe S1-NTD of the SARS-CoV-2 is highly similar to that of the newly isolated bat coronavirus RatG13 (>98%) but shares roughly 53% and 67% with those of the SARS-CoV or bat SARS-like CoV, respectively (Table 1).Analysis of the S1-NTD receptor binding domain ::: Results and discussionStructurally, we used the Dali server for aligning the S1-NTD of the SARS-CoV-2 with other coronaviruses from the different genera (Table 2).", [["SARS", "DISEASE", 251, 255], ["SARS", "DISEASE", 585, 589], ["C", "CHEMICAL", 115, 116], ["aa401-500", "GENE_OR_GENE_PRODUCT", 66, 75], ["aa601-700", "GENE_OR_GENE_PRODUCT", 80, 89], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 152, 158], ["SARS-CoV-2", "ORGANISM", 251, 261], ["bat coronavirus", "ORGANISM", 310, 325], ["RatG13", "ORGANISM", 326, 332], ["SARS-CoV", "ORGANISM", 389, 397], ["bat SARS-like CoV", "ORGANISM", 401, 418], ["coronaviruses", "ORGANISM", 607, 620], ["aa401", "DNA", 66, 71], ["aa601-700", "DNA", 80, 89], ["C-terminal domain", "DNA", 115, 132], ["S1 subunit", "PROTEIN", 140, 150], ["S1", "PROTEIN", 152, 154], ["CTD", "PROTEIN", 155, 158], ["S1", "PROTEIN", 176, 178], ["NTD receptor binding domain", "PROTEIN", 179, 206], ["S1", "PROTEIN", 237, 239], ["S1", "PROTEIN", 459, 461], ["NTD receptor binding domain", "PROTEIN", 462, 489], ["S1", "PROTEIN", 571, 573], ["bat coronavirus", "SPECIES", 310, 325], ["SARS-CoV", "SPECIES", 251, 259], ["bat coronavirus", "SPECIES", 310, 325], ["SARS-CoV", "SPECIES", 389, 397], ["SARS-CoV", "SPECIES", 585, 593], ["A more pronounced dissimilarity", "PROBLEM", 0, 31], ["aa401", "TEST", 66, 71], ["Analysis", "TEST", 160, 168], ["the SARS", "TEST", 247, 255], ["CoV", "TEST", 256, 259], ["the newly isolated bat coronavirus RatG13", "PROBLEM", 291, 332], ["the SARS", "TEST", 385, 393], ["bat SARS", "TEST", 401, 409], ["Analysis", "TEST", 443, 451], ["the SARS", "TEST", 581, 589], ["other coronaviruses", "PROBLEM", 601, 620], ["more", "OBSERVATION_MODIFIER", 2, 6], ["pronounced", "OBSERVATION_MODIFIER", 7, 17], ["dissimilarity", "OBSERVATION", 18, 31], ["regions", "ANATOMY_MODIFIER", 49, 56], ["terminal", "ANATOMY_MODIFIER", 117, 125], ["S1", "ANATOMY", 140, 142], ["subunit", "ANATOMY_MODIFIER", 143, 150], ["S1", "ANATOMY", 176, 178], ["SARS", "OBSERVATION", 389, 393], ["S1", "ANATOMY", 459, 461]]], ["As expected the S1-NTD of the SARS-CoV-2 was more similar to those of the Beta-coronaviruses, especially the SARS-CoV (the highest Z-Score, highest sequence identity and the lowest RMSD).", [["SARS", "DISEASE", 30, 34], ["S1", "GENE_OR_GENE_PRODUCT", 16, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["Beta-coronaviruses", "ORGANISM", 74, 92], ["SARS-CoV", "ORGANISM", 109, 117], ["S1", "PROTEIN", 16, 18], ["NTD", "PROTEIN", 19, 22], ["SARS-CoV", "SPECIES", 30, 38], ["Beta-coronaviruses", "SPECIES", 74, 92], ["SARS-CoV", "SPECIES", 109, 117], ["the SARS", "TEST", 26, 34], ["CoV", "TEST", 35, 38], ["the Beta-coronaviruses", "PROBLEM", 70, 92], ["the SARS", "TEST", 105, 113], ["CoV", "TEST", 114, 117], ["SARS", "OBSERVATION", 30, 34]]], ["However, all the NTDs were aligned with Z-scores ranging from 6 to 22.1 and RMSDs ranging from 1.1 to 4.2.", [["Z-scores", "TEST", 40, 48], ["RMSDs", "TEST", 76, 81], ["NTDs", "OBSERVATION", 17, 21]]], ["This similarity is due to the Galectin-like topology of the NTDs' core structures as previously documented (Li, 2012).Analysis of the S1-NTD receptor binding domain ::: Results and discussionThe primary sequence alignment also revealed some insertions shared by the SARS-CoV-2 and bat coronavirus RatG13 but not the SARS-CoV, located at positions aa72-82, aa144-147, aa244-246 and aa255-257 of the SARS-CoV-2 S protein (Fig. 2).Analysis of the S1-NTD receptor binding domain ::: Results and discussionTo further investigate the structural role of these inserts, we searched the Protein Data Bank using the largest insert 72GTNGTKR78 with 5 amino acids extensions on both N- and C-terminal sides, leading to 17aa long segment 67AIHVSGTNGTKRFDNPV83; then we analyzed the hits to see whether the aligned motifs were engaged in any identified structural function (Table 3).The GTNGTKR motif in binding protein receptors ::: Results and discussionWhen we searched the protein databank using the GTNGTKR motif, the first hit was the structure of the Mengo virus VP1 protein (Fig. 3a).", [["Galectin", "CHEMICAL", 30, 38], ["amino acids", "CHEMICAL", 640, 651], ["amino acids", "CHEMICAL", 640, 651], ["N", "CHEMICAL", 671, 672], ["C", "CHEMICAL", 678, 679], ["Galectin", "GENE_OR_GENE_PRODUCT", 30, 38], ["SARS-CoV-2", "ORGANISM", 266, 276], ["bat coronavirus RatG13", "ORGANISM", 281, 303], ["SARS-CoV", "ORGANISM", 316, 324], ["aa72-82", "GENE_OR_GENE_PRODUCT", 347, 354], ["aa144-147", "GENE_OR_GENE_PRODUCT", 356, 365], ["aa244-246", "GENE_OR_GENE_PRODUCT", 367, 376], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 398, 410], ["amino acids", "AMINO_ACID", 640, 651], ["Mengo virus", "ORGANISM", 1044, 1055], ["Galectin", "PROTEIN", 30, 38], ["S1", "PROTEIN", 134, 136], ["NTD receptor binding domain", "PROTEIN", 137, 164], ["SARS-CoV-2 and bat coronavirus RatG13", "DNA", 266, 303], ["SARS-CoV", "DNA", 316, 324], ["SARS-CoV-2 S protein", "DNA", 398, 418], ["S1", "PROTEIN", 444, 446], ["NTD receptor binding domain", "PROTEIN", 447, 474], ["N- and C-terminal sides", "PROTEIN", 671, 694], ["17aa long segment 67AIHVSGTNGTKRFDNPV83", "DNA", 707, 746], ["GTNGTKR motif", "DNA", 873, 886], ["binding protein receptors", "PROTEIN", 890, 915], ["GTNGTKR motif", "DNA", 990, 1003], ["Mengo virus VP1 protein", "PROTEIN", 1044, 1067], ["bat coronavirus Rat", "SPECIES", 281, 300], ["SARS-CoV", "SPECIES", 266, 274], ["bat coronavirus", "SPECIES", 281, 296], ["SARS-CoV", "SPECIES", 316, 324], ["Mengo virus", "SPECIES", 1044, 1055], ["the Galectin", "TEST", 26, 38], ["Analysis", "TEST", 118, 126], ["The primary sequence alignment", "TEST", 191, 221], ["some insertions", "PROBLEM", 236, 251], ["the SARS", "TEST", 262, 270], ["CoV", "TEST", 271, 274], ["bat coronavirus Rat", "TEST", 281, 300], ["the SARS", "TEST", 312, 320], ["CoV", "TEST", 321, 324], ["aa255", "TEST", 381, 386], ["the SARS", "TEST", 394, 402], ["CoV", "TEST", 403, 406], ["S protein", "TEST", 409, 418], ["Analysis", "TEST", 428, 436], ["the largest insert", "TREATMENT", 602, 620], ["5 amino acids extensions", "TREATMENT", 638, 662], ["the GTNGTKR motif", "TREATMENT", 986, 1003], ["NTDs", "OBSERVATION", 60, 64], ["S1", "ANATOMY", 134, 136], ["S1", "ANATOMY", 444, 446]]], ["The aligned segment was located on the VP1 GH loop, which forms along with the VP3 C-terminal loop a depression on the capsid that has been associated with receptor recognition and binding (Kim et al., 1990; Krishnaswamy and Rossmann, 1990).", [["depression", "DISEASE", 101, 111], ["C", "CHEMICAL", 83, 84], ["GH", "GENE_OR_GENE_PRODUCT", 43, 45], ["VP1 GH loop", "PROTEIN", 39, 50], ["VP3 C-terminal loop", "PROTEIN", 79, 98], ["the VP3 C-terminal loop a depression on the capsid", "PROBLEM", 75, 125], ["segment", "OBSERVATION_MODIFIER", 12, 19], ["VP1", "ANATOMY", 39, 42], ["GH loop", "OBSERVATION", 43, 50], ["terminal loop", "OBSERVATION", 85, 98], ["depression", "OBSERVATION", 101, 111]]], ["Although the depression described in the Mengo virus capsid is absent in the S1-NTD of the SARS-CoV-2, the target motif 72GTNGTKRFDN81 forms a similarly exposed loop with two neighboring loops containing the 255SSG257 motif (the identified insert 4) and the N-terminal loop (18LTT20 motif) on both sides (Fig. 3b).", [["depression", "DISEASE", 13, 23], ["SARS", "DISEASE", 91, 95], ["N-", "CHEMICAL", 258, 260], ["Mengo virus", "ORGANISM", 41, 52], ["capsid", "ORGANISM", 53, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 91, 101], ["S1", "PROTEIN", 77, 79], ["NTD", "PROTEIN", 80, 83], ["SARS-CoV-2", "DNA", 91, 101], ["target motif 72GTNGTKRFDN81", "DNA", 107, 134], ["255SSG257 motif", "DNA", 208, 223], ["insert 4", "DNA", 240, 248], ["N-terminal loop", "PROTEIN", 258, 273], ["18LTT20 motif", "PROTEIN", 275, 288], ["Mengo virus", "SPECIES", 41, 52], ["SARS-CoV", "SPECIES", 91, 99], ["the depression", "PROBLEM", 9, 23], ["the Mengo virus capsid", "TEST", 37, 59], ["the SARS", "TEST", 87, 95], ["CoV", "TEST", 96, 99], ["the N-terminal loop (18LTT20 motif", "TREATMENT", 254, 288], ["depression", "OBSERVATION", 13, 23], ["neighboring loops", "OBSERVATION", 175, 192]]], ["Whether this formation could play the same role as the Mengo virus VP1 and VP3 loops, which would, in turn, allow the SARS-CoV-2 to interact with the same receptor, need further investigation.", [["Mengo virus VP1", "ORGANISM", 55, 70], ["VP3", "GENE_OR_GENE_PRODUCT", 75, 78], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 118, 128], ["Mengo virus VP1 and VP3 loops", "DNA", 55, 84], ["Mengo virus", "SPECIES", 55, 66], ["the Mengo virus VP1", "TEST", 51, 70], ["further investigation", "TEST", 170, 191], ["VP3 loops", "ANATOMY", 75, 84]]], ["Moreover, the Mengo virus has been found to bind the murine cellular receptor vascular cell adhesion molecule 1 (VCAM-1) to enter and infect cells (Huber, 1994).", [["cellular", "ANATOMY", 60, 68], ["cells", "ANATOMY", 141, 146], ["Mengo virus", "ORGANISM", 14, 25], ["murine", "ORGANISM", 53, 59], ["cellular", "CELL", 60, 68], ["vascular cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 78, 111], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 113, 119], ["cells", "CELL", 141, 146], ["murine cellular receptor vascular cell adhesion molecule 1", "PROTEIN", 53, 111], ["VCAM", "PROTEIN", 113, 117], ["murine", "SPECIES", 53, 59], ["Mengo virus", "SPECIES", 14, 25], ["the Mengo virus", "PROBLEM", 10, 25], ["VCAM", "TEST", 113, 117], ["vascular", "ANATOMY", 78, 86], ["cell adhesion", "OBSERVATION", 87, 100], ["infect cells", "OBSERVATION", 134, 146]]], ["This receptor molecule is restricted to endothelial cells and is subject to upregulation under cytokines stimulation (Hosokawa et al., 2006; Singh et al., 2005).", [["endothelial cells", "ANATOMY", 40, 57], ["endothelial cells", "CELL", 40, 57], ["endothelial cells", "CELL_TYPE", 40, 57], ["cytokines", "PROTEIN", 95, 104], ["upregulation under cytokines stimulation", "TREATMENT", 76, 116], ["endothelial cells", "OBSERVATION", 40, 57]]], ["Given the high cytokine amounts stimulated by the SARS-CoV-2 (Huang et al., 2020) and pre-existing heart disease (hypertension and coronary heart disease) being one of the major co-morbidities of the fatality cases (Deng and Peng, 2020), it is interesting to explore the possibility of the SARS-CoV-2 binding the VCAM-1 receptor via its S1-NTD.The GTNGTKR motif in binding protein receptors ::: Results and discussionThe mouse hepatitis coronavirus (MHV) also binds another cell adhesion molecule, the murine carcinoembryonic antigen-related cell adhesion molecule 1a (mCEACAM1a), using its S1-NTD (Peng et al., 2011).", [["heart", "ANATOMY", 99, 104], ["coronary", "ANATOMY", 131, 139], ["heart", "ANATOMY", 140, 145], ["cell", "ANATOMY", 474, 478], ["heart disease", "DISEASE", 99, 112], ["hypertension", "DISEASE", 114, 126], ["coronary heart disease", "DISEASE", 131, 153], ["SARS", "DISEASE", 290, 294], ["hepatitis coronavirus", "DISEASE", 427, 448], ["CoV-2", "ORGANISM", 55, 60], ["heart", "ORGAN", 99, 104], ["heart", "ORGAN", 140, 145], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 290, 300], ["VCAM-1 receptor", "GENE_OR_GENE_PRODUCT", 313, 328], ["S1-NTD", "GENE_OR_GENE_PRODUCT", 337, 343], ["mouse hepatitis coronavirus", "ORGANISM", 421, 448], ["MHV", "ORGANISM", 450, 453], ["cell", "CELL", 474, 478], ["murine", "ORGANISM", 502, 508], ["carcinoembryonic antigen-related cell adhesion molecule 1a", "GENE_OR_GENE_PRODUCT", 509, 567], ["mCEACAM1a", "GENE_OR_GENE_PRODUCT", 569, 578], ["cytokine", "PROTEIN", 15, 23], ["VCAM-1 receptor", "PROTEIN", 313, 328], ["S1", "PROTEIN", 337, 339], ["NTD", "PROTEIN", 340, 343], ["GTNGTKR motif", "DNA", 348, 361], ["binding protein receptors", "PROTEIN", 365, 390], ["cell adhesion molecule", "PROTEIN", 474, 496], ["murine carcinoembryonic antigen-related cell adhesion molecule 1a", "PROTEIN", 502, 567], ["mCEACAM1a", "PROTEIN", 569, 578], ["S1", "PROTEIN", 591, 593], ["mouse", "SPECIES", 421, 426], ["hepatitis coronavirus", "SPECIES", 427, 448], ["murine", "SPECIES", 502, 508], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 290, 298], ["mouse hepatitis coronavirus", "SPECIES", 421, 448], ["MHV", "SPECIES", 450, 453], ["the high cytokine amounts", "TREATMENT", 6, 31], ["pre-existing heart disease", "PROBLEM", 86, 112], ["hypertension", "PROBLEM", 114, 126], ["coronary heart disease)", "PROBLEM", 131, 154], ["the SARS", "TEST", 286, 294], ["CoV", "TEST", 295, 298], ["the VCAM", "TEST", 309, 317], ["NTD", "PROBLEM", 340, 343], ["The mouse hepatitis coronavirus", "PROBLEM", 417, 448], ["another cell adhesion molecule", "TEST", 466, 496], ["the murine carcinoembryonic antigen", "TEST", 498, 533], ["heart", "ANATOMY", 99, 104], ["disease", "OBSERVATION", 105, 112], ["hypertension", "OBSERVATION", 114, 126], ["coronary heart", "ANATOMY", 131, 145], ["disease", "OBSERVATION", 146, 153], ["S1", "ANATOMY", 337, 339], ["NTD", "OBSERVATION", 340, 343], ["cell adhesion molecule", "OBSERVATION", 474, 496], ["cell adhesion", "OBSERVATION", 542, 555], ["S1", "ANATOMY", 591, 593]]], ["Therefore, as a next step, we compared the MHV and SARS-CoV-2 S1-NTDs.", [["MHV", "ORGANISM", 43, 46], ["MHV", "SPECIES", 43, 46], ["SARS-CoV", "SPECIES", 51, 59], ["the MHV", "TEST", 39, 46], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["NTDs", "PROBLEM", 65, 69]]], ["We found that the receptor-binding motif of the MHV S1-NTD also presents a motif 168NTNGNK173 with some similarity to insert 1 (72GTNGTKR78) of the SARS-CoV-2 S1-NTD.", [["SARS", "DISEASE", 148, 152], ["MHV S1", "ORGANISM", 48, 54], ["receptor-binding motif", "PROTEIN", 18, 40], ["MHV S1", "PROTEIN", 48, 54], ["NTD", "PROTEIN", 55, 58], ["insert 1", "DNA", 118, 126], ["SARS-CoV-2 S1-NTD", "DNA", 148, 165], ["a motif", "TEST", 73, 80], ["the SARS", "TEST", 144, 152], ["CoV", "TEST", 153, 156], ["NTD", "PROBLEM", 162, 165], ["MHV S1", "ANATOMY", 48, 54], ["CoV", "ANATOMY", 153, 156], ["S1", "ANATOMY", 159, 161], ["NTD", "OBSERVATION", 162, 165]]], ["However, when the S1-NTDs were compared in the quaternary structures of the S proteins, the above motifs seem to occupy opposite positions (Fig. 3c and d).", [["S1", "GENE_OR_GENE_PRODUCT", 18, 20], ["S1", "PROTEIN", 18, 20], ["S proteins", "PROTEIN", 76, 86], ["the S1-NTDs", "PROBLEM", 14, 25]]], ["Besides, Peng et al. identified four receptor binding motifs in the MHV S1-NTD (RBM1-4) (Peng et al., 2011).", [["MHV S1", "PROTEIN", 68, 74], ["four receptor binding motifs", "PROBLEM", 32, 60], ["the MHV S1", "TEST", 64, 74], ["NTD", "PROBLEM", 75, 78], ["RBM1", "TEST", 80, 84], ["binding motifs", "OBSERVATION", 46, 60], ["MHV", "ANATOMY", 68, 71], ["S1", "ANATOMY_MODIFIER", 72, 74]]], ["By comparing the MHV-receptor interaction interface and the exposed amino acids on the receptor-binding surface of the SARS-CoV-2 S1-NTD, we found that the N-terminal aa15-21 segments adopt different conformations (Fig. 3d), and this segment in the MHV (RBM1) contains three residues critical for receptor binding affinity (Peng et al., 2011).", [["amino acids", "CHEMICAL", 68, 79], ["amino acids", "CHEMICAL", 68, 79], ["N-", "CHEMICAL", 156, 158], ["amino acids", "AMINO_ACID", 68, 79], ["RBM1", "GENE_OR_GENE_PRODUCT", 254, 258], ["SARS-CoV-2 S1", "PROTEIN", 119, 132], ["NTD", "PROTEIN", 133, 136], ["N-terminal aa15-21 segments", "PROTEIN", 156, 183], ["MHV", "PROTEIN", 249, 252], ["RBM1", "PROTEIN", 254, 258], ["MHV", "SPECIES", 249, 252], ["the exposed amino acids", "TREATMENT", 56, 79], ["the SARS", "TEST", 115, 123], ["CoV", "TEST", 124, 127], ["NTD", "PROBLEM", 133, 136], ["the N-terminal aa15", "PROBLEM", 152, 171], ["receptor binding affinity", "PROBLEM", 297, 322], ["amino acids", "OBSERVATION", 68, 79], ["SARS", "OBSERVATION", 119, 123], ["segment", "ANATOMY_MODIFIER", 234, 241], ["MHV", "ANATOMY", 249, 252]]], ["Therefore, it seems unlikely that the SARS-CoV-2 would bind the same receptor.", [["SARS", "DISEASE", 38, 42], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["the SARS-CoV", "PROBLEM", 34, 46], ["seems unlikely", "UNCERTAINTY", 14, 28]]], ["However, this observation should be taken with care since it is based on the predicted model of the SARS-CoV-2 S1-NTD.The GTNGTKR motif in binding protein receptors ::: Results and discussionTaken all together, the presence of the GTNGTKR motif in the SARS-CoV-2 S1-NTD seems to be a potentially evolutionary feature that SARS-CoV-2 acquired to allow its S1-NTD to bind to protein receptors.", [["SARS", "DISEASE", 100, 104], ["SARS", "DISEASE", 252, 256], ["GTNGTKR", "GENE_OR_GENE_PRODUCT", 231, 238], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 252, 265], ["CoV-2", "ORGANISM", 327, 332], ["S1-NTD", "GENE_OR_GENE_PRODUCT", 355, 361], ["GTNGTKR motif", "DNA", 122, 135], ["binding protein receptors", "PROTEIN", 139, 164], ["GTNGTKR motif", "DNA", 231, 244], ["SARS-CoV-2 S1", "DNA", 252, 265], ["NTD", "PROTEIN", 266, 269], ["S1", "PROTEIN", 355, 357], ["NTD", "PROTEIN", 358, 361], ["protein receptors", "PROTEIN", 373, 390], ["SARS-CoV", "SPECIES", 100, 108], ["the SARS", "TEST", 96, 104], ["CoV", "TEST", 105, 108], ["NTD", "PROBLEM", 114, 117], ["the GTNGTKR motif", "TEST", 227, 244], ["the SARS", "TEST", 248, 256], ["CoV", "TEST", 257, 260], ["NTD", "PROBLEM", 266, 269], ["SARS", "PROBLEM", 322, 326], ["CoV", "TEST", 327, 330]]], ["We believe that the above observations are worth investigating.The GTNGTKR motif in binding sugar receptors ::: Results and discussionAnother structure containing the analyzed motif was the tail spike protein 1 of the bacteriophage CBA120 (Podoviridae) (Chen et al., 2014).", [["sugar", "CHEMICAL", 92, 97], ["CBA120", "GENE_OR_GENE_PRODUCT", 232, 238], ["GTNGTKR motif", "DNA", 67, 80], ["binding sugar receptors", "PROTEIN", 84, 107], ["tail spike protein 1", "PROTEIN", 190, 210], ["the bacteriophage CBA120", "TREATMENT", 214, 238]]], ["The aligned motif GTNGTK was located within the receptor-binding domain, in the inverting region connecting the subdomain D3 and D4.", [["GTNGTK", "GENE_OR_GENE_PRODUCT", 18, 24], ["GTNGTK", "PROTEIN", 18, 24], ["receptor-binding domain", "PROTEIN", 48, 71], ["subdomain D3", "PROTEIN", 112, 124], ["D4", "PROTEIN", 129, 131], ["The aligned motif GTNGTK", "PROBLEM", 0, 24], ["motif GTNGTK", "OBSERVATION", 12, 24], ["subdomain D3", "OBSERVATION", 112, 124]]], ["Interestingly, unlike other tail spike proteins where the sugar-binding sites were located on the D3 subdomain (Barbirz et al., 2008; Muller et al., 2008; Steinbacher et al., 1996; Xiang et al., 2009), the D3-D4 inverting region of the CBA120 tail spike protein generates a hole that forms the sugar-binding site (Chen et al., 2014).", [["sugar", "CHEMICAL", 58, 63], ["sugar", "CHEMICAL", 294, 299], ["sugar", "SIMPLE_CHEMICAL", 58, 63], ["D3-D4", "GENE_OR_GENE_PRODUCT", 206, 211], ["sugar", "SIMPLE_CHEMICAL", 294, 299], ["tail spike proteins", "PROTEIN", 28, 47], ["sugar-binding sites", "PROTEIN", 58, 77], ["D3 subdomain", "PROTEIN", 98, 110], ["D3-D4 inverting region", "PROTEIN", 206, 228], ["CBA120 tail spike protein", "PROTEIN", 236, 261], ["sugar-binding site", "PROTEIN", 294, 312], ["other tail spike proteins", "PROBLEM", 22, 47], ["binding sites", "PROBLEM", 64, 77], ["the D3-D4 inverting region", "TREATMENT", 202, 228], ["a hole", "TREATMENT", 272, 278], ["tail spike", "OBSERVATION", 28, 38], ["CBA120 tail", "ANATOMY", 236, 247]]], ["Although the target motif was not directly involved in the sugar\u2019s interactions, the binding site (hole) is formed in the opposite direction of the GTNGTK loop, and a quite similar orientation of the motif is observed in the SARS-CoV-2 S1-NTD (Fig. 4).", [["sugar", "CHEMICAL", 59, 64], ["sugar", "SIMPLE_CHEMICAL", 59, 64], ["GTNGTK", "GENE_OR_GENE_PRODUCT", 148, 154], ["binding site", "DNA", 85, 97], ["GTNGTK loop", "PROTEIN", 148, 159], ["S1", "PROTEIN", 236, 238], ["NTD", "PROTEIN", 239, 242], ["the binding site (hole", "TREATMENT", 81, 103], ["the SARS", "TEST", 221, 229], ["CoV", "TEST", 230, 233], ["GTNGTK loop", "OBSERVATION", 148, 159]]], ["Besides, what could be the counterparts of the sugar-binding pocket of the CBA120 tail spike protein is one of the two pockets formed in the SARS-CoV-2 S1-NTD: the first situated on the top part of the domain and the other located above the \u03b2-sandwich core in the opposite direction of the GTNGTKR loop (Fig. 4c).", [["SARS", "DISEASE", 141, 145], ["sugar", "CHEMICAL", 47, 52], ["sugar", "SIMPLE_CHEMICAL", 47, 52], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 141, 154], ["sugar-binding pocket", "PROTEIN", 47, 67], ["CBA120 tail spike protein", "PROTEIN", 75, 100], ["SARS-CoV-2 S1", "PROTEIN", 141, 154], ["NTD", "PROTEIN", 155, 158], ["\u03b2-sandwich core", "PROTEIN", 241, 256], ["GTNGTKR loop", "PROTEIN", 290, 302], ["the CBA120 tail spike protein", "TEST", 71, 100], ["the two pockets", "PROBLEM", 111, 126], ["the SARS", "TEST", 137, 145], ["CoV", "TEST", 146, 149], ["pockets", "OBSERVATION_MODIFIER", 119, 126], ["CoV", "ANATOMY", 146, 149], ["opposite", "ANATOMY_MODIFIER", 264, 272], ["GTNGTKR loop", "OBSERVATION", 290, 302]]], ["This latter pocket is also aligned with the sugar-binding site in the NTD of bovine coronavirus (BCoV) (Fig. 5a and c).", [["sugar", "CHEMICAL", 44, 49], ["sugar", "SIMPLE_CHEMICAL", 44, 49], ["bovine coronavirus", "ORGANISM", 77, 95], ["BCoV", "CANCER", 97, 101], ["sugar-binding site", "PROTEIN", 44, 62], ["NTD", "PROTEIN", 70, 73], ["bovine", "SPECIES", 77, 83], ["bovine coronavirus", "SPECIES", 77, 95], ["BCoV", "SPECIES", 97, 101], ["This latter pocket", "PROBLEM", 0, 18], ["the sugar-binding site", "PROBLEM", 40, 62], ["bovine coronavirus", "TREATMENT", 77, 95], ["pocket", "OBSERVATION_MODIFIER", 12, 18], ["aligned", "OBSERVATION_MODIFIER", 27, 34], ["bovine coronavirus", "OBSERVATION", 77, 95]]], ["Peng et al. (Peng et al., 2012) reported that the pocket above the \u03b2-sandwich core is the sugar-binding site in BCoV NTD and through mutagenesis studies, they identified 4 residues critical for the NTD-receptor interaction Y162, E182, W184, and H185 and the binding was stabilized by the loop 10\u201311 (146NDLNKL151) (Fig. 5c).", [["sugar", "CHEMICAL", 90, 95], ["sugar", "SIMPLE_CHEMICAL", 90, 95], ["BCoV", "SIMPLE_CHEMICAL", 112, 116], ["\u03b2-sandwich core", "DNA", 67, 82], ["sugar-binding site", "PROTEIN", 90, 108], ["BCoV NTD", "PROTEIN", 112, 120], ["NTD", "PROTEIN", 198, 201], ["W184", "PROTEIN", 235, 239], ["H185", "PROTEIN", 245, 249], ["loop 10\u201311", "PROTEIN", 288, 298], ["the pocket", "PROBLEM", 46, 56], ["mutagenesis studies", "TEST", 133, 152]]], ["Interestingly, the corresponding pocket in the SARS-CoV-2 NTD also contains three amino acids (E154, F157, and Y160) with the same orientation than the four key residues identified in the BCoV NTD.", [["SARS", "DISEASE", 47, 51], ["amino acids", "CHEMICAL", 82, 93], ["amino acids", "CHEMICAL", 82, 93], ["amino acids", "AMINO_ACID", 82, 93], ["SARS-CoV-2 NTD", "PROTEIN", 47, 61], ["BCoV NTD", "PROTEIN", 188, 196], ["SARS-CoV", "SPECIES", 47, 55], ["the corresponding pocket", "PROBLEM", 15, 39], ["the SARS", "TEST", 43, 51], ["CoV", "TEST", 52, 55], ["three amino acids", "TEST", 76, 93], ["pocket", "OBSERVATION_MODIFIER", 33, 39], ["three", "OBSERVATION_MODIFIER", 76, 81], ["amino acids", "OBSERVATION", 82, 93], ["key residues", "OBSERVATION", 157, 169], ["BCoV NTD", "OBSERVATION", 188, 196]]], ["Moreover, the positions of E154 and Y160 are strikingly similar to that of Y162 and E182 in BCoV NTD (Fig. 5d).", [["E154", "GENE_OR_GENE_PRODUCT", 27, 31], ["Y160", "GENE_OR_GENE_PRODUCT", 36, 40], ["E154", "DNA", 27, 31], ["E154 and Y160", "TREATMENT", 27, 40]]], ["Besides, a counterpart of the stabilizing loop 10-11 is also present in the SARS-CoV-2 NTD, although shorter, but seems to share the NxxN motif.The GTNGTKR motif in binding sugar receptors ::: Results and discussionThese observations suggest that SARS-CoV-2 NTD might recognize a sugar receptor as well, and it is likely to be the same Neu5,9Ac2 that BCoV NTD binds to (Peng et al., 2012).The GTNGTKR motif in other structural functions ::: Results and discussionThe TNGTRRF motif was also present in the infectious bronchitis coronavirus (IBV) spike protein.", [["SARS", "DISEASE", 76, 80], ["SARS", "DISEASE", 247, 251], ["infectious bronchitis coronavirus", "DISEASE", 505, 538], ["sugar", "CHEMICAL", 173, 178], ["sugar", "CHEMICAL", 280, 285], ["SARS-CoV-2", "ORGANISM", 247, 257], ["Neu5", "GENE_OR_GENE_PRODUCT", 336, 340], ["9Ac2", "GENE_OR_GENE_PRODUCT", 341, 345], ["BCoV", "GENE_OR_GENE_PRODUCT", 351, 355], ["TNGTRRF", "GENE_OR_GENE_PRODUCT", 467, 474], ["infectious bronchitis coronavirus", "ORGANISM", 505, 538], ["IBV", "ORGANISM", 540, 543], ["SARS-CoV-2 NTD", "PROTEIN", 76, 90], ["NxxN motif", "PROTEIN", 133, 143], ["GTNGTKR motif", "DNA", 148, 161], ["binding sugar receptors", "PROTEIN", 165, 188], ["NTD", "PROTEIN", 258, 261], ["sugar receptor", "PROTEIN", 280, 294], ["Neu5", "PROTEIN", 336, 340], ["9Ac2", "PROTEIN", 341, 345], ["BCoV NTD", "PROTEIN", 351, 359], ["GTNGTKR motif", "DNA", 393, 406], ["TNGTRRF motif", "DNA", 467, 480], ["infectious bronchitis coronavirus (IBV) spike protein", "PROTEIN", 505, 558], ["infectious bronchitis coronavirus", "SPECIES", 505, 538], ["infectious bronchitis coronavirus", "SPECIES", 505, 538], ["IBV", "SPECIES", 540, 543], ["the SARS", "TEST", 72, 80], ["NTD", "PROBLEM", 87, 90], ["SARS", "PROBLEM", 247, 251], ["NTD", "PROBLEM", 258, 261], ["The TNGTRRF motif", "TREATMENT", 463, 480], ["the infectious bronchitis coronavirus", "PROBLEM", 501, 538], ["spike protein", "PROBLEM", 545, 558], ["SARS", "OBSERVATION", 76, 80], ["infectious", "OBSERVATION_MODIFIER", 505, 515]]], ["Despite the low primary sequence identity (11%), the pairwise structural alignment revealed that the SARS-CoV-2 S1-NTD shared a relatively high structural similarity with the S1-NTD of the IBV with a Dali Z-score of 8.6 and RMSD of 3.1 over 159 aligned residues (Table 2).", [["SARS", "DISEASE", 101, 105], ["IBV", "ORGANISM", 189, 192], ["SARS-CoV-2 S1-NTD", "DNA", 101, 118], ["S1", "PROTEIN", 175, 177], ["NTD", "PROTEIN", 178, 181], ["the pairwise structural alignment", "TEST", 49, 82], ["the SARS", "TEST", 97, 105], ["CoV", "TEST", 106, 109], ["a Dali Z-score", "TEST", 198, 212], ["RMSD", "TEST", 224, 228], ["relatively", "OBSERVATION_MODIFIER", 128, 138], ["high", "OBSERVATION", 139, 143], ["S1", "ANATOMY_MODIFIER", 175, 177], ["IBV", "ANATOMY", 189, 192]]], ["The aligned motif TNGTRRF was located within the S1-CTD of the IBV, in the subdomain connecting S1 and S2 (Shang et al., 2018).", [["TNGTRRF", "GENE_OR_GENE_PRODUCT", 18, 25], ["IBV", "ORGANISM", 63, 66], ["TNGTRRF", "PROTEIN", 18, 25], ["S1", "PROTEIN", 49, 51], ["CTD", "PROTEIN", 52, 55], ["S1", "PROTEIN", 96, 98], ["S2", "PROTEIN", 103, 105], ["motif TNGTRRF", "OBSERVATION", 12, 25], ["S1", "ANATOMY", 49, 51], ["CTD", "OBSERVATION", 52, 55], ["IBV", "OBSERVATION", 63, 66], ["subdomain", "ANATOMY_MODIFIER", 75, 84], ["S1", "ANATOMY_MODIFIER", 96, 98], ["S2", "ANATOMY", 103, 105]]], ["Although no functional features have been described for the subdomains of the S1-NTDs and S1-CTDs in the coronaviruses spikes, the target motif was found protruding from the surface of the trimer (Fig. 6a), suggesting that such protrusion might interact with the surrounding environment.The GTNGTKR motif in other structural functions ::: Results and discussionThe aligned fragment was also located at the C-terminal of the Mimivirus cyclophilin but it was missing from the deposited structure (Thai et al., 2008).", [["surface", "ANATOMY", 174, 181], ["C", "CHEMICAL", 406, 407], ["S1", "GENE_OR_GENE_PRODUCT", 78, 80], ["S1-CTDs", "GENE_OR_GENE_PRODUCT", 90, 97], ["coronaviruses", "ORGANISM", 105, 118], ["surface", "CELLULAR_COMPONENT", 174, 181], ["fragment", "CELLULAR_COMPONENT", 373, 381], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 434, 445], ["S1", "PROTEIN", 78, 80], ["NTDs", "PROTEIN", 81, 85], ["S1", "PROTEIN", 90, 92], ["CTDs", "PROTEIN", 93, 97], ["trimer", "PROTEIN", 189, 195], ["GTNGTKR motif", "DNA", 291, 304], ["C-terminal", "PROTEIN", 406, 416], ["Mimivirus cyclophilin", "PROTEIN", 424, 445], ["functional features", "PROBLEM", 12, 31], ["NTDs", "PROBLEM", 81, 85], ["CTDs", "PROBLEM", 93, 97], ["the coronaviruses spikes", "PROBLEM", 101, 125], ["the target motif", "PROBLEM", 127, 143], ["such protrusion", "PROBLEM", 223, 238], ["The aligned fragment", "PROBLEM", 361, 381], ["the Mimivirus cyclophilin", "TREATMENT", 420, 445], ["S1", "ANATOMY", 78, 80], ["S1", "ANATOMY", 90, 92], ["coronaviruses spikes", "OBSERVATION", 105, 125], ["protruding", "OBSERVATION_MODIFIER", 154, 164], ["surface", "OBSERVATION_MODIFIER", 174, 181], ["trimer", "ANATOMY_MODIFIER", 189, 195], ["protrusion", "OBSERVATION", 228, 238], ["aligned", "OBSERVATION_MODIFIER", 365, 372], ["fragment", "OBSERVATION", 373, 381], ["Mimivirus cyclophilin", "OBSERVATION", 424, 445]]], ["However, it is to note that this is the first virus-encoded cyclophilin but it lacks peptidyl-prolyl isomerase, an activity that several viruses such human immunodeficiency virus type 1 and SARS-CoV exploit the host cyclophilin for (Chen et al., 2005; Sorin and Kalpana, 2006).", [["human immunodeficiency virus", "DISEASE", 150, 178], ["prolyl", "CHEMICAL", 94, 100], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 60, 71], ["peptidyl-prolyl isomerase", "GENE_OR_GENE_PRODUCT", 85, 110], ["human immunodeficiency virus type 1", "ORGANISM", 150, 185], ["SARS-CoV", "ORGANISM", 190, 198], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 216, 227], ["cyclophilin", "PROTEIN", 60, 71], ["peptidyl-prolyl isomerase", "PROTEIN", 85, 110], ["human immunodeficiency virus", "SPECIES", 150, 178], ["human immunodeficiency virus type 1", "SPECIES", 150, 185], ["SARS-CoV", "SPECIES", 190, 198], ["the first virus", "PROBLEM", 36, 51], ["cyclophilin", "TREATMENT", 60, 71], ["peptidyl-prolyl isomerase", "PROBLEM", 85, 110], ["several viruses such human immunodeficiency virus type 1", "PROBLEM", 129, 185], ["SARS", "PROBLEM", 190, 194], ["the host cyclophilin", "TREATMENT", 207, 227], ["Sorin", "TREATMENT", 252, 257]]], ["Interestingly, the viral cyclophilin was located on the surface of mature Mimivirus virions, and given the absence of the catalytic activity, the authors suggested that the protein may play a structural role yet to be identified in the Mimivirus life cycle (Thai et al., 2008).", [["surface", "ANATOMY", 56, 63], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 25, 36], ["surface", "CELLULAR_COMPONENT", 56, 63], ["Mimivirus virions", "ORGANISM", 74, 91], ["viral cyclophilin", "PROTEIN", 19, 36], ["the viral cyclophilin", "PROBLEM", 15, 36], ["mature Mimivirus virions", "PROBLEM", 67, 91], ["viral cyclophilin", "OBSERVATION", 19, 36], ["mature", "OBSERVATION_MODIFIER", 67, 73], ["Mimivirus virions", "OBSERVATION", 74, 91]]], ["Since the Mimivirus can cause pneumonia in humans (La Scola et al., 2005; Saadi et al., 2013), and the exact position of the cyclophilin is yet to be determined, a question could be asked whether the 221NGTKRF226 motif could play a role in the virus pathogenesis that could be shared by the SARS-CoV-2.The GTNGTKR motif in other structural functions ::: Results and discussionBesides viruses, the search for a functional GTNGTKR motif in the deposited protein structures revealed a similar motif in the folylpolyglutamate synthetase (FPGS) of Lactobacillus casei, an enzyme that catalyzes the MgATP-dependent glutamylation of folate coenzymes (Fig. 6b).", [["pneumonia", "DISEASE", 30, 39], ["folylpolyglutamate", "CHEMICAL", 503, 521], ["MgATP", "CHEMICAL", 593, 598], ["folate", "CHEMICAL", 626, 632], ["folylpolyglutamate", "CHEMICAL", 503, 521], ["MgATP", "CHEMICAL", 593, 598], ["folate", "CHEMICAL", 626, 632], ["humans", "ORGANISM", 43, 49], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 125, 136], ["221NGTKRF226", "GENE_OR_GENE_PRODUCT", 200, 212], ["SARS-CoV-2", "ORGANISM", 291, 301], ["GTNGTKR", "GENE_OR_GENE_PRODUCT", 421, 428], ["folylpolyglutamate synthetase", "GENE_OR_GENE_PRODUCT", 503, 532], ["Lactobacillus casei", "ORGANISM", 543, 562], ["MgATP", "SIMPLE_CHEMICAL", 593, 598], ["folate", "SIMPLE_CHEMICAL", 626, 632], ["cyclophilin", "PROTEIN", 125, 136], ["221NGTKRF226 motif", "DNA", 200, 218], ["GTNGTKR motif", "DNA", 306, 319], ["GTNGTKR motif", "DNA", 421, 434], ["folylpolyglutamate synthetase", "PROTEIN", 503, 532], ["FPGS", "PROTEIN", 534, 538], ["humans", "SPECIES", 43, 49], ["Lactobacillus casei", "SPECIES", 543, 562], ["humans", "SPECIES", 43, 49], ["SARS-CoV", "SPECIES", 291, 299], ["Lactobacillus casei", "SPECIES", 543, 562], ["pneumonia", "PROBLEM", 30, 39], ["the cyclophilin", "TREATMENT", 121, 136], ["the virus pathogenesis", "PROBLEM", 240, 262], ["a functional GTNGTKR motif", "TEST", 408, 434], ["the deposited protein structures", "TEST", 438, 470], ["Lactobacillus casei", "TREATMENT", 543, 562], ["an enzyme", "TEST", 564, 573], ["the MgATP", "TEST", 589, 598], ["folate coenzymes", "TEST", 626, 642], ["Mimivirus", "OBSERVATION", 10, 19], ["can cause", "UNCERTAINTY", 20, 29], ["pneumonia", "OBSERVATION", 30, 39], ["Lactobacillus casei", "ANATOMY", 543, 562]]], ["The aligned motif 42IHVTGTNG49 was located on the putative nucleotide-binding P loop (GTNGKGS) that resembles the consensus P-loop sequence found in many other adenylate and uridylate kinase (Smith and Rayment, 1996; Sun et al., 1998).", [["nucleotide", "CHEMICAL", 59, 69], ["nucleotide", "CHEMICAL", 59, 69], ["adenylate", "CHEMICAL", 160, 169], ["uridylate", "CHEMICAL", 174, 183], ["adenylate", "SIMPLE_CHEMICAL", 160, 169], ["uridylate kinase", "GENE_OR_GENE_PRODUCT", 174, 190], ["aligned motif 42IHVTGTNG49", "DNA", 4, 30], ["putative nucleotide-binding P loop", "DNA", 50, 84], ["GTNGKGS", "DNA", 86, 93], ["consensus P-loop sequence", "DNA", 114, 139], ["uridylate kinase", "PROTEIN", 174, 190], ["the consensus P-loop sequence", "TEST", 110, 139]]], ["Moreover, a \u03a9 loop near the P loop binding site was also suggested to play a role in the activity of the FPGS, especially the Serine residue.", [["Serine", "CHEMICAL", 126, 132], ["FPGS", "GENE_OR_GENE_PRODUCT", 105, 109], ["\u03a9 loop", "PROTEIN", 12, 18], ["P loop binding site", "DNA", 28, 47], ["FPGS", "PROTEIN", 105, 109], ["a \u03a9 loop near the P loop binding site", "TREATMENT", 10, 47], ["the FPGS", "TEST", 101, 109], ["the Serine residue", "PROBLEM", 122, 140]]], ["Interestingly, a similarly shaped loop is also found in the SARS-CoV-2 S1-NTD adjacent to the GTNGTKR loop, formed by the insert 4 (254SSSG257) also rich in serine residues (Fig. 6c and d).ConclusionsGiven the severity and the widespread nature of the infection, it is safe to assume that the SARS-CoV-2 has a more efficient way to penetrate and infect cells.", [["cells", "ANATOMY", 353, 358], ["SARS", "DISEASE", 60, 64], ["infection", "DISEASE", 252, 261], ["SARS", "DISEASE", 293, 297], ["serine", "CHEMICAL", 157, 163], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 60, 73], ["GTNGTKR", "GENE_OR_GENE_PRODUCT", 94, 101], ["serine", "AMINO_ACID", 157, 163], ["SARS-CoV-2", "ORGANISM", 293, 303], ["cells", "CELL", 353, 358], ["SARS-CoV-2 S1", "PROTEIN", 60, 73], ["NTD", "PROTEIN", 74, 77], ["GTNGTKR loop", "PROTEIN", 94, 106], ["a similarly shaped loop", "PROBLEM", 15, 38], ["the SARS", "TEST", 56, 64], ["CoV", "TEST", 65, 68], ["NTD", "PROBLEM", 74, 77], ["serine residues", "TREATMENT", 157, 172], ["the severity", "PROBLEM", 206, 218], ["the infection", "PROBLEM", 248, 261], ["the SARS", "TEST", 289, 297], ["infect cells", "PROBLEM", 346, 358], ["similarly", "OBSERVATION_MODIFIER", 17, 26], ["shaped", "OBSERVATION_MODIFIER", 27, 33], ["loop", "OBSERVATION", 34, 38], ["SARS", "OBSERVATION", 60, 64], ["CoV", "ANATOMY", 65, 68], ["GTNGTKR loop", "ANATOMY", 94, 106], ["serine residues", "OBSERVATION", 157, 172], ["widespread", "OBSERVATION_MODIFIER", 227, 237], ["infection", "OBSERVATION", 252, 261], ["infect cells", "OBSERVATION", 346, 358]]], ["Besides, based on the comparison of the SARS-CoV-2 and SARS-CoV receptor-binding domains, it seems that SARS-CoV-2 evolved in a way that allowed it to maintain and enhance the binding of the ACE2 receptor via its S1-CTD, but also acquired a different S1-NTD that according to our analysis might bind other receptors (protein or sugar receptor).", [["SARS", "DISEASE", 40, 44], ["sugar", "CHEMICAL", 328, 333], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 191, 204], ["S1-CTD", "GENE_OR_GENE_PRODUCT", 213, 219], ["sugar receptor", "GENE_OR_GENE_PRODUCT", 328, 342], ["SARS-CoV-2 and SARS-CoV receptor-binding domains", "PROTEIN", 40, 88], ["ACE2 receptor", "PROTEIN", 191, 204], ["S1", "PROTEIN", 213, 215], ["CTD", "PROTEIN", 216, 219], ["S1", "PROTEIN", 251, 253], ["NTD", "PROTEIN", 254, 257], ["protein or sugar receptor", "PROTEIN", 317, 342], ["SARS-CoV", "SPECIES", 55, 63], ["the SARS", "TEST", 36, 44], ["CoV", "TEST", 45, 48], ["SARS", "PROBLEM", 55, 59], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["our analysis", "TEST", 276, 288]]], ["More precisely, the acquisition of the GTNGTKR motif, found at the active sites of structural and nonstructural proteins of other viruses and organisms, might allow the SARS-CoV-2 to recognize other receptors/co-receptors besides the ACE2.ConclusionsMoreover, our results suggest that the apparition of the GTNGTKR motif points more toward an evolutionary trait of the SARS-CoV-2 rather than the hypothesis of an engineered virus; Under functional constraints, proteins tend to evolve in a way that their tertiary structures could perform the needed functions regardless of the changes in their primary sequences (Goldstein, 2008; Siltberg-Liberles et al., 2011; Worth et al., 2009) and the two main factors driving the evolution of the S proteins are the need for better adaptation to the host receptors and the need to evade the immune system of the host to ensure better infectivity (Li, 2015; Li, 2016).", [["immune system", "ANATOMY", 831, 844], ["SARS", "DISEASE", 369, 373], ["GTNGTKR", "GENE_OR_GENE_PRODUCT", 39, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 169, 179], ["ACE2", "GENE_OR_GENE_PRODUCT", 234, 238], ["GTNGTKR", "GENE_OR_GENE_PRODUCT", 307, 314], ["SARS-CoV-2", "ORGANISM", 369, 379], ["GTNGTKR motif", "DNA", 39, 52], ["structural and nonstructural proteins", "PROTEIN", 83, 120], ["co-receptors", "PROTEIN", 209, 221], ["ACE2", "PROTEIN", 234, 238], ["GTNGTKR motif", "DNA", 307, 320], ["S proteins", "PROTEIN", 737, 747], ["host receptors", "PROTEIN", 790, 804], ["the GTNGTKR motif", "TEST", 35, 52], ["structural and nonstructural proteins of other viruses", "PROBLEM", 83, 137], ["organisms", "PROBLEM", 142, 151], ["the SARS", "TEST", 165, 173], ["the GTNGTKR motif points", "PROBLEM", 303, 327], ["the SARS", "TEST", 365, 373], ["CoV", "TEST", 374, 377], ["an engineered virus", "PROBLEM", 410, 429], ["the S proteins", "PROBLEM", 733, 747], ["the host receptors", "TREATMENT", 786, 804], ["engineered virus", "OBSERVATION", 413, 429]]], ["Therefore, it is more plausible to assume that the SARS-CoV-2 acquired the GTNGTKR motif during its evolutionary parkour under functional constraints.", [["SARS", "DISEASE", 51, 55], ["SARS-CoV-2", "ORGANISM", 51, 61], ["GTNGTKR", "GENE_OR_GENE_PRODUCT", 75, 82], ["SARS-CoV-2", "DNA", 51, 61], ["GTNGTKR motif", "DNA", 75, 88], ["the SARS", "TEST", 47, 55], ["CoV", "TEST", 56, 59], ["the GTNGTKR motif", "TREATMENT", 71, 88], ["functional constraints", "OBSERVATION", 127, 149]]], ["As for the exact mechanism of acquisition and the origin of this motif, we believe that further investigations are needed not only in the context of the SARS-CoV-2 infection but as a pertinent motif for viral proteins activity in general.Sequences retrieval and alignment ::: Material and methodsA total of 1652 SARS-CoV-2 S protein complete sequences available at the NCBI Virus portal were retrieved.", [["SARS", "DISEASE", 153, 157], ["infection", "DISEASE", 164, 173], ["SARS", "DISEASE", 312, 316], ["SARS-CoV-2", "ORGANISM", 153, 163], ["Virus portal", "MULTI-TISSUE_STRUCTURE", 374, 386], ["viral proteins", "PROTEIN", 203, 217], ["SARS-CoV-2 S protein complete sequences", "DNA", 312, 351], ["SARS-CoV", "SPECIES", 153, 161], ["SARS-CoV", "SPECIES", 312, 320], ["further investigations", "TEST", 88, 110], ["the SARS-CoV-2 infection", "PROBLEM", 149, 173], ["viral proteins activity", "PROBLEM", 203, 226], ["Sequences retrieval", "TEST", 238, 257], ["SARS", "TEST", 312, 316], ["CoV", "TEST", 317, 320], ["S protein complete sequences", "TEST", 323, 351], ["SARS", "OBSERVATION", 153, 157], ["infection", "OBSERVATION", 164, 173], ["portal", "ANATOMY", 380, 386]]], ["The sequences of SARS-CoV GC02 isolate (AY390556) and two bat isolates: a bat SARS-like coronavirus (MG772934) and the recently isolated RatG13 bat coronavirus (MN996532) were also retrieved, and their S glycoproteins were compared to that of the SARS-CoV-2 (RefSeq: YP_009724390.1).Sequences retrieval and alignment ::: Material and methodsFirst, we performed a multiple alignment of the S proteins of the 1652 SARS-CoV-2 strains to see if any dissimilarities were present and analyzed the occurrence of mutations in comparison to the reference sequence.", [["SARS-like coronavirus", "DISEASE", 78, 99], ["SARS-CoV GC02", "ORGANISM", 17, 30], ["bat SARS-like coronavirus", "ORGANISM", 74, 99], ["MG772934", "ORGANISM", 101, 109], ["RatG13 bat coronavirus", "ORGANISM", 137, 159], ["MN996532", "CANCER", 161, 169], ["SARS-CoV-2", "ORGANISM", 412, 422], ["S glycoproteins", "PROTEIN", 202, 217], ["S proteins", "PROTEIN", 389, 399], ["coronavirus", "SPECIES", 88, 99], ["RatG13 bat coronavirus", "SPECIES", 137, 159], ["SARS-CoV GC02", "SPECIES", 17, 30], ["RatG13 bat coronavirus", "SPECIES", 137, 159], ["SARS-CoV", "SPECIES", 247, 255], ["The sequences", "TEST", 0, 13], ["SARS", "TEST", 17, 21], ["CoV GC02 isolate", "TEST", 22, 38], ["two bat isolates", "TEST", 54, 70], ["a bat SARS", "PROBLEM", 72, 82], ["coronavirus", "PROBLEM", 88, 99], ["their S glycoproteins", "TEST", 196, 217], ["the SARS", "TEST", 243, 251], ["CoV", "TEST", 252, 255], ["Sequences retrieval", "TEST", 283, 302], ["the S proteins", "TEST", 385, 399], ["CoV", "TEST", 417, 420], ["mutations", "PROBLEM", 505, 514]]], ["Next, we compared the similarity of the S glycoprotein of the SARS-CoV-2 (RefSeq: YP_009724390.1) to that of the selected 4 related coronaviruses strains mentioned above: 1) aligning the full-length proteins of the 4 stains altogether; 2) aligning the full-length SARS-CoV-2 S protein to that of each of the related strains separately; 3) aligning portions (100aa windows) of the SARS-CoV-2 S protein by to that of each of the related strains separately.Sequences retrieval and alignment ::: Material and methodsAll sequence alignments were performed using the Muscle algorithm implemented in the MEGA-X software or BLASTp suite of the U.S. National Library of Medicine.Sequences retrieval and alignment ::: Material and methodsFor the search of motifs similar to the GTNGTKR motif in the Protein Data Bank deposited structures, the BLASTp suite of the U.S. National Library of Medicine was used by adjusting parameters to search for a short input sequence.3D structure models ::: Material and methodsThree crystal structures of the SARS-CoV-2 Spike protein (containing the S1-NTD) were retrieved from the Protein Data Bank (PDB ID: 6vyb, 6vxx, and 6vsb).", [["SARS-CoV-2", "ORGANISM", 62, 72], ["coronaviruses", "ORGANISM", 132, 145], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 380, 392], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 1033, 1043], ["6vxx", "GENE_OR_GENE_PRODUCT", 1139, 1143], ["6vsb", "GENE_OR_GENE_PRODUCT", 1149, 1153], ["S glycoprotein", "PROTEIN", 40, 54], ["SARS-CoV-2", "DNA", 62, 72], ["full-length proteins", "PROTEIN", 187, 207], ["full-length SARS-CoV-2 S protein", "PROTEIN", 252, 284], ["SARS-CoV-2 S protein", "PROTEIN", 380, 400], ["GTNGTKR motif", "DNA", 768, 781], ["short input sequence", "DNA", 936, 956], ["SARS-CoV-2 Spike protein", "PROTEIN", 1033, 1057], ["S1", "PROTEIN", 1074, 1076], ["NTD", "PROTEIN", 1077, 1080], ["Protein Data Bank", "PROTEIN", 1106, 1123], ["6vyb", "PROTEIN", 1133, 1137], ["6vxx", "PROTEIN", 1139, 1143], ["6vsb", "PROTEIN", 1149, 1153], ["SARS-CoV", "SPECIES", 62, 70], ["the SARS", "TEST", 58, 66], ["CoV", "TEST", 67, 70], ["the selected 4 related coronaviruses strains", "PROBLEM", 109, 153], ["the full-length SARS", "TEST", 248, 268], ["CoV", "TEST", 269, 272], ["S protein", "TEST", 275, 284], ["aa windows", "TEST", 361, 371], ["the SARS", "TEST", 376, 384], ["CoV", "TEST", 385, 388], ["Sequences retrieval", "TEST", 454, 473], ["All sequence alignments", "TEST", 512, 535], ["the Muscle algorithm", "TEST", 557, 577], ["Sequences retrieval", "TEST", 670, 689], ["the GTNGTKR motif", "TEST", 764, 781], ["a short input sequence", "TEST", 934, 956], ["the SARS", "TEST", 1029, 1037], ["CoV", "TEST", 1038, 1041], ["Spike protein", "TEST", 1044, 1057], ["6vyb", "TEST", 1133, 1137], ["6vxx", "TEST", 1139, 1143], ["Muscle", "ANATOMY", 561, 567], ["SARS", "OBSERVATION", 1033, 1037]]], ["Since all of these structures lacks some fragments of interest (especially the GTNGTKR motif), the sequence of S glycoprotein of the SARS-CoV-2 (Reference ID: YP_009724390.1) was submitted to I-Tasser (https://zhanglab.ccmb.med.umich.edu/I-TASSER/) and Swiss-Model (https://swissmodel.expasy.org/) servers for the prediction of complete 3D structure models (Waterhouse et al., 2018; Yang and Zhang, 2015).", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 111, 125], ["GTNGTKR motif", "DNA", 79, 92], ["S glycoprotein", "PROTEIN", 111, 125], ["some", "OBSERVATION_MODIFIER", 36, 40], ["fragments", "OBSERVATION_MODIFIER", 41, 50]]], ["The quality of the predicted 3D structures was evaluated using the MolProbity server (http://molprobity.biochem.duke.edu) (Williams et al., 2018) and the best models were selected for the analysis.Structural alignment and analysis ::: Material and methodsAll structural alignments were performed using the Dali server (http://ekhidna2.biocenter.helsinki.fi/dali/) (Holm, 2020).", [["the analysis", "TEST", 184, 196], ["structural alignments", "OBSERVATION", 259, 280]]], ["The PyMOL Molecular Graphics System, Version 2.0 Schr\u00f6dinger, LLC was used for 3D structure visualization and analysis, and the preparation of all the figures containing 3D structures.CRediT authorship contribution statement", [["3D structure visualization", "TEST", 79, 105], ["analysis", "TEST", 110, 118], ["LLC", "ANATOMY", 62, 65]]]], "5405330f85660bb35ec960a144e904c54c4c67a7": [["This technique like other data mining techniques has been integrated into a bunch of open-source tools, such as WEKA [11] , TANAGRA [10] , fpm [4] and DM-MCDA [1] .", [["fpm [4]", "SIMPLE_CHEMICAL", 139, 146], ["This technique", "TREATMENT", 0, 14]]], ["Most public tools are desktop-based and don't provide intuitive use for the data mining community, hence reduce the chance of re-usability and/or upgradability by developers.IntroductionIn this demo, we (1) implement a baseline approach to extract association rules from given data, (2) propose an approach based on multiple criteria analysis to rank the extracted rules according to the decision maker's preferences, (3) demonstrate the idea of association rules mining through road accident data as a case study, where the dataset containing information on location, drivers, and the accident characteristics, the vehicles involved and victims [2] , and (4) present the preliminary results of the proposed system.", [["an approach", "TREATMENT", 295, 306], ["multiple criteria analysis", "TEST", 316, 342], ["a case study", "TEST", 501, 513]]], ["Figure 1 shows our framework architecture which includes three main modules: data preprocessing, association rules mining, and multiple criteria analysis.", [["multiple criteria analysis", "TEST", 127, 153]]], ["Afterward, we use multiple criteria analysis to rank the relevant rules based on user preferences and assign the result to different relevant categories.", [["multiple criteria analysis", "TEST", 18, 44]]], ["The system was implemented on R [7] and r shiny [9] , providing interactive and user-friendly interfaces for different modules.", [["different modules", "PROBLEM", 109, 126]]], ["The system can be extended with new data sets on demand, rendering information retrieval and query linked data using SPARQL queries (data linkage).Quality Measurement of Association RulesIn order to select interesting rules from the large set of extracted rules, constraints on various measures of significance and interest are used [5] .", [["large", "OBSERVATION_MODIFIER", 233, 238]]], ["Due to page limitations, we refer readers to [5] for further references.Multiple Criteria Analysis (MCA)MCA is a sub-field of operational research, and management science, dedicated to the development of decision support tools in order to solve complex decision problems involving multiple criteria objectives.", [["Multiple Criteria Analysis", "TEST", 72, 98], ["MCA", "ANATOMY", 104, 107]]], ["When modeling a real decision problem using multiple criteria analysis, several issues [8] can be considered: choice, sorting and ranking.", [["multiple criteria analysis", "TEST", 44, 70]]], ["In our context of a large number of extracted rules, we apply the multiple criteria ranking precisely, in a method called ELECTRE (ELimination and Choice Expressing REality) TRI [5, 6] .", [["large", "OBSERVATION_MODIFIER", 20, 25], ["number", "OBSERVATION_MODIFIER", 26, 32]]], ["The partial concordance indices c j (a, b h ): (it represents the degree of concordance with the hypothesis of outranking of a over b where a is rule and b is profile):Multiple Criteria Analysis (MCA)2.", [["partial", "OBSERVATION_MODIFIER", 4, 11], ["MCA", "ANATOMY", 196, 199]]], ["The discordance indices d j (a, b h ): (it represents the degree of discordance with the hypothesis that a outranks b on elementary criterion g j ).Multiple Criteria Analysis (MCA)3.", [["Multiple Criteria Analysis", "TEST", 148, 174], ["MCA", "ANATOMY", 176, 179]]], ["The credibility indices \u03c3(a, b h ): (it represents the credibility of the outranking of a over b on criterion j):Multiple Criteria Analysis (MCA)where, K j is the weight of criteria j, C j (a, b h ) is the partial concordance index of criteria j, andMultiple Criteria Analysis (MCA)The pseudo-code of the proposed algorithm takes as input a list of extracted rules (a 1 , a 2 ,...,a n ), a list of quality measurement (support, confidence,lift), a list of profiles (b 1 , b 2 ) and the preference (p), indifference (q), veto (v), cutting level \u03bb thresholds.", [["The credibility indices", "TEST", 0, 23], ["Multiple Criteria Analysis", "TEST", 113, 139], ["Multiple Criteria Analysis", "TEST", 250, 276], ["the proposed algorithm", "TREATMENT", 301, 323], ["MCA", "ANATOMY", 141, 144]]], ["It computes the concordance, discordance and credibility indices for each rule under a given quality measurement.", [["credibility indices", "TEST", 45, 64]]], ["After iterating all extracted rules, the algorithm compares the credibility indices \u03c3(a, b h ) and the default value of \u03bb (0.7) then generates a list of relevant rules [5] .DemonstrationFirstly, users are allowed to upload a new CSV dataset or use SPARQL query to retrieve data from linked data (Dbpedia, wikidata, etc.).", [["the algorithm", "TEST", 37, 50], ["the default value", "TEST", 99, 116]]], ["As shown in Fig. 2 , the left panel displays data file input for a dataset (support CSV file) and parameter settings for some thresholds (attributes, minsup, minconf, etc).", [["a dataset (support CSV file", "TREATMENT", 65, 92], ["parameter settings", "TREATMENT", 98, 116], ["some thresholds", "PROBLEM", 121, 136], ["Fig", "OBSERVATION", 12, 15], ["left", "ANATOMY_MODIFIER", 25, 29]]], ["Secondly, users extract association rules and the main panel displays seven different tabs to characterize association rules across data sources and their summaries information.", [["the main panel", "TEST", 46, 60]]], ["Summary tab shows the summary of rules mining algorithm, ScatterP lot tab shows the scatter-plot of extracted rules, F requentItemsets tab shows frequent itemsets from data, and the rest of tabs shows interactive techniques to visualize association rules.", [["rules mining algorithm", "TEST", 33, 55], ["ScatterP lot tab", "TEST", 57, 73], ["interactive techniques", "TREATMENT", 201, 223]]], ["The parameters configuration panel is displayed on the left side including method choice and the list of association rules with quality measurement.", [["The parameters configuration panel", "TEST", 0, 34], ["quality measurement", "TEST", 128, 147], ["left", "ANATOMY_MODIFIER", 55, 59]]], ["The main panel presents different steps for ELECTRE TRI (Eqs (1)-(3) ), afterward, user can move to the bottom panels and clicks 'Decision matrix' tab to see the performance table of association rules associated with predefined thresholds (Table 2 ) and quality measurement.", [["TRI", "CHEMICAL", 52, 55], ["The main panel", "TEST", 0, 14], ["ELECTRE TRI (Eqs", "TEST", 44, 60], ["quality measurement", "TEST", 254, 273], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Furthermore, user can move to other tabs for different computations and assign association rules to different categories (The set of categories to which the rules must be assigned to is completely ordered from the best to the worst), the rules in the first category will be the most relevant ones to user preferences (Table 1) .", [["different computations", "PROBLEM", 45, 67]]], ["Association rules mining algorithms produce a large number of rules.", [["large", "OBSERVATION_MODIFIER", 46, 51], ["number", "OBSERVATION_MODIFIER", 52, 58]]], ["Based on this study, the integration of multiple criteria analysis within the association rules process performs well and produces relevant rules.", [["this study", "TEST", 9, 19], ["multiple criteria analysis", "TEST", 40, 66], ["multiple", "OBSERVATION_MODIFIER", 40, 48]]], ["After eliminating the rules users are not interested in, eleven significant rules were obtained in this case study (R1, R2, R5, R10, R15, R20, R30, R31, R15, R22, R13).ConclusionThis demo paper presents an open-source software for information retrieval by combining data mining especially association rules analysis and multiple criteria analysis.", [["R13", "CELL_LINE", 163, 166], ["this case study", "TEST", 99, 114], ["R5", "TEST", 124, 126], ["multiple criteria analysis", "TEST", 320, 346], ["R5", "ANATOMY_MODIFIER", 124, 126]]], ["Afterward, users obtain association rules extracted by the Apriori algorithm and the relevant rules are chosen using multiple criteria analysis approach.", [["the Apriori algorithm", "TEST", 55, 76]]], ["In the future, we aim to extend the system with more data mining algorithms in the context of big data.", [["big data", "TEST", 94, 102]]]], "3aeb264d986c987ced699cb2c711eb022b697d5a": [["IntroductionThe apparent lack of pattern of composition and distribution of bases in DNA sequences have been one of the enduring problems of molecular biology.", [["DNA", "CELLULAR_COMPONENT", 85, 88], ["DNA sequences", "DNA", 85, 98], ["composition and distribution of bases in DNA sequences", "PROBLEM", 44, 98], ["composition", "OBSERVATION", 44, 55], ["bases", "ANATOMY_MODIFIER", 76, 81]]], ["Chargaff's rule provided a clear relationship between the numbers of guanines and cytosines, and between adenines and thymines in duplex DNA sequences, understood well by the Watson-Crick model.", [["guanines", "CHEMICAL", 69, 77], ["cytosines", "CHEMICAL", 82, 91], ["adenines", "CHEMICAL", 105, 113], ["guanines", "CHEMICAL", 69, 77], ["cytosines", "CHEMICAL", 82, 91], ["adenines", "CHEMICAL", 105, 113], ["thymines", "CHEMICAL", 118, 126], ["guanines", "SIMPLE_CHEMICAL", 69, 77], ["cytosines", "SIMPLE_CHEMICAL", 82, 91], ["adenines", "SIMPLE_CHEMICAL", 105, 113], ["thymines", "SIMPLE_CHEMICAL", 118, 126], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["duplex DNA sequences", "DNA", 130, 150], ["guanines and cytosines", "TREATMENT", 69, 91], ["adenines", "TREATMENT", 105, 113], ["duplex DNA sequences", "TEST", 130, 150]]], ["However, no clear relationship has been found as yet between the occurrences of these four bases in an individual strand of a gene sequence, although much work have been done on understanding nucleotide frequencies and base distributions in DNA sequences.", [["nucleotide", "CHEMICAL", 192, 202], ["nucleotide", "CHEMICAL", 192, 202], ["DNA", "CELLULAR_COMPONENT", 241, 244], ["DNA sequences", "DNA", 241, 254], ["a gene sequence", "TEST", 124, 139], ["nucleotide frequencies and base distributions in DNA sequences", "PROBLEM", 192, 254], ["no", "UNCERTAINTY", 9, 11], ["clear", "OBSERVATION", 12, 17], ["base", "ANATOMY_MODIFIER", 219, 223]]], ["To cite a few examples, Sueoka [1] proposed a unitary theory based on genetic and evolutionary considerations which attempted to account for the main characteristics of the distribution of DNA base composition in nature.", [["DNA", "CELLULAR_COMPONENT", 189, 192], ["DNA base composition", "PROBLEM", 189, 209], ["DNA", "OBSERVATION", 189, 192], ["base", "OBSERVATION_MODIFIER", 193, 197], ["composition", "OBSERVATION_MODIFIER", 198, 209]]], ["The author considered the GC content of DNA sequences of organisms and mutations of GC base pairs to AT base pairs and vice versa over many generations from which a distribution function of the GC content of DNA molecules at equilibrium was obtained based on assumptions of rather uniform mutation and selection pressures affecting base pair conversions.IntroductionGoldman and Yang [2] proposed a codon-based model for the evolution of protein-coding DNA sequences using a Markov process to describe substitutions between codons.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["DNA", "CELLULAR_COMPONENT", 452, 455], ["DNA sequences", "DNA", 40, 53], ["AT base pairs", "DNA", 101, 114], ["DNA molecules", "PROTEIN", 208, 221], ["protein-coding DNA sequences", "DNA", 437, 465], ["DNA sequences of organisms", "PROBLEM", 40, 66], ["mutations of GC base pairs", "PROBLEM", 71, 97], ["DNA molecules", "PROBLEM", 208, 221], ["rather uniform mutation", "PROBLEM", 274, 297], ["base pair conversions", "TREATMENT", 332, 353], ["a codon", "TREATMENT", 396, 403], ["coding DNA sequences", "PROBLEM", 445, 465], ["a Markov process", "TREATMENT", 472, 488], ["substitutions between codons", "TREATMENT", 501, 529]]], ["They used codon level information to model synonymous and asynonymous nucleotide substitution applicable to homologous sequences with no insertion/deletion gaps or with gaps removed.", [["nucleotide", "CHEMICAL", 70, 80], ["nucleotide", "CHEMICAL", 70, 80], ["asynonymous nucleotide substitution", "TREATMENT", 58, 93], ["homologous sequences", "TEST", 108, 128], ["insertion/deletion gaps", "TREATMENT", 137, 160]]], ["A 61661 matrix of codon substitution rates (excluding the three stop codons) is used, assuming that mutations occur at the three codon positions independently and only single-nucleotide substitutions are permitted to occur at any instant.", [["nucleotide", "CHEMICAL", 175, 185], ["nucleotide", "CHEMICAL", 175, 185], ["codon positions", "DNA", 129, 144], ["codon substitution rates", "TREATMENT", 18, 42], ["mutations", "PROBLEM", 100, 109], ["single-nucleotide substitutions", "TREATMENT", 168, 199]]], ["Using several constraints and refinements on the nucleotide substitution rates, the transition/ transversion bias and amino acid differences, they show that their codon based model gives better phylogenies than simple nucleotide substitution model.", [["nucleotide", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 118, 128], ["nucleotide", "CHEMICAL", 218, 228], ["nucleotide", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 118, 128], ["nucleotide", "CHEMICAL", 218, 228], ["amino acid", "AMINO_ACID", 118, 128], ["the nucleotide substitution rates", "TREATMENT", 45, 78], ["the transition/ transversion bias", "TREATMENT", 80, 113], ["amino acid differences", "PROBLEM", 118, 140], ["simple nucleotide substitution model", "TREATMENT", 211, 247]]], ["However, the possible patterns arising from this model is very large and computationally very slow requiring Monte Carlo simulations, maximum likelihood methods and other approximations to arrive at quantitative results.", [["very", "OBSERVATION_MODIFIER", 58, 62], ["large", "OBSERVATION", 63, 68]]], ["While the model is useful for pairwise distance measures and for phylogenies, a relationship defining base composition in a DNA sequence is not clearly realised.IntroductionIn a recent paper, Qi Ding et al [3] formulated an approach to determine a linear regression model for DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 124, 127], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["DNA sequence", "DNA", 124, 136], ["DNA sequences", "DNA", 276, 289], ["pairwise distance measures", "TEST", 30, 56], ["a DNA sequence", "TEST", 122, 136], ["Qi Ding et al [3", "TREATMENT", 192, 208], ["an approach", "TREATMENT", 221, 232], ["DNA sequences", "TEST", 276, 289]]], ["By regarding a DNA primary sequence as a random process in time and defining the nucleotides' random distribution functions in three ways based on chemical structures they proposed two methods to measure their similarities.", [["nucleotides", "CHEMICAL", 81, 92], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["DNA primary sequence", "DNA", 15, 35], ["the nucleotides' random distribution functions in three ways", "PROBLEM", 77, 137]]], ["Relating the random distribution functions by a linear regression equation enabled them to construct six new models to analyse the DNA sequences and quantify their similarities and dissimilarities.", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA sequences", "DNA", 131, 144], ["a linear regression equation", "PROBLEM", 46, 74], ["the DNA sequences", "TEST", 127, 144]]], ["The optimal model can be chosen based on the amount of information contained or lost in the process.IntroductionSeveral other studies have also focussed on nucleotide asymmetries in DNA sequences to gain an insight into correlations, if any, in base composition and distribution.", [["nucleotide", "CHEMICAL", 156, 166], ["nucleotide", "CHEMICAL", 156, 166], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["DNA sequences", "DNA", 182, 195], ["IntroductionSeveral other studies", "TEST", 100, 133], ["nucleotide asymmetries in DNA sequences", "PROBLEM", 156, 195], ["base", "ANATOMY_MODIFIER", 245, 249], ["distribution", "OBSERVATION_MODIFIER", 266, 278]]], ["Arnold et al [4] used tetranucleotide frequencies in a third order Markov chain to predict the frequencies of longer oligonucleotides in the yeast genome and observed that the oligonucleotide frequencies depended strongly on base composition.", [["yeast genome", "DNA", 141, 153], ["yeast", "SPECIES", 141, 146], ["yeast", "SPECIES", 141, 146], ["tetranucleotide frequencies", "TREATMENT", 22, 49], ["a third order Markov chain", "TREATMENT", 53, 79], ["longer oligonucleotides", "PROBLEM", 110, 133], ["the oligonucleotide frequencies", "PROBLEM", 172, 203], ["yeast genome", "OBSERVATION", 141, 153]]], ["Freeman [5] considered several prokaryotic DNA genomic sequences and found, from base composition asymmetries like purine excess over pyrimidines and coding strand excess, that the global minima of the purine excesses correlated with the origin of replication, and the maxima with the likely terminus for prokaryotic genomes and that such a prominent correlation between the purine excess and replication direction probably leads to excess pyrimidine accumulation in the sense strand and accordingly should increase the less mutationally vulnerable purine content of the coding strand.", [["purine", "CHEMICAL", 115, 121], ["pyrimidines", "CHEMICAL", 134, 145], ["purine", "CHEMICAL", 202, 208], ["purine", "CHEMICAL", 375, 381], ["pyrimidine", "CHEMICAL", 440, 450], ["purine", "CHEMICAL", 549, 555], ["purine", "CHEMICAL", 115, 121], ["pyrimidines", "CHEMICAL", 134, 145], ["purine", "CHEMICAL", 202, 208], ["purine", "CHEMICAL", 375, 381], ["pyrimidine", "CHEMICAL", 440, 450], ["purine", "CHEMICAL", 549, 555], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["purine", "SIMPLE_CHEMICAL", 115, 121], ["pyrimidines", "SIMPLE_CHEMICAL", 134, 145], ["purine", "SIMPLE_CHEMICAL", 202, 208], ["purine", "SIMPLE_CHEMICAL", 375, 381], ["pyrimidine", "SIMPLE_CHEMICAL", 440, 450], ["purine", "SIMPLE_CHEMICAL", 549, 555], ["prokaryotic DNA genomic sequences", "DNA", 31, 64], ["prokaryotic genomes", "DNA", 305, 324], ["several prokaryotic DNA genomic sequences", "PROBLEM", 23, 64], ["base composition asymmetries", "PROBLEM", 81, 109], ["purine excess over pyrimidines", "PROBLEM", 115, 145], ["coding strand excess", "PROBLEM", 150, 170], ["prokaryotic genomes", "PROBLEM", 305, 324], ["the purine excess", "PROBLEM", 371, 388], ["excess pyrimidine accumulation", "PROBLEM", 433, 463], ["purine excess", "OBSERVATION", 115, 128], ["strand excess", "OBSERVATION", 157, 170], ["purine excesses", "OBSERVATION", 202, 217], ["replication", "OBSERVATION", 248, 259], ["prokaryotic genomes", "OBSERVATION", 305, 324], ["purine excess", "OBSERVATION", 375, 388], ["pyrimidine accumulation", "OBSERVATION", 440, 463]]], ["Prusak and Grzybowski [6] observed that there is a strong non-random distribution of nucleotides in the cytochrome b sequence in several species with the highest differences at the third codon position which is also the codon position of the strongest compositional bias; some species like quail, frog, python and elk appeared to prefer C over A in the light DNA strand whereas species belonging to the artiodactyls contained fewer pyrimidines compared to other species investigated.IntroductionSuch studies serve to also highlight the complexity of base arrangements in a DNA sequence and the difficulties in finding any inherent pattern or signal sequences in such arrangements, especially in a character based representation of the hundreds and thousands of nucleotides comprising the sequences.", [["pyrimidines", "CHEMICAL", 432, 443], ["nucleotides", "CHEMICAL", 85, 96], ["pyrimidines", "CHEMICAL", 432, 443], ["nucleotides", "CHEMICAL", 761, 772], ["cytochrome b", "GENE_OR_GENE_PRODUCT", 104, 116], ["quail", "ORGANISM", 290, 295], ["frog", "ORGANISM_SUBDIVISION", 297, 301], ["DNA", "CELLULAR_COMPONENT", 359, 362], ["artiodactyls", "SIMPLE_CHEMICAL", 403, 415], ["DNA", "CELLULAR_COMPONENT", 573, 576], ["cytochrome b sequence", "DNA", 104, 125], ["third codon position", "DNA", 181, 201], ["light DNA strand", "DNA", 353, 369], ["DNA sequence", "DNA", 573, 585], ["quail", "SPECIES", 290, 295], ["quail", "SPECIES", 290, 295], ["elk", "SPECIES", 314, 317], ["Prusak", "TEST", 0, 6], ["a strong non-random distribution of nucleotides", "PROBLEM", 49, 96], ["the cytochrome b sequence", "TEST", 100, 125], ["several species", "PROBLEM", 129, 144], ["some species", "PROBLEM", 272, 284], ["the artiodactyls", "TREATMENT", 399, 415], ["pyrimidines", "TREATMENT", 432, 443], ["IntroductionSuch studies", "TEST", 483, 507], ["a DNA sequence", "TEST", 571, 585], ["nucleotides", "TREATMENT", 761, 772], ["the sequences", "TEST", 784, 797], ["strong", "OBSERVATION_MODIFIER", 51, 57], ["non-random", "OBSERVATION_MODIFIER", 58, 68], ["distribution", "OBSERVATION_MODIFIER", 69, 81], ["nucleotides", "OBSERVATION", 85, 96], ["highest", "OBSERVATION_MODIFIER", 154, 161]]], ["However, a graphical representation can be expected to provide visual clues to any inherent pattern or regularity as distinct from a purely random distribution of the bases which could be expected to generate a corresponding random distribution in the representative plot.", [["distinct", "OBSERVATION_MODIFIER", 117, 125], ["bases", "ANATOMY_MODIFIER", 167, 172]]], ["Indeed, a purine-pyrimidine sequence map proposed by Peng et al [7] provided a visual rendition of the growth of purine and pyrimidine numbers in a DNA sequence, which was interpreted by the authors as indicative of an inherent fractal nature in the purine-pyrimidine structure of the DNA sequences.", [["purine", "CHEMICAL", 10, 16], ["pyrimidine", "CHEMICAL", 17, 27], ["purine", "CHEMICAL", 113, 119], ["pyrimidine", "CHEMICAL", 124, 134], ["purine", "CHEMICAL", 250, 256], ["pyrimidine", "CHEMICAL", 257, 267], ["purine", "CHEMICAL", 10, 16], ["pyrimidine", "CHEMICAL", 17, 27], ["purine", "CHEMICAL", 113, 119], ["pyrimidine", "CHEMICAL", 124, 134], ["purine", "CHEMICAL", 250, 256], ["pyrimidine", "CHEMICAL", 257, 267], ["purine", "SIMPLE_CHEMICAL", 10, 16], ["purine", "SIMPLE_CHEMICAL", 113, 119], ["pyrimidine", "SIMPLE_CHEMICAL", 124, 134], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["purine", "SIMPLE_CHEMICAL", 250, 256], ["DNA", "CELLULAR_COMPONENT", 285, 288], ["DNA sequence", "DNA", 148, 160], ["DNA sequences", "DNA", 285, 298], ["a purine-pyrimidine sequence map", "TREATMENT", 8, 40], ["pyrimidine numbers", "TEST", 124, 142], ["a DNA sequence", "TEST", 146, 160], ["the DNA sequences", "TEST", 281, 298], ["fractal", "OBSERVATION", 228, 235]]], ["The chaos generator representation of Jeffreys [8] with its double-scoop depletion pattern reflected largely the abundance, or sparseness, of various dinucleotides and higher combinations, and also showed characteristic variations for different classes of organisms.IntroductionGraphical representations of DNA sequences assigning the four individual nucleotides to designated axes on a Cartesian grid provide a more direct visual indication of the progression of nucleotides in a sequence, akin, in some respects, to the Wilson cloud chamber for particle tracks.", [["dinucleotides", "CHEMICAL", 150, 163], ["nucleotides", "CHEMICAL", 351, 362], ["nucleotides", "CHEMICAL", 464, 475], ["DNA", "CELLULAR_COMPONENT", 307, 310], ["DNA sequences", "DNA", 307, 320], ["its double-scoop depletion pattern", "TREATMENT", 56, 90], ["sparseness", "PROBLEM", 127, 137], ["various dinucleotides", "PROBLEM", 142, 163], ["characteristic variations", "PROBLEM", 205, 230], ["different classes of organisms", "PROBLEM", 235, 265], ["DNA sequences", "TEST", 307, 320], ["the progression of nucleotides", "PROBLEM", 445, 475], ["abundance", "OBSERVATION_MODIFIER", 113, 122]]], ["The first graphical representation of a DNA sequence was proposed by Hamori and Ruskin [9] based on a 3D Cartesian axis system that generated a visual map of the sequence of bases in a selected DNA sequence.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["DNA", "CELLULAR_COMPONENT", 194, 197], ["DNA sequence", "DNA", 40, 52], ["DNA sequence", "DNA", 194, 206], ["a DNA sequence", "TEST", 38, 52], ["a 3D Cartesian axis system", "TREATMENT", 100, 126], ["a selected DNA sequence", "TEST", 183, 206], ["bases", "ANATOMY_MODIFIER", 174, 179]]], ["A 2D representation was proposed by Gates [10] and rediscovered independently by Nandy [11] and Leong & Morgenthaler [12] , with different axes identifications for the four bases.", [["Leong & Morgenthaler", "TREATMENT", 96, 116], ["bases", "ANATOMY_MODIFIER", 173, 178]]], ["These were followed subsequently by many different approaches to render a visual representation of the DNA sequences [13, 14] , and their applications have been found to be very useful in elucidating different characteristics of DNA sequences that are not easily accessible in other ways.", [["DNA", "CELLULAR_COMPONENT", 103, 106], ["DNA", "CELLULAR_COMPONENT", 229, 232], ["DNA sequences", "DNA", 103, 116], ["DNA sequences", "DNA", 229, 242], ["the DNA sequences", "TEST", 99, 116], ["DNA sequences", "PROBLEM", 229, 242]]], ["For example, Gates [10] referred to large scale structures seen in the plots of some sequences; such structures were also reported by Nandy and Nandy [15] , and recently by Larionov et al [16] who reported, inter alia, the presence of gigantic palindromes in mouse and human chromosomal sequences.", [["chromosomal", "ANATOMY", 275, 286], ["mouse", "ORGANISM", 259, 264], ["human", "ORGANISM", 269, 274], ["gigantic palindromes", "DNA", 235, 255], ["mouse and human chromosomal sequences", "DNA", 259, 296], ["mouse", "SPECIES", 259, 264], ["human", "SPECIES", 269, 274], ["mouse", "SPECIES", 259, 264], ["human", "SPECIES", 269, 274], ["gigantic palindromes in mouse and human chromosomal sequences", "PROBLEM", 235, 296], ["gigantic palindromes", "OBSERVATION", 235, 255]]], ["Liao et al [17] have shown that 2D graphical methods that convert a DNA sequence to a series of co-ordinates and therefrom construct distance matrices can be used for computation of molecular phylogeny without need for multiple alignments; Wang et al [18] constructed a 3D representation in which a DNA sequence could be denoted mathematically and a similarity matrix constructed for multiple sequences to derive a phylogenetic tree by virtue of the fuzzy theory.", [["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["DNA sequence", "DNA", 68, 80], ["DNA sequence", "DNA", 299, 311], ["a DNA sequence", "TEST", 66, 80], ["a DNA sequence", "TEST", 297, 311]]], ["Lo et al [19] have shown using a 3D trajectory method that global views of DNA sequences can be obtained such that different types of DNA sequences can be easily distinguished and any local differences and similarities between two DNA sequences can also be easily observed.IntroductionFurthermore, numerical characterisation techniques based on graphical representations have enabled quantitative estimations of sequence similarities and dissimilarities [see review 14] .", [["DNA", "CELLULAR_COMPONENT", 75, 78], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["DNA", "CELLULAR_COMPONENT", 231, 234], ["DNA sequences", "DNA", 75, 88], ["DNA sequences", "DNA", 134, 147], ["DNA sequences", "DNA", 231, 244], ["DNA sequences", "TEST", 75, 88], ["DNA sequences", "TEST", 134, 147], ["two DNA sequences", "TEST", 227, 244], ["numerical characterisation techniques", "TEST", 298, 335]]], ["Basically there have been two approaches for numerical characterization, both of which use the graphical representation to map a DNA sequence into a set of numbers.", [["DNA", "CELLULAR_COMPONENT", 129, 132], ["DNA sequence", "DNA", 129, 141], ["numerical characterization", "TEST", 45, 71], ["a DNA sequence", "TEST", 127, 141]]], ["One approach using geometrical mapping proposed by Raychaudhury and Nandy [20] have been found to be useful for several calculations based on the 2D graphical representation [14] , and extended recently to an abstract 20D modelling for protein sequences [21] , where individual sequences are indexed by numerical descriptors.", [["geometrical mapping", "TREATMENT", 19, 38], ["protein sequences", "TEST", 236, 253]]], ["The other approach is to use matrix methods by forming ratios of graph theoretic and Euclidean distances between nodes of the graphical plots, first formulated for DNA sequences in Randic et al [22] .", [["DNA", "CELLULAR_COMPONENT", 164, 167], ["DNA sequences", "DNA", 164, 177], ["matrix methods", "TREATMENT", 29, 43], ["the graphical plots", "TEST", 122, 141], ["DNA sequences", "TEST", 164, 177]]], ["Since invariants associated with matrix formulation are well-known, individual sequences can be indexed by one or more such invariants of various orders; it is expected that these would be sufficiently characteristic of the underlying sequences to enable unique characterization.", [["matrix", "ANATOMY", 33, 39], ["matrix", "CELLULAR_COMPONENT", 33, 39], ["matrix formulation", "TREATMENT", 33, 51]]], ["This technique has been the most widely used method of choice for the researchers in this field who have defined different types of matrices to construct various invariants to describe the DNA sequences.", [["DNA", "CELLULAR_COMPONENT", 189, 192], ["DNA sequences", "DNA", 189, 202], ["the DNA sequences", "TEST", 185, 202]]], ["However, the difficulties associated with computing various parameters for very large matrices that are natural for large sequences have restricted the numerical characterizations to leading eigenvalues and the like [14] .IntroductionIn principle, however, many of the indices used to characterize numerically DNA representations are graph invariants that describe the distribution of nodes and/or node-node connections in these graphs.", [["nodes", "ANATOMY", 385, 390], ["node-node", "ANATOMY", 398, 407], ["DNA", "CELLULAR_COMPONENT", 310, 313], ["computing various parameters", "TEST", 42, 70], ["very large matrices", "PROBLEM", 75, 94], ["large sequences", "PROBLEM", 116, 131], ["the indices", "TEST", 265, 276], ["numerically DNA representations", "PROBLEM", 298, 329], ["graph invariants", "PROBLEM", 334, 350], ["nodes and/or node-node connections in these graphs", "PROBLEM", 385, 435], ["distribution", "OBSERVATION_MODIFIER", 369, 381], ["nodes", "OBSERVATION", 385, 390], ["node", "OBSERVATION", 398, 402], ["node", "OBSERVATION", 403, 407]]], ["In the parlance of graph theory, many authors have referred to some of these indices as Topological Indices (TIs) and applications have been made not only to DNA sequences but also to proteins, viral surfaces, RNA secondary structures and small molecules [23, 24] .", [["DNA", "CELLULAR_COMPONENT", 158, 161], ["DNA sequences", "TEST", 158, 171], ["small molecules", "PROBLEM", 239, 254], ["small", "OBSERVATION_MODIFIER", 239, 244]]], ["Consequently, the method is of more general application taking into consideration that the type of graph representations referred to above have been extended from DNA/ RNA to the study of other types of relevant biological sequences.", [["DNA", "CELLULAR_COMPONENT", 163, 166], ["the study", "TEST", 175, 184]]], ["In particular, Gonz\u00e1lez-D\u00edaz et al. extended these representations to the study of protein sequences [25] and Mass Spectra outcomes of proteins and/or protein serum profiles in parasites [26] , toxicoproteomics and diagnosis of cancer patients [27, 28] .", [["serum", "ANATOMY", 159, 164], ["cancer", "ANATOMY", 228, 234], ["cancer", "DISEASE", 228, 234], ["serum", "ORGANISM_SUBSTANCE", 159, 164], ["cancer", "CANCER", 228, 234], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 235, 243], ["the study of protein sequences", "TEST", 70, 100], ["proteins", "TEST", 135, 143], ["protein serum profiles", "TEST", 151, 173], ["parasites", "TEST", 177, 186], ["toxicoproteomics", "TREATMENT", 194, 210], ["cancer", "PROBLEM", 228, 234], ["cancer", "OBSERVATION", 228, 234]]], ["In any case, the various numerical parameters of DNA/RNA graph representations (TIs or otherwise) may be used not only to study sequence-sequence similarity but also to fit Quantitative Structure-Activity Relationship (QSAR) models.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["DNA/RNA graph representations", "TREATMENT", 49, 78], ["study sequence", "TEST", 122, 136]]], ["Structure here refers not only to drug structure but also to DNA sequence, RNA sequence or secondary structure, and protein sequences or 3D structure [see review 28] .IntroductionThus, the utility of graphical methods in revealing different types of hidden structures and similarities/dissimilarities in and between DNA and other biological sequences can be considered to be well demonstrated.IntroductionIn this light, a perusal of the representative patterns of conserved gene sequences appears to indicate a possible relationship between the numbers of the various nucleotides in conserved gene sequences.", [["nucleotides", "CHEMICAL", 568, 579], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["DNA", "CELLULAR_COMPONENT", 316, 319], ["DNA sequence", "DNA", 61, 73], ["conserved gene sequences", "DNA", 464, 488], ["conserved gene sequences", "DNA", 583, 607], ["DNA sequence", "TEST", 61, 73], ["RNA sequence", "TEST", 75, 87], ["secondary structure, and protein sequences", "TEST", 91, 133], ["graphical methods", "TEST", 200, 217], ["hidden structures", "PROBLEM", 250, 267], ["DNA", "PROBLEM", 316, 319], ["other biological sequences", "TEST", 324, 350]]], ["Here we use the 2D graphical representation method to show that plots of the conserved gene sequences trace out apparently curved paths that are also visually similar across species for the same gene.", [["conserved gene sequences", "DNA", 77, 101], ["the conserved gene sequences", "TEST", 73, 101], ["curved paths", "PROBLEM", 123, 135]]], ["The nature of these curves is seen to generally imply a so far undescribed quadratic relationship between intra-purine and intra-pyrimidine differences, whereas the null hypothesis would have indicated random directionless walks.", [["intra-pyrimidine", "CHEMICAL", 123, 139], ["intra-purine", "SIMPLE_CHEMICAL", 106, 118], ["intra-pyrimidine", "SIMPLE_CHEMICAL", 123, 139], ["the null hypothesis", "PROBLEM", 161, 180], ["curves", "OBSERVATION", 20, 26]]], ["With such empirical relationship between the two basic nucleotide differences, we propose a probable mutation path to explaining the relationships.", [["nucleotide", "CHEMICAL", 55, 65], ["the two basic nucleotide differences", "PROBLEM", 41, 77]]], ["We then hypothesize that the parameters of such relationships could be a property of the underlying gene sequences and speculate that extensive alterations of such genes by accretion or deletion of DNA fragments would be s only if the modified sequences subscribe to the same basic parameterised relation.MethodsHere we use the random walk system envisaged in the Nandy plot [11] based on a 2D Cartesian grid where the four bases are assigned to the four cardinal directions: guanine (g) to the positive x-direction, thymine (t) to the negative y-direction, adenine (a) to the negative x-direction and cytosine (c) to the positive y-direction.", [["guanine", "CHEMICAL", 476, 483], ["thymine", "CHEMICAL", 517, 524], ["adenine", "CHEMICAL", 558, 565], ["cytosine", "CHEMICAL", 602, 610], ["guanine", "CHEMICAL", 476, 483], ["thymine", "CHEMICAL", 517, 524], ["adenine", "CHEMICAL", 558, 565], ["cytosine", "CHEMICAL", 602, 610], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["guanine", "SIMPLE_CHEMICAL", 476, 483], ["thymine", "SIMPLE_CHEMICAL", 517, 524], ["adenine", "SIMPLE_CHEMICAL", 558, 565], ["cytosine", "SIMPLE_CHEMICAL", 602, 610], ["DNA fragments", "DNA", 198, 211], ["modified sequences", "DNA", 235, 253], ["negative x-direction", "PROTEIN", 577, 597], ["cytosine (c)", "PROTEIN", 602, 614], ["the underlying gene sequences", "PROBLEM", 85, 114], ["deletion of DNA fragments", "PROBLEM", 186, 211], ["a 2D Cartesian grid", "TREATMENT", 389, 408], ["extensive", "OBSERVATION_MODIFIER", 134, 143]]], ["The method to plot a DNA sequence is to start at the origin and take a step in the positive x-direction for a guanine base, in the negative x-direction for an adenine, positive y-direction for a cytosine and the negative y-direction for a thymine, and proceed likewise for each succeeding base in the sequence, starting each step from the end of the last one taken.", [["guanine", "CHEMICAL", 110, 117], ["adenine", "CHEMICAL", 159, 166], ["cytosine", "CHEMICAL", 195, 203], ["thymine", "CHEMICAL", 239, 246], ["guanine", "CHEMICAL", 110, 117], ["adenine", "CHEMICAL", 159, 166], ["cytosine", "CHEMICAL", 195, 203], ["thymine", "CHEMICAL", 239, 246], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["guanine", "SIMPLE_CHEMICAL", 110, 117], ["adenine", "SIMPLE_CHEMICAL", 159, 166], ["cytosine", "SIMPLE_CHEMICAL", 195, 203], ["thymine", "SIMPLE_CHEMICAL", 239, 246], ["DNA sequence", "DNA", 21, 33], ["a DNA sequence", "TEST", 19, 33], ["a guanine base", "TEST", 108, 122], ["a cytosine", "TREATMENT", 193, 203], ["a thymine", "TREATMENT", 237, 246]]], ["This way a succession of bases in the original DNA sequences is represented by a succession of points in the 2D plot, the overall trace being a representation of the distribution of bases in the DNA sequence (see e.g., Fig. 1 human beta globin).", [["DNA", "CELLULAR_COMPONENT", 47, 50], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["human", "ORGANISM", 226, 231], ["beta globin", "GENE_OR_GENE_PRODUCT", 232, 243], ["DNA sequences", "DNA", 47, 60], ["DNA sequence", "DNA", 195, 207], ["human beta globin", "PROTEIN", 226, 243], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["the original DNA sequences", "TEST", 34, 60], ["the 2D plot", "TEST", 105, 116], ["the DNA sequence", "TEST", 191, 207], ["bases", "ANATOMY_MODIFIER", 25, 30], ["overall", "OBSERVATION_MODIFIER", 122, 129], ["trace", "OBSERVATION_MODIFIER", 130, 135], ["distribution", "OBSERVATION_MODIFIER", 166, 178], ["bases", "ANATOMY_MODIFIER", 182, 187]]], ["The axes essentially represent the excess of guanine over adenine along the x-axis and the excess of cytosine over thymine along the y-axis; thus the plots are basically of instantaneous values of intra-pyrimidine, intra-purine differences as we proceed along the sequence.", [["guanine", "CHEMICAL", 45, 52], ["adenine", "CHEMICAL", 58, 65], ["cytosine", "CHEMICAL", 101, 109], ["thymine", "CHEMICAL", 115, 122], ["intra-pyrimidine", "CHEMICAL", 197, 213], ["guanine", "CHEMICAL", 45, 52], ["adenine", "CHEMICAL", 58, 65], ["cytosine", "CHEMICAL", 101, 109], ["thymine", "CHEMICAL", 115, 122], ["intra-pyrimidine", "CHEMICAL", 197, 213], ["intra-purine", "CHEMICAL", 215, 227], ["guanine", "SIMPLE_CHEMICAL", 45, 52], ["adenine", "SIMPLE_CHEMICAL", 58, 65], ["cytosine", "SIMPLE_CHEMICAL", 101, 109], ["thymine", "SIMPLE_CHEMICAL", 115, 122], ["intra-pyrimidine", "SIMPLE_CHEMICAL", 197, 213], ["intra-purine", "SIMPLE_CHEMICAL", 215, 227], ["guanine over adenine", "TREATMENT", 45, 65], ["cytosine over thymine", "TREATMENT", 101, 122], ["intra-pyrimidine", "TREATMENT", 197, 213], ["excess", "OBSERVATION_MODIFIER", 35, 41]]], ["The end point of such a curve will be given by (N G -N A , N C -N T ), where by N A , N C , N G, N T we mean the total number of adenines, cytosines, guanines and thymines in the sequence being plotted.", [["adenines", "CHEMICAL", 129, 137], ["cytosines", "CHEMICAL", 139, 148], ["guanines", "CHEMICAL", 150, 158], ["N G -N A , N C -N T", "CHEMICAL", 48, 67], ["N A", "CHEMICAL", 80, 83], ["N C", "CHEMICAL", 86, 89], ["N", "CHEMICAL", 92, 93], ["N", "CHEMICAL", 97, 98], ["adenines", "CHEMICAL", 129, 137], ["cytosines", "CHEMICAL", 139, 148], ["guanines", "CHEMICAL", 150, 158], ["thymines", "CHEMICAL", 163, 171], ["N C -N T", "SIMPLE_CHEMICAL", 59, 67], ["N A", "SIMPLE_CHEMICAL", 80, 83], ["N C", "SIMPLE_CHEMICAL", 86, 89], ["N G", "SIMPLE_CHEMICAL", 92, 95], ["adenines", "SIMPLE_CHEMICAL", 129, 137], ["cytosines", "SIMPLE_CHEMICAL", 139, 148], ["guanines", "SIMPLE_CHEMICAL", 150, 158], ["thymines", "SIMPLE_CHEMICAL", 163, 171], ["adenines", "TREATMENT", 129, 137], ["cytosines", "TREATMENT", 139, 148], ["guanines", "TREATMENT", 150, 158], ["thymines", "TREATMENT", 163, 171]]], ["GC-rich sequences therefore plot mostly in the first quadrant, AT-rich sequences in the third quadrant on this axes system.MethodsOnce the co-ordinates are available, we use an Excel spreadsheet to plot the graph and apply the Add Trendline feature of the Excel software to fit the best polynomials for our analysis, with axes transformation where required to conform to the software's curve fitting engine.", [["GC-rich sequences", "DNA", 0, 17], ["AT-rich sequences", "DNA", 63, 80], ["GC-rich sequences", "TEST", 0, 17], ["plot", "TEST", 28, 32], ["our analysis", "TEST", 303, 315], ["axes transformation", "PROBLEM", 322, 341], ["third quadrant", "ANATOMY", 88, 102]]], ["Fig. 1 shows a plot of the human beta globin gene complete cds generated using the above algorithm.", [["human", "ORGANISM", 27, 32], ["beta globin", "GENE_OR_GENE_PRODUCT", 33, 44], ["human beta globin gene", "DNA", 27, 49], ["cds", "DNA", 59, 62], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["a plot", "TEST", 13, 19], ["the human beta globin gene", "TREATMENT", 23, 49], ["the above algorithm", "TEST", 79, 98]]], ["We note that a DNA sequence that consists of a succession of short segments each having a complete mix of a,g,c,t with equal contributions of each of the bases within each of the segments would be expected to generate a dense cluster of points around the origin; a random distribution of the a,g,c,t along the sequence could be expected to generate a random walk.", [["DNA", "CELLULAR_COMPONENT", 15, 18], ["DNA sequence", "DNA", 15, 27], ["a DNA sequence", "TEST", 13, 27], ["short segments", "OBSERVATION_MODIFIER", 61, 75], ["equal", "OBSERVATION_MODIFIER", 119, 124], ["contributions", "OBSERVATION", 125, 138], ["bases", "ANATOMY_MODIFIER", 154, 159], ["segments", "ANATOMY_MODIFIER", 179, 187], ["dense", "OBSERVATION_MODIFIER", 220, 225], ["cluster", "OBSERVATION_MODIFIER", 226, 233], ["origin", "ANATOMY_MODIFIER", 255, 261], ["random", "OBSERVATION_MODIFIER", 265, 271], ["distribution", "OBSERVATION_MODIFIER", 272, 284]]], ["The human beta globin gene sequence complete cds inclusive of all introns and exons (Fig. 1) shows a distinct pattern where the bases appear to follow one another with some regularity, with the total extent of the representative plot arising from the non-equal composition of the bases in the sequence; other beta globin sequences produce similar plots implying that the human beta globin gene cds is not an arbitrary random sequence.", [["human", "ORGANISM", 4, 9], ["beta globin", "GENE_OR_GENE_PRODUCT", 10, 21], ["beta globin", "GENE_OR_GENE_PRODUCT", 309, 320], ["human", "ORGANISM", 371, 376], ["beta globin", "GENE_OR_GENE_PRODUCT", 377, 388], ["cds", "GENE_OR_GENE_PRODUCT", 394, 397], ["human beta globin gene sequence", "DNA", 4, 35], ["cds", "DNA", 45, 48], ["introns", "DNA", 66, 73], ["exons", "DNA", 78, 83], ["beta globin sequences", "DNA", 309, 330], ["human beta globin gene cds", "DNA", 371, 397], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 371, 376], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 371, 376], ["The human beta globin gene sequence", "TEST", 0, 35], ["a distinct pattern where the bases", "PROBLEM", 99, 133], ["other beta globin sequences", "TEST", 303, 330], ["an arbitrary random sequence", "TEST", 405, 433], ["all introns", "OBSERVATION", 62, 73], ["distinct", "OBSERVATION_MODIFIER", 101, 109], ["pattern", "OBSERVATION", 110, 117], ["bases", "ANATOMY_MODIFIER", 128, 133], ["regularity", "OBSERVATION_MODIFIER", 173, 183], ["total extent", "OBSERVATION_MODIFIER", 194, 206], ["representative", "OBSERVATION_MODIFIER", 214, 228], ["plot", "OBSERVATION", 229, 233], ["bases", "ANATOMY_MODIFIER", 280, 285]]], ["Fig. 2 shows the close similarity of the shapes of the plots of three sequences of histone H4 genes of wheat, maize and chicken, demonstrating that these sequences are not random but have a close kinship in base distribution.", [["histone H4", "GENE_OR_GENE_PRODUCT", 83, 93], ["wheat", "ORGANISM_SUBDIVISION", 103, 108], ["maize", "ORGANISM_SUBDIVISION", 110, 115], ["chicken", "ORGANISM", 120, 127], ["histone H4 genes", "DNA", 83, 99], ["wheat", "SPECIES", 103, 108], ["maize", "SPECIES", 110, 115], ["chicken", "SPECIES", 120, 127], ["wheat", "SPECIES", 103, 108], ["maize", "SPECIES", 110, 115], ["chicken", "SPECIES", 120, 127], ["these sequences", "TEST", 148, 163], ["base", "ANATOMY_MODIFIER", 207, 211]]], ["A randomisation of the bases in the human beta globin gene [29] produces, on the other hand, a simple linear plot (Fig. 3) in the third quadrant of the axes system as can be intuitively expected for an unorganised mixture of the four bases along the sequence.ResultsTo further demonstrate that the base distribution in these gene sequences are non-random, and generally true for conserved gene sequences, we have generated graphical representations of several conserved genes, a selection of which are shown in Fig. 4 .", [["human", "ORGANISM", 36, 41], ["beta globin", "GENE_OR_GENE_PRODUCT", 42, 53], ["human beta globin gene", "DNA", 36, 58], ["conserved gene sequences", "DNA", 379, 403], ["conserved genes", "DNA", 460, 475], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["A randomisation of the bases", "TEST", 0, 28], ["the human beta globin gene", "TEST", 32, 58], ["a simple linear plot", "PROBLEM", 93, 113], ["these gene sequences", "TEST", 319, 339], ["bases", "ANATOMY_MODIFIER", 23, 28], ["human", "ANATOMY", 36, 41], ["beta globin", "OBSERVATION", 42, 53], ["simple", "OBSERVATION_MODIFIER", 95, 101], ["linear", "OBSERVATION_MODIFIER", 102, 108], ["plot", "OBSERVATION", 109, 113], ["third", "ANATOMY_MODIFIER", 130, 135], ["quadrant", "ANATOMY_MODIFIER", 136, 144], ["axes", "ANATOMY_MODIFIER", 152, 156], ["four", "ANATOMY_MODIFIER", 229, 233], ["bases", "ANATOMY_MODIFIER", 234, 239], ["base", "ANATOMY_MODIFIER", 298, 302]]], ["Plots of several alpha globin genes are included here to show that there is shape similarity between the same genes from different species indicating that entire gene sequences inclusive of introns and exons have close similarities.", [["alpha globin", "GENE_OR_GENE_PRODUCT", 17, 29], ["alpha globin genes", "DNA", 17, 35], ["introns", "DNA", 190, 197], ["exons", "DNA", 202, 207], ["several alpha globin genes", "PROBLEM", 9, 35], ["different species", "PROBLEM", 121, 138], ["entire gene sequences", "PROBLEM", 155, 176], ["introns and exons", "PROBLEM", 190, 207], ["alpha globin genes", "OBSERVATION", 17, 35]]], ["This can also be seen in the plots of several histones, tubulins and heat shock proteins, of which some representative samples are given in Figs.", [["samples", "ANATOMY", 119, 126], ["histones", "GENE_OR_GENE_PRODUCT", 46, 54], ["tubulins", "GENE_OR_GENE_PRODUCT", 56, 64], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 69, 88], ["samples", "CANCER", 119, 126], ["histones", "PROTEIN", 46, 54], ["tubulins", "PROTEIN", 56, 64], ["heat shock proteins", "PROTEIN", 69, 88], ["several histones", "PROBLEM", 38, 54], ["heat shock proteins", "PROBLEM", 69, 88], ["can also be seen", "UNCERTAINTY", 5, 21], ["several", "OBSERVATION_MODIFIER", 38, 45], ["histones", "OBSERVATION", 46, 54]]], ["4 and 5.ResultsWith our observation that the sequences of the conserved genes, both intronless and with-introns, have close similarities, we can start to enquire whether these sequences have any discernible patterns.", [["conserved genes", "DNA", 62, 77], ["intronless", "DNA", 84, 94], ["introns", "DNA", 104, 111], ["our observation", "TEST", 20, 35]]], ["We notice that the general nature of the DNA walks on the 2D representation as per the Nandy prescription [11] shown in the above figures is directional and curvilinear.", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["curvilinear", "OBSERVATION_MODIFIER", 157, 168]]], ["A simple 2 nd degree polynomial produces reasonable fits.", [["A simple 2 nd degree polynomial produces reasonable fits", "PROBLEM", 0, 56], ["simple 2 nd degree", "OBSERVATION_MODIFIER", 2, 20], ["reasonable fits", "OBSERVATION", 41, 56]]], ["A selection of the plots with the trendlines is shown in Fig. 6 and 7 corresponding to the sequences shown in the previous two figures.", [["the sequences", "TEST", 87, 100]]], ["A list of the details of the fits and statistics are given in Table 1 .ResultsWhile this nature of the base distributions is found across many different sequences of eukaryotic genes, it is also very much evident in the case of viral sequences like the H5N1 neuraminidase which are known to mutate very rapidly; other plots from a sample of over 600 sequences of the H5N1 neuraminidase show similar quadratic forms.", [["H5N1 neuraminidase", "ORGANISM", 253, 271], ["H5N1 neuraminidase", "ORGANISM", 367, 385], ["eukaryotic genes", "DNA", 166, 182], ["viral sequences", "DNA", 228, 243], ["H5N1 neuraminidase", "PROTEIN", 253, 271], ["H5N1 neuraminidase", "PROTEIN", 367, 385], ["H5N1", "SPECIES", 253, 257], ["viral sequences", "PROBLEM", 228, 243], ["the H5N1 neuraminidase", "PROBLEM", 249, 271], ["the H5N1 neuraminidase", "TEST", 363, 385], ["base", "ANATOMY_MODIFIER", 103, 107], ["eukaryotic genes", "OBSERVATION", 166, 182], ["H5N1", "OBSERVATION", 253, 257]]], ["Interestingly, plots of the wheat, maize and chicken histone H4 genes, which are also intronless genes, can also be fitted by polynomials of degree 2, similar to the case of the viral genes.", [["wheat", "ORGANISM_SUBDIVISION", 28, 33], ["chicken", "ORGANISM", 45, 52], ["histone H4", "GENE_OR_GENE_PRODUCT", 53, 63], ["wheat, maize and chicken histone H4 genes", "DNA", 28, 69], ["intronless genes", "DNA", 86, 102], ["viral genes", "DNA", 178, 189], ["wheat", "SPECIES", 28, 33], ["maize", "SPECIES", 35, 40], ["chicken", "SPECIES", 45, 52], ["wheat", "SPECIES", 28, 33], ["maize", "SPECIES", 35, 40], ["chicken", "SPECIES", 45, 52], ["chicken histone H4 genes", "PROBLEM", 45, 69], ["chicken histone", "OBSERVATION", 45, 60], ["H4 genes", "OBSERVATION", 61, 69], ["viral genes", "OBSERVATION", 178, 189]]], ["Chicken beta globin gene with intron sequences that are quite different compared to the mammalian genes plot in the first quadrant, but it also can be fit by a quadratic polynomial.", [["Chicken beta globin", "GENE_OR_GENE_PRODUCT", 0, 19], ["Chicken beta globin gene", "DNA", 0, 24], ["intron sequences", "DNA", 30, 46], ["mammalian genes plot", "DNA", 88, 108], ["Chicken", "SPECIES", 0, 7], ["Chicken", "SPECIES", 0, 7], ["Chicken beta globin gene with intron sequences", "TREATMENT", 0, 46], ["beta globin", "OBSERVATION", 8, 19], ["quadrant", "ANATOMY", 122, 130]]], ["This is however not true of all gene sequences.", [["gene sequences", "DNA", 32, 46]]], ["The mouse beta globin gene sequence representation in the 2D framework gives a very poor fit for the quadratic function (R 2 = 0.06) but much better statistics with a cubic polynomial (R 2 = 0.53) ( Table 1) ; the human delta globin gene also shows very good statistics when fitted with a cubic polynomial (R 2 = 0.98).", [["mouse", "ORGANISM", 4, 9], ["beta globin", "GENE_OR_GENE_PRODUCT", 10, 21], ["human", "ORGANISM", 214, 219], ["delta globin", "GENE_OR_GENE_PRODUCT", 220, 232], ["mouse beta globin gene sequence", "DNA", 4, 35], ["human delta globin gene", "DNA", 214, 237], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 214, 219], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 214, 219], ["The mouse beta globin gene sequence representation", "TREATMENT", 0, 50], ["the quadratic function", "TEST", 97, 119], ["a cubic polynomial", "TEST", 165, 183], ["the human delta globin gene", "TEST", 210, 237], ["a cubic polynomial", "TEST", 287, 305], ["beta globin", "OBSERVATION", 10, 21]]], ["Some sequences where significantly large segments are at variance with the overall pattern too cannot be put into such slots.", [["Some sequences", "TEST", 0, 14], ["significantly large segments", "PROBLEM", 21, 49], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["large", "OBSERVATION_MODIFIER", 35, 40], ["segments", "OBSERVATION_MODIFIER", 41, 49]]], ["The rat myosin heavy chain gene sequence where the intron sequences have been hypothesized to have grown through accretion of large fragments [30] , for example, presents a highly compact form on the 2D plot [15] and cannot be fit by the simple polynomials we have used so far.", [["rat", "ORGANISM", 4, 7], ["myosin heavy chain", "GENE_OR_GENE_PRODUCT", 8, 26], ["rat myosin heavy chain gene sequence", "DNA", 4, 40], ["intron sequences", "DNA", 51, 67], ["rat", "SPECIES", 4, 7], ["The rat myosin heavy chain gene sequence", "TREATMENT", 0, 40], ["the intron sequences", "TEST", 47, 67], ["large fragments", "PROBLEM", 126, 141], ["the 2D plot", "TEST", 196, 207], ["large", "OBSERVATION_MODIFIER", 126, 131], ["fragments", "OBSERVATION", 132, 141]]], ["However, sufficiently large numbers of sequences are seen to follow the apparent quadratic relationship with good statistics that it is of interest to try to understand the underlying pattern.DiscussionThe equations that fit the curvilinear patterns of the base distributions with reasonable statistics are of the formDiscussionandDiscussionwhere a,b,c,d are parameters,Discussionand n A , n C , n G , n T are the instantaneous values of the numbers of a, c, g, t present up to the particular position (x,y) on the sequence, starting the count from the beginning, i.e. the 59-end, of the sequence.", [["the count", "TEST", 534, 543], ["large", "OBSERVATION_MODIFIER", 22, 27], ["base", "ANATOMY_MODIFIER", 257, 261]]], ["These are our empirical equations connecting the intrapurine (x) and intra-pyrimidine (y) numbers obtained from the observations of the patterns on the 2D graphical plots.", [["intrapurine", "CHEMICAL", 49, 60], ["intra-pyrimidine", "CHEMICAL", 69, 85], ["the intrapurine", "TREATMENT", 45, 60]]], ["While the majority of the plots shown are well-represented by such polynomials of the second degree, the fits could be improved in some instances by fitting higher degree polynomials as mentioned earlier; e.g., in the case of the human beta-globin gene a polynomial of the third degree yields better statistics (R 2 = 0.94) than the second degree (R 2 = 0.81), for the human delta globin gene the statistics for the quadratic and cubic fits are R 2 = 0.87 and R 2 = 0.98, respectively.", [["human", "ORGANISM", 230, 235], ["beta-globin", "GENE_OR_GENE_PRODUCT", 236, 247], ["human", "ORGANISM", 369, 374], ["delta globin", "GENE_OR_GENE_PRODUCT", 375, 387], ["human beta-globin gene", "DNA", 230, 252], ["human delta globin gene", "DNA", 369, 392], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 369, 374], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 369, 374], ["fitting higher degree polynomials", "PROBLEM", 149, 182], ["the human delta globin", "TEST", 365, 387], ["the quadratic and cubic fits", "TEST", 412, 440], ["second degree", "OBSERVATION_MODIFIER", 86, 99], ["could be", "UNCERTAINTY", 110, 118], ["improved", "OBSERVATION_MODIFIER", 119, 127], ["higher degree", "OBSERVATION_MODIFIER", 157, 170]]], ["We, however, consider the second degree form for now for conformity without excessive loss of statistical significance.DiscussionThe origin of such a relationship as in equations 1 and 2 could be traced to mutational changes in a sequence, where we restrict our analysis for the moment to transitional types of mutations since this is the dominant mode.", [["excessive loss of statistical significance", "PROBLEM", 76, 118], ["mutational changes", "PROBLEM", 206, 224], ["our analysis", "TEST", 258, 270], ["transitional types of mutations", "PROBLEM", 289, 320]]], ["Consider a mutation of a cytosine to thymine in one strand of a DNA in a GC-rich sequence.", [["cytosine", "CHEMICAL", 25, 33], ["thymine", "CHEMICAL", 37, 44], ["cytosine", "CHEMICAL", 25, 33], ["thymine", "CHEMICAL", 37, 44], ["cytosine", "SIMPLE_CHEMICAL", 25, 33], ["thymine", "SIMPLE_CHEMICAL", 37, 44], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["GC-rich sequence", "DNA", 73, 89], ["a cytosine to thymine", "TREATMENT", 23, 44], ["a DNA", "TEST", 62, 67]]], ["The opposite strand, calling it strand 2 for convenience, will initially have a bulge for the original paired guanine, and the event leads to following possibilities [31] : (a) the DNA repair mechanism reverse mutates the thymine to cytosine in strand 1, thus negating the effect of the original mutation; (b) the guanine in strand 2 is replaced by an adenine; and (c) a third possibility in case the damage repair coincides with replication, that the DNA is elongated by pairing the mutated thymine in strand 1 with a new adenine in strand 2 and addition of a cytosine in strand 1 to match the guanine in strand 2 left over after the original mutation, i.e. creation of a T-A pair and addition of a new C-G pair.", [["guanine", "CHEMICAL", 110, 117], ["thymine", "CHEMICAL", 222, 229], ["cytosine", "CHEMICAL", 233, 241], ["guanine", "CHEMICAL", 314, 321], ["adenine", "CHEMICAL", 352, 359], ["thymine", "CHEMICAL", 492, 499], ["adenine", "CHEMICAL", 523, 530], ["cytosine", "CHEMICAL", 561, 569], ["guanine", "CHEMICAL", 595, 602], ["guanine", "CHEMICAL", 110, 117], ["thymine", "CHEMICAL", 222, 229], ["cytosine", "CHEMICAL", 233, 241], ["guanine", "CHEMICAL", 314, 321], ["adenine", "CHEMICAL", 352, 359], ["thymine", "CHEMICAL", 492, 499], ["adenine", "CHEMICAL", 523, 530], ["cytosine", "CHEMICAL", 561, 569], ["guanine", "CHEMICAL", 595, 602], ["guanine", "SIMPLE_CHEMICAL", 110, 117], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["thymine", "SIMPLE_CHEMICAL", 222, 229], ["cytosine", "SIMPLE_CHEMICAL", 233, 241], ["adenine", "SIMPLE_CHEMICAL", 352, 359], ["DNA", "CELLULAR_COMPONENT", 452, 455], ["thymine", "SIMPLE_CHEMICAL", 492, 499], ["adenine", "SIMPLE_CHEMICAL", 523, 530], ["cytosine", "SIMPLE_CHEMICAL", 561, 569], ["guanine", "SIMPLE_CHEMICAL", 595, 602], ["C-G", "GENE_OR_GENE_PRODUCT", 704, 707], ["T-A pair", "DNA", 673, 681], ["C-G pair", "DNA", 704, 712], ["a bulge", "PROBLEM", 78, 85], ["the DNA repair mechanism", "TREATMENT", 177, 201], ["the thymine to cytosine in strand", "TREATMENT", 218, 251], ["the original mutation", "PROBLEM", 283, 304], ["the guanine in strand 2", "TREATMENT", 310, 333], ["the damage repair", "TREATMENT", 397, 414], ["replication", "TREATMENT", 430, 441], ["a new adenine in strand 2", "TREATMENT", 517, 542], ["a cytosine in strand", "TREATMENT", 559, 579], ["the guanine in strand", "TREATMENT", 591, 612], ["the original mutation", "PROBLEM", 631, 652], ["a T-A pair", "TREATMENT", 671, 681], ["a new C-G pair", "TREATMENT", 698, 712], ["strand", "OBSERVATION_MODIFIER", 13, 19], ["bulge", "OBSERVATION", 80, 85], ["damage repair", "OBSERVATION", 401, 414], ["left", "ANATOMY_MODIFIER", 615, 619], ["mutation", "OBSERVATION", 644, 652]]], ["Such an event would be quite rare, especially in coding regions since it will alter the reading frames unless the total change leads to addition of three base pairs; several intronless gene sequences indeed show very small contribution from the quadratic term compared to the interrupted genes, e.g. petunia hsp70G ( Table 1 ).", [["coding regions", "DNA", 49, 63], ["reading frames", "DNA", 88, 102], ["intronless gene sequences", "DNA", 174, 199], ["interrupted genes", "DNA", 276, 293], ["three base pairs", "TREATMENT", 148, 164], ["several intronless gene sequences", "PROBLEM", 166, 199], ["very small contribution from the quadratic term", "PROBLEM", 212, 259], ["very", "OBSERVATION_MODIFIER", 212, 216], ["small", "OBSERVATION_MODIFIER", 217, 222]]], ["The example of the mutation event of cytosine to thymine in strand 1 can be considered to change the intra-pyrimidine difference, n C-T , in strand 1 and trigger a change in the intrapurine difference, n G-A , in strand 2.", [["cytosine", "CHEMICAL", 37, 45], ["thymine", "CHEMICAL", 49, 56], ["cytosine", "CHEMICAL", 37, 45], ["thymine", "CHEMICAL", 49, 56], ["intra-pyrimidine", "CHEMICAL", 101, 117], ["intrapurine", "CHEMICAL", 178, 189], ["cytosine", "SIMPLE_CHEMICAL", 37, 45], ["thymine", "SIMPLE_CHEMICAL", 49, 56], ["intra-pyrimidine", "SIMPLE_CHEMICAL", 101, 117], ["intrapurine", "SIMPLE_CHEMICAL", 178, 189], ["G-A", "SIMPLE_CHEMICAL", 204, 207], ["the mutation", "PROBLEM", 15, 27], ["cytosine to thymine", "TREATMENT", 37, 56], ["the intra-pyrimidine difference", "PROBLEM", 97, 128], ["the intrapurine difference", "PROBLEM", 174, 200]]], ["The two changes can be related byDiscussionwhere the first term on the right relates to the probability of the G to A change in strand 2 and the second term to the probability of the third type of response, i.e. DNA elongation by addition of a C in strand 1; the (1) and (2) in equation 4 are strand identifiers and we have definedDiscussionWe expect q,p since the probability of DNA elongation will be significantly lower than effecting only a replacement of theDiscussionUsing recursion and keeping up to first order terms in q/p, equation (7) reduces toDiscussionwhere by O3 we mean terms of higher orders (dropping the conventional form O(3) so as not to confuse with the strand number indicators).", [["DNA", "CELLULAR_COMPONENT", 212, 215], ["DNA", "CELLULAR_COMPONENT", 380, 383], ["A change in strand 2", "PROBLEM", 116, 136], ["DNA elongation", "PROBLEM", 212, 226], ["a C in strand", "TREATMENT", 242, 255], ["DNA elongation", "PROBLEM", 380, 394], ["a replacement of theDiscussionUsing recursion", "TREATMENT", 443, 488], ["right", "ANATOMY_MODIFIER", 71, 76], ["elongation", "OBSERVATION_MODIFIER", 216, 226]]], ["For many mutations over a long sequence, this takes the formDiscussionwhere a,b are redefined constants with b,a.", [["many mutations", "PROBLEM", 4, 18]]], ["This equation relates changes in the intra-pyrimidine numbers in strand 1 to intrapurine numbers in strand 2 where the n C-T and n G-A are as defined in equations 5 and 6 above.", [["intra-pyrimidine", "CHEMICAL", 37, 53], ["intrapurine", "CHEMICAL", 77, 88], ["intrapurine", "SIMPLE_CHEMICAL", 77, 88], ["G-A", "GENE_OR_GENE_PRODUCT", 131, 134], ["This equation", "TEST", 0, 13], ["intrapurine numbers", "TEST", 77, 96], ["the n C", "TEST", 115, 122]]], ["Now, Chargaff's rule states thatDiscussionand since from Watson-Crick rule we know n C 1 \u00f0 \u00de~n G 2 \u00f0 \u00de and n C 2 \u00f0 \u00de~n G 1 \u00f0 \u00de, and similarly for A,T, then from the above we haveDiscussionas a consequence of which,DiscussionExcluding some pathological cases or very short segments where one or the other type of nucleotide is conspicuous by its absence, e.g., as in poly-adenylation segments where only A's dominate and the others are absent, in a real gene sequence we can expect the second term within each of the square brackets above to be%1, implying thatDiscussionwhich transforms Eq.", [["nucleotide", "CHEMICAL", 312, 322], ["nucleotide", "CHEMICAL", 312, 322], ["G 1", "PROTEIN", 119, 122], ["poly-adenylation segments", "PROTEIN", 366, 391], ["C", "TEST", 85, 86], ["G", "TEST", 95, 96], ["C", "TEST", 109, 110], ["G", "TEST", 119, 120], ["\u00de", "TEST", 125, 126], ["some pathological cases", "PROBLEM", 234, 257], ["very short segments", "PROBLEM", 261, 280], ["the square brackets", "TREATMENT", 512, 531], ["very", "OBSERVATION_MODIFIER", 261, 265], ["short segments", "OBSERVATION_MODIFIER", 266, 280]]], ["(9) toDiscussionor, dropping the strand number indicator since all quantities now refer to the same strand,DiscussionFrom similar considerations for the AT-rich sequences considering the mutations of adenine to guanine for example, we can obtain the equationDiscussionwhere n C-T and n G-A are as defined in Eqs.", [["adenine", "CHEMICAL", 200, 207], ["guanine", "CHEMICAL", 211, 218], ["adenine", "CHEMICAL", 200, 207], ["guanine", "CHEMICAL", 211, 218], ["adenine", "SIMPLE_CHEMICAL", 200, 207], ["guanine", "SIMPLE_CHEMICAL", 211, 218], ["C-T", "GENE_OR_GENE_PRODUCT", 276, 279], ["G-A", "GENE_OR_GENE_PRODUCT", 286, 289], ["AT-rich sequences", "DNA", 153, 170], ["adenine to guanine", "TREATMENT", 200, 218], ["the equation", "TEST", 246, 258]]], ["Equations 16 and 17 are similar to equations 1 and 2 and conform to the general shapes of the sequence plots.", [["Equations", "TEST", 0, 9], ["the sequence plots", "TEST", 90, 108]]], ["This shows that the path traced out by the nucleotide sequence of a gene follows some pattern that can be ascribed to the accumulated effects of spot mutations over evolutionary time scales.", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 43, 53], ["the path", "TEST", 16, 24], ["the nucleotide sequence", "TEST", 39, 62], ["spot mutations", "PROBLEM", 145, 159]]], ["The actual plots of the gene sequences in the 2D grid representation show reasonable conformity with the predicted curves with variations that could be ascribed in part to the higher order terms and other factors described below.", [["the gene sequences", "TEST", 20, 38], ["the 2D grid representation", "TEST", 42, 68], ["reasonable conformity", "OBSERVATION", 74, 95]]], ["It is to be noted that equations 16, 17 have been derived independent of any graphical representations or reference frames, and they are functions of the instantaneous values of the base counts only.", [["the base counts", "TEST", 178, 193], ["base", "ANATOMY_MODIFIER", 182, 186]]], ["Equations 16-17 have been developed on the basis of transition type mutations only.", [["Equations", "TEST", 0, 9], ["transition type mutations", "PROBLEM", 52, 77]]], ["Transverse mutations are much less frequent than the transition mutations and will affect these equations to a smaller extent.", [["Transverse mutations", "PROBLEM", 0, 20], ["the transition mutations", "PROBLEM", 49, 73], ["smaller extent", "OBSERVATION_MODIFIER", 111, 125]]], ["Consider a mutation of a cytosine to an adenine.", [["cytosine", "CHEMICAL", 25, 33], ["adenine", "CHEMICAL", 40, 47], ["cytosine", "CHEMICAL", 25, 33], ["adenine", "CHEMICAL", 40, 47], ["cytosine", "SIMPLE_CHEMICAL", 25, 33], ["adenine", "SIMPLE_CHEMICAL", 40, 47], ["a cytosine", "TREATMENT", 23, 33], ["an adenine", "TREATMENT", 37, 47]]], ["This will result again in a bulge in the guanine in the opposite strand and the repair mechanism will either re-establish the cytosine or replace the guanine with a thymine, or replace the guanine in strand 2 with a thymine and add a CG base pair to the DNA thus elongating it.", [["guanine", "CHEMICAL", 41, 48], ["cytosine", "CHEMICAL", 126, 134], ["guanine", "CHEMICAL", 150, 157], ["thymine", "CHEMICAL", 165, 172], ["guanine", "CHEMICAL", 189, 196], ["thymine", "CHEMICAL", 216, 223], ["guanine", "CHEMICAL", 41, 48], ["cytosine", "CHEMICAL", 126, 134], ["guanine", "CHEMICAL", 150, 157], ["thymine", "CHEMICAL", 165, 172], ["guanine", "CHEMICAL", 189, 196], ["thymine", "CHEMICAL", 216, 223], ["guanine", "SIMPLE_CHEMICAL", 41, 48], ["cytosine", "SIMPLE_CHEMICAL", 126, 134], ["guanine", "SIMPLE_CHEMICAL", 150, 157], ["thymine", "SIMPLE_CHEMICAL", 165, 172], ["guanine", "SIMPLE_CHEMICAL", 189, 196], ["thymine", "SIMPLE_CHEMICAL", 216, 223], ["DNA", "CELLULAR_COMPONENT", 254, 257], ["CG base pair", "DNA", 234, 246], ["a bulge in the guanine", "PROBLEM", 26, 48], ["the repair mechanism", "TREATMENT", 76, 96], ["the cytosine", "TREATMENT", 122, 134], ["the guanine", "TREATMENT", 146, 157], ["a thymine", "TREATMENT", 163, 172], ["the guanine in strand", "TREATMENT", 185, 206], ["a thymine", "TREATMENT", 214, 223], ["a CG base pair", "TREATMENT", 232, 246], ["the DNA", "PROBLEM", 250, 257], ["bulge", "OBSERVATION", 28, 33], ["repair", "OBSERVATION", 80, 86]]], ["This will reduce the n C-T (1) by 1 unit and also reduce the n G-A (2) by 1 unit as well as have, as before, a small probability of adding an extra guanine in strand 2 by virtue of the additional base pair elongating the DNA.", [["guanine", "CHEMICAL", 148, 155], ["guanine", "CHEMICAL", 148, 155], ["DNA", "CELLULAR_COMPONENT", 221, 224], ["the n C-T", "TREATMENT", 17, 26], ["the n G-A", "TREATMENT", 57, 66], ["an extra guanine in strand", "TREATMENT", 139, 165], ["small", "OBSERVATION_MODIFIER", 111, 116], ["DNA", "OBSERVATION", 221, 224]]], ["Thus we will have an equation of the type of Eq.4 again except that the coefficients in this instance will be much lower in value than for these parameters in the transition type mutation case.", [["these parameters", "TEST", 139, 155]]], ["Again, we end up with equations of the form 16 to 17, this time for transverse type mutations, but with much smaller parameter values, so those equations can be considered to be quite general.DiscussionIt is also possible that as a result of mutations more than one base pair are added during the repair and replication phases.", [["transverse type mutations", "PROBLEM", 68, 93], ["mutations", "PROBLEM", 242, 251], ["the repair", "TREATMENT", 293, 303]]], ["That the third order terms seem to be required for good fits to some of the gene sequences has already been noted earlier.", [["the gene sequences", "TEST", 72, 90]]], ["Such modifications to the intra-purine, intrapyrimidine relationship can result in deviations from the smooth distribution that first order approximation equations like Eq.16, 17 would imply.", [["intrapyrimidine", "CHEMICAL", 40, 55], ["intrapyrimidine", "CHEMICAL", 40, 55], ["intra-purine", "SIMPLE_CHEMICAL", 26, 38], ["intrapyrimidine", "SIMPLE_CHEMICAL", 40, 55], ["smooth", "OBSERVATION_MODIFIER", 103, 109]]], ["This could be the underlying reason for the deviations between the actual representative plots of the various sequences and their fitted curves observed in several graphs.DiscussionThere is a further assumption that underlies the applicability of this analysis.", [["the deviations", "PROBLEM", 40, 54], ["the various sequences", "TEST", 98, 119], ["their fitted curves", "TEST", 124, 143], ["this analysis", "TEST", 247, 260]]], ["We assume that in the case of the conserved gene sequences inclusive of introns and the coding segments, extensive restructuring through recombinations have not taken place.", [["conserved gene sequences", "DNA", 34, 58], ["introns", "DNA", 72, 79], ["introns and the coding segments", "PROBLEM", 72, 103], ["extensive", "OBSERVATION_MODIFIER", 105, 114], ["restructuring", "OBSERVATION", 115, 128]]], ["Indeed the first order formalism developed here implicitly assumes that all changes to a DNA sequence that have resulted in the form that we observe now have taken place through mutational changes only, and recombinations and transpositions have not had any major impact on the sequences.DiscussionA couple of points of interest arising from these equations may be mentioned here.", [["DNA", "CELLULAR_COMPONENT", 89, 92], ["DNA sequence", "DNA", 89, 101], ["a DNA sequence", "TEST", 87, 101]]], ["First, homologous sequences of conserved genes of the intronless or with-introns varieties that have the same general shape on the 2D plots therefore have similar describing equations, and the coefficients of the variables have similar order of magnitude values.", [["conserved genes", "DNA", 31, 46], ["intronless", "DNA", 54, 64], ["-introns varieties", "DNA", 72, 90], ["the intronless", "PROBLEM", 50, 64], ["introns varieties", "PROBLEM", 73, 90]]], ["This would seem to indicate that these gene sequences have inherent characteristics that are expressed by the values of the parameters of the describing equations, whereby major deviations in base distributions that necessitate large departures from the characteristic values could be inimical to the functioning of the gene and thus would either be rejected, or would render the gene ineffective.", [["these gene sequences", "PROBLEM", 33, 53], ["major deviations in base distributions", "PROBLEM", 172, 210], ["large departures", "PROBLEM", 228, 244], ["major", "OBSERVATION_MODIFIER", 172, 177], ["deviations", "OBSERVATION", 178, 188], ["base", "ANATOMY_MODIFIER", 192, 196], ["large", "OBSERVATION_MODIFIER", 228, 233]]], ["A case could be made from the human alpha globin 1 pseudogene: although it shares a reasonable degree of homology with the functional alpha 1 globin gene and has the 3 exon-2 intron architecture of the globin family, its 2D plot shows a wide variation in base distribution from the alpha globin gene (Fig. 8) , and the coefficients of fitted polynomial also are quite different from the other mammalian alpha globin family fits (Table 1) .", [["human", "ORGANISM", 30, 35], ["alpha globin 1", "GENE_OR_GENE_PRODUCT", 36, 50], ["alpha 1 globin", "GENE_OR_GENE_PRODUCT", 134, 148], ["globin", "GENE_OR_GENE_PRODUCT", 202, 208], ["alpha globin", "GENE_OR_GENE_PRODUCT", 282, 294], ["alpha globin", "GENE_OR_GENE_PRODUCT", 403, 415], ["human alpha globin 1 pseudogene", "DNA", 30, 61], ["alpha 1 globin gene", "DNA", 134, 153], ["globin family", "DNA", 202, 215], ["alpha globin gene", "DNA", 282, 299], ["mammalian alpha globin family", "PROTEIN", 393, 422], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["its 2D plot", "TEST", 217, 228], ["a wide variation in base distribution", "PROBLEM", 235, 272], ["globin", "ANATOMY", 202, 208], ["wide", "OBSERVATION_MODIFIER", 237, 241], ["variation", "OBSERVATION_MODIFIER", 242, 251], ["base", "ANATOMY_MODIFIER", 255, 259], ["alpha globin gene", "OBSERVATION", 282, 299], ["alpha globin", "OBSERVATION", 403, 415]]], ["It may also be mentioned that transposons are found in many instances to insert segments into genes which are then excised out in successive replication cycles.", [["transposons", "DNA", 30, 41], ["successive replication cycles", "TREATMENT", 130, 159], ["successive", "OBSERVATION_MODIFIER", 130, 140], ["replication cycles", "OBSERVATION", 141, 159]]], ["If DNA sequences have inherent characteristics, which are encapsulated by the polynomial expression, and the inserted segments lead to incompatibility with such characteristics, then such excisions can be understood.DiscussionWe note that reversion of mutated genes to ancestral forms is not totally unknown.", [["DNA", "CELLULAR_COMPONENT", 3, 6], ["DNA sequences", "DNA", 3, 16], ["mutated genes", "DNA", 252, 265], ["DNA sequences", "TEST", 3, 16], ["such excisions", "TREATMENT", 183, 197], ["mutated genes to ancestral forms", "PROBLEM", 252, 284], ["encapsulated", "OBSERVATION_MODIFIER", 58, 70], ["polynomial expression", "OBSERVATION", 78, 99]]], ["A case in point is the recent study of reversion of mutant hothead gene in Arabidopsis thaliana to genes that existed in plants of two or more generations ago [32] .", [["Arabidopsis thaliana", "ORGANISM", 75, 95], ["mutant hothead gene", "DNA", 52, 71], ["Arabidopsis thaliana", "SPECIES", 75, 95], ["Arabidopsis thaliana", "SPECIES", 75, 95], ["the recent study", "TEST", 19, 35], ["mutant hothead gene in Arabidopsis thaliana", "PROBLEM", 52, 95], ["Arabidopsis thaliana", "OBSERVATION", 75, 95]]], ["The authors have hypothesized that a template-directed restoration of ancestral DNA passed on in an RNA cache could underlie the mechanism of such reversion; the existence of such a mechanism that lies outside the DNA genome could lead to the high-frequency modification of DNA sequences in a template-directed manner, perhaps by the postulated RNA cache that could allow it to persist for several generations.", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["DNA", "CELLULAR_COMPONENT", 274, 277], ["ancestral DNA", "DNA", 70, 83], ["DNA genome", "DNA", 214, 224], ["DNA sequences", "DNA", 274, 287], ["a template", "TREATMENT", 35, 45], ["ancestral DNA", "PROBLEM", 70, 83], ["an RNA cache", "PROBLEM", 97, 109], ["such reversion", "PROBLEM", 142, 156], ["the DNA genome", "PROBLEM", 210, 224], ["DNA sequences", "PROBLEM", 274, 287], ["the postulated RNA cache", "PROBLEM", 330, 354], ["ancestral DNA", "OBSERVATION", 70, 83], ["RNA cache", "OBSERVATION", 345, 354]]], ["While Lolle et al's RNA cache [32] would need to carry an exact duplicate of the ancestral sequence, in the case of gene sequences of the types considered here that may or may not contain intron segments and could be quite large, we could postulate existence of some as yet unknown mechanism for monitoring conformity with the overall intra-purine intra-pyrimidine base distribution pattern, as perhaps for long range correlations [7, 33] .", [["intra-pyrimidine", "CHEMICAL", 348, 364], ["intra-pyrimidine", "CHEMICAL", 348, 364], ["intra-pyrimidine", "SIMPLE_CHEMICAL", 348, 364], ["intron segments", "DNA", 188, 203], ["large", "OBSERVATION", 223, 228]]], ["In this connection it is also interesting to consider the possibility of the existence of some error correcting code in DNA sequences as speculated upon by Liebovitch et al [34] .", [["DNA", "CELLULAR_COMPONENT", 120, 123], ["DNA sequences", "DNA", 120, 133], ["DNA sequences", "TEST", 120, 133]]], ["They considered the DNA sequence as a digital code of four symbols and speculated that since the integrity of modern information encoding is secured by having error correcting codes built in, DNA sequences might also have such codes to allow repair enzymes to protect the fidelity of nonreplicating DNA and increase the accuracy of replication.", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["DNA sequence", "DNA", 20, 32], ["DNA sequences", "DNA", 192, 205], ["repair enzymes", "PROTEIN", 242, 256], ["nonreplicating DNA", "DNA", 284, 302], ["the DNA sequence", "TEST", 16, 32], ["repair enzymes", "TREATMENT", 242, 256], ["nonreplicating DNA", "PROBLEM", 284, 302]]], ["In such a case if a linear block error correcting code is present in DNA then some bases would be a linear function of the other bases in each set of bases.", [["DNA", "CELLULAR_COMPONENT", 69, 72], ["a linear block error", "PROBLEM", 18, 38], ["linear", "OBSERVATION_MODIFIER", 100, 106], ["function", "OBSERVATION", 107, 115], ["bases", "ANATOMY_MODIFIER", 129, 134], ["bases", "ANATOMY_MODIFIER", 150, 155]]], ["Although the authors were unable to find any such simple code in the lac operon and cytochrome c gene they investigated, the suggestion remains an intriguing possibility nevertheless.", [["lac operon", "GENE_OR_GENE_PRODUCT", 69, 79], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 84, 96], ["lac operon", "DNA", 69, 79], ["cytochrome c gene", "DNA", 84, 101], ["the lac operon", "TREATMENT", 65, 79], ["cytochrome c gene", "TREATMENT", 84, 101]]], ["Given that we are considering highly conserved genes whose functions are important to the survival of the organism, mechanisms such as these would provide a survival advantage and could be used under conditions that compromised the continued functioning of the organism or the requirements of the monitoring process.DiscussionSecond, the basic patterns, and therefore the describing equations, have the same form irrespective of the intron content of the genes considered here.", [["the organism", "PROBLEM", 102, 114], ["a survival advantage", "TREATMENT", 155, 175], ["the organism", "PROBLEM", 257, 269], ["the monitoring process", "TEST", 293, 315]]], ["This could be indicative of the monitoring process hypothesized above also functioning irrespective of whether the sequences are intronless or intron-rich.", [["intron-rich", "PROBLEM", 143, 154], ["could be indicative of", "UNCERTAINTY", 5, 27]]], ["Since mutations and other evolutionary changes have led to modifications in the coding sequences within the requirements of maintaining protein functionality, the introns may have a role to play such as maintaining the structure of base arrangements so that the restrictions implied by the equations 16, 17 can continue to apply.", [["coding sequences", "DNA", 80, 96], ["introns", "DNA", 163, 170], ["protein functionality", "OBSERVATION", 136, 157]]], ["We could perhaps consider for support for this contention the globin genes where the beta globins separated from the alphas quite late, but the introns of the beta globin cluster are generally longer than the alpha globins while the coding sequences, though with differences, remain at almost the same length.", [["globin", "GENE_OR_GENE_PRODUCT", 62, 68], ["beta globins", "GENE_OR_GENE_PRODUCT", 85, 97], ["alphas", "GENE_OR_GENE_PRODUCT", 117, 123], ["beta globin", "GENE_OR_GENE_PRODUCT", 159, 170], ["alpha globins", "GENE_OR_GENE_PRODUCT", 209, 222], ["globin genes", "DNA", 62, 74], ["beta globins", "DNA", 85, 97], ["introns", "DNA", 144, 151], ["beta globin cluster", "DNA", 159, 178], ["alpha globins", "PROTEIN", 209, 222], ["support", "TREATMENT", 30, 37], ["this contention the globin genes", "PROBLEM", 42, 74], ["the beta globins", "TEST", 81, 97], ["the coding sequences", "TEST", 229, 249], ["globin genes", "OBSERVATION", 62, 74], ["beta globin cluster", "OBSERVATION", 159, 178]]], ["If sustained, such a hypothesis could lend support to the intron late theory.DiscussionWe note in passing that for the majority of the gene sequences of the vertebrates, the 2D plots display an overall shape that is concave going in the clockwise direction; correspondingly, the coefficient of the second degree variable is negative.", [["overall", "OBSERVATION_MODIFIER", 194, 201], ["shape", "OBSERVATION_MODIFIER", 202, 207], ["concave", "OBSERVATION_MODIFIER", 216, 223], ["negative", "OBSERVATION", 324, 332]]], ["This is seen even in the case of the chicken beta globin gene where the large intron component makes it GC-rich, the human beta globin gene which is AT-rich, as also the alpha globin genes of the horse, rhesus monkey and human which are all GC-rich.", [["chicken", "ORGANISM", 37, 44], ["beta globin", "GENE_OR_GENE_PRODUCT", 45, 56], ["human", "ORGANISM", 117, 122], ["beta globin", "GENE_OR_GENE_PRODUCT", 123, 134], ["alpha globin", "GENE_OR_GENE_PRODUCT", 170, 182], ["horse", "ORGANISM", 196, 201], ["rhesus monkey", "ORGANISM", 203, 216], ["human", "ORGANISM", 221, 226], ["chicken beta globin gene", "DNA", 37, 61], ["human beta globin gene", "DNA", 117, 139], ["alpha globin genes", "DNA", 170, 188], ["chicken", "SPECIES", 37, 44], ["human", "SPECIES", 117, 122], ["horse", "SPECIES", 196, 201], ["rhesus monkey", "SPECIES", 203, 216], ["human", "SPECIES", 221, 226], ["chicken", "SPECIES", 37, 44], ["human", "SPECIES", 117, 122], ["rhesus monkey", "SPECIES", 203, 216], ["human", "SPECIES", 221, 226], ["the chicken beta globin gene", "TREATMENT", 33, 61], ["the large intron component", "PROBLEM", 68, 94], ["large", "OBSERVATION_MODIFIER", 72, 77], ["intron", "OBSERVATION", 78, 84], ["alpha globin", "OBSERVATION", 170, 182]]], ["Plots of some viral sequences such as the H5N1 neuraminidase, on the other hand, have concavity in the opposite direction and the sign of the coefficient of the second degree variable is positive.", [["H5N1 neuraminidase", "ORGANISM", 42, 60], ["H5N1 neuraminidase", "PROTEIN", 42, 60], ["some viral sequences", "TEST", 9, 29], ["the H5N1 neuraminidase", "PROBLEM", 38, 60], ["H5N1 neuraminidase", "OBSERVATION", 42, 60], ["concavity", "OBSERVATION", 86, 95], ["positive", "OBSERVATION", 187, 195]]], ["Interestingly this is also seen in the case of the wheat histone H4 gene, which is claimed by some authors to have viral features [35] ; their origins from before the eukaryote split could also be a factor.", [["histone H4", "GENE_OR_GENE_PRODUCT", 57, 67], ["wheat histone H4 gene", "DNA", 51, 72], ["wheat", "SPECIES", 51, 56], ["wheat", "SPECIES", 51, 56], ["viral features", "PROBLEM", 115, 129]]], ["Whether this is just chance coincidence or whether it is symptomatic of some deeper characteristic arising from base composition and distribution differences in prokaryotic and eukaryotic sequences remains an intriguing question.DiscussionIn summary, our observations have shown that the 2D plots of intra-purine versus intra-pyrimidine differences in conserved gene sequences exhibit an apparent pattern in base distribution of the sequences that mimic the behaviour essentially of a polynomial of degree 2, and in some cases of degree 3.", [["intra-purine", "CHEMICAL", 300, 312], ["intra-pyrimidine", "CHEMICAL", 320, 336], ["intra-pyrimidine", "CHEMICAL", 320, 336], ["intra-purine", "SIMPLE_CHEMICAL", 300, 312], ["intra-pyrimidine", "SIMPLE_CHEMICAL", 320, 336], ["prokaryotic and eukaryotic sequences", "DNA", 161, 197], ["conserved gene sequences", "DNA", 352, 376], ["symptomatic", "PROBLEM", 57, 68], ["the 2D plots of intra-purine versus intra-pyrimidine differences in conserved gene sequences", "PROBLEM", 284, 376], ["symptomatic", "OBSERVATION_MODIFIER", 57, 68], ["base", "OBSERVATION_MODIFIER", 112, 116], ["composition", "OBSERVATION_MODIFIER", 117, 128], ["distribution", "OBSERVATION_MODIFIER", 133, 145], ["base", "ANATOMY_MODIFIER", 408, 412]]], ["This is found over a wide cross section of sequences, from e.g., the members of the globin family, the histones, tubulins and heat shock proteins.", [["globin", "GENE_OR_GENE_PRODUCT", 84, 90], ["histones", "GENE_OR_GENE_PRODUCT", 103, 111], ["tubulins", "GENE_OR_GENE_PRODUCT", 113, 121], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 126, 145], ["globin family", "PROTEIN", 84, 97], ["histones", "PROTEIN", 103, 111], ["tubulins", "PROTEIN", 113, 121], ["heat shock proteins", "PROTEIN", 126, 145], ["the histones", "PROBLEM", 99, 111], ["heat shock proteins", "TREATMENT", 126, 145]]], ["Viral sequences such as the H5N1 neuraminidase, although known to mutate rapidly, also exhibit similar structure.", [["H5N1 neuraminidase", "ORGANISM", 28, 46], ["H5N1 neuraminidase", "PROTEIN", 28, 46], ["H5N1 neuraminidase", "SPECIES", 28, 46], ["Viral sequences", "TEST", 0, 15], ["the H5N1 neuraminidase", "PROBLEM", 24, 46], ["H5N1", "OBSERVATION", 28, 32], ["similar structure", "OBSERVATION", 95, 112]]], ["We have seen that this may arise from the non-symmetrical mutation repair mechanism where e.g., a cytosine mutating to thymine in a GCrich sequence could lead to negating the mutation, to replacing the original paired guanine with adenine, or elongating the DNA by addition of a CG pair along with coupling the thymine with an adenine.", [["cytosine", "CHEMICAL", 98, 106], ["thymine", "CHEMICAL", 119, 126], ["guanine", "CHEMICAL", 218, 225], ["adenine", "CHEMICAL", 231, 238], ["thymine", "CHEMICAL", 311, 318], ["adenine", "CHEMICAL", 327, 334], ["cytosine", "CHEMICAL", 98, 106], ["thymine", "CHEMICAL", 119, 126], ["guanine", "CHEMICAL", 218, 225], ["adenine", "CHEMICAL", 231, 238], ["thymine", "CHEMICAL", 311, 318], ["adenine", "CHEMICAL", 327, 334], ["cytosine", "SIMPLE_CHEMICAL", 98, 106], ["thymine", "SIMPLE_CHEMICAL", 119, 126], ["guanine", "SIMPLE_CHEMICAL", 218, 225], ["adenine", "SIMPLE_CHEMICAL", 231, 238], ["DNA", "CELLULAR_COMPONENT", 258, 261], ["thymine", "SIMPLE_CHEMICAL", 311, 318], ["adenine", "SIMPLE_CHEMICAL", 327, 334], ["GCrich sequence", "DNA", 132, 147], ["the non-symmetrical mutation repair", "TREATMENT", 38, 73], ["a cytosine", "TREATMENT", 96, 106], ["a GCrich sequence", "TEST", 130, 147], ["the mutation", "PROBLEM", 171, 183], ["adenine", "TREATMENT", 231, 238], ["elongating the DNA", "PROBLEM", 243, 261], ["a CG pair", "TREATMENT", 277, 286], ["coupling the thymine", "TREATMENT", 298, 318], ["an adenine", "TREATMENT", 324, 334]]], ["Equivalent considerations apply to AT-rich sequences as well.DiscussionSince these observations appear true for intron-rich sequences also, the intron sequences may play a regulatory role in preserving sequence integrity as indicated by the intra-purine intra-pyrimidine relationships permitting greater flexibility in changes in coding sequences.DiscussionNot unexpectedly, we have seen that homologous genes have characteristic equations where the coefficients of the describing polynomials are quite close.", [["intra-pyrimidine", "CHEMICAL", 254, 270], ["intra-pyrimidine", "CHEMICAL", 254, 270], ["AT-rich sequences", "DNA", 35, 52], ["intron", "DNA", 112, 118], ["intron sequences", "DNA", 144, 160], ["coding sequences", "DNA", 330, 346], ["homologous genes", "DNA", 393, 409], ["intron-rich sequences", "TEST", 112, 133], ["the intron sequences", "TEST", 140, 160]]], ["Assuming that the DNA fidelity processes fit to this scheme of preferential arrangement of bases in conserved segments, our observations raise the possibility that DNA fragments, introduced into such segments by processes such as transpositions, that do not conform to the overall fit may be preferentially excised by the replication machinery to retain the integrity of the host sequence.", [["DNA", "CELLULAR_COMPONENT", 18, 21], ["DNA", "CELLULAR_COMPONENT", 164, 167], ["DNA fragments", "DNA", 164, 177], ["the DNA fidelity processes", "PROBLEM", 14, 40], ["DNA fragments", "PROBLEM", 164, 177], ["bases", "ANATOMY_MODIFIER", 91, 96], ["segments", "ANATOMY_MODIFIER", 110, 118], ["raise the possibility", "UNCERTAINTY", 137, 158], ["DNA fragments", "OBSERVATION", 164, 177]]], ["If our observations here in gene sequences are extendible further to genomic sequences then it would imply that not all genetic modifications would be sustainable.", [["genomic sequences", "DNA", 69, 86], ["gene sequences", "TEST", 28, 42]]]], "0c188cbef221e8118400729b9fcbc2e2feb73acd": [["IntroductionAsthma is one of the most common chronic immune diseases in humans and is characterized by chronic allergic inflammatory reactions in the airways, resulting in bronchoconstriction, vasodilation, activation of airway edema, and diseases occurring in all age groups from young to old [1, 2] .", [["airways", "ANATOMY", 150, 157], ["airway", "ANATOMY", 221, 227], ["IntroductionAsthma", "DISEASE", 0, 18], ["immune diseases", "DISEASE", 53, 68], ["allergic inflammatory reactions", "DISEASE", 111, 142], ["airway edema", "DISEASE", 221, 233], ["humans", "ORGANISM", 72, 78], ["airways", "MULTI-TISSUE_STRUCTURE", 150, 157], ["airway edema", "PATHOLOGICAL_FORMATION", 221, 233], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["chronic immune diseases in humans", "PROBLEM", 45, 78], ["chronic allergic inflammatory reactions in the airways", "PROBLEM", 103, 157], ["bronchoconstriction", "PROBLEM", 172, 191], ["vasodilation", "PROBLEM", 193, 205], ["airway edema", "PROBLEM", 221, 233], ["diseases", "PROBLEM", 239, 247], ["most common", "OBSERVATION_MODIFIER", 33, 44], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["immune diseases", "OBSERVATION", 53, 68], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["allergic", "OBSERVATION_MODIFIER", 111, 119], ["inflammatory", "OBSERVATION", 120, 132], ["airways", "ANATOMY", 150, 157], ["bronchoconstriction", "OBSERVATION", 172, 191], ["vasodilation", "OBSERVATION_MODIFIER", 193, 205], ["airway", "ANATOMY", 221, 227], ["edema", "OBSERVATION", 228, 233], ["diseases", "OBSERVATION", 239, 247]]], ["More than 300 million people worldwide have been diagnosed with asthma, and due to the continued increase in asthma prevalence, it is expected that the number of asthma patients will reach nearly 400 million by 2020 [3] .", [["asthma", "DISEASE", 64, 70], ["asthma", "DISEASE", 109, 115], ["asthma", "DISEASE", 162, 168], ["people", "ORGANISM", 22, 28], ["patients", "ORGANISM", 169, 177], ["people", "SPECIES", 22, 28], ["patients", "SPECIES", 169, 177], ["asthma", "PROBLEM", 64, 70], ["asthma prevalence", "PROBLEM", 109, 126], ["asthma", "PROBLEM", 162, 168], ["asthma", "OBSERVATION", 64, 70], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["asthma", "OBSERVATION", 109, 115], ["asthma", "OBSERVATION", 162, 168]]], ["Air pollution by particulate matter 10 (PM10) is a risk factor for exacerbation of asthma [4, 5] .Introductionhospitalization rates for asthma/chronic obstructive pulmonary disease (COPD) patients [10] .", [["pulmonary", "ANATOMY", 163, 172], ["PM10", "CHEMICAL", 40, 44], ["asthma", "DISEASE", 83, 89], ["asthma", "DISEASE", 136, 142], ["chronic obstructive pulmonary disease", "DISEASE", 143, 180], ["COPD", "DISEASE", 182, 186], ["pulmonary", "ORGAN", 163, 172], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["Air pollution", "PROBLEM", 0, 13], ["exacerbation", "PROBLEM", 67, 79], ["asthma", "PROBLEM", 83, 89], ["Introductionhospitalization rates", "TREATMENT", 98, 131], ["asthma", "PROBLEM", 136, 142], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 143, 187], ["asthma", "OBSERVATION", 83, 89], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["obstructive", "OBSERVATION_MODIFIER", 151, 162], ["pulmonary", "ANATOMY", 163, 172], ["disease", "OBSERVATION", 173, 180], ["COPD", "OBSERVATION", 182, 186]]], ["In recent years, the concentration of PM10 in the environment has been steadily decreasing in Korea, but is still higher than in other countries [11] .", [["PM10", "CHEMICAL", 38, 42], ["PM10", "CHEMICAL", 38, 42], ["PM10", "SIMPLE_CHEMICAL", 38, 42], ["steadily", "OBSERVATION_MODIFIER", 71, 79], ["decreasing", "OBSERVATION_MODIFIER", 80, 90], ["higher", "OBSERVATION_MODIFIER", 114, 120]]], ["Due to rapid industrialization in Korea, the air quality has greatly deteriorated.", [["the air quality", "TEST", 41, 56], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["industrialization", "OBSERVATION", 13, 30], ["air quality", "OBSERVATION", 45, 56], ["greatly", "OBSERVATION_MODIFIER", 61, 68], ["deteriorated", "OBSERVATION_MODIFIER", 69, 81]]], ["In addition, health problems are increasing in the society as the number of days of dust storms in Asian countries, such as China and Mongolia, exceeds the air quality standard of PM10 even in spring, fall, and winter [12, 13] . erefore, as public interest in PM10 increases, studies are being actively conducted to prevent or improve the adverse effects caused by PM10induced inflammation and various diseases.", [["PM10", "CHEMICAL", 180, 184], ["PM10", "CHEMICAL", 260, 264], ["inflammation", "DISEASE", 377, 389], ["PM10", "SIMPLE_CHEMICAL", 260, 264], ["health problems", "PROBLEM", 13, 28], ["studies", "TEST", 276, 283], ["the adverse effects", "PROBLEM", 335, 354], ["PM10induced inflammation", "PROBLEM", 365, 389], ["various diseases", "PROBLEM", 394, 410], ["increasing", "OBSERVATION_MODIFIER", 33, 43], ["inflammation", "OBSERVATION", 377, 389], ["various", "OBSERVATION_MODIFIER", 394, 401], ["diseases", "OBSERVATION", 402, 410]]], ["Among the studies for the development of therapeutic agents, compounds derived from plants with few side effects are gaining attention as potential therapeutic agents.IntroductionRosa laevigata (RL) is a plant belonging to the family Rosaceae that has long been used predominantly for medicinal purposes in Korea and China, and the fruits of RL are often used as tonic or painkillers [14] .", [["fruits", "ANATOMY", 332, 338], ["IntroductionRosa laevigata", "ORGANISM", 167, 193], ["RL)", "ORGANISM", 195, 198], ["Rosaceae", "ORGANISM", 234, 242], ["fruits", "ORGANISM_SUBDIVISION", 332, 338], ["IntroductionRosa laevigata", "SPECIES", 167, 193], ["IntroductionRosa laevigata", "SPECIES", 167, 193], ["the studies", "TEST", 6, 17], ["therapeutic agents", "TREATMENT", 41, 59], ["few side effects", "PROBLEM", 96, 112], ["therapeutic agents", "TREATMENT", 148, 166]]], ["A recent pharmacological study of RL has suggested that relief from various diseases including the function of flavonoids in relieving oxidative stress, inflammation, and apoptosis and total saponins in RL protect against liver disease caused by carbon tetrachloride [15] [16] [17] .", [["liver", "ANATOMY", 222, 227], ["RL", "CHEMICAL", 34, 36], ["flavonoids", "CHEMICAL", 111, 121], ["inflammation", "DISEASE", 153, 165], ["RL", "CHEMICAL", 203, 205], ["liver disease", "DISEASE", 222, 235], ["carbon tetrachloride", "CHEMICAL", 246, 266], ["15] [16] [17]", "CHEMICAL", 268, 281], ["flavonoids", "CHEMICAL", 111, 121], ["saponins", "CHEMICAL", 191, 199], ["carbon tetrachloride", "CHEMICAL", 246, 266], ["RL", "CANCER", 34, 36], ["flavonoids", "SIMPLE_CHEMICAL", 111, 121], ["saponins", "SIMPLE_CHEMICAL", 191, 199], ["RL", "SIMPLE_CHEMICAL", 203, 205], ["liver", "ORGAN", 222, 227], ["carbon tetrachloride", "SIMPLE_CHEMICAL", 246, 266], ["15] [16] [17]", "SIMPLE_CHEMICAL", 268, 281], ["A recent pharmacological study", "TEST", 0, 30], ["various diseases", "PROBLEM", 68, 84], ["flavonoids", "TREATMENT", 111, 121], ["relieving oxidative stress", "PROBLEM", 125, 151], ["inflammation", "PROBLEM", 153, 165], ["apoptosis", "PROBLEM", 171, 180], ["total saponins in RL", "TREATMENT", 185, 205], ["liver disease", "PROBLEM", 222, 235], ["carbon tetrachloride", "TREATMENT", 246, 266], ["inflammation", "OBSERVATION", 153, 165], ["liver", "ANATOMY", 222, 227]]], ["However, the anti-inflammatory effect on epithelial cells in the lungs related to allergic asthma is the only study in our epidermal growth factor-(EGF-) induced inflammation model [18] . erefore, in the present study, we investigated the mechanism through which PM10 causes inflammatory responses in pulmonary epithelial cells.", [["epithelial cells", "ANATOMY", 41, 57], ["lungs", "ANATOMY", 65, 70], ["pulmonary epithelial cells", "ANATOMY", 301, 327], ["allergic asthma", "DISEASE", 82, 97], ["inflammation", "DISEASE", 162, 174], ["PM10", "CHEMICAL", 263, 267], ["PM10", "CHEMICAL", 263, 267], ["epithelial cells", "CELL", 41, 57], ["lungs", "ORGAN", 65, 70], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 123, 146], ["EGF", "GENE_OR_GENE_PRODUCT", 148, 151], ["PM10", "SIMPLE_CHEMICAL", 263, 267], ["pulmonary epithelial cells", "CELL", 301, 327], ["epithelial cells", "CELL_TYPE", 41, 57], ["pulmonary epithelial cells", "CELL_TYPE", 301, 327], ["epithelial cells in the lungs", "PROBLEM", 41, 70], ["allergic asthma", "PROBLEM", 82, 97], ["our epidermal growth factor", "TEST", 119, 146], ["induced inflammation model", "PROBLEM", 154, 180], ["inflammatory responses in pulmonary epithelial cells", "PROBLEM", 275, 327], ["anti-inflammatory", "OBSERVATION_MODIFIER", 13, 30], ["epithelial cells", "OBSERVATION", 41, 57], ["lungs", "ANATOMY", 65, 70], ["related to", "UNCERTAINTY", 71, 81], ["allergic asthma", "OBSERVATION", 82, 97], ["inflammatory", "OBSERVATION", 275, 287], ["pulmonary", "ANATOMY", 301, 310], ["epithelial cells", "OBSERVATION", 311, 327]]], ["In addition, we investigated the effectiveness and treatment mechanisms of RL in an inflammatory model induced by PM10.Reagents.", [["RL", "CHEMICAL", 75, 77], ["PM10", "CHEMICAL", 114, 118], ["RL", "SIMPLE_CHEMICAL", 75, 77], ["PM10", "SIMPLE_CHEMICAL", 114, 118], ["treatment mechanisms of RL", "TREATMENT", 51, 77], ["inflammatory", "OBSERVATION", 84, 96]]], ["Fine dust (PM10-like) (European ReferenceMaterial ERM-CZ120) was purchased from Sigma-Aldrich (St. Louis, MO, USA).", [["PM10", "CHEMICAL", 11, 15], ["St. Louis", "ORGANISM", 95, 104], ["dust", "OBSERVATION", 5, 9]]], ["MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-[2H]-tetrazolium bromide) was purchased from Invitrogen (Waltham, MA, USA).", [["MTT", "CHEMICAL", 0, 3], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-[2H]-tetrazolium bromide", "CHEMICAL", 5, 71], ["MTT", "CHEMICAL", 0, 3], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-[2H]-tetrazolium bromide", "CHEMICAL", 5, 71], ["MTT", "SIMPLE_CHEMICAL", 0, 3], ["3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-[2H]-tetrazolium bromide", "SIMPLE_CHEMICAL", 5, 71], ["MTT", "TEST", 0, 3], ["dimethyl", "TREATMENT", 12, 20], ["thiazolyl", "TREATMENT", 23, 32], ["-diphenyl", "TREATMENT", 37, 46], ["tetrazolium bromide", "TREATMENT", 52, 71]]], ["Rabbit anti-NF-\u03baB p65, anti-COX-2, anti-Lamin B1, anti-phospho-ERK1/2, anti-ERK1/2, anti-phospho-JNK, anti-JNK, anti-phospho-p38, and anti-p38 were purchased from Cell Signaling Tech (CST, Beverly, MA, USA), and mouse anti-\u03b2-actin, goat antimouse IgG-HRP, and goat anti-rabbit IgG-HRP antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).Sample Preparation.RL extract preparation and UPLC/ ESI-QTOF-MS analysis have been described in our previous study [18] .", [["Cell", "ANATOMY", 163, 167], ["RL extract", "CHEMICAL", 378, 388], ["anti-NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 7, 21], ["COX-2", "GENE_OR_GENE_PRODUCT", 28, 33], ["anti-Lamin B1", "GENE_OR_GENE_PRODUCT", 35, 48], ["anti-phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 50, 69], ["anti-ERK1/2", "GENE_OR_GENE_PRODUCT", 71, 82], ["anti-phospho-JNK", "GENE_OR_GENE_PRODUCT", 84, 100], ["anti-JNK", "GENE_OR_GENE_PRODUCT", 102, 110], ["anti-phospho-p38", "GENE_OR_GENE_PRODUCT", 112, 128], ["-p38", "GENE_OR_GENE_PRODUCT", 138, 142], ["Cell", "CELL", 163, 167], ["mouse", "ORGANISM", 212, 217], ["anti-\u03b2-actin", "GENE_OR_GENE_PRODUCT", 218, 230], ["goat", "ORGANISM", 232, 236], ["IgG-HRP", "GENE_OR_GENE_PRODUCT", 247, 254], ["goat", "ORGANISM", 260, 264], ["HRP", "GENE_OR_GENE_PRODUCT", 281, 284], ["Rabbit anti-NF-\u03baB p65", "PROTEIN", 0, 21], ["COX-2", "PROTEIN", 28, 33], ["anti-Lamin B1", "PROTEIN", 35, 48], ["anti-phospho-ERK1/2", "PROTEIN", 50, 69], ["anti-ERK1/2", "PROTEIN", 71, 82], ["anti-phospho", "PROTEIN", 84, 96], ["JNK", "PROTEIN", 97, 100], ["anti-JNK", "PROTEIN", 102, 110], ["anti-phospho", "PROTEIN", 112, 124], ["p38", "PROTEIN", 125, 128], ["anti-p38", "PROTEIN", 134, 142], ["mouse anti-\u03b2-actin", "PROTEIN", 212, 230], ["goat antimouse IgG", "PROTEIN", 232, 250], ["HRP", "PROTEIN", 251, 254], ["goat anti-rabbit IgG", "PROTEIN", 260, 280], ["HRP antibodies", "PROTEIN", 281, 295], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 212, 217], ["goat", "SPECIES", 232, 236], ["antimouse", "SPECIES", 237, 246], ["goat", "SPECIES", 260, 264], ["anti-rabbit", "SPECIES", 265, 276], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 212, 217], ["goat", "SPECIES", 232, 236], ["goat", "SPECIES", 260, 264], ["anti-rabbit", "SPECIES", 265, 276], ["Rabbit anti-NF", "TEST", 0, 14], ["anti-COX", "TEST", 23, 31], ["anti-Lamin B1", "TREATMENT", 35, 48], ["anti-phospho", "TEST", 50, 62], ["ERK1", "TEST", 63, 67], ["anti-ERK1", "TEST", 71, 80], ["anti-phospho", "TEST", 84, 96], ["JNK", "TEST", 97, 100], ["anti-JNK", "TEST", 102, 110], ["anti-phospho", "TEST", 112, 124], ["anti", "TEST", 134, 138], ["CST", "TEST", 184, 187], ["mouse anti-\u03b2-actin", "TREATMENT", 212, 230], ["goat antimouse IgG", "TEST", 232, 250], ["HRP", "TEST", 251, 254], ["goat anti-rabbit IgG", "TEST", 260, 280], ["HRP antibodies", "PROBLEM", 281, 295], ["RL extract preparation", "TREATMENT", 378, 400], ["UPLC/ ESI", "TEST", 405, 414], ["MS analysis", "TEST", 420, 431], ["our previous study", "TEST", 455, 473]]], ["Briefly, RL was extracted with distilled water for 3 h at 100\u00b0C. e extract was filtered and evaporated using a rotary vacuum evaporator at 60\u00b0C. Finally, the extract was powdered by lyophilization at \u221280\u00b0C for 24 h.Cell LineCulture.", [["extract", "ANATOMY", 158, 165], ["Cell", "ANATOMY", 215, 219], ["e extract", "CHEMICAL", 65, 74], ["Cell", "CELL", 215, 219], ["e extract", "TREATMENT", 65, 74], ["a rotary vacuum evaporator", "TREATMENT", 109, 135], ["lyophilization", "TREATMENT", 182, 196]]], ["A549 cells were purchased from American Type Culture Collection (ATCC, MD, USA). e cells were cultured using Dulbecco's modified Eagle's medium mixed with 10% FBS (Gibco, NY, USA) and 1X antibiotic-antimycotic solution (ABAM, Corning Inc., NY, USA) at 37\u00b0C and 5% CO 2 conditions.MTT Assay.To assess the cytotoxic effect of PM10, A549 cells were seeded in a 96-well plate (1 \u00d7 10 4 cells/well) and incubated for 24 h.", [["A549 cells", "ANATOMY", 0, 10], ["e cells", "ANATOMY", 81, 88], ["A549 cells", "ANATOMY", 330, 340], ["cells", "ANATOMY", 382, 387], ["PM10", "CHEMICAL", 324, 328], ["CO", "CHEMICAL", 264, 266], ["MTT", "CHEMICAL", 280, 283], ["A549 cells", "CELL", 0, 10], ["e cells", "CELL", 81, 88], ["FBS", "ORGANISM_SUBSTANCE", 159, 162], ["PM10", "SIMPLE_CHEMICAL", 324, 328], ["A549 cells", "CELL", 330, 340], ["cells", "CELL", 382, 387], ["A549 cells", "CELL_LINE", 0, 10], ["A549 cells", "CELL_LINE", 330, 340], ["ATCC", "SPECIES", 65, 69], ["A549 cells", "PROBLEM", 0, 10], ["e cells", "PROBLEM", 81, 88], ["Dulbecco", "TEST", 109, 117], ["1X antibiotic-antimycotic solution", "TREATMENT", 184, 218], ["MTT Assay", "TEST", 280, 289], ["A549 cells", "TREATMENT", 330, 340]]], ["After starvation, the cells were treated with PM10 at varying final concentrations of 25, 50, 100, 200, and 400 \u03bcg/mL and incubated for 24 h.", [["cells", "ANATOMY", 22, 27], ["PM10", "CHEMICAL", 46, 50], ["PM10", "CHEMICAL", 46, 50], ["cells", "CELL", 22, 27], ["PM10", "SIMPLE_CHEMICAL", 46, 50], ["PM10", "TREATMENT", 46, 50]]], ["After removing media from each well, MTT solution (5 mg/mL) was added and reacted for 2 h [19] .", [["MTT", "CHEMICAL", 37, 40], ["MTT", "CHEMICAL", 37, 40], ["MTT", "SIMPLE_CHEMICAL", 37, 40], ["media", "TREATMENT", 15, 20], ["MTT solution", "TREATMENT", 37, 49]]], ["Finally, 100 \u03bcL of dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA) was added to dissolve formazan, and the absorbance was measured at 540 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).MTT Assay.To evaluate the cell protective effect of RL, each concentration (15.625, 31.25, 62.5, 125 , and 250 \u03bcg/mL) was pretreated 1 h before PM10-induced cell damage.", [["cell", "ANATOMY", 235, 239], ["cell", "ANATOMY", 366, 370], ["dimethyl sulfoxide", "CHEMICAL", 19, 37], ["DMSO", "CHEMICAL", 39, 43], ["formazan", "CHEMICAL", 102, 110], ["RL", "CHEMICAL", 261, 263], ["PM10", "CHEMICAL", 353, 357], ["dimethyl sulfoxide", "CHEMICAL", 19, 37], ["DMSO", "CHEMICAL", 39, 43], ["formazan", "CHEMICAL", 102, 110], ["MTT", "CHEMICAL", 209, 212], ["PM10", "CHEMICAL", 353, 357], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 19, 37], ["DMSO", "SIMPLE_CHEMICAL", 39, 43], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 45, 58], ["St. Louis", "ORGANISM", 60, 69], ["formazan", "SIMPLE_CHEMICAL", 102, 110], ["cell", "CELL", 235, 239], ["RL", "SIMPLE_CHEMICAL", 261, 263], ["PM10", "SIMPLE_CHEMICAL", 353, 357], ["cell", "CELL", 366, 370], ["dimethyl sulfoxide (DMSO", "TREATMENT", 19, 43], ["a microplate", "TEST", 160, 172], ["MTT Assay", "TEST", 209, 218], ["induced cell damage", "PROBLEM", 358, 377], ["cell", "OBSERVATION", 235, 239], ["protective effect", "OBSERVATION_MODIFIER", 240, 257], ["cell damage", "OBSERVATION", 366, 377]]], ["For PM10 treatment, PM10 (100 \u03bcg/mL) was added and incubated for 24 h.", [["PM10", "CHEMICAL", 4, 8], ["PM10", "CHEMICAL", 20, 24], ["PM10", "CHEMICAL", 4, 8], ["PM10", "CHEMICAL", 20, 24], ["PM10", "SIMPLE_CHEMICAL", 4, 8], ["PM10", "SIMPLE_CHEMICAL", 20, 24], ["PM10 treatment", "TREATMENT", 4, 18], ["PM10", "TREATMENT", 20, 24]]], ["MTT assay was then conducted following the method described above.Western Blot Analysis.To assess the anti-inflammatory responses of RL, A549 cells were seeded in a 6-well plate (2 \u00d7 10 5 cells/well) and incubated for 24 h.", [["A549 cells", "ANATOMY", 137, 147], ["cells", "ANATOMY", 188, 193], ["MTT", "CHEMICAL", 0, 3], ["RL", "CELL", 133, 135], ["A549 cells", "CELL", 137, 147], ["cells", "CELL", 188, 193], ["A549 cells", "CELL_LINE", 137, 147], ["MTT assay", "TEST", 0, 9], ["Blot Analysis", "TEST", 74, 87], ["A549 cells", "PROBLEM", 137, 147], ["a 6-well plate", "TREATMENT", 163, 177], ["anti-inflammatory", "OBSERVATION_MODIFIER", 102, 119], ["RL", "ANATOMY", 133, 135], ["A549 cells", "OBSERVATION", 137, 147]]], ["After starvation, the cells were pretreated with RL 125 and 250 \u03bcg/mL.", [["cells", "ANATOMY", 22, 27], ["RL", "CHEMICAL", 49, 51], ["cells", "CELL", 22, 27]]], ["PM10 (100 \u03bcg/mL) was then added to the cells and incubated for 24 h.", [["cells", "ANATOMY", 39, 44], ["PM10", "CHEMICAL", 0, 4], ["PM10", "CHEMICAL", 0, 4], ["PM10", "SIMPLE_CHEMICAL", 0, 4], ["cells", "CELL", 39, 44], ["PM10", "TREATMENT", 0, 4]]], ["Cells were harvested in fresh tubes and lysed using lysis buffer and samples were extracted using a nuclear and cytoplasmic extraction kit (NE-PER) ( ermo Scientific, Rockford, USA) [20] .", [["Cells", "ANATOMY", 0, 5], ["tubes", "ANATOMY", 30, 35], ["samples", "ANATOMY", 69, 76], ["nuclear", "ANATOMY", 100, 107], ["cytoplasmic", "ANATOMY", 112, 123], ["Cells", "CELL", 0, 5], ["cytoplasmic", "ORGANISM_SUBSTANCE", 112, 123], ["NE", "PROTEIN", 140, 142], ["fresh tubes", "TREATMENT", 24, 35], ["lysis buffer", "TREATMENT", 52, 64], ["a nuclear and cytoplasmic extraction kit", "TREATMENT", 98, 138], ["fresh tubes", "OBSERVATION", 24, 35]]], ["Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA) was used to measure protein concentrations.", [["Bio-Rad", "GENE_OR_GENE_PRODUCT", 0, 7], ["Bio-Rad protein assay reagent", "TEST", 0, 29], ["Bio", "TEST", 31, 34], ["Hercules", "TEST", 40, 48]]], ["Each sample was separated in a 10% SDS-PAGE gel at 120 V for 120 min and then electrotransferred to a nitrocellulose membrane for 75 min at 100 V. e membranes were blocked with 5% bovine serum albumin. e membranes were incubated with the primary antibody, COX-2 (1 : 1000), phospho-NF-\u03baB p65 (1 : 1000), NF-\u03baB p65 (1 : 1000), phospho-ERK (1 : 1000), ERK (1 : 1000), phospho-JNK (1 : 1000), JNK (1 : 1000), phospho-p38 (1 : 1000), p38 (1 : 1000), \u03b2-actin (1 : 5000), or Lamin B (1 : 3000), overnight at 4\u00b0C. Membranes were extensively washed and then incubated with one of the following secondary antibodies: goat anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP. e protein expression levels were measured using an Image-Quant LAS 500 (GE Healthcare Life Sciences, NSW, Australia). e intensities of the specific bands were calculated using ImageJ software (NIH, NY, USA).Total RNA Isolation and Real-Time Polymerase Chain Reaction (RT-PCR).To analyze the transcription level of proinflammatory cytokines in A549 cells, we used real-time PCR.", [["sample", "ANATOMY", 5, 11], ["membrane", "ANATOMY", 117, 125], ["e membranes", "ANATOMY", 147, 158], ["serum", "ANATOMY", 187, 192], ["e membranes", "ANATOMY", 202, 213], ["Membranes", "ANATOMY", 507, 516], ["A549 cells", "ANATOMY", 1005, 1015], ["nitrocellulose", "CHEMICAL", 102, 116], ["phospho", "CHEMICAL", 326, 333], ["phospho", "CHEMICAL", 366, 373], ["phospho", "CHEMICAL", 406, 413], ["\u03b2-actin", "CHEMICAL", 446, 453], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["bovine", "ORGANISM", 180, 186], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["albumin", "GENE_OR_GENE_PRODUCT", 193, 200], ["membranes", "CELLULAR_COMPONENT", 204, 213], ["COX-2", "GENE_OR_GENE_PRODUCT", 256, 261], ["phospho-NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 274, 291], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 304, 313], ["phospho-ERK", "GENE_OR_GENE_PRODUCT", 326, 337], ["ERK", "GENE_OR_GENE_PRODUCT", 350, 353], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 366, 377], ["JNK", "GENE_OR_GENE_PRODUCT", 390, 393], ["phospho-p38", "GENE_OR_GENE_PRODUCT", 406, 417], ["p38", "GENE_OR_GENE_PRODUCT", 430, 433], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 446, 453], ["Lamin B", "GENE_OR_GENE_PRODUCT", 469, 476], ["Membranes", "ORGANISM_SUBSTANCE", 507, 516], ["goat", "ORGANISM", 608, 612], ["HRP", "GENE_OR_GENE_PRODUCT", 629, 632], ["goat", "ORGANISM", 637, 641], ["HRP", "GENE_OR_GENE_PRODUCT", 657, 660], ["A549 cells", "CELL", 1005, 1015], ["primary antibody", "PROTEIN", 238, 254], ["COX", "PROTEIN", 256, 259], ["phospho", "PROTEIN", 274, 281], ["NF-\u03baB p65", "PROTEIN", 282, 291], ["NF-\u03baB p65", "PROTEIN", 304, 313], ["phospho", "PROTEIN", 326, 333], ["ERK", "PROTEIN", 334, 337], ["ERK", "PROTEIN", 350, 353], ["phospho", "PROTEIN", 366, 373], ["JNK", "PROTEIN", 374, 377], ["JNK", "PROTEIN", 390, 393], ["phospho", "PROTEIN", 406, 413], ["p38", "PROTEIN", 414, 417], ["p38", "PROTEIN", 430, 433], ["\u03b2-actin", "PROTEIN", 446, 453], ["Lamin B", "PROTEIN", 469, 476], ["secondary antibodies", "PROTEIN", 586, 606], ["goat anti-rabbit IgG", "PROTEIN", 608, 628], ["HRP", "PROTEIN", 629, 632], ["goat anti-mouse IgG", "PROTEIN", 637, 656], ["HRP", "PROTEIN", 657, 660], ["proinflammatory cytokines", "PROTEIN", 976, 1001], ["A549 cells", "CELL_LINE", 1005, 1015], ["bovine", "SPECIES", 180, 186], ["goat", "SPECIES", 608, 612], ["anti-rabbit", "SPECIES", 613, 624], ["goat", "SPECIES", 637, 641], ["anti-mouse", "SPECIES", 642, 652], ["bovine", "SPECIES", 180, 186], ["goat", "SPECIES", 608, 612], ["goat", "SPECIES", 637, 641], ["a 10% SDS", "TREATMENT", 29, 38], ["a nitrocellulose membrane", "TREATMENT", 100, 125], ["5% bovine serum albumin", "TREATMENT", 177, 200], ["the primary antibody", "TEST", 234, 254], ["COX", "TEST", 256, 259], ["phospho", "TEST", 274, 281], ["NF", "TEST", 282, 284], ["NF", "TEST", 304, 306], ["\u03baB p65", "TEST", 307, 313], ["phospho", "TEST", 326, 333], ["ERK", "TEST", 334, 337], ["ERK", "TEST", 350, 353], ["phospho", "TEST", 366, 373], ["JNK", "TEST", 374, 377], ["JNK", "TEST", 390, 393], ["phospho-p38", "TEST", 406, 417], ["p38", "TEST", 430, 433], ["\u03b2-actin", "TEST", 446, 453], ["Lamin B", "TEST", 469, 476], ["goat anti-rabbit IgG", "TREATMENT", 608, 628], ["e protein expression levels", "TEST", 662, 689], ["an Image", "TEST", 710, 718], ["the specific bands", "PROBLEM", 797, 815], ["Total RNA Isolation", "TREATMENT", 869, 888], ["Real-Time Polymerase Chain Reaction", "TREATMENT", 893, 928], ["RT-PCR", "TEST", 930, 936], ["proinflammatory cytokines in A549 cells", "PROBLEM", 976, 1015], ["RNA Isolation", "OBSERVATION", 875, 888], ["A549 cells", "OBSERVATION", 1005, 1015]]], ["A549 cells were seeded in a 96-well plate (2 \u00d7 10 5 cells/ well) and incubated for 24 h.", [["A549 cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 52, 57], ["A549 cells", "CELL", 0, 10], ["cells", "CELL", 52, 57], ["A549 cells", "CELL_LINE", 0, 10], ["A549 cells", "TEST", 0, 10]]], ["After starvation, the cells were pretreated with RL 125 and 250 \u03bcg/mL.", [["cells", "ANATOMY", 22, 27], ["RL", "CHEMICAL", 49, 51], ["cells", "CELL", 22, 27]]], ["Next, PM10 (100 \u03bcg/ mL) was added and incubated for 24 h. e total RNA was isolated from each cell treatment using Hybrid-RTM (GeneAll, South Korea) [21, 22] .", [["cell", "ANATOMY", 93, 97], ["PM10", "CHEMICAL", 6, 10], ["PM10", "CHEMICAL", 6, 10], ["PM10", "SIMPLE_CHEMICAL", 6, 10], ["cell", "CELL", 93, 97], ["PM10", "TREATMENT", 6, 10], ["total RNA", "TREATMENT", 60, 69], ["each cell treatment", "TREATMENT", 88, 107]]], ["Total RNA (500 ng) was converted to cDNA using oligo (dT) at incubation conditions of 55\u00b0C for 60 min followed by 85\u00b0C for 5 min and then stored at 4\u00b0C until further use.", [["cDNA", "DNA", 36, 40], ["Total RNA", "TREATMENT", 0, 9], ["oligo (dT)", "TREATMENT", 47, 57]]], ["Real-time quantitative PCR was performed using the Universal SYBR Green Master Mix (Applied Biosystems, USA). cDNA was amplified using the following conditions: 95\u00b0C for 15 min followed by 40 cycles at 95\u00b0C for 30 s, 59\u00b0C for 30 s, and 72\u00b0C for 30 s.", [["cDNA", "DNA", 110, 114], ["quantitative PCR", "TEST", 10, 26]]], ["Real-time PCR analysis was performed on an Applied Biosystems StepOne system (Applied Biosystems, USA) [23] .", [["Real-time PCR analysis", "TEST", 0, 22]]], ["In this study, quantification based on the relative expression of a target gene versus GAPDH gene (2 -\u0394\u0394Ct ) was employed to determine the level of mRNA expression. e primer sequences used for the real-time PCR analysis are listed in Table 1 .StatisticalAnalysis.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 87, 92], ["2 -\u0394\u0394Ct", "GENE_OR_GENE_PRODUCT", 99, 106], ["target gene", "DNA", 68, 79], ["GAPDH gene", "DNA", 87, 97], ["primer sequences", "DNA", 167, 183], ["this study", "TEST", 3, 13], ["e primer sequences", "TEST", 165, 183], ["the real-time PCR analysis", "TEST", 193, 219], ["StatisticalAnalysis", "TEST", 243, 262]]], ["Statistical analysis of the data was performed using the GraphPad Prism 5 software package (GraphPad Software, San Diego, CA, USA).", [["Statistical analysis of the data", "TEST", 0, 32]]], ["An unpaired test (one-tailed) was conducted to analyze all the data.", [["An unpaired test", "TEST", 0, 16]]], ["Values less than 0.05 were considered significant.", [["Values", "TEST", 0, 6]]], ["All data are presented as the mean \u00b1 SEM.COX-2 Expression Level and Cell Viability in A549 CellsTreated with PM10.", [["Cell", "ANATOMY", 68, 72], ["A549", "ANATOMY", 86, 90], ["PM10", "CHEMICAL", 109, 113], ["COX-2", "GENE_OR_GENE_PRODUCT", 41, 46], ["Cell", "CELL", 68, 72], ["A549 CellsTreated", "CELL", 86, 103], ["PM10", "SIMPLE_CHEMICAL", 109, 113], ["COX", "PROTEIN", 41, 44], ["All data", "TEST", 0, 8], ["COX", "TEST", 41, 44], ["Expression Level", "TEST", 47, 63], ["Cell Viability", "TEST", 68, 82], ["PM10", "TREATMENT", 109, 113], ["Cell Viability", "OBSERVATION", 68, 82]]], ["COX-2 is a well-known proinflammatory gene that is overexpressed in terms of immune reactivity. erefore, we used western blot analysis to examine PM10-induced inflammation in the A549 cells.", [["A549 cells", "ANATOMY", 179, 189], ["PM10", "CHEMICAL", 146, 150], ["inflammation", "DISEASE", 159, 171], ["PM10", "CHEMICAL", 146, 150], ["COX-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["PM10", "SIMPLE_CHEMICAL", 146, 150], ["A549 cells", "CELL", 179, 189], ["COX-2", "PROTEIN", 0, 5], ["proinflammatory gene", "DNA", 22, 42], ["A549 cells", "CELL_LINE", 179, 189], ["COX", "TEST", 0, 3], ["immune reactivity", "PROBLEM", 77, 94], ["western blot analysis", "TEST", 113, 134], ["PM10", "TEST", 146, 150], ["inflammation in the A549 cells", "PROBLEM", 159, 189], ["proinflammatory gene", "OBSERVATION", 22, 42], ["immune reactivity", "OBSERVATION", 77, 94], ["inflammation", "OBSERVATION", 159, 171], ["A549 cells", "OBSERVATION", 179, 189]]], ["When PM10 was added at 25-400 \u03bcg/mL for 24 h in the A549 cell line, the expression level of COX-2 protein was as follows (Figure 1 (a)): when PM10 was added at 100 and 200 \u03bcg/mL concentrations, COX-2 expression level was significantly higher than the nontreated group.", [["A549 cell line", "ANATOMY", 52, 66], ["PM10", "CHEMICAL", 5, 9], ["PM10", "CHEMICAL", 142, 146], ["PM10", "CHEMICAL", 5, 9], ["PM10", "CHEMICAL", 142, 146], ["PM10", "SIMPLE_CHEMICAL", 5, 9], ["A549 cell line", "CELL", 52, 66], ["COX-2", "GENE_OR_GENE_PRODUCT", 92, 97], ["PM10", "SIMPLE_CHEMICAL", 142, 146], ["COX-2", "GENE_OR_GENE_PRODUCT", 194, 199], ["A549 cell line", "CELL_LINE", 52, 66], ["COX-2 protein", "PROTEIN", 92, 105], ["COX", "PROTEIN", 194, 197], ["PM10", "TREATMENT", 5, 9], ["the A549 cell line", "TREATMENT", 48, 66], ["COX", "TEST", 92, 95], ["COX-2 expression level", "TEST", 194, 216], ["A549 cell line", "OBSERVATION", 52, 66]]], ["In addition, cell viability in the PM10-treated cells was confirmed using MTT assay (Figure 1(b) ).", [["cell", "ANATOMY", 13, 17], ["cells", "ANATOMY", 48, 53], ["PM10", "CHEMICAL", 35, 39], ["PM10", "CHEMICAL", 35, 39], ["MTT", "CHEMICAL", 74, 77], ["cell", "CELL", 13, 17], ["PM10", "SIMPLE_CHEMICAL", 35, 39], ["cells", "CELL", 48, 53], ["PM10-treated cells", "CELL_LINE", 35, 53], ["cell viability", "TEST", 13, 27], ["the PM10-treated cells", "TREATMENT", 31, 53], ["MTT assay", "TEST", 74, 83], ["cell viability", "OBSERVATION", 13, 27]]], ["When PM10 was added to the A549 cells at each concentration for 24 h, cell viability decreased in a concentration-dependent manner.", [["A549 cells", "ANATOMY", 27, 37], ["cell", "ANATOMY", 70, 74], ["PM10", "CHEMICAL", 5, 9], ["PM10", "CHEMICAL", 5, 9], ["PM10", "SIMPLE_CHEMICAL", 5, 9], ["A549 cells", "CELL", 27, 37], ["cell", "CELL", 70, 74], ["A549 cells", "CELL_LINE", 27, 37], ["the A549 cells", "TREATMENT", 23, 37], ["cell viability", "TEST", 70, 84], ["viability", "OBSERVATION_MODIFIER", 75, 84], ["decreased", "OBSERVATION_MODIFIER", 85, 94]]], ["In particular, there was a significant difference compared to the control at 100 and 200 \u03bcg/mL. erefore, considering these results, we selected the optimal concentration of PM10 as 100 \u03bcg/mL for the subsequent studies.Cell Protective Effects of RL on PM10-Treated A549 Cells.Before observing the anti-inflammatory effect of RL, we used MTT assay to analyze the cytotoxicity of RL. e cell viability of A549 cells treated with RL up to 500 \u03bcg/mL for 25 h is shown in Figure 2 (a).", [["Cell", "ANATOMY", 218, 222], ["A549 Cells", "ANATOMY", 264, 274], ["cell", "ANATOMY", 383, 387], ["A549 cells", "ANATOMY", 401, 411], ["PM10", "CHEMICAL", 173, 177], ["PM10", "CHEMICAL", 251, 255], ["RL", "CHEMICAL", 425, 427], ["PM10", "CHEMICAL", 173, 177], ["MTT", "CHEMICAL", 336, 339], ["PM10", "SIMPLE_CHEMICAL", 173, 177], ["Cell", "CELL", 218, 222], ["RL", "SIMPLE_CHEMICAL", 245, 247], ["PM10", "SIMPLE_CHEMICAL", 251, 255], ["A549 Cells", "CELL", 264, 274], ["RL", "SIMPLE_CHEMICAL", 324, 326], ["cell", "CELL", 383, 387], ["A549 cells", "CELL", 401, 411], ["A549 cells", "CELL_LINE", 401, 411], ["a significant difference", "PROBLEM", 25, 49], ["PM10", "TREATMENT", 173, 177], ["the subsequent studies", "TEST", 195, 217], ["MTT assay", "TEST", 336, 345], ["the cytotoxicity of RL", "PROBLEM", 357, 379], ["A549 cells", "PROBLEM", 401, 411], ["RL", "TREATMENT", 425, 427], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION_MODIFIER", 39, 49], ["A549 Cells", "OBSERVATION", 264, 274], ["RL", "ANATOMY", 377, 379], ["cell viability", "OBSERVATION", 383, 397], ["A549 cells", "OBSERVATION", 401, 411]]], ["RL showed no toxicity to cells when treated at 250 \u03bcg/mL, but cytotoxicity was observed at 500 \u03bcg/mL. erefore, we used RL concentrations of up to 250 \u03bcg/mL for the subsequent studies.", [["cells", "ANATOMY", 25, 30], ["RL", "CHEMICAL", 0, 2], ["toxicity", "DISEASE", 13, 21], ["cells", "CELL", 25, 30], ["toxicity to cells", "PROBLEM", 13, 30], ["cytotoxicity", "PROBLEM", 62, 74], ["RL concentrations", "TREATMENT", 119, 136], ["the subsequent studies", "TEST", 160, 182], ["no", "UNCERTAINTY", 10, 12], ["toxicity", "OBSERVATION", 13, 21]]], ["Based on the results in Figure 1 , we observed the protective effect of RL against PM10-induced cytotoxicity.", [["RL", "CHEMICAL", 72, 74], ["PM10", "CHEMICAL", 83, 87], ["PM10", "CHEMICAL", 83, 87], ["RL", "SIMPLE_CHEMICAL", 72, 74], ["PM10", "SIMPLE_CHEMICAL", 83, 87], ["RL against PM10", "TREATMENT", 72, 87], ["cytotoxicity", "PROBLEM", 96, 108]]], ["We found that the cell viability of A549 cells exposed to PM10 (100 \u03bcg/mL) decreased by about 75% (Figure 2(b) ).", [["cell", "ANATOMY", 18, 22], ["A549 cells", "ANATOMY", 36, 46], ["PM10", "CHEMICAL", 58, 62], ["PM10", "CHEMICAL", 58, 62], ["cell", "CELL", 18, 22], ["A549 cells", "CELL", 36, 46], ["PM10", "SIMPLE_CHEMICAL", 58, 62], ["A549 cells", "CELL_LINE", 36, 46], ["the cell viability", "TEST", 14, 32], ["A549 cells", "TEST", 36, 46], ["PM10", "TEST", 58, 62], ["cell viability", "OBSERVATION", 18, 32], ["A549 cells", "OBSERVATION", 36, 46]]], ["However, cell viability was increased when A549 cells were pretreated with 125 and 250 \u03bcg/mL RL an hour before exposure to PM10. erefore, the anti-inflammatory effect of RL was evaluated at 125 and 250 \u03bcg/mL, which suppressed the PM10-induced decrease in cell viability.Inhibitory Effects of RL on COX-2 Protein Expression inPM10-Treated A549 Cells.", [["cell", "ANATOMY", 9, 13], ["A549 cells", "ANATOMY", 43, 53], ["cell", "ANATOMY", 255, 259], ["A549 Cells", "ANATOMY", 338, 348], ["PM10", "CHEMICAL", 123, 127], ["RL", "CHEMICAL", 170, 172], ["PM10", "CHEMICAL", 230, 234], ["PM10", "CHEMICAL", 123, 127], ["PM10", "CHEMICAL", 230, 234], ["cell", "CELL", 9, 13], ["A549 cells", "CELL", 43, 53], ["RL", "SIMPLE_CHEMICAL", 170, 172], ["PM10", "SIMPLE_CHEMICAL", 230, 234], ["cell", "CELL", 255, 259], ["RL", "SIMPLE_CHEMICAL", 292, 294], ["COX-2", "GENE_OR_GENE_PRODUCT", 298, 303], ["inPM10", "GENE_OR_GENE_PRODUCT", 323, 329], ["A549 Cells", "CELL", 338, 348], ["A549 cells", "CELL_LINE", 43, 53], ["COX", "PROTEIN", 298, 301], ["inPM10", "PROTEIN", 323, 329], ["Treated A549 Cells", "CELL_LINE", 330, 348], ["cell viability", "TEST", 9, 23], ["A549 cells", "PROBLEM", 43, 53], ["decrease in cell viability", "PROBLEM", 243, 269], ["COX", "TEST", 298, 301], ["Expression inPM10", "TEST", 312, 329], ["cell viability", "OBSERVATION", 9, 23], ["anti-inflammatory", "OBSERVATION_MODIFIER", 142, 159], ["decrease", "OBSERVATION_MODIFIER", 243, 251], ["cell viability", "OBSERVATION", 255, 269], ["RL", "OBSERVATION_MODIFIER", 292, 294], ["A549 Cells", "OBSERVATION", 338, 348]]], ["When A549 cells were exposed to 100 \u03bcg/mL of PM10, COX-2 protein expression level increased ( Figure 3 ).", [["A549 cells", "ANATOMY", 5, 15], ["PM10", "CHEMICAL", 45, 49], ["A549 cells", "CELL", 5, 15], ["PM10", "SIMPLE_CHEMICAL", 45, 49], ["COX-2", "GENE_OR_GENE_PRODUCT", 51, 56], ["A549 cells", "CELL_LINE", 5, 15], ["COX", "PROTEIN", 51, 54], ["A549 cells", "TREATMENT", 5, 15], ["COX", "TEST", 51, 54], ["protein expression level", "TEST", 57, 81]]], ["However, when cells were pretreated with RL at 125-250 \u03bcg/mL for 1 h, COX-2 protein expression levels decreased in a dose-dependent manner compared to the PM10 induction group. erefore, we further investigated the effect of RL on the upstream signal of COX-2 and proinflammatory cytokine expression.Inhibitory Effects of RL on MAPK/NF-\u03baB Pathways in PM10-Treated A549 Cells.e mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cell (NF-\u03baB) pathway is activated by several stimuli and causes immune system dysfunction by expressing various inflammatory mediators.", [["cells", "ANATOMY", 14, 19], ["immune system", "ANATOMY", 541, 554], ["RL", "CHEMICAL", 41, 43], ["PM10", "CHEMICAL", 155, 159], ["PM10", "CHEMICAL", 350, 354], ["PM10", "CHEMICAL", 155, 159], ["cells", "CELL", 14, 19], ["COX-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["PM10", "SIMPLE_CHEMICAL", 155, 159], ["RL", "SIMPLE_CHEMICAL", 224, 226], ["COX-2", "GENE_OR_GENE_PRODUCT", 253, 258], ["RL", "SIMPLE_CHEMICAL", 321, 323], ["MAPK", "GENE_OR_GENE_PRODUCT", 327, 331], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 332, 337], ["PM10", "SIMPLE_CHEMICAL", 350, 354], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 376, 408], ["MAPK", "GENE_OR_GENE_PRODUCT", 410, 414], ["kappa-light-chain-enhancer of activated B cell", "GENE_OR_GENE_PRODUCT", 435, 481], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 483, 488], ["COX", "PROTEIN", 70, 73], ["COX-2", "PROTEIN", 253, 258], ["proinflammatory cytokine", "PROTEIN", 263, 287], ["MAPK", "PROTEIN", 327, 331], ["NF-\u03baB", "PROTEIN", 332, 337], ["mitogen-activated protein kinase", "PROTEIN", 376, 408], ["MAPK", "PROTEIN", 410, 414], ["NF-\u03baB", "PROTEIN", 483, 488], ["inflammatory mediators", "PROTEIN", 589, 611], ["COX", "TEST", 70, 73], ["protein expression levels", "TEST", 76, 101], ["the PM10 induction group", "TREATMENT", 151, 175], ["COX", "TEST", 253, 256], ["proinflammatory cytokine expression", "PROBLEM", 263, 298], ["MAPK", "TEST", 327, 331], ["NF", "TEST", 332, 334], ["A549 Cells", "TEST", 363, 373], ["mitogen", "TEST", 376, 383], ["activated protein kinase", "TEST", 384, 408], ["MAPK", "TEST", 410, 414], ["nuclear factor kappa-light", "TEST", 420, 446], ["activated B cell", "PROBLEM", 465, 481], ["immune system dysfunction", "PROBLEM", 541, 566], ["decreased", "OBSERVATION_MODIFIER", 102, 111], ["proinflammatory cytokine expression", "OBSERVATION", 263, 298], ["immune system dysfunction", "OBSERVATION", 541, 566], ["inflammatory", "OBSERVATION_MODIFIER", 589, 601]]], ["When A549 cells were treated with PM10 at a concentration of 100 \u03bcg/ mL, phosphorylation of c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) 1/2, and p38, as well as translocation of NF-\u03baB p65 to the nucleus, was increased compared to the nontreated group (Figures 4(a) -4(d)).", [["A549 cells", "ANATOMY", 5, 15], ["nucleus", "ANATOMY", 226, 233], ["PM10", "CHEMICAL", 34, 38], ["PM10", "CHEMICAL", 34, 38], ["N", "CHEMICAL", 98, 99], ["A549 cells", "CELL", 5, 15], ["PM10", "SIMPLE_CHEMICAL", 34, 38], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 92, 115], ["JNK", "GENE_OR_GENE_PRODUCT", 117, 120], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 123, 160], ["ERK", "GENE_OR_GENE_PRODUCT", 162, 165], ["1/2", "GENE_OR_GENE_PRODUCT", 167, 170], ["p38", "GENE_OR_GENE_PRODUCT", 176, 179], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 209, 218], ["nucleus", "CELLULAR_COMPONENT", 226, 233], ["A549 cells", "CELL_LINE", 5, 15], ["c-Jun N-terminal kinase", "PROTEIN", 92, 115], ["JNK", "PROTEIN", 117, 120], ["extracellular signal-regulated kinase (ERK) 1/2", "PROTEIN", 123, 170], ["p38", "PROTEIN", 176, 179], ["NF-\u03baB p65", "PROTEIN", 209, 218], ["PM10", "TREATMENT", 34, 38], ["phosphorylation", "TEST", 73, 88], ["c", "TEST", 92, 93], ["extracellular signal", "TEST", 123, 143], ["ERK", "TEST", 162, 165], ["p38", "TEST", 176, 179], ["NF", "TEST", 209, 211], ["Figures", "TEST", 283, 290], ["nucleus", "ANATOMY", 226, 233], ["increased", "OBSERVATION_MODIFIER", 239, 248]]], ["With RL pretreatment, phosphorylation of JNK and ERK decreased in a concentration-dependent manner.", [["RL", "SIMPLE_CHEMICAL", 5, 7], ["JNK", "GENE_OR_GENE_PRODUCT", 41, 44], ["ERK", "GENE_OR_GENE_PRODUCT", 49, 52], ["JNK", "PROTEIN", 41, 44], ["ERK", "PROTEIN", 49, 52], ["RL pretreatment", "TREATMENT", 5, 20], ["phosphorylation of JNK", "TEST", 22, 44], ["ERK", "TEST", 49, 52], ["RL", "OBSERVATION_MODIFIER", 5, 7], ["pretreatment", "OBSERVATION", 8, 20], ["decreased", "OBSERVATION_MODIFIER", 53, 62]]], ["However, the phosphorylation of p38 tended to be somewhat suppressed, although there was no significant difference compared to the PM10 alone group.", [["PM10", "CHEMICAL", 131, 135], ["PM10", "CHEMICAL", 131, 135], ["p38", "GENE_OR_GENE_PRODUCT", 32, 35], ["PM10", "SIMPLE_CHEMICAL", 131, 135], ["p38", "PROTEIN", 32, 35], ["the phosphorylation of p38", "TEST", 9, 35], ["significant difference", "PROBLEM", 92, 114], ["no", "UNCERTAINTY", 89, 91], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["difference", "OBSERVATION", 104, 114]]], ["In addition, RL reduced the nuclear translocation of NF-\u03baB p65 in a concentration-dependent manner compared to the PM10 alone group.", [["nuclear", "ANATOMY", 28, 35], ["PM10", "CHEMICAL", 115, 119], ["PM10", "CHEMICAL", 115, 119], ["RL", "SIMPLE_CHEMICAL", 13, 15], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 53, 62], ["PM10", "SIMPLE_CHEMICAL", 115, 119], ["NF-\u03baB p65", "PROTEIN", 53, 62], ["RL", "OBSERVATION_MODIFIER", 13, 15], ["reduced", "OBSERVATION_MODIFIER", 16, 23], ["nuclear translocation", "OBSERVATION", 28, 49]]], ["Consequently, RL mitigates PM10-induced inflammatory response through the MAPK/NF-\u03baB pathway.Inhibitory Effects of RL on Proinflammatory CytokinemRNA Expression in PM10-Treated A549 Cells.", [["A549 Cells", "ANATOMY", 177, 187], ["RL", "CHEMICAL", 14, 16], ["PM10", "CHEMICAL", 27, 31], ["PM10", "CHEMICAL", 164, 168], ["PM10", "CHEMICAL", 27, 31], ["RL", "SIMPLE_CHEMICAL", 14, 16], ["PM10", "SIMPLE_CHEMICAL", 27, 31], ["MAPK", "GENE_OR_GENE_PRODUCT", 74, 78], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 79, 84], ["RL", "SIMPLE_CHEMICAL", 115, 117], ["CytokinemRNA", "GENE_OR_GENE_PRODUCT", 137, 149], ["PM10", "SIMPLE_CHEMICAL", 164, 168], ["A549 Cells", "CELL", 177, 187], ["MAPK", "PROTEIN", 74, 78], ["NF-\u03baB", "PROTEIN", 79, 84], ["Proinflammatory CytokinemRNA", "PROTEIN", 121, 149], ["PM10-Treated A549 Cells", "CELL_LINE", 164, 187], ["RL mitigates PM10", "TREATMENT", 14, 31], ["inflammatory response", "PROBLEM", 40, 61], ["the MAPK", "TEST", 70, 78], ["inflammatory response", "OBSERVATION", 40, 61], ["RL", "OBSERVATION_MODIFIER", 115, 117], ["Proinflammatory CytokinemRNA", "OBSERVATION", 121, 149], ["A549 Cells", "OBSERVATION", 177, 187]]], ["Using realtime PCR, we measured the mRNA expression levels of proinflammatory cytokines when A549 cells were exposed to PM10. e PM10-treated group had significantly higher mRNA expression levels of IL-6, IL-13, IL-17, IL-1\u03b2, and TNF-\u03b1 than the nontreated group.", [["A549 cells", "ANATOMY", 93, 103], ["PM10", "CHEMICAL", 120, 124], ["PM10", "CHEMICAL", 128, 132], ["PM10", "CHEMICAL", 120, 124], ["PM10", "CHEMICAL", 128, 132], ["A549 cells", "CELL", 93, 103], ["PM10", "SIMPLE_CHEMICAL", 128, 132], ["IL-6", "GENE_OR_GENE_PRODUCT", 198, 202], ["IL-13", "GENE_OR_GENE_PRODUCT", 204, 209], ["IL-17", "GENE_OR_GENE_PRODUCT", 211, 216], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 218, 223], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 229, 234], ["proinflammatory cytokines", "PROTEIN", 62, 87], ["A549 cells", "CELL_LINE", 93, 103], ["IL-1\u03b2", "PROTEIN", 218, 223], ["TNF-\u03b1", "PROTEIN", 229, 234], ["realtime PCR", "TEST", 6, 18], ["proinflammatory cytokines", "TREATMENT", 62, 87], ["A549 cells", "TREATMENT", 93, 103], ["IL", "TEST", 198, 200], ["IL", "TEST", 204, 206], ["IL", "TEST", 211, 213], ["IL", "TEST", 218, 220], ["TNF", "TEST", 229, 232], ["proinflammatory cytokines", "OBSERVATION", 62, 87]]], ["However, the RL pretreatment group showed a concentration-dependent decrease in the mRNA expression of proinflammatory cytokines including IL-1\u03b2, TNF-\u03b1, and IL-17 ( Figures 5(a)-5(c) ).", [["RL", "SIMPLE_CHEMICAL", 13, 15], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 139, 144], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 146, 151], ["IL-17", "GENE_OR_GENE_PRODUCT", 157, 162], ["proinflammatory cytokines", "PROTEIN", 103, 128], ["IL-1\u03b2", "PROTEIN", 139, 144], ["TNF", "PROTEIN", 146, 149], ["IL", "PROTEIN", 157, 159], ["a concentration-dependent decrease", "PROBLEM", 42, 76], ["proinflammatory cytokines", "TEST", 103, 128], ["IL", "TEST", 139, 141], ["TNF", "TEST", 146, 149], ["IL", "TEST", 157, 159], ["Figures", "TEST", 165, 172], ["dependent", "OBSERVATION_MODIFIER", 58, 67], ["decrease", "OBSERVATION_MODIFIER", 68, 76], ["proinflammatory cytokines", "OBSERVATION", 103, 128], ["IL", "ANATOMY", 157, 159]]], ["In addition, IL-6 and IL-13 did not show significant differences, but showed a tendency to decrease compared to the PM10 alone group (Figures 5(d) and 5(e) ).DiscussionPM10 is known to reach the bronchial tubes and lungs directly, aggravating asthma symptoms or increasing asthma rates. e PM10 used in this study was collected from road dust near a tunnel in Wislostrada, Poland, and is very similar to the fine dust collected in China [24] .", [["bronchial tubes", "ANATOMY", 195, 210], ["lungs", "ANATOMY", 215, 220], ["PM10", "CHEMICAL", 116, 120], ["DiscussionPM10", "CHEMICAL", 158, 172], ["asthma", "DISEASE", 243, 249], ["asthma", "DISEASE", 273, 279], ["PM10", "CHEMICAL", 289, 293], ["PM10", "CHEMICAL", 116, 120], ["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["IL-13", "GENE_OR_GENE_PRODUCT", 22, 27], ["PM10", "SIMPLE_CHEMICAL", 116, 120], ["bronchial tubes", "TISSUE", 195, 210], ["lungs", "ORGAN", 215, 220], ["IL-6", "PROTEIN", 13, 17], ["IL", "PROTEIN", 22, 24], ["IL", "TEST", 13, 15], ["a tendency", "PROBLEM", 77, 87], ["aggravating asthma symptoms", "PROBLEM", 231, 258], ["increasing asthma rates", "PROBLEM", 262, 285], ["this study", "TEST", 302, 312], ["decrease", "OBSERVATION_MODIFIER", 91, 99], ["bronchial", "ANATOMY", 195, 204], ["tubes", "OBSERVATION", 205, 210], ["lungs", "ANATOMY", 215, 220], ["increasing", "OBSERVATION_MODIFIER", 262, 272], ["asthma", "OBSERVATION", 273, 279], ["tunnel", "OBSERVATION", 349, 355]]], ["According to Evidence-Based Complementary and Alternative MedicineGenesForward primer (5\u2032-3\u2032) Reverse primer (5\u2032-3\u2032) GAPDH GCCACATCGCTCAGACACC CCCAATACGACCAAATCCGT TNF-\u03b1 GCAGGTCTACTTTGGGTCATTG GCGTTTGGGAAGGTTGGA IL-1\u03b2 TCAGCCAATCTTCATTGCTCAA TGGCGAGCTCAGGTACTTCTG IL-6 AGGGCTCTTCGGCAAATGTA GAAGGAATGCCCATTAACAACAA IL-13 CTGCAGTGCCATCGAGAAGA GACCTTGTGCGGGCAGAA IL- Values are means \u00b1 SEM. * P < 0.05 compared to the control group. # P < 0.05; ## P < 0.01 compared to only PM10-treated group. previous studies, PM10 was used to induce increased mRNA expression of COX-2 protein and proinflammatory cytokines in HaCaT cells and RAW 264.7 cell lines [24] . erefore, we investigated whether PM10 can induce inflammation by increasing the expression level of COX-2 protein in the A549 cell line. e COX enzyme, which converts arachidonic acid to prostaglandin H 2 , has two isoforms [25] .", [["HaCaT cells", "ANATOMY", 608, 619], ["RAW 264.7 cell lines", "ANATOMY", 624, 644], ["A549 cell line", "ANATOMY", 773, 787], ["PM10", "CHEMICAL", 470, 474], ["PM10", "CHEMICAL", 508, 512], ["PM10", "CHEMICAL", 685, 689], ["inflammation", "DISEASE", 701, 713], ["arachidonic acid", "CHEMICAL", 818, 834], ["prostaglandin H", "CHEMICAL", 838, 853], ["PM10", "CHEMICAL", 470, 474], ["PM10", "CHEMICAL", 508, 512], ["PM10", "CHEMICAL", 685, 689], ["arachidonic acid", "CHEMICAL", 818, 834], ["prostaglandin H 2", "CHEMICAL", 838, 855], ["GAPDH", "GENE_OR_GENE_PRODUCT", 117, 122], ["PM10", "SIMPLE_CHEMICAL", 470, 474], ["PM10", "SIMPLE_CHEMICAL", 508, 512], ["COX-2", "GENE_OR_GENE_PRODUCT", 561, 566], ["HaCaT cells", "CELL", 608, 619], ["RAW 264.7 cell lines", "CELL", 624, 644], ["PM10", "SIMPLE_CHEMICAL", 685, 689], ["COX-2", "GENE_OR_GENE_PRODUCT", 752, 757], ["A549 cell line", "CELL", 773, 787], ["COX", "GENE_OR_GENE_PRODUCT", 791, 794], ["arachidonic acid", "SIMPLE_CHEMICAL", 818, 834], ["prostaglandin H 2", "GENE_OR_GENE_PRODUCT", 838, 855], ["Reverse primer", "DNA", 94, 108], ["GAPDH", "PROTEIN", 117, 122], ["TNF", "PROTEIN", 164, 167], ["COX-2 protein", "PROTEIN", 561, 574], ["proinflammatory cytokines", "PROTEIN", 579, 604], ["HaCaT cells", "CELL_LINE", 608, 619], ["RAW 264.7 cell lines", "CELL_LINE", 624, 644], ["COX-2 protein", "PROTEIN", 752, 765], ["A549 cell line", "CELL_LINE", 773, 787], ["COX enzyme", "PROTEIN", 791, 801], ["Alternative MedicineGenesForward primer", "TREATMENT", 46, 85], ["GAPDH", "TEST", 117, 122], ["GCCACATCGCTCAGACACC", "TEST", 123, 142], ["CCCAATACGACCAAATCCGT", "TEST", 143, 163], ["TNF", "TEST", 164, 167], ["GCAGGTCTACTTTGGGTCATTG", "TEST", 170, 192], ["GCGTTTGGGAAGGTTGGA", "TEST", 193, 211], ["IL", "TEST", 212, 214], ["IL", "TEST", 263, 265], ["IL", "TEST", 313, 315], ["previous studies", "TEST", 490, 506], ["increased mRNA expression", "PROBLEM", 532, 557], ["COX", "TEST", 561, 564], ["proinflammatory cytokines", "TEST", 579, 604], ["HaCaT cells", "TEST", 608, 619], ["cell lines", "TEST", 634, 644], ["inflammation", "PROBLEM", 701, 713], ["COX", "TEST", 752, 755], ["the A549 cell line", "TREATMENT", 769, 787], ["e COX enzyme", "TEST", 789, 801], ["arachidonic acid", "TEST", 818, 834], ["prostaglandin H", "TEST", 838, 853], ["HaCaT cells", "ANATOMY", 608, 619], ["cell lines", "OBSERVATION", 634, 644], ["inflammation", "OBSERVATION", 701, 713], ["A549 cell line", "OBSERVATION", 773, 787]]], ["Among them, COX-2 is rapidly expressed during inflammation and is known to be involved in allergic asthma, arthritis, rheumatism, and various diseases [26, 27] .", [["inflammation", "DISEASE", 46, 58], ["allergic asthma", "DISEASE", 90, 105], ["arthritis", "DISEASE", 107, 116], ["rheumatism", "DISEASE", 118, 128], ["COX-2", "GENE_OR_GENE_PRODUCT", 12, 17], ["COX-2", "PROTEIN", 12, 17], ["inflammation", "PROBLEM", 46, 58], ["allergic asthma", "PROBLEM", 90, 105], ["arthritis", "PROBLEM", 107, 116], ["rheumatism", "PROBLEM", 118, 128], ["various diseases", "PROBLEM", 134, 150], ["inflammation", "OBSERVATION", 46, 58], ["known to be", "UNCERTAINTY", 66, 77], ["allergic asthma", "OBSERVATION", 90, 105], ["arthritis", "OBSERVATION", 107, 116], ["rheumatism", "OBSERVATION", 118, 128]]], ["In this study, we treated A549 cells with PM10 at 25-400 \u03bcg/ mL for 24 h and found that the expression level of COX-2 was gradually increased in 100 and 200 \u03bcg/mL treatment groups.", [["A549 cells", "ANATOMY", 26, 36], ["PM10", "CHEMICAL", 42, 46], ["PM10", "CHEMICAL", 42, 46], ["A549 cells", "CELL", 26, 36], ["PM10", "SIMPLE_CHEMICAL", 42, 46], ["COX-2", "GENE_OR_GENE_PRODUCT", 112, 117], ["A549 cells", "CELL_LINE", 26, 36], ["COX", "PROTEIN", 112, 115], ["this study", "TEST", 3, 13], ["A549 cells", "TREATMENT", 26, 36], ["PM10", "TREATMENT", 42, 46], ["COX", "TEST", 112, 115]]], ["In addition, it has been reported that ROS is generated by metals including iron, resulting in oxidative damage and inflammatory reactions, which subsequently results in cell death [28] .", [["cell", "ANATOMY", 170, 174], ["ROS", "CHEMICAL", 39, 42], ["iron", "CHEMICAL", 76, 80], ["death", "DISEASE", 175, 180], ["iron", "CHEMICAL", 76, 80], ["ROS", "SIMPLE_CHEMICAL", 39, 42], ["metals", "SIMPLE_CHEMICAL", 59, 65], ["iron", "SIMPLE_CHEMICAL", 76, 80], ["cell", "CELL", 170, 174], ["iron", "TREATMENT", 76, 80], ["oxidative damage", "PROBLEM", 95, 111], ["inflammatory reactions", "PROBLEM", 116, 138], ["cell death", "PROBLEM", 170, 180], ["oxidative damage", "OBSERVATION", 95, 111], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["cell death", "OBSERVATION", 170, 180]]], ["We examined cell viability when A549 cells were exposed to PM10 at concentrations of 25-200 \u03bcg/mL and confirmed that the cells showed toxicity from 100 \u03bcg/mL. erefore, in this study, the exposure concentration of PM10 was set to 100 \u03bcg/mL to analyze whether there is an anti-inflammatory effect of RL, which has been traditionally used as a medicinal plant in Asia, on PM10-treated alveolar epithelial cells.GenesWhen RL was pretreated at 15.625-250 \u03bcg/mL concentration before PM10 was added to the A549 cells, we found that RL at 125 and 250 \u03bcg/mL relieves cytotoxicity induced by PM10.", [["cell", "ANATOMY", 12, 16], ["A549 cells", "ANATOMY", 32, 42], ["cells", "ANATOMY", 121, 126], ["alveolar epithelial cells", "ANATOMY", 382, 407], ["A549 cells", "ANATOMY", 499, 509], ["PM10", "CHEMICAL", 59, 63], ["toxicity", "DISEASE", 134, 142], ["PM10", "CHEMICAL", 213, 217], ["RL", "CHEMICAL", 298, 300], ["PM10", "CHEMICAL", 369, 373], ["GenesWhen", "CHEMICAL", 408, 417], ["PM10", "CHEMICAL", 477, 481], ["RL", "CHEMICAL", 525, 527], ["PM10", "CHEMICAL", 582, 586], ["PM10", "CHEMICAL", 59, 63], ["PM10", "CHEMICAL", 213, 217], ["PM10", "CHEMICAL", 369, 373], ["PM10", "CHEMICAL", 477, 481], ["cell", "CELL", 12, 16], ["A549 cells", "CELL", 32, 42], ["PM10", "SIMPLE_CHEMICAL", 59, 63], ["cells", "CELL", 121, 126], ["PM10", "SIMPLE_CHEMICAL", 213, 217], ["RL", "SIMPLE_CHEMICAL", 298, 300], ["PM10", "SIMPLE_CHEMICAL", 369, 373], ["alveolar epithelial cells", "CELL", 382, 407], ["PM10", "SIMPLE_CHEMICAL", 477, 481], ["A549 cells", "CELL", 499, 509], ["RL", "SIMPLE_CHEMICAL", 525, 527], ["PM10", "SIMPLE_CHEMICAL", 582, 586], ["A549 cells", "CELL_LINE", 32, 42], ["PM10-treated alveolar epithelial cells", "CELL_LINE", 369, 407], ["A549 cells", "CELL_LINE", 499, 509], ["A549 cells", "PROBLEM", 32, 42], ["toxicity", "PROBLEM", 134, 142], ["this study", "TEST", 171, 181], ["the exposure concentration of PM10", "TREATMENT", 183, 217], ["an anti-inflammatory effect of RL", "PROBLEM", 267, 300], ["PM10", "TREATMENT", 369, 373], ["alveolar epithelial cells", "PROBLEM", 382, 407], ["cytotoxicity", "PROBLEM", 558, 570], ["cell viability", "OBSERVATION", 12, 26], ["anti-inflammatory effect", "OBSERVATION", 270, 294], ["alveolar epithelial cells", "OBSERVATION", 382, 407]]], ["In addition, cell viability increased up to 85.06%.", [["cell", "ANATOMY", 13, 17], ["cell", "CELL", 13, 17], ["cell viability", "TEST", 13, 27], ["cell", "OBSERVATION", 13, 17], ["viability", "OBSERVATION_MODIFIER", 18, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["Considering these results, RL may protect cells by mitigating the oxidative stress and inflammatory response induced by PM10. erefore, to confirm the anti-inflammatory effects of RL, we set the treatment concentration of RL to 125 and 250 \u03bcg/mL and proceeded to the next analysis.GenesCOX-2 is a proinflammatory biomarker that produces PGE 2 , which mediates inflammation, pain, and fever [29] . erefore, to confirm the anti-inflammatory effect of RL, we investigated whether the expression level of COX-2 following PM10 exposure was reduced by pretreatment with RL.", [["cells", "ANATOMY", 42, 47], ["PM10", "CHEMICAL", 120, 124], ["inflammation", "DISEASE", 359, 371], ["pain", "DISEASE", 373, 377], ["fever", "DISEASE", 383, 388], ["PM10", "CHEMICAL", 516, 520], ["PGE 2", "CHEMICAL", 336, 341], ["PM10", "CHEMICAL", 516, 520], ["RL", "SIMPLE_CHEMICAL", 27, 29], ["cells", "CELL", 42, 47], ["PM10", "SIMPLE_CHEMICAL", 120, 124], ["RL", "SIMPLE_CHEMICAL", 179, 181], ["GenesCOX-2", "GENE_OR_GENE_PRODUCT", 280, 290], ["PGE 2", "GENE_OR_GENE_PRODUCT", 336, 341], ["RL", "SIMPLE_CHEMICAL", 448, 450], ["COX-2", "GENE_OR_GENE_PRODUCT", 500, 505], ["PM10", "SIMPLE_CHEMICAL", 516, 520], ["GenesCOX-2", "PROTEIN", 280, 290], ["PGE 2", "PROTEIN", 336, 341], ["COX-2", "PROTEIN", 500, 505], ["the oxidative stress", "PROBLEM", 62, 82], ["inflammatory response", "PROBLEM", 87, 108], ["the treatment concentration of RL", "TREATMENT", 190, 223], ["the next analysis", "TEST", 262, 279], ["a proinflammatory biomarker", "TEST", 294, 321], ["PGE 2", "PROBLEM", 336, 341], ["inflammation", "PROBLEM", 359, 371], ["pain", "PROBLEM", 373, 377], ["fever", "PROBLEM", 383, 388], ["COX", "TEST", 500, 503], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["inflammation", "OBSERVATION", 359, 371]]], ["After 24 h of exposure to PM10, the expression level of COX-2 was significantly increased; conversely, in RL-pretreated cells, PM10 expression was reduced in a dose-dependent manner. erefore, RL may suppress the production of PGE 2 .Genese MAPK pathway consists of ERK, JNK, and p38 kinase, which are known to play an important role in the proliferation of cells, controlling immune responses and activating inflammation related to the lungs.", [["cells", "ANATOMY", 120, 125], ["cells", "ANATOMY", 357, 362], ["lungs", "ANATOMY", 436, 441], ["PM10", "CHEMICAL", 26, 30], ["PM10", "CHEMICAL", 127, 131], ["PGE", "CHEMICAL", 226, 229], ["inflammation", "DISEASE", 408, 420], ["PM10", "CHEMICAL", 26, 30], ["PGE 2", "CHEMICAL", 226, 231], ["PM10", "SIMPLE_CHEMICAL", 26, 30], ["COX-2", "GENE_OR_GENE_PRODUCT", 56, 61], ["RL", "SIMPLE_CHEMICAL", 106, 108], ["cells", "CELL", 120, 125], ["PM10", "SIMPLE_CHEMICAL", 127, 131], ["PGE 2", "GENE_OR_GENE_PRODUCT", 226, 231], ["Genese MAPK", "GENE_OR_GENE_PRODUCT", 233, 244], ["ERK", "GENE_OR_GENE_PRODUCT", 265, 268], ["JNK", "GENE_OR_GENE_PRODUCT", 270, 273], ["p38 kinase", "GENE_OR_GENE_PRODUCT", 279, 289], ["cells", "CELL", 357, 362], ["lungs", "ORGAN", 436, 441], ["COX", "PROTEIN", 56, 59], ["RL-pretreated cells", "CELL_LINE", 106, 125], ["PM10", "PROTEIN", 127, 131], ["MAPK", "PROTEIN", 240, 244], ["ERK", "PROTEIN", 265, 268], ["JNK", "PROTEIN", 270, 273], ["p38 kinase", "PROTEIN", 279, 289], ["COX", "TEST", 56, 59], ["the production of PGE 2", "PROBLEM", 208, 231], ["Genese MAPK pathway", "TEST", 233, 252], ["ERK", "TEST", 265, 268], ["JNK", "TEST", 270, 273], ["p38 kinase", "TEST", 279, 289], ["the proliferation of cells", "PROBLEM", 336, 362], ["activating inflammation", "PROBLEM", 397, 420], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["reduced", "OBSERVATION_MODIFIER", 147, 154], ["inflammation", "OBSERVATION", 408, 420], ["lungs", "ANATOMY", 436, 441]]], ["ERKs activated by growth factors, mitogen, and cytokines are mainly involved in cell mitosis, cell proliferation, and survival; when ERKs are overexpressed, cancer is induced [30] .", [["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 94, 98], ["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 157, 163], ["ERKs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 80, 84], ["cell", "CELL", 94, 98], ["ERKs", "GENE_OR_GENE_PRODUCT", 133, 137], ["cancer", "CANCER", 157, 163], ["ERKs", "PROTEIN", 0, 4], ["growth factors", "PROTEIN", 18, 32], ["mitogen", "PROTEIN", 34, 41], ["cytokines", "PROTEIN", 47, 56], ["ERKs", "PROTEIN", 133, 137], ["mitogen", "TREATMENT", 34, 41], ["cell proliferation", "PROBLEM", 94, 112], ["cell mitosis", "OBSERVATION", 80, 92], ["cell proliferation", "OBSERVATION", 94, 112]]], ["JNK and p38 MAPK regulate the activity and expression of major inflammatory mediators including proteases and cytokines [31] .", [["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 8, 16], ["JNK", "PROTEIN", 0, 3], ["p38 MAPK", "PROTEIN", 8, 16], ["major inflammatory mediators", "PROTEIN", 57, 85], ["proteases", "PROTEIN", 96, 105], ["cytokines", "PROTEIN", 110, 119], ["JNK", "TEST", 0, 3], ["p38 MAPK", "TEST", 8, 16], ["major inflammatory mediators", "PROBLEM", 57, 85], ["cytokines", "TEST", 110, 119]]], ["NF-\u03baB is a transcriptional regulator that plays a major role in regulating the expression of COX-2.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["COX-2", "GENE_OR_GENE_PRODUCT", 93, 98], ["NF-\u03baB", "PROTEIN", 0, 5], ["COX-2", "PROTEIN", 93, 98], ["a transcriptional regulator", "TREATMENT", 9, 36]]], ["Normally, it binds to I\u03baB and is present in the cytoplasm in an inactive state.", [["cytoplasm", "ANATOMY", 48, 57], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 22, 25], ["cytoplasm", "ORGANISM_SUBSTANCE", 48, 57], ["I\u03baB", "PROTEIN", 22, 25], ["cytoplasm", "OBSERVATION_MODIFIER", 48, 57], ["inactive state", "OBSERVATION", 64, 78]]], ["However, when I\u03baB is phosphorylated and degraded by cytokine and LPS stimulation, NF-\u03baB is released into the nucleus and expression of various inflammatory factors, such as COX-2, cytokines, and chemokines, is induced [32] .GenesIn our study, when A549 cells were treated with PM10, MAPK phosphorylation and NF-\u03baB p65 nuclear translocation were activated.", [["nucleus", "ANATOMY", 109, 116], ["A549 cells", "ANATOMY", 248, 258], ["nuclear", "ANATOMY", 318, 325], ["LPS", "CHEMICAL", 65, 68], ["PM10", "CHEMICAL", 277, 281], ["PM10", "CHEMICAL", 277, 281], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 14, 17], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["nucleus", "CELLULAR_COMPONENT", 109, 116], ["COX-2", "GENE_OR_GENE_PRODUCT", 173, 178], ["A549 cells", "CELL", 248, 258], ["PM10", "SIMPLE_CHEMICAL", 277, 281], ["MAPK", "GENE_OR_GENE_PRODUCT", 283, 287], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 308, 317], ["I\u03baB", "PROTEIN", 14, 17], ["cytokine", "PROTEIN", 52, 60], ["NF-\u03baB", "PROTEIN", 82, 87], ["inflammatory factors", "PROTEIN", 143, 163], ["COX-2", "PROTEIN", 173, 178], ["cytokines", "PROTEIN", 180, 189], ["chemokines", "PROTEIN", 195, 205], ["A549 cells", "CELL_LINE", 248, 258], ["MAPK", "PROTEIN", 283, 287], ["NF-\u03baB p65", "PROTEIN", 308, 317], ["cytokine and LPS stimulation", "TREATMENT", 52, 80], ["NF", "TEST", 82, 84], ["various inflammatory factors", "PROBLEM", 135, 163], ["COX", "TEST", 173, 176], ["cytokines", "TREATMENT", 180, 189], ["our study", "TEST", 232, 241], ["A549 cells", "PROBLEM", 248, 258], ["PM10", "TREATMENT", 277, 281], ["MAPK phosphorylation", "TEST", 283, 303], ["NF", "TEST", 308, 310], ["nucleus", "ANATOMY", 109, 116], ["various", "OBSERVATION_MODIFIER", 135, 142], ["inflammatory factors", "OBSERVATION", 143, 163]]], ["Pretreatment with RL inhibited the activation of MAPK phosphorylation by PM10 treatment and suppressed nuclear translocation of NF-\u03baB p65. erefore, RL is expected to have a therapeutic effect by alleviating lung inflammation through this mechanism, even in asthma symptoms exacerbated by PM10.GenesInflammation progresses through the action of proinflammatory cytokines, and a representative method of treating inflammatory diseases is to regulate the action of cytokines.", [["nuclear", "ANATOMY", 103, 110], ["lung", "ANATOMY", 207, 211], ["RL", "CHEMICAL", 18, 20], ["PM10", "CHEMICAL", 73, 77], ["RL", "CHEMICAL", 148, 150], ["lung inflammation", "DISEASE", 207, 224], ["asthma", "DISEASE", 257, 263], ["PM10", "CHEMICAL", 288, 292], ["inflammatory diseases", "DISEASE", 411, 432], ["PM10", "CHEMICAL", 73, 77], ["RL", "SIMPLE_CHEMICAL", 18, 20], ["MAPK", "GENE_OR_GENE_PRODUCT", 49, 53], ["PM10", "SIMPLE_CHEMICAL", 73, 77], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 128, 137], ["lung", "ORGAN", 207, 211], ["PM10", "SIMPLE_CHEMICAL", 288, 292], ["MAPK", "PROTEIN", 49, 53], ["NF-\u03baB p65", "PROTEIN", 128, 137], ["proinflammatory cytokines", "PROTEIN", 344, 369], ["cytokines", "PROTEIN", 462, 471], ["MAPK phosphorylation", "TREATMENT", 49, 69], ["PM10 treatment", "TREATMENT", 73, 87], ["alleviating lung inflammation", "PROBLEM", 195, 224], ["asthma symptoms", "PROBLEM", 257, 272], ["GenesInflammation", "TREATMENT", 293, 310], ["proinflammatory cytokines", "PROBLEM", 344, 369], ["inflammatory diseases", "PROBLEM", 411, 432], ["therapeutic", "OBSERVATION_MODIFIER", 173, 184], ["lung", "ANATOMY", 207, 211], ["inflammation", "OBSERVATION", 212, 224], ["inflammatory", "OBSERVATION", 411, 423]]], ["IL-1\u03b2 and TNF-\u03b1 mediate inflammation by activating NF-\u03baB and AP-1.", [["inflammation", "DISEASE", 24, 36], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 10, 15], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 51, 56], ["AP-1", "GENE_OR_GENE_PRODUCT", 61, 65], ["IL-1\u03b2", "PROTEIN", 0, 5], ["TNF", "PROTEIN", 10, 13], ["NF-\u03baB", "PROTEIN", 51, 56], ["AP-1", "PROTEIN", 61, 65], ["IL", "TEST", 0, 2], ["TNF", "TEST", 10, 13], ["mediate inflammation", "PROBLEM", 16, 36], ["TNF", "ANATOMY", 10, 13], ["inflammation", "OBSERVATION", 24, 36]]], ["IL-6 induces the ERK pathway to regulate the differentiation and activation of T lymphocytes and is a cytokine that has recently been targeted for treating chronic inflammatory diseases such as asthma and rheumatoid arthritis [33] .", [["T lymphocytes", "ANATOMY", 79, 92], ["asthma", "DISEASE", 194, 200], ["rheumatoid arthritis", "DISEASE", 205, 225], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["ERK", "GENE_OR_GENE_PRODUCT", 17, 20], ["T lymphocytes", "CELL", 79, 92], ["IL-6", "PROTEIN", 0, 4], ["ERK", "PROTEIN", 17, 20], ["T lymphocytes", "CELL_TYPE", 79, 92], ["cytokine", "PROTEIN", 102, 110], ["the ERK pathway", "TEST", 13, 28], ["activation of T lymphocytes", "PROBLEM", 65, 92], ["chronic inflammatory diseases", "PROBLEM", 156, 185], ["asthma", "PROBLEM", 194, 200], ["rheumatoid arthritis", "PROBLEM", 205, 225], ["chronic", "OBSERVATION_MODIFIER", 156, 163], ["inflammatory", "OBSERVATION", 164, 176], ["asthma", "OBSERVATION", 194, 200], ["rheumatoid arthritis", "OBSERVATION", 205, 225]]], ["IL-13 increases the number of lung Evidence-Based Complementary and Alternative Medicine eosinophils and airway hypersensitivity, exacerbating allergic inflammation [34] .", [["lung", "ANATOMY", 30, 34], ["eosinophils", "ANATOMY", 89, 100], ["airway", "ANATOMY", 105, 111], ["airway hypersensitivity", "DISEASE", 105, 128], ["allergic inflammation", "DISEASE", 143, 164], ["IL-13", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 30, 34], ["eosinophils", "CELL", 89, 100], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["IL-13", "PROTEIN", 0, 5], ["eosinophils", "CELL_TYPE", 89, 100], ["IL", "TEST", 0, 2], ["Alternative Medicine eosinophils", "TREATMENT", 68, 100], ["airway hypersensitivity", "PROBLEM", 105, 128], ["exacerbating allergic inflammation", "PROBLEM", 130, 164], ["lung", "ANATOMY", 30, 34], ["airway", "ANATOMY", 105, 111], ["hypersensitivity", "OBSERVATION", 112, 128]]], ["Asthma has been believed to be caused primarily by increased 2 cytokines and eosinophils, but recently, asthma induced by environmental factors, such as air pollution and viral infections, has been found to be associated with an increase in neutrophils [35, 36] .", [["eosinophils", "ANATOMY", 77, 88], ["neutrophils", "ANATOMY", 241, 252], ["Asthma", "DISEASE", 0, 6], ["asthma", "DISEASE", 104, 110], ["viral infections", "DISEASE", 171, 187], ["eosinophils", "CELL", 77, 88], ["neutrophils", "CELL", 241, 252], ["cytokines", "PROTEIN", 63, 72], ["eosinophils", "CELL_TYPE", 77, 88], ["neutrophils", "CELL_TYPE", 241, 252], ["Asthma", "PROBLEM", 0, 6], ["increased 2 cytokines and eosinophils", "PROBLEM", 51, 88], ["asthma", "PROBLEM", 104, 110], ["environmental factors", "PROBLEM", 122, 143], ["air pollution", "PROBLEM", 153, 166], ["viral infections", "PROBLEM", 171, 187], ["an increase in neutrophils", "PROBLEM", 226, 252], ["believed to be", "UNCERTAINTY", 16, 30], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["2 cytokines", "OBSERVATION_MODIFIER", 61, 72], ["eosinophils", "OBSERVATION", 77, 88], ["air pollution", "OBSERVATION", 153, 166], ["viral", "OBSERVATION_MODIFIER", 171, 176], ["infections", "OBSERVATION", 177, 187], ["increase", "OBSERVATION_MODIFIER", 229, 237]]], ["IL-17 is one of the major 17 cytokines that play an important role in the development and progression of asthma, and its levels are elevated in the lungs of asthma patients.", [["lungs", "ANATOMY", 148, 153], ["asthma", "DISEASE", 105, 111], ["asthma", "DISEASE", 157, 163], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["lungs", "ORGAN", 148, 153], ["patients", "ORGANISM", 164, 172], ["IL-17", "PROTEIN", 0, 5], ["cytokines", "PROTEIN", 29, 38], ["patients", "SPECIES", 164, 172], ["the major 17 cytokines", "TREATMENT", 16, 38], ["asthma", "PROBLEM", 105, 111], ["its levels", "TEST", 117, 127], ["asthma patients", "PROBLEM", 157, 172], ["progression", "OBSERVATION_MODIFIER", 90, 101], ["asthma", "OBSERVATION", 105, 111], ["elevated", "OBSERVATION_MODIFIER", 132, 140], ["lungs", "ANATOMY", 148, 153], ["asthma", "OBSERVATION", 157, 163]]], ["IL-17 can also activate NF-\u03baB and MAPK signals [37] .", [["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 24, 29], ["MAPK", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL-17", "PROTEIN", 0, 5], ["NF-\u03baB", "PROTEIN", 24, 29], ["MAPK", "PROTEIN", 34, 38], ["IL", "TEST", 0, 2], ["NF", "TEST", 24, 26], ["MAPK signals", "TEST", 34, 46]]], ["We confirmed that proinflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6, IL-13, and IL-17) in A549 cells treated with PM10 had significantly increased mRNA expression.", [["A549 cells", "ANATOMY", 86, 96], ["PM10", "CHEMICAL", 110, 114], ["PM10", "CHEMICAL", 110, 114], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["IL-13", "GENE_OR_GENE_PRODUCT", 65, 70], ["IL-17", "GENE_OR_GENE_PRODUCT", 76, 81], ["A549 cells", "CELL", 86, 96], ["PM10", "SIMPLE_CHEMICAL", 110, 114], ["proinflammatory cytokines", "PROTEIN", 18, 43], ["TNF", "PROTEIN", 45, 48], ["IL-17", "PROTEIN", 76, 81], ["A549 cells", "CELL_LINE", 86, 96], ["proinflammatory cytokines", "TEST", 18, 43], ["TNF", "TEST", 45, 48], ["IL", "TEST", 52, 54], ["IL", "TEST", 59, 61], ["IL", "TEST", 65, 67], ["IL", "TEST", 76, 78], ["significantly increased mRNA expression", "PROBLEM", 119, 158], ["proinflammatory", "OBSERVATION_MODIFIER", 18, 33], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["mRNA expression", "OBSERVATION", 143, 158]]], ["Furthermore, RL has been shown to reduce these proinflammatory cytokines activated by PM10. erefore, we speculate that RL can alleviate asthma symptoms caused by air pollution by inhibiting proinflammatory cytokines, which increases eosinophils and neutrophils.GenesRL we used in this study was a medicinal herb used in previous experiments, and the compounds related to antiinflammatory effects such as quercetin and epicatechin were identified by LC-MS analysis [18] .", [["eosinophils", "ANATOMY", 233, 244], ["neutrophils", "ANATOMY", 249, 260], ["RL", "CHEMICAL", 13, 15], ["PM10", "CHEMICAL", 86, 90], ["RL", "CHEMICAL", 119, 121], ["asthma", "DISEASE", 136, 142], ["quercetin", "CHEMICAL", 404, 413], ["epicatechin", "CHEMICAL", 418, 429], ["quercetin", "CHEMICAL", 404, 413], ["epicatechin", "CHEMICAL", 418, 429], ["PM10", "SIMPLE_CHEMICAL", 86, 90], ["RL", "SIMPLE_CHEMICAL", 119, 121], ["eosinophils", "CELL", 233, 244], ["neutrophils", "CELL", 249, 260], ["quercetin", "SIMPLE_CHEMICAL", 404, 413], ["epicatechin", "SIMPLE_CHEMICAL", 418, 429], ["proinflammatory cytokines", "PROTEIN", 47, 72], ["proinflammatory cytokines", "PROTEIN", 190, 215], ["eosinophils", "CELL_TYPE", 233, 244], ["neutrophils", "CELL_TYPE", 249, 260], ["these proinflammatory cytokines", "TREATMENT", 41, 72], ["asthma symptoms", "PROBLEM", 136, 151], ["air pollution", "PROBLEM", 162, 175], ["proinflammatory cytokines", "TEST", 190, 215], ["eosinophils", "TEST", 233, 244], ["neutrophils", "TEST", 249, 260], ["this study", "TEST", 280, 290], ["a medicinal herb", "TREATMENT", 295, 311], ["antiinflammatory effects", "TREATMENT", 371, 395], ["quercetin", "TREATMENT", 404, 413], ["epicatechin", "TREATMENT", 418, 429], ["MS analysis", "TEST", 452, 463], ["air pollution", "OBSERVATION", 162, 175]]], ["In addition, RL contains flavonoids such as apigenin and kaempferide, as well as saponins such as ursolic acid, oleanolic acid, and \u03b2-sitosterol [38] .", [["apigenin", "CHEMICAL", 44, 52], ["kaempferide", "CHEMICAL", 57, 68], ["ursolic acid", "CHEMICAL", 98, 110], ["oleanolic acid", "CHEMICAL", 112, 126], ["\u03b2-sitosterol", "CHEMICAL", 132, 144], ["flavonoids", "CHEMICAL", 25, 35], ["apigenin", "CHEMICAL", 44, 52], ["kaempferide", "CHEMICAL", 57, 68], ["saponins", "CHEMICAL", 81, 89], ["ursolic acid", "CHEMICAL", 98, 110], ["oleanolic acid", "CHEMICAL", 112, 126], ["\u03b2-sitosterol", "CHEMICAL", 132, 144], ["flavonoids", "SIMPLE_CHEMICAL", 25, 35], ["apigenin", "SIMPLE_CHEMICAL", 44, 52], ["kaempferide", "SIMPLE_CHEMICAL", 57, 68], ["saponins", "SIMPLE_CHEMICAL", 81, 89], ["ursolic acid", "SIMPLE_CHEMICAL", 98, 110], ["oleanolic acid", "SIMPLE_CHEMICAL", 112, 126], ["\u03b2-sitosterol [38]", "SIMPLE_CHEMICAL", 132, 149], ["flavonoids", "TREATMENT", 25, 35], ["apigenin", "TREATMENT", 44, 52], ["kaempferide", "TREATMENT", 57, 68], ["saponins", "TREATMENT", 81, 89], ["ursolic acid", "TEST", 98, 110], ["oleanolic acid", "TEST", 112, 126], ["RL", "ANATOMY_MODIFIER", 13, 15], ["flavonoids", "OBSERVATION", 25, 35]]], ["Quercetin has been reported to inhibit PGE2 biosynthesis by downregulating cytokine-induced COX-2/iNOS in A549 cells [39] .", [["A549 cells", "ANATOMY", 106, 116], ["Quercetin", "CHEMICAL", 0, 9], ["PGE2", "CHEMICAL", 39, 43], ["Quercetin", "CHEMICAL", 0, 9], ["PGE2", "CHEMICAL", 39, 43], ["Quercetin", "SIMPLE_CHEMICAL", 0, 9], ["PGE2", "SIMPLE_CHEMICAL", 39, 43], ["COX-2", "GENE_OR_GENE_PRODUCT", 92, 97], ["iNOS", "GENE_OR_GENE_PRODUCT", 98, 102], ["A549 cells", "CELL", 106, 116], ["cytokine", "PROTEIN", 75, 83], ["COX-2", "PROTEIN", 92, 97], ["iNOS", "PROTEIN", 98, 102], ["A549 cells", "CELL_LINE", 106, 116], ["Quercetin", "TREATMENT", 0, 9], ["PGE2 biosynthesis", "TREATMENT", 39, 56], ["downregulating cytokine", "TEST", 60, 83], ["COX", "TEST", 92, 95], ["A549 cells", "TEST", 106, 116]]], ["In addition, it has been confirmed that Pbinduced inflammation in the rat kidney is alleviated by the regulation of the MAPK/NF-\u03baB signaling pathway, and apigenin inhibits the mRNA expression of proinflammatory cytokines induced by phorbol-12-myristate-13-acetate in A549 cells [40, 41] .", [["kidney", "ANATOMY", 74, 80], ["A549 cells", "ANATOMY", 267, 277], ["inflammation", "DISEASE", 50, 62], ["apigenin", "CHEMICAL", 154, 162], ["phorbol-12-myristate-13-acetate", "CHEMICAL", 232, 263], ["apigenin", "CHEMICAL", 154, 162], ["phorbol-12-myristate-13-acetate", "CHEMICAL", 232, 263], ["Pbinduced", "SIMPLE_CHEMICAL", 40, 49], ["rat", "ORGANISM", 70, 73], ["kidney", "ORGAN", 74, 80], ["MAPK", "GENE_OR_GENE_PRODUCT", 120, 124], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 125, 130], ["apigenin", "SIMPLE_CHEMICAL", 154, 162], ["phorbol-12-myristate-13-acetate", "SIMPLE_CHEMICAL", 232, 263], ["A549 cells", "CELL", 267, 277], ["MAPK", "PROTEIN", 120, 124], ["\u03baB", "PROTEIN", 128, 130], ["proinflammatory cytokines", "PROTEIN", 195, 220], ["A549 cells", "CELL_LINE", 267, 277], ["rat", "SPECIES", 70, 73], ["rat", "SPECIES", 70, 73], ["Pbinduced inflammation in the rat kidney", "PROBLEM", 40, 80], ["the MAPK", "TEST", 116, 124], ["apigenin", "TREATMENT", 154, 162], ["proinflammatory cytokines", "TEST", 195, 220], ["phorbol", "TEST", 232, 239], ["myristate", "TEST", 243, 252], ["acetate in A549 cells", "TREATMENT", 256, 277], ["inflammation", "OBSERVATION", 50, 62], ["rat", "ANATOMY_MODIFIER", 70, 73], ["kidney", "ANATOMY", 74, 80]]], ["Moreover, ursolic acid inhibited T-and B-cell activation, proliferation, and cytokine secretion, as well as the phosphorylation of ERK and JNK [42] .", [["B-cell", "ANATOMY", 39, 45], ["ursolic acid", "CHEMICAL", 10, 22], ["ursolic acid", "CHEMICAL", 10, 22], ["ursolic acid", "SIMPLE_CHEMICAL", 10, 22], ["T", "CELL", 33, 34], ["B-cell", "CELL", 39, 45], ["ERK", "GENE_OR_GENE_PRODUCT", 131, 134], ["JNK", "GENE_OR_GENE_PRODUCT", 139, 142], ["cytokine", "PROTEIN", 77, 85], ["ERK", "PROTEIN", 131, 134], ["JNK", "PROTEIN", 139, 142], ["ursolic acid", "TEST", 10, 22], ["T", "TEST", 33, 34], ["B-cell activation", "PROBLEM", 39, 56], ["proliferation", "PROBLEM", 58, 71], ["cytokine secretion", "PROBLEM", 77, 95], ["JNK", "TEST", 139, 142], ["cell activation", "OBSERVATION", 41, 56], ["cytokine secretion", "OBSERVATION", 77, 95]]], ["Our findings on RL-derived components support the hypothesis that RL alleviates PM10-induced inflammation in the lungs.", [["lungs", "ANATOMY", 113, 118], ["RL", "CHEMICAL", 66, 68], ["PM10", "CHEMICAL", 80, 84], ["inflammation", "DISEASE", 93, 105], ["PM10", "CHEMICAL", 80, 84], ["RL", "SIMPLE_CHEMICAL", 66, 68], ["PM10", "SIMPLE_CHEMICAL", 80, 84], ["lungs", "ORGAN", 113, 118], ["the hypothesis", "PROBLEM", 46, 60], ["inflammation in the lungs", "PROBLEM", 93, 118], ["inflammation", "OBSERVATION", 93, 105], ["lungs", "ANATOMY", 113, 118]]], ["Evidence-Based Complementary and Alternative Medicine 7ConclusionsIn summary, we confirmed that in A549 cells pretreated with R. laevigata, cytotoxicity induced by PM10 (100 \u03bcg/mL) exposure was attenuated.", [["A549 cells", "ANATOMY", 99, 109], ["PM10", "CHEMICAL", 164, 168], ["PM10", "CHEMICAL", 164, 168], ["A549 cells", "CELL", 99, 109], ["R. laevigata", "ORGANISM", 126, 138], ["PM10", "SIMPLE_CHEMICAL", 164, 168], ["A549 cells", "CELL_LINE", 99, 109], ["R. laevigata", "SPECIES", 126, 138], ["R. laevigata", "SPECIES", 126, 138], ["R. laevigata", "TREATMENT", 126, 138], ["cytotoxicity", "PROBLEM", 140, 152]]], ["In addition, RL suppressed the expression level of MAPK/NF-\u03baB pathways and its downstream signal, COX-2 in PM10-induced A549 cells.", [["A549 cells", "ANATOMY", 120, 130], ["PM10", "CHEMICAL", 107, 111], ["RL", "SIMPLE_CHEMICAL", 13, 15], ["MAPK", "GENE_OR_GENE_PRODUCT", 51, 55], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 56, 61], ["COX-2", "GENE_OR_GENE_PRODUCT", 98, 103], ["PM10", "SIMPLE_CHEMICAL", 107, 111], ["A549 cells", "CELL", 120, 130], ["MAPK", "PROTEIN", 51, 55], ["NF-\u03baB", "PROTEIN", 56, 61], ["COX-2", "PROTEIN", 98, 103], ["PM10-induced A549 cells", "CELL_LINE", 107, 130], ["MAPK/NF", "TEST", 51, 58], ["its downstream signal", "TEST", 75, 96], ["COX", "TEST", 98, 101], ["PM10", "TEST", 107, 111], ["A549 cells", "OBSERVATION", 120, 130]]], ["Moreover, RL downregulated the mRNA expression level of inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6, IL-13, and IL-17) in PM10-induced A549 cells. us, RL may be developed as a natural remedy for respiratory diseases caused by PM10 exposure.Data AvailabilityAll data generated or analyzed during this study are included within the article.Conflicts of Intereste authors declare that they have no conflicts of interest with the contents of this article.", [["A549 cells", "ANATOMY", 134, 144], ["respiratory", "ANATOMY", 194, 205], ["PM10", "CHEMICAL", 121, 125], ["respiratory diseases", "DISEASE", 194, 214], ["PM10", "CHEMICAL", 225, 229], ["PM10", "CHEMICAL", 225, 229], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-6", "GENE_OR_GENE_PRODUCT", 94, 98], ["IL-13", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL-17", "GENE_OR_GENE_PRODUCT", 111, 116], ["PM10", "SIMPLE_CHEMICAL", 121, 125], ["A549 cells", "CELL", 134, 144], ["PM10", "SIMPLE_CHEMICAL", 225, 229], ["inflammatory cytokines", "PROTEIN", 56, 78], ["TNF", "PROTEIN", 80, 83], ["IL-17", "PROTEIN", 111, 116], ["PM10-induced A549 cells", "CELL_LINE", 121, 144], ["inflammatory cytokines", "TEST", 56, 78], ["TNF", "TEST", 80, 83], ["IL", "TEST", 87, 89], ["IL", "TEST", 94, 96], ["IL", "TEST", 100, 102], ["IL", "TEST", 111, 113], ["respiratory diseases", "PROBLEM", 194, 214], ["All data", "TEST", 256, 264], ["this study", "TEST", 294, 304], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68], ["A549 cells", "OBSERVATION", 134, 144], ["PM10 exposure", "OBSERVATION", 225, 238]]]], "PMC6357399": [["BackgroundMore than 23 million oldest-old individuals (those aged 80+) live in China, contributing 18% of the oldest-old population worldwide in 2015.", [["individuals", "ORGANISM", 42, 53]]], ["The oldest-old are a highly vulnerable population in China and are among the most policy-neglected and socially disadvantaged people [2].", [["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132], ["highly", "OBSERVATION_MODIFIER", 21, 27], ["vulnerable", "OBSERVATION_MODIFIER", 28, 38], ["population", "OBSERVATION", 39, 49]]], ["The complex healthcare needs of the oldest-old (including disability, chronic diseases/multimorbidity, and cognitive impairment) are a substantial demand on the health system of China [5\u20137].", [["chronic diseases", "DISEASE", 70, 86], ["multimorbidity", "DISEASE", 87, 101], ["cognitive impairment", "DISEASE", 107, 127], ["chronic diseases", "PROBLEM", 70, 86], ["multimorbidity", "PROBLEM", 87, 101], ["cognitive impairment", "PROBLEM", 107, 127], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["diseases", "OBSERVATION", 78, 86]]], ["Consequently, this age group has the highest rates of healthcare expenditure and has also seen the fastest rise in healthcare expenditure in recent decades [8].BackgroundThere is a substantial concern from policymakers worldwide on how to manage and care for this expanding vulnerable population, and a need for more detailed insights into how the care needs of these oldest-old populations are changing.", [["fastest", "OBSERVATION_MODIFIER", 99, 106], ["rise", "OBSERVATION_MODIFIER", 107, 111], ["substantial", "OBSERVATION_MODIFIER", 181, 192]]], ["Two major views on the trends of morbidity among older adults have been proposed.", [["adults", "ORGANISM", 55, 61]]], ["The first is the compression of morbidity hypothesis [9, 10], which states that the age of onset of morbidity or disability can rise more rapidly than life expectancy (LE) [11], thus resulting in a shorter period of morbidity prior to death.", [["disability", "DISEASE", 113, 123], ["death", "DISEASE", 235, 240], ["morbidity hypothesis", "PROBLEM", 32, 52], ["morbidity", "PROBLEM", 100, 109], ["disability", "PROBLEM", 113, 123], ["morbidity", "PROBLEM", 216, 225], ["death", "PROBLEM", 235, 240], ["compression", "OBSERVATION_MODIFIER", 17, 28], ["morbidity", "OBSERVATION", 32, 41], ["morbidity", "OBSERVATION", 100, 109], ["morbidity", "OBSERVATION", 216, 225]]], ["A contrasting theory, the expansion of disability hypothesis, posits that reductions in mortality (and thus, increases in LE) may result in a shift in frailty over successive cohorts, as individuals with worse health are now likely to survive longer than they would have in the past [12, 13], resulting in populations of older individuals with higher rates of disability in older ages [12\u201315].", [["frailty", "DISEASE", 151, 158], ["disability", "DISEASE", 360, 370], ["disability hypothesis", "PROBLEM", 39, 60], ["expansion", "OBSERVATION_MODIFIER", 26, 35], ["reductions", "OBSERVATION_MODIFIER", 74, 84]]], ["The ways in which these theoretical frameworks function in the oldest-old populations are unclear, as these high-longevity individuals have already far outlived their cohort\u2019s LEs.", [["individuals", "ORGANISM", 123, 134], ["LEs", "CANCER", 176, 179]]], ["In addition, these two viewpoints are not necessarily opposing\u2014different sub-populations may experience expansions or compression of morbidity at the same time [16, 17], and different facets of health (disability, chronic diseases/multimorbidity, cognitive ability) may change in different directions across cohorts [16\u201318].BackgroundIn China, several studies have evaluated trends in disability/morbidity over time [16, 19\u201323].", [["disability", "DISEASE", 202, 212], ["chronic diseases", "DISEASE", 214, 230], ["multimorbidity", "DISEASE", 231, 245], ["disability", "DISEASE", 385, 395], ["expansions", "PROBLEM", 104, 114], ["compression of morbidity", "PROBLEM", 118, 142], ["chronic diseases", "PROBLEM", 214, 230], ["multimorbidity", "PROBLEM", 231, 245], ["several studies", "TEST", 344, 359], ["compression", "OBSERVATION_MODIFIER", 118, 129], ["morbidity", "OBSERVATION_MODIFIER", 133, 142], ["facets", "OBSERVATION_MODIFIER", 184, 190], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["diseases", "OBSERVATION", 222, 230]]], ["However, only one study by Zeng et al. [16] has focused on comparing how morbidity is changing across successive birth cohorts.", [["one study", "TEST", 14, 23]]], ["They suggested that successive cohorts of oldest-old individuals are living longer, but found mixed evidence on whether or not a compression of disability and morbidity was occurring [16].", [["disability", "DISEASE", 144, 154], ["individuals", "ORGANISM", 53, 64], ["a compression of disability", "PROBLEM", 127, 154], ["morbidity", "PROBLEM", 159, 168]]], ["Though these findings provide useful information on cross-sectional changes in disability and morbidity of Chinese oldest-old over a 10-year period, their analyses did not account for the fact that disability is a dynamic condition in the later life [24].", [["disability", "DISEASE", 79, 89], ["disability", "DISEASE", 198, 208]]], ["Individuals relapse and remit between disabled and disability-free life, and the interactions between disability and mortality change over time and by individual characteristics [25].", [["disability", "DISEASE", 102, 112]]], ["Research investigating the compression/expansion of disability in the oldest-old needs to incorporate a dynamic view of cohort variations in disability.", [["disability", "DISEASE", 52, 62], ["disability", "DISEASE", 141, 151], ["the compression/expansion of disability", "PROBLEM", 23, 62], ["compression", "OBSERVATION", 27, 38], ["expansion", "OBSERVATION_MODIFIER", 39, 48]]], ["Accurately accounting for these transitions leads to a more nuanced understanding of the lived experience with disability and avoids generating biased estimates of the level of disablement at the population level [25].", [["disability", "DISEASE", 111, 121], ["disablement", "DISEASE", 177, 188]]], ["In addition, though previous research has established that there are sociodemographic inequalities in disability and morbidity among older adults in China by urban/rural residence and socioeconomic status [23, 26\u201331], no research to date has explored how these inequalities have changed across birth cohorts.", [["disability", "DISEASE", 102, 112]]], ["Given the rapid pace of economic and infrastructural development and the recent implementation of universal healthcare coverage in China, it is important to explore whether potential gains in LE (and potential reductions in disability) are being experienced evenly across the oldest-old population.BackgroundIn this study, we utilized longitudinal survey data from a long-running study of 20,520 Chinese oldest-old and examined whether successive birth cohorts of octogenarians (aged 80\u201389 years), nonagenarians (aged 90\u201399 years), and centenarians (aged 100\u2013105 years) are living longer and with less disability.", [["disability", "DISEASE", 224, 234], ["disability", "DISEASE", 602, 612], ["octogenarians", "ORGANISM", 464, 477], ["universal healthcare coverage", "TREATMENT", 98, 127], ["this study", "TEST", 311, 321], ["longitudinal survey data", "TEST", 335, 359], ["running study", "TEST", 372, 385], ["rapid", "OBSERVATION_MODIFIER", 10, 15]]], ["We used a multistate life table (MSLT) model to estimate how partial LE (i.e., years lived between two ages, described in detail in the \u201cMethods\u201d section) and disability-free LE (DFLE) are changing within age groups over successive birth cohorts, a metric more directly applicable to understanding trends in population health than more commonly used measures focusing on changes over time periods.", [["disability", "DISEASE", 159, 169]]], ["In addition, we explored whether there is sociodemographic heterogeneity in partial LE and DFLE by urban/rural residence and educational attainment.Study population ::: MethodsData for our analyses are from the Chinese Longitudinal Healthy Longevity Survey (CLHLS), one of the largest samples of oldest-old in the world.", [["our analyses", "TEST", 185, 197], ["largest", "OBSERVATION_MODIFIER", 277, 284]]], ["The details of the sampling design, response rates, attrition, and systematic assessments of data quality across numerous measures have been described elsewhere [32].", [["systematic assessments", "TEST", 67, 89]]], ["In brief, the CLHLS, initiated in 1998, is an ongoing nationwide survey of Chinese oldest-old individuals, with the aim of collecting a comparable sample of octogenarians, nonagenarians, and centenarians in a randomly selected half of counties/cities in 22 provinces throughout China [32].", [["individuals", "ORGANISM", 94, 105]]], ["The total population of the 22 provinces accounts for about 90% of the total population in China according to the 2010 census [33].", [["total", "OBSERVATION_MODIFIER", 4, 9], ["population", "OBSERVATION_MODIFIER", 10, 20]]], ["Using a targeted random-sampling design, the CLHLS interviewed approximately equal numbers of octogenarians and nonagenarians living near the centenarians (e.g., in the same villages or streets) [32].", [["octogenarians", "TREATMENT", 94, 107]]], ["Each participant provided a written informed consent.", [["participant", "SPECIES", 5, 16]]], ["The informed consent was signed by the next-of-kin when the participant was not able to write.Study population ::: MethodsThe date of death was collected from official death certificates when available; otherwise, the next-of-kin and local residential committees were consulted.", [["death", "DISEASE", 134, 139], ["death", "DISEASE", 168, 173], ["participant", "SPECIES", 60, 71], ["Methods", "TREATMENT", 115, 122]]], ["An analysis by Gu and Dupre [34] demonstrated that the single-age-sex-specific mortality rates at oldest-old ages including centenarians in CLHLS fit well with the Kannisto model, a function that has been shown to best fit mortality trajectories at oldest-old ages in various countries with high-quality data [35].", [["An analysis", "TEST", 0, 11], ["the Kannisto model", "TREATMENT", 160, 178]]], ["According to previous reports [36\u201338], the CLHLS has documented good data quality, including assessments of mortality, age reporting, proxy response, sample attrition, and reliability and validity of major health measures.Study population ::: MethodsAs described in a previous study [16], three paired birth cohorts (earlier vs. later cohorts) who were born 10 years apart were interviewed at the same age in 1998 and 2008.", [["a previous study", "TEST", 266, 282]]], ["For paired age group 1, we compared participants born in 1909\u20131918 vs. 1919\u20131928 (octogenarians, aged 80\u201389 years in 1998 vs. 2008); for paired age group 2, we compared participants born in 1899\u20131908 vs. 1909\u20131918 (nonagenarians, aged 90\u201399 years in 1998 vs. 2008); and for paired age group 3, we compared participants born in 1893\u20131898 vs. 1903\u20131908 (centenarians, aged 100\u2013105 years in 1998 vs 2008).", [["participants", "SPECIES", 36, 48], ["participants", "SPECIES", 169, 181], ["participants", "SPECIES", 306, 318]]], ["For the earlier cohort (i.e., hereafter refer to as octogenarians, nonagenarians, and centenarians in 1998), follow-up information from the 2000 and 2002 waves were used to estimate the conditional probabilities of experiencing disability transitions and mortality.", [["disability", "DISEASE", 228, 238], ["disability transitions", "PROBLEM", 228, 250]]], ["For the later cohort (i.e., octogenarians, nonagenarians, and centenarians in 2008), follow-up information from the 2011 and 2014 waves were used to obtain similar estimates.DFLE ::: MethodsDisability was assessed by the Katz index [39] that included six essential ADLs: bathing, transferring, dressing, eating, toileting, and continence.", [["dressing", "TREATMENT", 294, 302], ["toileting", "TREATMENT", 312, 321]]], ["The Chinese version of the scale has been extensively tested and has been shown to yield reliable and valid responses [40, 41].", [["the scale", "TREATMENT", 23, 32]]], ["As described previously [39\u201341], we defined disability as needing personal assistance in performing one or more of the five essential activities (bathing, transferring, dressing, eating, and toileting) or being incontinent.DFLE ::: MethodsOur outcome measure is disability-free LE (DFLE), an easily interpretable metric for comparing population-level disability.", [["disability", "DISEASE", 44, 54], ["disability", "DISEASE", 351, 361], ["personal assistance", "TREATMENT", 66, 85], ["dressing", "TREATMENT", 169, 177], ["being incontinent", "PROBLEM", 205, 222]]], ["Its calculation procedure is outlined below (see the \u201cStatistical analyses\u201d section).", [["Its calculation procedure", "TREATMENT", 0, 25]]], ["DFLE distinguishes between life-years spent free of disability and years with an ADL disability, providing a more nuanced view of population-level disability than simple estimates of LE or disability prevalence.", [["disability", "DISEASE", 52, 62], ["ADL disability", "DISEASE", 81, 95], ["disability", "DISEASE", 147, 157], ["disability", "DISEASE", 189, 199], ["an ADL disability", "PROBLEM", 78, 95], ["level disability", "PROBLEM", 141, 157]]], ["It combines mortality and disability into a single measure, providing a convenient metric for measuring functional health at the population level [42].Sociodemographic variables ::: MethodsAs described previously [16], several key sociodemographic variables including age, sex (men/women), residence (urban/rural), and educational attainment (1+ year/no formal schooling) were considered in this study.", [["men", "ORGANISM", 278, 281], ["women", "ORGANISM", 282, 287], ["men", "SPECIES", 278, 281], ["women", "SPECIES", 282, 287], ["this study", "TEST", 391, 401]]], ["Educational attainment measures whether participants had completed formal schooling with two categories: 1+ year formal schooling and no any formal schooling.", [["participants", "SPECIES", 40, 52]]], ["This distinction is appropriate for the particular Chinese cohorts under study, who have large percentages of illiterate individuals [32, 41].", [["large", "OBSERVATION_MODIFIER", 89, 94]]], ["To capture socioeconomic disparities [44], these two variables\u2014residence and educational attainment\u2014were further used for subgroup analyses in this study.Statistical analyses ::: MethodsPrior research on changes in population-level disability in China has relied on period comparisons\u2014that is, measuring mortality and disability conditions in a population at different points in time and observing changes in the trends over time [19\u201323].", [["disability", "DISEASE", 232, 242], ["subgroup analyses", "TEST", 122, 139], ["this study", "TEST", 143, 153], ["level disability", "PROBLEM", 226, 242], ["disability conditions", "PROBLEM", 318, 339]]], ["However, though this approach may be useful for monitoring aggregate trends in population-level disability, these results do not easily translate to the experience of any given birth cohort of individuals.", [["disability", "DISEASE", 96, 106], ["individuals", "ORGANISM", 193, 204]]], ["In this study, we compared partial LE and DFLE across birth cohorts\u2014that is, total LE, and LE in disability-free and disabled life, bounded between two ages.", [["this study", "TEST", 3, 13]]], ["Additional file 1: Figure S1 displays a Lexis diagram showing the cohort comparison in ages 80\u201389 graphically.", [["a Lexis diagram", "TEST", 38, 53]]], ["We first estimated transition probabilities using longitudinal data from the observation period outlined in the dark dashed line (1998\u20132002 for the earlier cohort, 2008\u20132014 for the later cohort).", [["longitudinal data", "TEST", 50, 67]]], ["These transition probabilities were then used to estimate partial LE and DFLE in oldest-old age ranges (80\u201389, 90\u201399, 100\u2013105) for the birth cohorts.", [["These transition probabilities", "PROBLEM", 0, 30], ["the birth cohorts", "TREATMENT", 131, 148]]], ["Note that some birth cohorts are in the analysis more than once, as earlier cohorts in some analyses, and later cohorts in others.", [["some birth cohorts", "PROBLEM", 10, 28]]], ["The CLHLS sample was periodically refreshed, and in practice, few individuals are present in more than one cohort comparison (less than 5% of the earlier cohort in the comparison of 80\u201389-year-olds were included in the later cohort in the comparison of 90\u201399-year-olds, and less than 2% of the earlier cohort in the comparison of 90\u201399-year-olds were included in the later cohort in the comparison of 100\u2013105-year-olds).Statistical analyses ::: MethodsMore specifically, when generating the transition probabilities between nondisabled, disability, and death, our analysis method initially converted the CHLHS data to a person-year time scale, assuming that transitions between disability states occur at a random time between observations.", [["CLHLS sample", "ANATOMY", 4, 16], ["disability", "DISEASE", 537, 547], ["death", "DISEASE", 553, 558], ["disability", "DISEASE", 678, 688], ["individuals", "ORGANISM", 66, 77], ["person", "SPECIES", 620, 626], ["The CLHLS sample", "TEST", 0, 16], ["our analysis method", "TEST", 560, 579], ["few", "OBSERVATION_MODIFIER", 62, 65]]], ["We modeled these annual transition probabilities using a cumulative logistic regression model, stratified by initial disability state.", [["a cumulative logistic regression model", "TREATMENT", 55, 93]]], ["Though (as discussed above) a small percentage of individuals are included in multiple age groups in our analyses, there were no individuals contributing person-years of observation to the earlier and later cohorts within each age group comparison.", [["individuals", "ORGANISM", 50, 61], ["person", "SPECIES", 154, 160], ["a small percentage of individuals", "PROBLEM", 28, 61], ["small", "OBSERVATION_MODIFIER", 30, 35], ["no", "UNCERTAINTY", 126, 128]]], ["Models including an age2 and an age \u00d7 sex interaction were also tested, but their coefficients were not significant at \u03b1 = 0.05 and thus were removed in favor of the simpler model.Statistical analyses ::: MethodsTo generate estimates of partial LE and DFLE, we relied on microsimulation, a well-established tool in demographic research [46\u201350].", [["partial", "OBSERVATION_MODIFIER", 237, 244]]], ["The transition probability matrices, estimated as described above, were applied via microsimulation to separate synthetic cohorts of 100,000 individuals in each cohort and age group (who have the same sex, residence, educational attainment, and initial disability state distribution as the observed cohorts).", [["The transition probability matrices", "PROBLEM", 0, 35]]], ["The resulting 100,000-person synthetic cohort was analyzed to estimate partial LE and DFLE.", [["person", "SPECIES", 22, 28]]], ["Point estimates shown were from transition probabilities estimated from the full sample.", [["Point estimates", "PROBLEM", 0, 15], ["transition probabilities", "PROBLEM", 32, 56]]], ["In the microsimulation approach, LE and DFLE estimates were not a deterministic function of the transition probabilities and instead resulted from a complex interplay between disability state, age, and individual characteristics as individuals move year-by-year through the simulation.", [["the microsimulation approach", "TEST", 3, 31], ["LE and DFLE estimates", "TEST", 33, 54], ["the transition probabilities", "PROBLEM", 92, 120]]], ["Confidence intervals (CIs), which reflect both the uncertainty of the estimated parameters and the uncertainty from the microsimulation, were created by re-estimating the above analysis sequence using 499 bootstrap re-samples from each birth cohort under study.", [["bootstrap re-samples", "TEST", 205, 225]]], ["We took the central 95% of the distribution of these bootstrapped parameters as the 95% confidence interval and calculated non-parametric P values for differences in means between birth cohorts [51].Statistical analyses ::: MethodsInverse probability (IP) weights were included to correct for potential bias introduced from differential loss to follow-up.", [["calculated non-parametric P values", "TEST", 112, 146], ["potential bias", "PROBLEM", 293, 307], ["central", "OBSERVATION_MODIFIER", 12, 19]]], ["This method weighted complete cases (those not lost to follow-up) by the inverse of their probability of being a complete case and included the sociodemographic variables in Additional file 2: Table S1 and additional predictors that may influence the likelihood of loss to follow-up: province, marital status, ethnicity, co-residence with children, current smoking and alcohol use, self-reported hypertension, self-reported cardiovascular disease, and primary occupation (agricultural vs. non-agricultural) [52].", [["cardiovascular", "ANATOMY", 424, 438], ["smoking", "CHEMICAL", 357, 364], ["alcohol", "CHEMICAL", 369, 376], ["hypertension", "DISEASE", 396, 408], ["cardiovascular disease", "DISEASE", 424, 446], ["alcohol", "CHEMICAL", 369, 376], ["children", "ORGANISM", 339, 347], ["cardiovascular", "ANATOMICAL_SYSTEM", 424, 438], ["children", "SPECIES", 339, 347], ["hypertension", "PROBLEM", 396, 408], ["cardiovascular disease", "PROBLEM", 424, 446], ["hypertension", "OBSERVATION", 396, 408], ["cardiovascular", "ANATOMY", 424, 438], ["disease", "OBSERVATION", 439, 446]]], ["IP weights were generated separately by each age group and cohort included in these analyses.", [["IP weights", "TEST", 0, 10], ["these analyses", "TEST", 78, 92]]], ["The weight generating models also included the cross-sectional survey sampling weight [53, 54].", [["weight", "TEST", 79, 85]]], ["All analyses were conducted in SAS 9.4 (SAS Institute, Cary, NC), and transition probability estimates were obtained using PROC SURVEYLOGISTIC, accounting for sample design and the IP weight.ResultsAdditional file 2: Table S1 presents the baseline characteristics of the two birth cohorts, including 7334 octogenarians, 7705 nonagenarians, and 5481 centenarians who were interviewed in 1998 or 2008.", [["All analyses", "TEST", 0, 12], ["SAS", "TEST", 31, 34], ["PROC SURVEYLOGISTIC", "TREATMENT", 123, 142], ["the IP weight", "TEST", 177, 190]]], ["Across the three paired age groups, the later cohort had lower prevalence rates of disability than the earlier cohort.", [["disability", "DISEASE", 83, 93]]], ["We observed 4792 deaths in the earlier cohorts (1141 octogenarians, 1809 nonagenarians, and 1842 centenarians) during 4 years of follow-up and 7123 deaths in the later cohorts (1852 octogenarians, 3074 nonagenarians, and 2197 centenarians) over 6 years follow-up.ResultsTable 1 and Fig. 1 present the results by comparing partial total, disability-free, and disabled LE in ages 80\u201389, 90\u201399, and 100\u2013105 between successive 10-year birth cohorts, overall and by sex.", [["deaths", "DISEASE", 17, 23], ["deaths", "DISEASE", 148, 154]]], ["Most of this gain occurred among women, who experienced an increase in partial LE of 0.32 years (P = 0.012) across the two birth cohorts.", [["women", "ORGANISM", 33, 38], ["women", "SPECIES", 33, 38], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["partial", "OBSERVATION_MODIFIER", 71, 78]]], ["This increase in LE was entirely comprised of a 0.32-year rise in partial DFLE (P = 0.004).", [["LE", "GENE_OR_GENE_PRODUCT", 17, 19], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["LE", "ANATOMY_MODIFIER", 17, 19], ["partial", "OBSERVATION_MODIFIER", 66, 73]]], ["In Fig. 1, we observed that, though partial LE in ages 80\u201389 increased between these two birth cohorts, there was little evidence of a compression of morbidity\u2014that is, the proportion of life spent disability-free in these ages was little changed.", [["disability", "DISEASE", 198, 208], ["LE", "GENE_OR_GENE_PRODUCT", 44, 46], ["a compression of morbidity", "PROBLEM", 133, 159], ["little evidence of", "UNCERTAINTY", 114, 132], ["compression", "OBSERVATION", 135, 146], ["morbidity", "OBSERVATION", 150, 159]]], ["Although no increases in partial LE were observed among nonagenarians or centenarians, partial DFLE increased in these persons across successive 10-year birth cohorts, with a gain of 0.41 years (P < 0.001) among nonagenarians and 0.07 years (P = 0.050) among centenarians.", [["LE", "GENE_OR_GENE_PRODUCT", 33, 35], ["persons", "ORGANISM", 119, 126], ["persons", "SPECIES", 119, 126], ["increases in partial LE", "PROBLEM", 12, 35], ["no", "UNCERTAINTY", 9, 11], ["increases", "OBSERVATION_MODIFIER", 12, 21], ["partial", "OBSERVATION_MODIFIER", 25, 32], ["increased", "OBSERVATION_MODIFIER", 100, 109]]], ["As shown in Fig. 1, there was strong evidence that a compression of morbidity happened over successive cohorts among nonagenarians and centenarians\u2014more recently born cohorts are living substantially more of these years disability-free.", [["a compression of morbidity", "PROBLEM", 51, 77], ["compression", "OBSERVATION", 53, 64], ["morbidity", "OBSERVATION", 68, 77]]], ["Women appeared to be experiencing a more rapid compression of disability across cohorts than men\u2014partial DFLE rose by 0.58 years (P < 0.001) among nonagenarian women and by 0.09 years (P = 0.016) among centenarian women, compared with smaller gains of 0.18 disability-free years (P = 0.054) for nonagenarian men and negligible change for centenarian men.ResultsPartial LE estimates and the proportion of life spent disability-free and disabled by urban/rural residence and education are presented in Figs.", [["disability", "DISEASE", 62, 72], ["disability", "DISEASE", 415, 425], ["Women", "ORGANISM", 0, 5], ["women", "ORGANISM", 160, 165], ["women", "ORGANISM", 214, 219], ["men", "ORGANISM", 308, 311], ["men", "ORGANISM", 350, 353], ["Women", "SPECIES", 0, 5], ["women", "SPECIES", 160, 165], ["women", "SPECIES", 214, 219], ["men", "SPECIES", 308, 311], ["men", "SPECIES", 350, 353], ["a more rapid compression of disability", "PROBLEM", 34, 72], ["compression", "OBSERVATION", 47, 58]]], ["2 and 3, respectively, with detailed results in Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, Additional file 6: Table S5, Additional file 7: Table S6, and Additional file 8: Table S7.", [["S6", "PROTEIN", 189, 191]]], ["Urban residents aged 80\u201389 lived 0.39 years longer (P < 0.001) in the later cohort compared to the earlier cohort, with the majority of these additional life-years spent disability-free (0.25 years, P = 0.030).", [["disability", "DISEASE", 170, 180]]], ["In contrast, rural 80\u201389-year-old individuals saw a much smaller increase in partial LE (0.10 years, P = 0.392) and DFLE (0.10 years, P = 0.428).", [["individuals", "ORGANISM", 34, 45], ["a much smaller increase in partial LE", "PROBLEM", 50, 87], ["P", "TEST", 101, 102], ["DFLE", "TEST", 116, 120], ["P", "TEST", 134, 135], ["smaller", "OBSERVATION_MODIFIER", 57, 64], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["partial", "OBSERVATION_MODIFIER", 77, 84], ["LE", "ANATOMY_MODIFIER", 85, 87]]], ["Though partial LE increased faster for urban residents, the proportions of remaining life spent disability-free and disabled were little changed between the two cohorts.", [["disability", "DISEASE", 96, 106], ["LE", "GENE_OR_GENE_PRODUCT", 15, 17], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["faster", "OBSERVATION_MODIFIER", 28, 34]]], ["No urban/rural differences in partial LE were seen between birth cohorts in the 90\u201399 or 100\u2013105 age ranges.", [["LE", "GENE_OR_GENE_PRODUCT", 38, 40], ["urban/rural differences in partial LE", "PROBLEM", 3, 40], ["birth cohorts", "TEST", 59, 72], ["urban", "OBSERVATION_MODIFIER", 3, 8], ["rural differences", "OBSERVATION", 9, 26]]], ["As seen in Fig. 2, the urban population gained proportionately more years of disability-free life in ages 90\u201399, with the proportion of life-years lived disability-free rising from 55 to 70% across successive cohorts.", [["disability", "DISEASE", 77, 87]]], ["In contrast, partial DFLE increased by 0.12 years (P < 0.001) among rural 100\u2013105-year-old individuals between the earlier and later cohorts, compared to 0.02 years (P = 0.602) among urban residents.", [["individuals", "ORGANISM", 91, 102], ["partial", "OBSERVATION_MODIFIER", 13, 20], ["increased", "OBSERVATION_MODIFIER", 26, 35]]], ["An urban/rural disparity in partial LE was evident in octogenarians and nonagenarians, where partial LE for rural residents in the later cohort trailed behind total LE for urban residents born 10 years prior.ResultsPartial LE and DFLE gains across cohorts in ages 80\u201389 were largest in the population with no formal schooling (Fig. 3)\u2014partial LE increased by 0.31 years (P = 0.006) between the two birth cohorts for those without formal schooling.", [["An urban/rural disparity in partial LE", "PROBLEM", 0, 38], ["\u2014partial LE", "PROBLEM", 334, 345], ["octogenarians", "OBSERVATION", 54, 67], ["largest", "OBSERVATION_MODIFIER", 275, 282], ["increased", "OBSERVATION_MODIFIER", 346, 355]]], ["Though gains in partial LE were stronger among those with no education in ages 80\u201389, LE in this group still trailed behind those who received some formal schooling, particularly among men.", [["LE", "GENE_OR_GENE_PRODUCT", 24, 26], ["men", "ORGANISM", 185, 188], ["men", "SPECIES", 185, 188]]], ["Figure 3 suggests that there was little compression of disability happening in either schooling group in ages 80\u201389.", [["disability", "DISEASE", 55, 65], ["little compression of disability", "PROBLEM", 33, 65], ["little", "OBSERVATION_MODIFIER", 33, 39], ["compression", "OBSERVATION", 40, 51]]], ["Partial LE was little changed across cohorts in ages 90\u201399 and 100\u2013105.", [["LE", "GENE_OR_GENE_PRODUCT", 8, 10], ["Partial LE", "PROBLEM", 0, 10], ["LE", "ANATOMY_MODIFIER", 8, 10], ["little", "OBSERVATION_MODIFIER", 15, 21], ["changed", "OBSERVATION", 22, 29]]], ["Those with no formal schooling saw a larger rise in partial DFLE of 0.47 years (P < 0.001) in ages 90\u201399 (compared to 0.27 years [P = 0.008] for those with some formal schooling) and 0.09 years (P = 0.028) in ages 100\u2013105 (compared to no change for those with some formal schooling).", [["larger", "OBSERVATION_MODIFIER", 37, 43], ["rise", "OBSERVATION_MODIFIER", 44, 48], ["partial", "OBSERVATION_MODIFIER", 52, 59]]], ["For both those with and without schooling, evidence for the compression of disability was stronger in women than in men across successive cohorts.Comparisons with previous studies in China and other countries ::: DiscussionOur longitudinal findings are largely consistent with a previous study that compared birth cohorts cross-sectionally in China [16], though some differences are noted.", [["disability", "DISEASE", 75, 85], ["women", "ORGANISM", 102, 107], ["men", "ORGANISM", 116, 119], ["women", "SPECIES", 102, 107], ["men", "SPECIES", 116, 119], ["the compression of disability", "PROBLEM", 56, 85], ["previous studies", "TEST", 163, 179], ["a previous study", "TEST", 277, 293], ["largely consistent with", "UNCERTAINTY", 253, 276]]], ["Comparing cohorts between only the 1998 and 2008 waves, Zeng et al. also found a decrease in the prevalence of ADL disability, which aligns with our finding of increases in partial DFLE across birth cohorts.", [["ADL disability", "DISEASE", 111, 125], ["ADL disability", "PROBLEM", 111, 125], ["partial DFLE across birth cohorts", "PROBLEM", 173, 206], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["increases", "OBSERVATION_MODIFIER", 160, 169], ["partial", "OBSERVATION_MODIFIER", 173, 180]]], ["Zeng et al. found a slight decline in mortality across birth cohorts at all ages, while we only found appreciable increases in partial LE in ages 80\u201389.", [["a slight decline", "PROBLEM", 18, 34], ["slight", "OBSERVATION_MODIFIER", 20, 26], ["decline", "OBSERVATION_MODIFIER", 27, 34], ["appreciable", "OBSERVATION_MODIFIER", 102, 113], ["increases", "OBSERVATION_MODIFIER", 114, 123]]], ["However, Zeng\u2019s study used a modeling approach (parametric survival models) that prioritized precision in measuring the hazard of mortality, a substantially different approach than the generalized logistic hazard model used in our analyses to measure transitions between multiple outcome states.", [["Zeng\u2019s study", "TEST", 9, 21], ["a modeling approach (parametric survival models", "TREATMENT", 27, 74]]], ["Though our models found no significant differences in partial LE between cohorts at ages 90\u201399 and 100\u2013105, the CIs around these estimates are fairly wide.", [["significant differences in partial LE between cohorts", "PROBLEM", 27, 80], ["no", "UNCERTAINTY", 24, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["differences", "OBSERVATION_MODIFIER", 39, 50], ["partial", "OBSERVATION_MODIFIER", 54, 61], ["fairly", "OBSERVATION_MODIFIER", 143, 149], ["wide", "OBSERVATION_MODIFIER", 150, 154]]], ["Future MSLT work could potentially utilize recent advances in parametric multistate survival models to improve model fit by specifying different underlying hazards for different state transitions [55], but more dedicated methodological work is needed to adapt these methods to demographic applications.", [["recent advances in parametric multistate survival models", "TREATMENT", 43, 99]]], ["In addition, our finding on the more rapid improvements in LE and DFLE among the urban resident population indirectly supports Zeng\u2019s argument that the changes of ADL are mostly based on contextual changes due to the rapid economic development in urban areas [16].", [["DFLE", "DISEASE", 66, 70], ["contextual changes", "PROBLEM", 187, 205], ["rapid", "OBSERVATION_MODIFIER", 37, 42], ["improvements", "OBSERVATION_MODIFIER", 43, 55], ["rapid", "OBSERVATION_MODIFIER", 217, 222], ["economic", "OBSERVATION_MODIFIER", 223, 231]]], ["A more detailed discussion of potential factors leading to the observed increases in LE and DFLE in China\u2019s oldest-old is discussed below.Comparisons with previous studies in China and other countries ::: DiscussionAlthough direct comparisons of DFLE across different countries are somewhat problematic due to methodological differences (e.g., MSLTs vs Sullivan\u2019s method) and differences in outcome measures of disability and/or morbidity [56], it is useful to place our findings in the context of other research on DFLE in the oldest-old.", [["DFLE", "DISEASE", 92, 96], ["disability", "DISEASE", 411, 421], ["LE", "GENE_OR_GENE_PRODUCT", 85, 87], ["DFLE", "CANCER", 516, 520], ["previous studies", "TEST", 155, 171], ["somewhat problematic", "PROBLEM", 282, 302], ["methodological differences", "PROBLEM", 310, 336], ["Sullivan\u2019s method", "TREATMENT", 353, 370], ["increases", "OBSERVATION_MODIFIER", 72, 81]]], ["Findings from Great Britain [57], Denmark [58], and the USA [59] suggest that oldest-old individuals in these countries are living longer and with fewer years of disability, than in previous years, though there is some evidence of countervailing trends in younger ages [60].", [["disability", "DISEASE", 162, 172], ["individuals", "ORGANISM", 89, 100]]], ["However, trends in the oldest-old have been mixed in other countries; for example, in Sweden, one study found that oldest-old individuals are living longer and with less disability [61], while another found stagnation in ADL disability and declines in physical functioning [62].", [["disability", "DISEASE", 170, 180], ["ADL disability", "DISEASE", 221, 235], ["declines in physical functioning", "DISEASE", 240, 272], ["individuals", "ORGANISM", 126, 137], ["ADL disability", "PROBLEM", 221, 235]]], ["Research in both Japan [63] and Singapore [64] has found increasing LE over time among those aged 85+, but declining DFLE as a portion of the remaining life.Key factors impacting LE and DFLE ::: DiscussionPrior research suggests several key factors impacting LE and DFLE at oldest-old ages: differing levels of mortality selection to oldest-old ages [65]; differences in life-course stressors, diseases, and health behaviors [66, 67]; and access to and quality of healthcare services at oldest-old ages [68].", [["LE", "GENE_OR_GENE_PRODUCT", 68, 70], ["LE", "GENE_OR_GENE_PRODUCT", 259, 261], ["increasing LE", "PROBLEM", 57, 70], ["diseases", "PROBLEM", 394, 402], ["increasing", "OBSERVATION_MODIFIER", 57, 67]]], ["In this study, we aimed to describe cohort differences, but were not able to disentangle the various roles of these key factors.", [["this study", "TEST", 3, 13]]], ["As reliable mortality statistics in China have only become available in recent years, ascertaining changes in the level of mortality selection of the older Chinese cohorts in our study is difficult.", [["our study", "TEST", 175, 184]]], ["In the sections below, we discussed other contextual trends in Chinese society that may have contributed to our findings.Key factors impacting LE and DFLE ::: DiscussionThe Chinese oldest-old have witnessed great socioeconomic and epidemiological transitions throughout their life course.", [["sections", "ANATOMY", 7, 15]]], ["These cohorts underwent the Sino-Japanese and domestic wars (1937\u20131949) in childhood, experienced famine and social disruption in the Great Leap Forward (1958\u20131961) and the Cultural Revolution (1966\u20131976), and lived through a massive shift from a centrally planned to a market-based economy in their adulthood [20].", [["social disruption", "OBSERVATION", 109, 126], ["Great Leap", "ANATOMY", 134, 144]]], ["This shift brought increasing inequality and disruption of healthcare systems across the country, leading to less access to care in the late 1990s, particularly in rural regions [20, 69, 70].", [["increasing", "OBSERVATION_MODIFIER", 19, 29], ["inequality", "OBSERVATION_MODIFIER", 30, 40]]], ["Nevertheless, since the epidemic of severe acute respiratory syndrome in 2003, the implementation of the New Rural Cooperative Medical System and the Urban Medical Schemes, coupled with policies and benefits targeting the oldest-old since 1995, has made medical care more accessible and affordable, though the reimbursement level is still low [71, 72].Key factors impacting LE and DFLE ::: DiscussionIn recent years, policymakers in China have dedicated significant resources to improving health and well-being of older adults.", [["acute respiratory syndrome", "DISEASE", 43, 69], ["severe acute respiratory syndrome", "PROBLEM", 36, 69], ["the reimbursement level", "TEST", 306, 329], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["respiratory syndrome", "OBSERVATION", 49, 69]]], ["A central tenant of these recent healthcare reforms was to promote equity [73], and our results suggest that these efforts have begun to show successes.", [["central", "OBSERVATION_MODIFIER", 2, 9], ["tenant", "OBSERVATION_MODIFIER", 10, 16]]], ["Women and those without formal schooling, often thought of as disadvantaged subgroups in China, were more likely to experience a compression of disability in this study, consistent with results from period-based comparisons [23, 31].", [["compression of disability", "DISEASE", 129, 154], ["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5], ["a compression of disability", "PROBLEM", 127, 154], ["this study", "TEST", 158, 168]]], ["The disabling effects of some major diseases (e.g., stroke and cardiometabolic diseases) have also declined during the last few decades in China [21, 74, 75].", [["stroke", "DISEASE", 52, 58], ["cardiometabolic diseases", "DISEASE", 63, 87], ["some major diseases", "PROBLEM", 25, 44], ["stroke", "PROBLEM", 52, 58], ["cardiometabolic diseases", "PROBLEM", 63, 87], ["disabling", "OBSERVATION_MODIFIER", 4, 13], ["some", "OBSERVATION_MODIFIER", 25, 29], ["major", "OBSERVATION_MODIFIER", 30, 35], ["diseases", "OBSERVATION", 36, 44]]], ["The empirical observation of gains in DFLE in this study may partially reflect the success of these investments/programs for improving functional health in the oldest-old.Key factors impacting LE and DFLE ::: DiscussionDifferences in access to healthcare may also be one of the explanations for the increasing urban-rural disparity in disability [33, 43].", [["disability", "DISEASE", 335, 345], ["this study", "TEST", 46, 56], ["these investments/programs", "TREATMENT", 94, 120]]], ["Over the life course of these oldest-old individuals, substantial disparities existed in access to and quality of healthcare between urban and rural residents.", [["substantial disparities", "PROBLEM", 54, 77]]], ["When the collectively funded welfare programs (Cooperative Medical Scheme, or hezuo yiliao) were abandoned in most rural areas in the early 1980s, healthcare became predominantly employment-based.", [["Cooperative Medical Scheme", "TREATMENT", 47, 73], ["hezuo yiliao", "TREATMENT", 78, 90]]], ["This gap in coverage remained wide by 2003, when the New Rural Cooperative Medical System was launched.", [["coverage", "OBSERVATION_MODIFIER", 12, 20], ["wide", "OBSERVATION_MODIFIER", 30, 34]]], ["Older adults in rural areas have less access to preventative care and/or timely treatment and are more likely to cite financial constraints as a barrier to accessing care [33].", [["preventative care", "TREATMENT", 48, 65], ["timely treatment", "TREATMENT", 73, 89]]], ["Conversely, urban residents have benefited more from recent programs increasing access to medical care, including the Urban Employer-sponsored Medical Scheme and the Urban Resident Medical Scheme.Key factors impacting LE and DFLE ::: DiscussionThe broader economic and social trends may influence the changes of LE and DFLE, e.g., disadvantaging rural oldest-old individuals.", [["individuals", "ORGANISM", 363, 374]]], ["A substantial urban-rural gap in economic development has existed for decades in China and has even widened in recent years with rapid socioeconomic development in urban areas [78].", [["A substantial urban-rural gap", "PROBLEM", 0, 29], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["urban", "OBSERVATION_MODIFIER", 14, 19], ["-rural gap", "OBSERVATION", 19, 29], ["economic", "OBSERVATION_MODIFIER", 33, 41], ["widened", "OBSERVATION_MODIFIER", 100, 107], ["rapid", "OBSERVATION_MODIFIER", 129, 134]]], ["This growing gap may directly explain a substantial portion of the urban/rural inequality found in our study.", [["This growing gap", "PROBLEM", 0, 16], ["the urban/rural inequality", "PROBLEM", 63, 89], ["our study", "TEST", 99, 108], ["may directly explain", "UNCERTAINTY", 17, 37], ["substantial", "OBSERVATION_MODIFIER", 40, 51], ["portion", "OBSERVATION_MODIFIER", 52, 59], ["urban", "OBSERVATION_MODIFIER", 67, 72], ["rural inequality", "OBSERVATION", 73, 89]]], ["In addition, the high rates of rural to urban migration of younger adults, largely for increased economic opportunities, may reduce available care and support networks of oldest-old adults.", [["adults", "ORGANISM", 182, 188], ["high", "OBSERVATION_MODIFIER", 17, 21]]], ["Previous research has found that these \u201cleft behind\u201d older adults (where an adult child has migrated away to an urban area) are more likely to experience poor health and that this effect was amplified for those in low-income households and for older individuals [79].", [["left", "ANATOMY_MODIFIER", 40, 44], ["more likely", "UNCERTAINTY", 128, 139]]], ["Finally, changes in health behaviors may contribute to our findings.", [["changes in health behaviors", "PROBLEM", 9, 36]]], ["For instance, the prevalence of smoking in Chinese older men has been decreasing in recent decades [80].Key factors impacting LE and DFLE ::: DiscussionThough the above contextual information on China\u2019s oldest-old suggests that these changing circumstances\u2014increasing healthcare access, improvements in economic well-being, and improving health behaviors in earlier life\u2014have led to overall improvements in functioning among successive generations of the oldest-old, our current analyses are not able to disentangle these interrelated sources of variation.", [["smoking", "CHEMICAL", 32, 39], ["men", "ORGANISM", 57, 60], ["men", "SPECIES", 57, 60], ["decreasing", "OBSERVATION_MODIFIER", 70, 80]]], ["Changes in LE and DFLE are the end result of a series of complex processes, and we believe that our results are unlikely to be driven by any one of these contextual changes in isolation.", [["LE", "GENE_OR_GENE_PRODUCT", 11, 13], ["Changes in LE and DFLE", "PROBLEM", 0, 22], ["LE", "ANATOMY_MODIFIER", 11, 13]]], ["Our findings suggest that the concerted efforts of China\u2019s policymakers in improving healthcare accessibility, though not without flaws, have contributed to improvements in well-being at these ages.", [["China\u2019s policymakers", "TREATMENT", 51, 71]]], ["However, the growing urban-rural divide suggests that policymakers seeking to learn from China\u2019s successes be cognizant of the need to ensure equality of access to care improvements across population subgroups.Strengths and limitations ::: DiscussionOne of the main strengths of our analysis is the focus on understanding changes in disability across birth cohorts.", [["disability", "DISEASE", 333, 343], ["our analysis", "TEST", 279, 291]]], ["With a few notable exceptions [60, 81\u201383], most work investigating compression of disability has relied on period-based comparisons which aggregate information across a large number of birth cohorts.", [["disability", "DISEASE", 82, 92], ["compression of disability", "PROBLEM", 67, 92], ["few", "OBSERVATION_MODIFIER", 7, 10], ["notable", "OBSERVATION_MODIFIER", 11, 18], ["large", "OBSERVATION_MODIFIER", 169, 174]]], ["Though this approach may be useful for monitoring aggregate trends in population-level disability, these results do not easily translate to the experience of any given cohort of individuals.", [["disability", "DISEASE", 87, 97], ["individuals", "ORGANISM", 178, 189]]], ["Measuring changes in disability in cohort perspective is preferable, providing results that match more closely with the lived experience of individuals in a population [82, 83].", [["Measuring changes in disability", "PROBLEM", 0, 31], ["disability", "OBSERVATION_MODIFIER", 21, 31]]], ["Our analyses, centered on evaluating how partial LE and DFLE are changing within age groups over birth cohorts, provide information that is more directly applicable to understanding trends in population health over successive generations.", [["Our analyses", "TEST", 0, 12]]], ["Another strength is that our analyses use the largest nationally representative cohort of the oldest-old in the world, providing us with a unique opportunity to examine disability changes in a substantial fraction of the global oldest-old.Strengths and limitations ::: DiscussionThis study also has several limitations.", [["disability", "DISEASE", 169, 179], ["disability changes", "PROBLEM", 169, 187], ["This study", "TEST", 279, 289], ["substantial", "OBSERVATION_MODIFIER", 193, 204], ["fraction", "OBSERVATION_MODIFIER", 205, 213]]], ["Individuals who experience a disability transition between waves of data collection are assumed to experience only a single transition during the period between surveys, which likely misses shorter-term transitions between disability statuses.", [["disability", "DISEASE", 223, 233], ["a disability transition between waves of data collection", "PROBLEM", 27, 83], ["disability statuses", "PROBLEM", 223, 242]]], ["The Markov assumption that no unobserved transitions occur before death is a particularly problematic one, as this makes the somewhat unrealistic assumption that individuals who were observed as disability-free and die before the next wave experienced no disability prior to death [84].", [["death", "DISEASE", 66, 71], ["death", "DISEASE", 275, 280], ["individuals", "ORGANISM", 162, 173], ["unobserved transitions", "PROBLEM", 30, 52]]], ["To explore the potential for this assumption to bias our results, we conducted a sensitivity analysis wherein we re-allocated a portion of the life-year prior to death for initially disability-free individuals who died before the next wave, with the proportion of this year allocated as disabled generated by a random draw from the uniform distribution.", [["death", "DISEASE", 162, 167], ["a sensitivity analysis", "TEST", 79, 101], ["uniform", "OBSERVATION_MODIFIER", 332, 339], ["distribution", "OBSERVATION_MODIFIER", 340, 352]]], ["As expected, LE spent disabled increases in the adjusted estimates, and LE spent disability-free declines (Additional file 9: Table S8).", [["disability", "DISEASE", 81, 91]]], ["Differences are larger for men than for women, largely as a function of fewer men reporting an ADL disability in later life.", [["ADL disability", "DISEASE", 95, 109], ["men", "ORGANISM", 27, 30], ["women", "ORGANISM", 40, 45], ["men", "ORGANISM", 78, 81], ["men", "SPECIES", 27, 30], ["women", "SPECIES", 40, 45], ["men", "SPECIES", 78, 81], ["larger", "OBSERVATION_MODIFIER", 16, 22]]], ["Nonetheless, the substantive findings on cohort differences in the adjusted results follow closely to those from the standard, unadjusted MSLT model.Strengths and limitations ::: DiscussionSecond, the time between interviews varied between the two periods under study, with a 2-year period between the 1998, 2000, and 2002 waves of CLHLS data collection and a 3-year period elapsing between the 2008, 2011, and 2014 waves of data collection.", [["CLHLS data collection", "PROBLEM", 332, 353], ["data collection", "TEST", 425, 440]]], ["This difference in time periods may lead us to miss proportionately more short-term transitions in the 2008\u20132014 period, lowering the predicted transition rates of both onset of disability and recovery from disability.", [["disability", "DISEASE", 178, 188], ["disability", "DISEASE", 207, 217]]], ["Based on prior empirical and simulation studies, these downward biases are in large part offsetting [85], and the 1-year difference in observation periods should still produce unbiased partial total LE and DFLE estimates [86].Strengths and limitations ::: DiscussionThird, as mentioned previously, our modeling approach prioritizes estimating DFLE as the primary outcome, which leads to less precision in our estimation of partial total LE compared to other modeling approaches (such as standard hazard modeling).", [["simulation studies", "TEST", 29, 47], ["these downward biases", "PROBLEM", 49, 70], ["unbiased partial total LE and DFLE estimates", "PROBLEM", 176, 220], ["large", "OBSERVATION_MODIFIER", 78, 83], ["partial", "OBSERVATION_MODIFIER", 185, 192]]], ["Fourth, the available CLHLS analysis weights are cross-sectional in nature and thus inapplicable to our birth cohort-based analyses.", [["the available CLHLS analysis weights", "TEST", 8, 44]]], ["Without cohort sampling weights, our analyses must thus be understood as representing the CLHLS study cohort, which may not precisely match the experience of the Chinese oldest-old population as a whole.", [["cohort sampling weights", "TEST", 8, 31], ["the CLHLS study", "TEST", 86, 101]]], ["Fifth, due to the sample size, we were not able to perform more subgroup analyses for socioeconomic inequality except residence and education.", [["size", "OBSERVATION_MODIFIER", 25, 29]]], ["Finally, the measure of disability is limited to ADL disability, excluding instrumental ADL (IADL) disability and/or functional limitation.", [["disability", "DISEASE", 24, 34], ["disability", "DISEASE", 53, 63], ["disability", "DISEASE", 99, 109], ["instrumental ADL (IADL) disability and/or functional limitation", "PROBLEM", 75, 138]]], ["Given the amount of overlap between ADL and IADL disability in the oldest-old, expanding our outcome measure to include IADL disability would be unlikely to substantially alter our findings.", [["IADL disability", "DISEASE", 44, 59], ["IADL disability", "DISEASE", 120, 135], ["overlap between ADL and IADL disability", "PROBLEM", 20, 59], ["IADL disability", "PROBLEM", 120, 135], ["amount", "OBSERVATION_MODIFIER", 10, 16]]], ["However, we suggest caution when generalizing our results to other facets of health, as trends in specific morbidities or lower-level functional limitations may not exactly follow the patterns of ADL disability.", [["ADL disability", "DISEASE", 196, 210], ["specific morbidities", "PROBLEM", 98, 118], ["lower-level functional limitations", "PROBLEM", 122, 156]]], ["Our reliance on a single measure of disability did not permit us to evaluate whether disability in China is following the dynamic equilibrium scenario, in which severe (ADL) disability is declining, but less severe disability is increasing [16, 17].ConclusionsThese findings show that China\u2019s oldest-old are living with less disability as a whole over successive generations.", [["disability", "DISEASE", 85, 95], ["disability", "DISEASE", 174, 184], ["disability", "DISEASE", 215, 225], ["severe (ADL) disability", "PROBLEM", 161, 184], ["less severe disability", "PROBLEM", 203, 225], ["a whole over successive generations", "TREATMENT", 339, 374], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["increasing", "OBSERVATION_MODIFIER", 229, 239]]], ["LE is increasing among octogenarians, and a compression of disability is occurring among nonagenarians and centenarians.", [["disability", "DISEASE", 59, 69], ["a compression of disability", "PROBLEM", 42, 69], ["increasing", "OBSERVATION_MODIFIER", 6, 16], ["among", "OBSERVATION_MODIFIER", 17, 22], ["octogenarians", "OBSERVATION", 23, 36]]], ["However, we also found a widening gap in partial LE and DFLE between rural and urban areas.", [["a widening gap in partial LE", "PROBLEM", 23, 51], ["widening", "OBSERVATION_MODIFIER", 25, 33], ["gap", "OBSERVATION", 34, 37], ["partial", "OBSERVATION_MODIFIER", 41, 48], ["LE", "ANATOMY_MODIFIER", 49, 51], ["rural", "OBSERVATION_MODIFIER", 69, 74], ["urban", "OBSERVATION_MODIFIER", 79, 84]]]], "02336a02f8e7d85f34d2d992f309c59c8fe9492a": [["IntroductionAlthough as of May 1, 2020, the confirmed number cases of Covid-19 in the US has passed 1,062,446, non-pharmaceutical interventions such as strict self-quarantine for families, maintaining social distancing, stopping mass gatherings, and closure of schools and universities among others has dramatically slowed down the spread of Covid-19 and saved a large number of lives.", [["Covid", "TEST", 70, 75], ["non-pharmaceutical interventions", "TREATMENT", 111, 143], ["large", "OBSERVATION_MODIFIER", 363, 368]]], ["Some investigators who published their mathematical projection of the dynamics of Covid-19 in Science suggested \"prolonged or intermittent social distancing\" which may drive the outbreak of Covid-19 into 2022 (1) .", [["Covid", "TEST", 82, 87]]], ["Meanwhile, MIT researchers questioned the \"intermittent social distancing\" policy and worried that relaxing public interventions may cause an exponential explosion of Covid-19 (2) .", [["Covid-19", "CHEMICAL", 167, 175], ["public interventions", "TREATMENT", 108, 128], ["Covid", "TEST", 167, 172]]], ["Now it is a critical decision point as to whether public health intervention measures should remain in place or should be lifted for reopening economy.", [["public health intervention measures", "TREATMENT", 50, 85]]], ["A key to correctly answering this question is to reconstruct the complex epidemic dynamic systems from the data, precisely predict the extent or duration of COVID-19, and develop a causal inference framework for devising practical implementable public health interventions to control the spread of Covid-19 in the US.IntroductionThe basic mathematical models which underlying many statistical and computer methods for predicting the dynamics of the Covid-19 are the susceptible-exposed-infected-recovered (SEIR) models and their various versions (3) (4) (5) (6) .", [["Covid-19", "SPECIES", 298, 306], ["COVID", "TEST", 157, 162], ["practical implementable public health interventions", "TREATMENT", 221, 272], ["Covid", "TEST", 298, 303], ["the Covid", "TEST", 445, 454], ["infected", "OBSERVATION", 486, 494]]], ["Although these epidemiological models are useful for estimating the dynamics of transmission, and evaluating the impact of intervention strategies, they have some critical limitations (7, 8) .", [["intervention strategies", "TREATMENT", 123, 146]]], ["First, the SEIR models assume a homogeneous population which is evenly mixed.", [["a homogeneous population", "PROBLEM", 30, 54], ["homogeneous", "OBSERVATION_MODIFIER", 32, 43], ["population", "OBSERVATION", 44, 54], ["evenly", "OBSERVATION_MODIFIER", 64, 70], ["mixed", "OBSERVATION_MODIFIER", 71, 76]]], ["These parameters are not identified (9) , which leads to low accuracy and a wide range of predictions.", [["low accuracy", "PROBLEM", 57, 69], ["low accuracy", "OBSERVATION_MODIFIER", 57, 69]]], ["This will dramatically limit our ability to simulate interventions and improve prediction accuracy.IntroductionTo overcome these limitations, we developed an artificial intelligence (AI) and causal inference integrated intervention auto-encoder (IAE) to reconstruct nonlinear time-varying epidemic dynamic systems, model health intervention plan and make multi-step predictions of the response trajectory of the Covid-19 over time with multiple interventions (fig, S1) (10) .IntroductionInterventions include strict travel restriction, no large group gatherings, mandatory quarantine, restricted public transportation, and school closures.", [["interventions", "TREATMENT", 53, 66], ["prediction accuracy", "TEST", 79, 98], ["an artificial intelligence (AI)", "PROBLEM", 155, 186], ["the Covid", "TEST", 408, 417], ["multiple interventions", "TREATMENT", 436, 458], ["IntroductionInterventions", "TREATMENT", 475, 500], ["strict travel restriction", "TREATMENT", 509, 534]]], ["Similar to reproducing number in the epidemiological models, the various interventions are quantified as control variable taking values in the interval [0, 1].", [["the various interventions", "TREATMENT", 61, 86], ["number", "OBSERVATION_MODIFIER", 23, 29]]], ["A value of 1 for intervention indicates that intervention is the strongest and reproducing number R is close to zero.", [["A value", "TEST", 0, 7], ["intervention", "TREATMENT", 17, 29], ["intervention", "TREATMENT", 45, 57]]], ["A value of zero for intervention variables indicates that no restrictions on social-economic activities are imposed.", [["A value", "TEST", 0, 7], ["intervention variables", "TEST", 20, 42]]], ["As shown in Figure S1 , the IAE determines the intervention response (similar to counterfactual outputs) for a set of time varying and system adjusted interventions and evaluates the impact of different intervention strategies and their implementation times on curbing the spread of Covid-19 and provides timely selection of an optimal sequence of intervention strategies to balance public health and economy reopening.SEIR model.", [["interventions", "TREATMENT", 151, 164], ["different intervention strategies", "TREATMENT", 193, 226], ["Covid", "TEST", 283, 288], ["intervention strategies", "TREATMENT", 348, 371], ["economy reopening", "TREATMENT", 401, 418]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)SEIR modelThe copyright holder for this preprint this version posted May 11, 2020 We first introduce the susceptible-exposed-infected-recovered (SEIR) model which is a mathematical compartmental model based on the average behavior of a population under study (1) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 206, 226], ["med", "ANATOMY", 99, 102], ["infected", "OBSERVATION", 321, 329]]], ["The SEIR model is defined asSEIR modelwhere , E(t), I(t) and are the numbers of susceptible, exposed, infected and recovered (recovery or death) individuals at time , respectively, is the population size, and and are transmission, incubation and recovery rate at time , respectively.SEIR modelSolving the differential equations (1)-(4), we obtain ,SEIR modelwhere and are the initial values of , E(t), I(t) and .SEIR modelFor the convenience of discussion, is denoted by .The observed is a nonlinear function of history of , parameters and .", [["death", "DISEASE", 138, 143], ["The SEIR model", "TEST", 0, 14], ["the differential equations", "TEST", 301, 327], ["infected", "OBSERVATION_MODIFIER", 102, 110], ["population", "OBSERVATION_MODIFIER", 188, 198], ["size", "OBSERVATION_MODIFIER", 199, 203]]], ["Public health interventions such as social distancing, regional lockdowns, quarantine and intensive testing can change these parameters.", [["Public health interventions", "TREATMENT", 0, 27], ["intensive testing", "TEST", 90, 107]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)SEIR modelThe copyright holder for this preprint this version posted May 11, 2020SEIR modelwere is the number of time lags.SEIR modelThe intervention measure can also be written as .Stacked autoencodersSingle layer autoencoder (AE) is a three layer feedforward neural network (2) .", [["neural network", "ANATOMY", 457, 471], ["CC", "CHEMICAL", 0, 2], ["neural network", "MULTI-TISSUE_STRUCTURE", 457, 471], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 206, 226], ["The intervention measure", "TREATMENT", 329, 353], ["Stacked autoencoders", "PROBLEM", 378, 398], ["med", "ANATOMY", 99, 102], ["layer", "OBSERVATION_MODIFIER", 405, 410], ["autoencoder", "OBSERVATION_MODIFIER", 411, 422]]], ["The first layer is the input layer, the third layer is the reconstruction layer, and the second layer is the hidden layer.", [["layer", "OBSERVATION_MODIFIER", 10, 15], ["input", "OBSERVATION_MODIFIER", 23, 28], ["layer", "OBSERVATION_MODIFIER", 29, 34], ["third", "OBSERVATION_MODIFIER", 40, 45], ["layer", "OBSERVATION_MODIFIER", 46, 51], ["reconstruction", "OBSERVATION_MODIFIER", 59, 73], ["layer", "OBSERVATION_MODIFIER", 74, 79], ["second", "OBSERVATION_MODIFIER", 89, 95], ["layer", "OBSERVATION_MODIFIER", 96, 101], ["hidden", "OBSERVATION_MODIFIER", 109, 115], ["layer", "OBSERVATION_MODIFIER", 116, 121]]], ["The input vector is mapped to the hidden layer to capture the features of the transmission dynamics of Covid-19 with public health intervention.Stacked autoencodersAE attempts to generate an output that reconstructs its input by mapping the hidden vector to the reconstruction layer.", [["autoencodersAE", "PROTEIN", 152, 166], ["The input vector", "TREATMENT", 0, 16], ["Covid", "TEST", 103, 108], ["public health intervention", "TREATMENT", 117, 143], ["Stacked autoencodersAE attempts", "TREATMENT", 144, 175], ["an output", "PROBLEM", 188, 197]]], ["The single layer AE attempts to minimize the error between the input vector and the reconstruction vector.", [["the error", "PROBLEM", 41, 50], ["the input vector", "TREATMENT", 59, 75], ["the reconstruction vector", "TREATMENT", 80, 105]]], ["We develop stacked autoencoders with 4 layers that consist of two single-layer AEs stacked layer by layer (2) .", [["stacked autoencoders", "PROBLEM", 11, 31], ["stacked autoencoders", "OBSERVATION", 11, 31], ["4 layers", "OBSERVATION_MODIFIER", 37, 45], ["layer", "OBSERVATION_MODIFIER", 91, 96]]], ["The dimensions of the input layer, the first hidden layer and the second hidden layer are 8, 32 and 4, respectively ( Figure .", [["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["input", "OBSERVATION_MODIFIER", 22, 27], ["layer", "OBSERVATION_MODIFIER", 28, 33], ["first", "OBSERVATION_MODIFIER", 39, 44], ["hidden", "OBSERVATION_MODIFIER", 45, 51], ["layer", "OBSERVATION_MODIFIER", 52, 57], ["second", "OBSERVATION_MODIFIER", 66, 72], ["hidden", "OBSERVATION_MODIFIER", 73, 79], ["layer", "OBSERVATION_MODIFIER", 80, 85]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Stacked autoencodersThe copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint S1(a)).", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint S1", "GENE_OR_GENE_PRODUCT", 340, 359], ["CC", "TEST", 0, 2], ["Stacked autoencoders", "PROBLEM", 196, 216], ["The copyright holder", "TREATMENT", 216, 236], ["med", "ANATOMY", 99, 102]]], ["After the first single-layer AE is trained, we remove the reconstruction layer of the first single layer AE and keep the hidden layer of the first single AE as the input layer of the second single-layer AE.", [["the reconstruction layer", "TREATMENT", 54, 78], ["layer", "OBSERVATION_MODIFIER", 128, 133], ["layer", "OBSERVATION_MODIFIER", 170, 175]]], ["Repeat the training process for the second single-layer AE.", [["Repeat the training process", "TREATMENT", 0, 27]]], ["The output of the final node that fully connects to the hidden layer of the second single-layer AE is the predicted number of cases and intervention measure .Sequence of Public Health InterventionsThe potential outcome framework that is also referred as the Rubin Causal Model (3)Intervention Autoencoder for Real-Time Identification, Prediction and Control of Nonlinear Time-Varying Epidemic Dynamic SystemsThe IAE uses sequence-to-sequence multi-input/output architectures to model health intervention plan and make multi-step prediction of the response trajectory of Covid-19 over time with multiple interventions ( Figure S1 Figure S1 (b)).", [["node", "ANATOMY", 24, 28], ["node", "MULTI-TISSUE_STRUCTURE", 24, 28], ["IAE", "DNA", 412, 415], ["The output", "TEST", 0, 10], ["intervention measure", "TREATMENT", 136, 156], ["Public Health Interventions", "TREATMENT", 170, 197], ["Intervention Autoencoder", "TREATMENT", 280, 304], ["sequence", "TEST", 421, 429], ["Covid", "TEST", 570, 575], ["multiple interventions", "TREATMENT", 594, 616], ["output", "OBSERVATION_MODIFIER", 4, 10], ["final", "OBSERVATION_MODIFIER", 18, 23], ["node", "OBSERVATION", 24, 28], ["hidden", "OBSERVATION_MODIFIER", 56, 62], ["layer", "OBSERVATION_MODIFIER", 63, 68]]], ["The algorithm for training and forecasting of IAE is summarized as follows.AlgorithmStep 1.", [["IAE", "DISEASE", 46, 49], ["IAE", "CANCER", 46, 49]]], ["Initialization.AlgorithmRandomly select for samples with time points.", [["samples", "ANATOMY", 44, 51]]], ["Using the data for US and all states and regions, we train the network.", [["US", "TEST", 19, 21]]], ["Repeat above procedure five times.Algorithm.", [["Repeat above procedure", "TREATMENT", 0, 22], ["Algorithm", "TEST", 34, 43]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint(which was not certified by peer review)Step 2.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Select such that error is the smallest, i.e., and .(which was not certified by peer review)Step 3.", [["smallest", "OBSERVATION_MODIFIER", 30, 38]]], ["Define the equation that is implemented by neural networks:(which was not certified by peer review).(which was not certified by peer review)Train the network to estimate the parameters in the network, assuming that is estimated in step 2.", [["neural networks", "ANATOMY", 43, 58], ["neural networks", "MULTI-TISSUE_STRUCTURE", 43, 58]]], ["Using the trained autoencoder (1) as auto-encoder (2) .", [["auto-encoder", "TREATMENT", 37, 49]]], ["Predict using the formula:Forecasting Procedures.", [["Forecasting Procedures", "TREATMENT", 26, 48]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint(which was not certified by peer review)The trained IAE was used to forecast the future number of new or cumulative cases of Covid-19 for US and each state.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["Covid", "TEST", 460, 465], ["US", "TEST", 473, 475], ["med", "ANATOMY", 99, 102]]], ["The recursive multiple-step forecasting involved using a one-step model multiple times where the prediction for the preceding time step and intervention strategy were used as an input for making a prediction on the following time step ( Figure S1 (b)).", [["intervention strategy", "TREATMENT", 140, 161], ["multiple", "OBSERVATION_MODIFIER", 14, 22]]], ["For example, for forecasting the number of new confirmed cases for the one more next day, the predicted number of new cases and intervention measure in one-step forecasting would be used as an observational input in order to predict day 2.", [["intervention measure", "TREATMENT", 128, 148], ["new", "OBSERVATION_MODIFIER", 114, 117]]], ["The summation of the final forecasted number of new or cumulative confirmed cases for each state was taken as the prediction of the total number of new or cumulative confirmed cases of Covid-19 in US.Data SourcesThe analysis is based on the surveillance data of confirmed and new Covid-19 cases in the US up to April 24, 2020.", [["Covid", "TEST", 185, 190], ["The analysis", "TEST", 212, 224], ["the surveillance data", "TEST", 237, 258], ["new Covid", "TEST", 276, 285], ["new", "OBSERVATION_MODIFIER", 48, 51]]], ["Data on the number of confirmed, new and death cases of Covid-19 from January 22, 2020 to April 24 were obtained from the John Hopkins Coronavirus Resource Center (https://coronavirus.jhu.edu/MAP.HTML).Data Pre-processingA segment of time series with 8 days was viewed as a sample of data and segments of time series was taken as the training samples.", [["death", "DISEASE", 41, 46], ["Covid", "TEST", 56, 61], ["the training samples", "TEST", 330, 350]]], ["One element from the time series and intervention data matrix is randomly selected as a start day of the segment and its 7 successive days were selected as the other days to form a segment of time series.", [["intervention data matrix", "TREATMENT", 37, 61]]], ["Let be the index of the segment and be the column index of the matrix that was selected as the starting day.", [["matrix", "ANATOMY", 63, 69], ["Let", "GENE_OR_GENE_PRODUCT", 0, 3], ["matrix", "CELLULAR_COMPONENT", 63, 69], ["index", "OBSERVATION_MODIFIER", 11, 16], ["segment", "ANATOMY_MODIFIER", 24, 31], ["column", "OBSERVATION_MODIFIER", 43, 49], ["matrix", "ANATOMY_MODIFIER", 63, 69]]], ["The segment time series can be represented as .", [["segment time", "OBSERVATION_MODIFIER", 4, 16]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["S1 ).", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1", "PROTEIN", 0, 2]]], ["The average errors of 1-step, 5step and 10-step forecasting were 0.0035, 0.016 and 0.0012, respectively.Outbreak of Covid-19 in the US passed the peak time.", [["Covid-19", "SPECIES", 116, 124], ["Covid", "TEST", 116, 121], ["average", "OBSERVATION_MODIFIER", 4, 11], ["errors", "OBSERVATION_MODIFIER", 12, 18]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["To study the impact of relaxing intervention restrictions on the spread of Covid-19 in the US, we presented the results in Figure 1 .", [["relaxing intervention restrictions", "TREATMENT", 23, 57], ["Covid", "TEST", 75, 80]]], ["We considered four scenarios of interventions: scenario 1 followed current intervention measures, scenarios 2 and 3 relaxed 20% and 40% of the intervention measures, and scenario 4 increased 20% of the intervention measure, after April 25, .", [["scenario", "TREATMENT", 47, 55], ["current intervention measures", "TREATMENT", 67, 96], ["scenarios", "TREATMENT", 98, 107], ["the intervention measures", "TREATMENT", 139, 164], ["scenario", "TREATMENT", 170, 178]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Figure 1 showed that if we relaxed 40% of the intervention measure, the spread of Covid-19 would be over on August 7, with 1,869,185 cumulative cases (an increase of 317,284 cases or 20.4% of cumulative cases more than if the current intervention measure was followed) of Covid-19 in the US (table S3) .", [["Covid", "TEST", 82, 87], ["Covid", "TEST", 272, 277]]], ["To avoid increasing the number of new cases, we can increase the number of coronavirus tests.Covid-19Public health interventions such as city lockdowns, traffic restrictions, quarantines, contact tracing, canceling gatherings and school closure will slow down the spread of Covid-19.", [["coronavirus", "ORGANISM", 75, 86], ["coronavirus tests", "TEST", 75, 92], ["contact tracing", "TEST", 188, 203], ["school closure", "TREATMENT", 230, 244], ["Covid", "TEST", 274, 279]]], ["Figure 3 plotted the intervention measure in the US under four scenarios of interventions as a function .", [["interventions", "TREATMENT", 76, 89]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint of times starting with January 22, 2020 and ending with the end of September, 2020.(which was not certified by peer review)Intervention measure is a matric to quantify the degree of controlling infection.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 530, 539], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["controlling infection", "PROBLEM", 518, 539], ["med", "ANATOMY", 99, 102], ["infection", "OBSERVATION", 530, 539]]], ["Figure 3 showed that the intervention curve started with a low intervention measure and then the trend of the intervention curve was, in general, increased until the end of February, 2020, when Spring break began.", [["the intervention curve", "TEST", 21, 43], ["a low intervention measure", "TREATMENT", 57, 83]]], ["Spring break substantially reduced prevention measures and caused a large-scale outbreak of Covid-19 in the US.", [["Covid-19", "CHEMICAL", 92, 100], ["Covid-19", "SPECIES", 92, 100], ["Covid", "TEST", 92, 97], ["substantially", "OBSERVATION_MODIFIER", 13, 26], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["large", "OBSERVATION_MODIFIER", 68, 73]]], ["Then, the government implemented strict quarantine and social distance policies, and hence the intervention measure increased again.", [["social distance policies", "TREATMENT", 55, 79], ["the intervention", "TREATMENT", 91, 107]]], ["The average intervention measure of the US, 50 states and 5 other regions at the peak time was 0.54 (Table 1 and table S4 ).", [["the US", "TEST", 36, 42], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["In other words, when the intervention measure was close to 0.5, interventions were sufficiently strong to decrease the number of new cases of Covid-19.", [["interventions", "TREATMENT", 64, 77], ["Covid", "TEST", 142, 147]]], ["Finally, the intervention measure steadily and quickly increased to 1 when the number of new cases rapidly deceased and the spread of Covid-19 was completely stopped.", [["Covid-19", "CHEMICAL", 134, 142], ["Covid", "TEST", 134, 139]]], ["Figure 3 also showed that even if the intervention measure was assumed to decrease 40%, the intervention measure could still quickly and steadily increase to 1 and then the spread of Covid-19 would stop.", [["Covid", "TEST", 183, 188]]], ["Negative correlation coefficients indicated that increasing the intervention measure would decrease the number of new cases.", [["new", "OBSERVATION_MODIFIER", 114, 117]]], ["To investigate the relationship between the intervention .", [["the intervention", "TREATMENT", 40, 56]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint measure and widely used reproduction number R(t), we first used SIR model to calculate the reproduction number R(t) and then calculate the Spearman correlation coefficient between the intervention measure and reproduction number R(t).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint measure", "TREATMENT", 319, 343], ["the intervention measure", "TREATMENT", 516, 540], ["med", "ANATOMY", 99, 102]]], ["We obtain the Spearman correlation coefficient of 0.585 between the intervention measure and reproduction number, using the number of new cases in the US and 50 states from April 1 to April 29.DiscussionIn summary, this report have addressed several important issues in forecasting the is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint require causal inference as a basic tool for forecasting and evaluating the dynamics of Covid-19 in the US.", [["The copyright holder", "TREATMENT", 420, 440], ["medRxiv", "TREATMENT", 544, 551], ["Covid", "TEST", 649, 654], ["med", "ANATOMY", 324, 327]]], ["We used counterfactual outcome as a general framework for modeling health intervention plan and making multi-step prediction of the response trajectory of Covid-19 over time with a sequence of public health interventions.", [["Covid", "TEST", 155, 160], ["public health interventions", "TREATMENT", 193, 220]]], ["As illustration, we evaluated four scenarios of interventions and predicted that if we relaxed 40% of intervention measure, the spread of Covid-19 would be over on August 7, with 1,869,185 cumulative cases (increased 317,284 cases or 20.4% of cumulative cases than following the current intervention measure) of Covid-19 in US.", [["interventions", "TREATMENT", 48, 61], ["intervention", "TREATMENT", 102, 114], ["Covid", "TEST", 138, 143], ["the current intervention", "TREATMENT", 275, 299], ["Covid", "TEST", 312, 317]]], ["However, if we increased 20% of the intervention measure, for example, by increasing the ratio of coronavirus tests, the spread of Covid-19 would be over on July 23, with 1, 296,487 cumulative cases (reduced 16.5% of cumulative cases than following the current intervention measure).(which was not certified by peer review)The third issue is to simultaneously estimate the trajectory of the dynamics of Covid-19 and the intervention measure.", [["coronavirus", "ORGANISM", 98, 109], ["the intervention measure", "TREATMENT", 32, 56], ["coronavirus tests", "TEST", 98, 115], ["Covid", "TEST", 131, 136], ["the current intervention measure", "TREATMENT", 249, 281], ["Covid", "TEST", 403, 408], ["the intervention measure", "TREATMENT", 416, 440]]], ["We proposed to use intervention measure as a control variable that comprehensively quantified the public health interventions and incorporate the intervention measure as an input into the IAE model.", [["intervention measure", "TREATMENT", 19, 39], ["the public health interventions", "TREATMENT", 94, 125], ["the intervention", "TREATMENT", 142, 158]]], ["Therefore, the IAE model jointly estimate the number of cases and intervention measure.(which was not certified by peer review)The four issue is interpretation of intervention measure.", [["intervention measure", "TREATMENT", 66, 86], ["intervention measure", "TREATMENT", 163, 183]]], ["We could not investigate the impact of all individual elements of the interventions because many were introduced simultaneously across the US.", [["the interventions", "TREATMENT", 66, 83], ["the US", "TEST", 135, 141]]], ["If the individual intervention data are available, the IAE model can quantify the effect of the specific intervention on the controlling spread of Covid-19.", [["the individual intervention data", "TEST", 3, 35], ["the specific intervention", "TREATMENT", 92, 117], ["Covid", "TEST", 147, 152]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint Figure 1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["The reported and forecasted curves of newly confirmed cases of Covid-19 in the US with three scenarios of interventions as a function of time , starting date from January 22, 2020.", [["Covid", "TEST", 63, 68], ["interventions", "TREATMENT", 106, 119]]], ["Scenario 1 followed the current intervention measure, scenarios 2 and 3 relaxed 20% and 40% of the intervention measure, and scenario 4 increased 20% of the current intervention measure.(which was not certified by peer review).", [["the intervention measure", "TREATMENT", 95, 119], ["the current intervention measure", "TREATMENT", 153, 185]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint", "TREATMENT", 319, 335], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint", "TREATMENT", 319, 335], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 11, 2020. . https://doi.org/10.1101/2020.05.04.20091272 doi: medRxiv preprint Table S1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102], ["S1", "ANATOMY", 342, 344]]], ["Errors of the 10-Step ahead predicting the number of cumulative cases of Covid-19 in the US.(which was not certified by peer review)1-step 2-step 3-step 4-step 5-step 6-step 7-step 8-step 9-step 10-", [["Covid", "TEST", 73, 78]]]], "ba11bd3beec17905e8c013ce9598a0922240ca85": [["Abstract: Recently, there have been many efforts to use mobile apps as an aid in contact tracing to control the spread of the SARS-CoV-2 (Covid-19) pandemic.", [["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "ORGANISM", 126, 136], ["Covid-19", "ORGANISM", 138, 146], ["SARS-CoV", "SPECIES", 126, 134], ["mobile apps", "TREATMENT", 56, 67], ["contact tracing", "TEST", 81, 96], ["the SARS", "TEST", 122, 130], ["CoV", "TEST", 131, 134], ["Covid", "TEST", 138, 143], ["pandemic", "PROBLEM", 148, 156]]], ["However, although many apps aim to protect individual privacy, the very nature of contact tracing must reveal some otherwise protected personal information.", [["contact tracing", "TEST", 82, 97]]], ["Digital contact tracing has endemic privacy risks that cannot be removed by technological means, and which may require legal or economic solutions.", [["Digital contact tracing", "TEST", 0, 23], ["economic solutions", "TREATMENT", 128, 146]]]], "5715185ac5cbe9b3f3b9960b235af0cc9d4e99b2": [["IntroductionNontyphoidal Salmonella enterica (NTS) is responsible for an estimated 150,716 illnesses, 1,565 hospitalizations, and 29 deaths each year in Canada, of which the majority are foodborne [1] .", [["deaths", "DISEASE", 133, 139], ["Nontyphoidal Salmonella enterica", "ORGANISM", 12, 44], ["NTS", "CANCER", 46, 49], ["Salmonella enterica", "SPECIES", 25, 44], ["Salmonella enterica", "SPECIES", 25, 44], ["IntroductionNontyphoidal Salmonella enterica (NTS", "TREATMENT", 0, 49], ["Nontyphoidal", "OBSERVATION_MODIFIER", 12, 24], ["Salmonella enterica", "OBSERVATION", 25, 44]]], ["On a worldwide level, diarrheal and invasive infections caused by NTSData sourcesSalmonellosis is a reportable disease in Ontario under the Health Protection and Promotion Act [29] , and it is diagnosed by the isolation of Salmonella enterica from stool (most samples), rectal swabs, urine, blood, or any other sterile site.", [["stool", "ANATOMY", 248, 253], ["samples", "ANATOMY", 260, 267], ["rectal swabs", "ANATOMY", 270, 282], ["urine", "ANATOMY", 284, 289], ["blood", "ANATOMY", 291, 296], ["diarrheal", "DISEASE", 22, 31], ["infections", "DISEASE", 45, 55], ["NTSData", "CHEMICAL", 66, 73], ["Salmonellosis", "DISEASE", 81, 94], ["Salmonella enterica", "ORGANISM", 223, 242], ["stool", "ORGANISM_SUBSTANCE", 248, 253], ["samples", "CANCER", 260, 267], ["rectal swabs", "ORGANISM_SUBSTANCE", 270, 282], ["urine", "ORGANISM_SUBSTANCE", 284, 289], ["blood", "ORGANISM_SUBSTANCE", 291, 296], ["Salmonella enterica", "SPECIES", 223, 242], ["Salmonella enterica", "SPECIES", 223, 242], ["diarrheal", "PROBLEM", 22, 31], ["invasive infections", "PROBLEM", 36, 55], ["Salmonellosis", "PROBLEM", 81, 94], ["Salmonella enterica", "PROBLEM", 223, 242], ["rectal swabs, urine, blood", "TEST", 270, 296], ["any other sterile site", "PROBLEM", 301, 323], ["invasive", "OBSERVATION_MODIFIER", 36, 44], ["infections", "OBSERVATION", 45, 55], ["rectal", "ANATOMY", 270, 276]]], ["All Salmonella spp. isolates are sent to the public health laboratories for serotyping based on the Kauffmann-White method [30] .", [["Salmonella spp.", "ORGANISM", 4, 19], ["Salmonella spp.", "SPECIES", 4, 19], ["Salmonella spp.", "SPECIES", 4, 19], ["All Salmonella spp. isolates", "TREATMENT", 0, 28], ["serotyping", "TEST", 76, 86], ["the Kauffmann", "TEST", 96, 109]]], ["Public health unit personnel follow up on each reported Salmonella enterica case to provide case management, discover potential causes of disease and report all their findings to the Ontario Ministry of Health and Long-Term Care's integrated Public Health Information System (iPHIS) [31] .", [["Salmonella enterica", "SPECIES", 56, 75], ["Salmonella enterica", "SPECIES", 56, 75], ["case management", "TREATMENT", 92, 107], ["disease", "PROBLEM", 138, 145]]], ["For this study, data on reported NTS infections were acquired from the Ontario Ministry of Health and Long-Term Care and were extracted from the iPHIS database by Public Health Ontario on 2018/12/10.", [["NTS infections", "DISEASE", 33, 47], ["this study", "TEST", 4, 14], ["reported NTS infections", "PROBLEM", 24, 47], ["Long-Term Care", "TREATMENT", 102, 116]]], ["We obtained data related to Salmonella cases' forward sortation area (FSA) (the first three digits of the postal code), disease onset date, serotype, age, sex, outbreak and travel history that were diagnosed in the city of Toronto between January 1, 2015, and December 31, 2017.", [["Salmonella cases", "PROBLEM", 28, 44], ["serotype", "PROBLEM", 140, 148]]], ["Specifically, the cases were coded with unique case IDs and client IDs; the residential addresses were provided at the forward sortation area (FSA) and public health unit (PHU)-levels; the ages were aggregated to five-year age categories; and dates of disease onset were provided as months and years, rather than specific dates.", [["disease onset", "PROBLEM", 252, 265]]], ["We included in our study the top four NTS serotypes, S. Enteritidis (n = 620), S. Typhimurium (n = 150), S. Thompson (n = 138), and S. Heidelberg (n = 136).", [["S. Enteritidis", "ORGANISM", 53, 67], ["S. Typhimurium", "ORGANISM", 79, 93], ["S. Enteritidis", "SPECIES", 53, 67], ["S. Typhimurium", "SPECIES", 79, 93], ["S. Enteritidis", "SPECIES", 53, 67], ["S. Typhimurium", "SPECIES", 79, 93], ["our study", "TEST", 15, 24]]], ["This study was reviewed and received ethics clearance through a University of Waterloo Ethics Committee (ORE # 40133), who determined that informed consent was not required, since only de-identified secondary data was used for the research.Study settingOur study involved the city of Toronto (Degrees, Minutes, Seconds (DMS) 43\u02da44 0 30@ North, 79\u02da22 0 24@ West), the capital of the province of Ontario, and the largest city in Canada, situated along Lake Ontario's northwestern coast (Fig 1) .Study settingThe analysis was conducted at the forward sortation area FSA-level, a well-defined geographical area represented by the first three characters of the postal code, designated by Canada Post Corporation, and based on the mail delivery regions of postal facilities.", [["This study", "TEST", 0, 10], ["Study setting", "TEST", 240, 253], ["Our study", "TEST", 253, 262], ["The analysis", "TEST", 506, 518], ["a well-defined geographical area", "PROBLEM", 574, 606], ["capital", "OBSERVATION_MODIFIER", 367, 374], ["largest", "OBSERVATION_MODIFIER", 411, 418], ["geographical", "OBSERVATION_MODIFIER", 589, 601], ["area", "OBSERVATION_MODIFIER", 602, 606]]], ["Population estimates and the cartographical boundary files for each FSA were obtained from the 2016 Census of Population [32, 33] .", [["Population estimates", "TEST", 0, 20], ["each FSA", "TEST", 63, 71]]], ["We excluded an FSA with less than 2,000 residents (n = 1) to obtain stable incidence rates.", [["an FSA", "TEST", 12, 18], ["FSA", "OBSERVATION", 15, 18], ["stable", "OBSERVATION_MODIFIER", 68, 74]]], ["The annual population sizes of the 95 FSAs ranged from 2,951 to 75,897, with a mean of 28,737.", [["The annual population sizes", "TEST", 0, 27], ["FSAs", "TEST", 38, 42], ["annual", "OBSERVATION_MODIFIER", 4, 10], ["population", "OBSERVATION_MODIFIER", 11, 21], ["sizes", "OBSERVATION_MODIFIER", 22, 27]]], ["Toronto FSAs were mapped using the City's commonly used projection, Universal Transverse Mercator (UTM), North American Datum (NAD) 1983, Zone 17 North.Disease mappingSpatial heterogeneity of FSA-level NTS infection rates of the top four serotypes was evaluated and compared by following a stepwise analytical framework, which is described below.Disease mappingDisease mapping and the global and local cluster analysis were performed using ArcGIS 10.7.1 (Environmental Systems Research Institute, Inc., Redlands, CA, USA).Disease mappingAll reported cases during the 3-year study period were geocoded and spatially joined to the FSA level.", [["infection", "DISEASE", 206, 215], ["Toronto FSAs", "TREATMENT", 0, 12], ["Disease mappingSpatial heterogeneity of FSA", "PROBLEM", 152, 195], ["level NTS infection", "PROBLEM", 196, 215], ["a stepwise analytical framework", "TEST", 288, 319], ["Disease mappingDisease mapping", "TEST", 346, 376], ["local cluster analysis", "TEST", 396, 418], ["ArcGIS", "TEST", 440, 446], ["Disease mapping", "TEST", 522, 537], ["FSA", "OBSERVATION_MODIFIER", 192, 195], ["NTS", "OBSERVATION_MODIFIER", 202, 205], ["infection", "OBSERVATION", 206, 215], ["top", "OBSERVATION_MODIFIER", 229, 232], ["four", "OBSERVATION_MODIFIER", 233, 237], ["serotypes", "OBSERVATION", 238, 247]]], ["Incidence rates (IRs) per 100,000 persons for each serotype were calculated, by dividing the 3-year total number of cases per FSA by the 3-year total population estimates obtained from the 2016 Census of Population.", [["persons", "SPECIES", 34, 41], ["each serotype", "PROBLEM", 46, 59]]], ["Natural breaks that decrease the variance within classes and increase the variance between classes were used to classify IRs into five categories [34] .", [["Natural breaks", "PROBLEM", 0, 14], ["decrease", "OBSERVATION_MODIFIER", 20, 28], ["increase", "OBSERVATION_MODIFIER", 61, 69]]], ["In addition, to account for unstable IRs of FSAs with small populations, we used Spatial Empirical Bayes method [35] with 2nd order queen contiguity weights to smooth these rates [36] .", [["unstable IRs of FSAs", "PROBLEM", 28, 48], ["small populations", "PROBLEM", 54, 71], ["Spatial Empirical Bayes method", "TREATMENT", 81, 111], ["small", "OBSERVATION_MODIFIER", 54, 59], ["populations", "OBSERVATION", 60, 71]]], ["The queen criterion defines neighbors as spatial units sharing a common edge or a common vertex.", [["common edge", "ANATOMY", 65, 76], ["common vertex", "ANATOMY", 82, 95]]], ["In Toronto, where several irregularly shaped FSAs are present, using the queen criterion is recommended [37] .", [["FSAs", "CANCER", 45, 49], ["several irregularly shaped FSAs", "PROBLEM", 18, 49], ["irregularly", "OBSERVATION_MODIFIER", 26, 37], ["shaped", "OBSERVATION_MODIFIER", 38, 44], ["FSAs", "OBSERVATION", 45, 49]]], ["Distribution of non-smoothed and smoothed IRs of the four major NTS serotype infections across Toronto's FSAs were illustrated by choropleth maps in ArcGIS 10.7.1.Spatial and space-time clustering analysisGlobal and local Moran's I. The Spatial Statistics Toolbox in ArcGIS 10.7.1 was used to evaluate global and local clustering of serotype specific NTS infection rates.Spatial and space-time clustering analysisFor the spatial statistical analysis, each FSA was represented by a polygon, its populationweighted centroid, and its serotype-specific infection rate.", [["infections", "DISEASE", 77, 87], ["infection", "DISEASE", 355, 364], ["infection", "DISEASE", 549, 558], ["NTS serotype", "ORGANISM", 64, 76], ["the four major NTS serotype infections", "PROBLEM", 49, 87], ["Toronto's FSAs", "TEST", 95, 109], ["choropleth maps", "TEST", 130, 145], ["ArcGIS", "TEST", 149, 155], ["ArcGIS", "TEST", 267, 273], ["serotype specific NTS infection rates", "PROBLEM", 333, 370], ["the spatial statistical analysis", "TEST", 417, 449], ["its serotype-specific infection rate", "PROBLEM", 527, 563], ["serotype", "OBSERVATION_MODIFIER", 68, 76], ["infections", "OBSERVATION", 77, 87], ["infection", "OBSERVATION", 355, 364], ["serotype-specific", "OBSERVATION_MODIFIER", 531, 548], ["infection", "OBSERVATION", 549, 558]]], ["Euclidean distance bands were used to measure distances from each FSA centroid to neighboring FSA centroid.", [["Euclidean distance bands", "PROBLEM", 0, 24], ["FSA centroid", "OBSERVATION", 94, 106]]], ["The \"zone of indifference\" conceptualization, a modified form of a distance decay parameter, was applied to account for zoning and edge effects [38] .", [["a distance decay parameter", "TREATMENT", 65, 91], ["zone", "OBSERVATION_MODIFIER", 5, 9]]], ["This parameter gives maximum weights for the target FSA andPLOS ONESpatial clustering and demographic characteristics of Salmonella infections in Toronto, Canada all neighboring FSAs within a defined distance band, and once this distance is surpassed, neighboring FSAs are allocated smaller and smaller weights as the distance from the target FSA becomes greater.", [["Salmonella infections", "DISEASE", 121, 142], ["Salmonella", "SPECIES", 121, 131], ["This parameter", "TEST", 0, 14], ["maximum weights", "TEST", 21, 36], ["Salmonella infections", "PROBLEM", 121, 142], ["Salmonella infections", "OBSERVATION", 121, 142], ["smaller", "OBSERVATION_MODIFIER", 283, 290], ["smaller", "OBSERVATION_MODIFIER", 295, 302], ["greater", "OBSERVATION_MODIFIER", 355, 362]]], ["The null hypothesis for both global and local cluster analyses assumes a complete spatial randomness, i.e., that FSAs with high or low IRs are randomly distributed across the study area [38] .", [["FSAs", "GENE_OR_GENE_PRODUCT", 113, 117], ["The null hypothesis", "PROBLEM", 0, 19], ["both global and local cluster analyses", "PROBLEM", 24, 62], ["a complete spatial randomness", "PROBLEM", 71, 100], ["FSAs", "TEST", 113, 117], ["high or low IRs", "PROBLEM", 123, 138], ["high", "OBSERVATION_MODIFIER", 123, 127], ["low IRs", "OBSERVATION_MODIFIER", 131, 138]]], ["The null hypothesis is rejected when FSAs with high or low IRs are more spatially clustered than would be expected if the underlying spatial processes were truly random.", [["FSAs", "GENE_OR_GENE_PRODUCT", 37, 41], ["The null hypothesis", "PROBLEM", 0, 19], ["FSAs", "TEST", 37, 41], ["high or low IRs", "PROBLEM", 47, 62], ["the underlying spatial processes", "PROBLEM", 118, 150], ["null", "OBSERVATION_MODIFIER", 4, 8], ["hypothesis", "OBSERVATION", 9, 19], ["low IRs", "OBSERVATION_MODIFIER", 55, 62]]], ["When the null hypothesis is rejected, a Z-score and a p-value are given for the identified cluster.PLOS ONEGlobal clustering of serotype specific NTS IRs was evaluated using the global Moran's I approach [39] .", [["serotype specific NTS IRs", "DNA", 128, 153], ["a Z-score", "TEST", 38, 47], ["a p-value", "TEST", 52, 61], ["serotype specific NTS IRs", "TREATMENT", 128, 153], ["rejected", "OBSERVATION", 28, 36]]], ["Several Euclidean distances with 1 km increments were manually selected and included in the model, starting with the 3.3 km distance band that was required for each FSA to have at least one neighbor.", [["the 3.3 km distance band", "TREATMENT", 113, 137]]], ["A large, positive Z-score (values \ufffd 1.96), a statistically significant p value (p \ufffd 0.05) and a positive Moran's I Index signified that FSA-level IRs clustered, while a large, negative Z-score (values \ufffd -1.96) and a significant p-value and a negative Moran's I index signified that FSA-level IRs were dispersed in the study area [39] .", [["FSA", "PROTEIN", 136, 139], ["FSA", "PROTEIN", 282, 285], ["A large, positive Z-score", "PROBLEM", 0, 25], ["values", "TEST", 27, 33], ["Moran's I Index", "TEST", 105, 120], ["FSA", "TEST", 136, 139], ["level IRs", "TEST", 140, 149], ["values", "TEST", 194, 200], ["a significant p-value", "PROBLEM", 214, 235], ["Moran's I index", "TEST", 251, 266], ["FSA", "TEST", 282, 285], ["level IRs", "TEST", 286, 295], ["large", "OBSERVATION_MODIFIER", 2, 7], ["large", "OBSERVATION_MODIFIER", 169, 174]]], ["For the local cluster analysis, we included the distance band that indicated maximum spatial clustering (highest Zscore) of IRs at the global clustering stage.", [["the local cluster analysis", "TEST", 4, 30], ["the distance band", "TEST", 44, 61], ["maximum spatial clustering", "PROBLEM", 77, 103], ["maximum", "OBSERVATION_MODIFIER", 77, 84], ["spatial", "OBSERVATION_MODIFIER", 85, 92], ["clustering", "OBSERVATION_MODIFIER", 93, 103], ["global", "OBSERVATION_MODIFIER", 135, 141], ["clustering stage", "OBSERVATION", 142, 158]]], ["If global spatial clustering was not significant, we used the 3.3 km distance band that was required for each FSA to have at least one neighbor.PLOS ONELocal Moran's I statistics were used to detect local spatial clusters of FSA-level nonsmoothed IRs during the study period [40] .PLOS ONEThe local Moran's I statistic of spatial associations is given as:PLOS ONEwhere x i is an attribute (i.e. infection rate) of future i (i.e. forward sortation area), \ufffd X is the mean of the corresponding attribute, w ij is the spatial weight between future i and j, and:PLOS ONEWith n equating to the total number of features.", [["infection", "DISEASE", 395, 404], ["global spatial clustering", "PROBLEM", 3, 28], ["the 3.3 km distance band", "TREATMENT", 58, 82], ["ij", "TREATMENT", 504, 506]]], ["The local Moran's I statistic recognizes hot spots (i.e., high-high IR areas), cold spots (i.e., low-low IR areas) and outlier areas (high-low and low-high IR areas).", [["hot spots", "PROBLEM", 41, 50], ["cold spots", "PROBLEM", 79, 89], ["outlier areas", "PROBLEM", 119, 132], ["hot spots", "OBSERVATION_MODIFIER", 41, 50], ["cold spots", "OBSERVATION_MODIFIER", 79, 89], ["outlier", "OBSERVATION_MODIFIER", 119, 126], ["areas", "OBSERVATION_MODIFIER", 127, 132], ["high", "OBSERVATION_MODIFIER", 134, 138]]], ["A statistically significant positive Local Moran's I Index indicates that the target FSA is surrounded by FSAs with identical IRs (high-high: FSA with a high rate enclosed by FSAs with high rates; low-low: FSA with a low rate surrounded by FSAs with low rates).", [["identical IRs", "TEST", 116, 129], ["high rates", "PROBLEM", 185, 195], ["a low rate", "PROBLEM", 215, 225], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["positive", "OBSERVATION_MODIFIER", 28, 36]]], ["A statistically significant negative local Moran's I Index signifies that the target FSA is surrounded by FSAs with different IRs (high-low: FSA with a high rate surrounded by FSAs with low rates; low-high: FSA with a low rate surrounded by FSAs with high rates).PLOS ONEScan statistic.", [["PLOS", "DNA", 263, 267], ["different IRs", "TEST", 116, 129], ["a high rate", "PROBLEM", 150, 161], ["low rates", "PROBLEM", 186, 195], ["a low rate", "PROBLEM", 216, 226], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["negative", "OBSERVATION_MODIFIER", 28, 36]]], ["The scan statistic [41] with SaTScan software version 9.6 was used to identify purely spatial and space-time clusters of serotype specific NTS infections.", [["NTS infections", "DISEASE", 139, 153], ["The scan statistic", "TEST", 0, 18], ["SaTScan software version", "TEST", 29, 53], ["serotype specific NTS infections", "PROBLEM", 121, 153]]], ["At the first step, we created separate models for S. Enteritidis, S. Typhimurium, S. Thompson, and S. Heidelberg infections, and used a retrospective discrete Poisson model, which assumes that the number of infections in each FSA are Poisson-distributed, based on a known background population [42] .", [["infections", "DISEASE", 113, 123], ["infections", "DISEASE", 207, 217], ["S. Enteritidis", "ORGANISM", 50, 64], ["S. Typhimurium", "ORGANISM", 66, 80], ["S. Thompson", "ORGANISM", 82, 93], ["S. Heidelberg", "ORGANISM", 99, 112], ["S. Enteritidis", "SPECIES", 50, 64], ["S. Typhimurium", "SPECIES", 66, 80], ["S. Enteritidis", "SPECIES", 50, 64], ["S. Typhimurium", "SPECIES", 66, 80], ["S. Enteritidis", "PROBLEM", 50, 64], ["S. Heidelberg infections", "PROBLEM", 99, 123], ["a retrospective discrete Poisson model", "TREATMENT", 134, 172], ["infections in each FSA", "PROBLEM", 207, 229], ["infections", "OBSERVATION", 113, 123], ["infections", "OBSERVATION", 207, 217]]], ["At the second step we built a multinomial model, in which each outcome was a salmonellosis case, with each case belonging to one of the four Salmonella serotypes, Enteritidis, Typhimurium, Thompson, and Heidelberg.", [["salmonellosis", "DISEASE", 77, 90], ["Enteritidis", "ORGANISM", 163, 174], ["Enteritidis", "SPECIES", 163, 174], ["Typhimurium", "SPECIES", 176, 187], ["Typhimurium", "SPECIES", 176, 187], ["a salmonellosis case", "PROBLEM", 75, 95], ["the four Salmonella serotypes", "PROBLEM", 132, 161], ["Enteritidis", "PROBLEM", 163, 174], ["salmonellosis", "OBSERVATION", 77, 90]]], ["The multinomial scan statistic concurrently looks for high or low clusters of any of the four serotypes, adjusting for the overall geographical distribution of salmonellosis, and accounting for the multiple comparisons among the four serotypes when calculating the p-values [43] .PLOS ONELatitude and longitude Cartesian coordinates for each FSA centroid were calculated in Arc-GIS 10.7.1.", [["salmonellosis", "DISEASE", 160, 173], ["PLOS", "DNA", 280, 284], ["longitude Cartesian coordinates", "DNA", 301, 332], ["Arc", "DNA", 374, 377], ["The multinomial scan statistic", "TEST", 0, 30], ["high or low clusters", "PROBLEM", 54, 74], ["the four serotypes", "PROBLEM", 85, 103], ["salmonellosis", "PROBLEM", 160, 173], ["the p-values", "TEST", 261, 273], ["each FSA centroid", "PROBLEM", 337, 354], ["low clusters", "OBSERVATION_MODIFIER", 62, 74], ["geographical", "OBSERVATION_MODIFIER", 131, 143], ["distribution", "OBSERVATION_MODIFIER", 144, 156], ["salmonellosis", "OBSERVATION", 160, 173]]], ["The smallest temporal and spatial units were the month of infection onset and the centroid of an FSA, respectively.", [["infection", "DISEASE", 58, 67], ["infection onset", "PROBLEM", 58, 73], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["temporal", "OBSERVATION_MODIFIER", 13, 21], ["spatial units", "OBSERVATION_MODIFIER", 26, 39], ["infection", "OBSERVATION", 58, 67]]], ["Only high IR clusters were examined.", [["high", "OBSERVATION_MODIFIER", 5, 9]]], ["In the space-time analysis we used a cylinder with a circular spatial base and height relating to time to identify high IR clusters [44] .", [["a cylinder", "TREATMENT", 35, 45], ["a circular spatial base", "TREATMENT", 51, 74], ["base", "ANATOMY_MODIFIER", 70, 74]]], ["Circular scanning window was selected to detect large, compact clusters.", [["Circular scanning window", "TEST", 0, 24], ["large, compact clusters", "PROBLEM", 48, 71], ["large", "OBSERVATION_MODIFIER", 48, 53]]], ["The scanning window moves across simultaneously in space and time comparing the rate of infections inside of the scanning window to the rate of infections outside of the scanning window using a Monte Carlo hypothesis testing with 999 replications [18] .", [["infections", "DISEASE", 88, 98], ["infections", "DISEASE", 144, 154], ["The scanning window", "TEST", 0, 19], ["infections", "PROBLEM", 88, 98], ["the scanning window", "TEST", 109, 128], ["infections", "PROBLEM", 144, 154], ["the scanning window", "TEST", 166, 185], ["a Monte Carlo hypothesis testing", "TEST", 192, 224], ["infections", "OBSERVATION", 88, 98], ["infections", "OBSERVATION", 144, 154]]], ["If the infection rate is significantly (p-value \ufffd0.05) higher inside the window a relative risk is estimated, and a high rate cluster is identified.", [["infection", "DISEASE", 7, 16], ["the infection rate", "TEST", 3, 21], ["p-value", "TEST", 40, 47], ["a high rate cluster", "PROBLEM", 114, 133], ["infection", "OBSERVATION", 7, 16]]], ["Salmonellosis is mainly a foodborne disease, and the contaminated food sources could be widespread; therefore, we set the scanning window to include up to 50% of the study population and up to 50% of the study period, to detect large primary and secondary clusters.PLOS ONETo circumvent the assumption that the relative risk of salmonellosis is similar throughout a significant spatial or space-time cluster, we also present and illustrate the relative risk for each FSA that belonged to a significant cluster.", [["Salmonellosis", "DISEASE", 0, 13], ["foodborne disease", "DISEASE", 26, 43], ["salmonellosis", "DISEASE", 328, 341], ["Salmonellosis", "PROBLEM", 0, 13], ["a foodborne disease", "PROBLEM", 24, 43], ["the scanning window", "TEST", 118, 137], ["the study population", "TEST", 162, 182], ["the study", "TEST", 200, 209], ["large primary and secondary clusters", "PROBLEM", 228, 264], ["salmonellosis", "PROBLEM", 328, 341], ["each FSA", "PROBLEM", 462, 470], ["foodborne disease", "OBSERVATION", 26, 43], ["large", "OBSERVATION_MODIFIER", 228, 233], ["primary", "OBSERVATION_MODIFIER", 234, 241], ["secondary clusters", "OBSERVATION", 246, 264], ["salmonellosis", "OBSERVATION", 328, 341]]], ["The relative risk (RR) for each FSA belonging to a cluster is obtained from Eq (3):PLOS ONEWhere c is the total number of salmonellosis cases in an FSA, e is the total number of expected cases in an FSA, and C is the total number of observed cases in Toronto.", [["salmonellosis", "DISEASE", 122, 135], ["RR", "TEST", 19, 21]]], ["The RR is the estimated risk within an FSA divided by the risk outside of the FSA.", [["The RR", "TEST", 0, 6], ["FSA", "ANATOMY", 78, 81]]], ["If the RR is greater than 1, salmonellosis cases within that FSA have a higher risk to have salmonellosis than cases from all the other FSAs.PLOS ONEStatistically significant space and space-time clusters were visualized in ArcGIS 10.7.1.", [["salmonellosis", "DISEASE", 29, 42], ["salmonellosis", "DISEASE", 92, 105], ["PLOS", "DNA", 141, 145], ["the RR", "TEST", 3, 9], ["salmonellosis cases", "PROBLEM", 29, 48], ["salmonellosis", "PROBLEM", 92, 105], ["significant space and space-time clusters", "PROBLEM", 163, 204], ["ArcGIS", "TEST", 224, 230], ["salmonellosis", "OBSERVATION", 92, 105], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["space", "OBSERVATION_MODIFIER", 175, 180]]], ["The outbreak history of cases that were included in statistically significant space-time clusters were assessed to evaluate if local outbreaks explained the clustering of cases.Case-case multinomial logistic regression analysisTo compare individual-level demographic characteristics and seasonal factors among different NTS serotypes a case-case analysis [45, 46] was conducted.", [["local outbreaks", "PROBLEM", 127, 142], ["regression analysis", "TEST", 208, 227], ["seasonal factors", "PROBLEM", 287, 303]]], ["A multinomial logistic regression model was built where the outcome variable had four categories representing salmonellosis infections caused by serotypes Enteritidis, Typhimurium, Thompson, and Heidelberg.", [["salmonellosis infections", "DISEASE", 110, 134], ["serotypes Enteritidis", "ORGANISM", 145, 166], ["Enteritidis", "SPECIES", 155, 166], ["Typhimurium", "SPECIES", 168, 179], ["Typhimurium", "SPECIES", 168, 179], ["A multinomial logistic regression model", "PROBLEM", 0, 39], ["salmonellosis infections", "PROBLEM", 110, 134], ["serotypes Enteritidis", "PROBLEM", 145, 166], ["salmonellosis infections", "OBSERVATION", 110, 134], ["serotypes Enteritidis", "OBSERVATION", 145, 166]]], ["Serotype Enteritidis was included in the model as the base category to which the other three serotypes were compared.Case-case multinomial logistic regression analysisThe predictor variables were year, season, age group, sex, outbreak status, and travel history.", [["Serotype Enteritidis", "ORGANISM", 0, 20], ["Serotype Enteritidis", "SPECIES", 0, 20], ["Serotype Enteritidis", "SPECIES", 0, 20], ["Serotype Enteritidis", "PROBLEM", 0, 20], ["regression analysis", "TEST", 148, 167], ["Enteritidis", "OBSERVATION", 9, 20]]], ["The categorical age variable was divided into five categories: cases aged between 0 and 9, 10 and 19, 20 and 39, 40 and 59, and cases 60 years of age and greater.", [["greater", "OBSERVATION_MODIFIER", 154, 161]]], ["Three FSAs with High-High S. Enteritidis IRs, four FSA with High-Low IRs, two FSAs with Low-Low IRs, and three FSAs with Low-High were identified using the Local Moran's I method (Fig 4, S1 Fig, S1 Table) .", [["S. Enteritidis", "ORGANISM", 26, 40], ["S. Enteritidis", "SPECIES", 26, 40], ["S. Enteritidis", "SPECIES", 26, 40], ["Three FSAs", "TEST", 0, 10], ["High-High S. Enteritidis IRs", "PROBLEM", 16, 44], ["four FSA", "TEST", 46, 54], ["High-Low IRs", "PROBLEM", 60, 72], ["two FSAs", "PROBLEM", 74, 82], ["Low-Low IRs", "PROBLEM", 88, 99], ["three FSAs", "PROBLEM", 105, 115], ["High", "OBSERVATION_MODIFIER", 16, 20], ["High S.", "OBSERVATION_MODIFIER", 21, 28], ["Enteritidis", "OBSERVATION", 29, 40], ["Low IRs", "OBSERVATION_MODIFIER", 65, 72], ["Low IRs", "OBSERVATION_MODIFIER", 92, 99]]], ["Three FSAs with High-High S. Typhimurium IRs, four FSA with High-Low IRs, three FSAs with Low-Low IRs, and seven FSAs with Low-High were identified using the local Moran's I method (Fig 4, S1 Fig, S1 Table) .Disease mappingSeventeen FSAs with High-High S. Thompson IRs, four FSA with High-Low IRs, twenty FSAs with Low-Low IRs, and seven FSAs with Low-High were identified using the local Moran's I method (Fig 4, S1 Fig, S1 Table) .Disease mappingThree FSAs with High-High S. Heidelberg IRs, two FSA with High-Low IRs, four FSAs with Low-Low IRs, and two FSAs with Low-High were identified using the Local Moran's I method (Fig 4, S1 Fig, Fig 1, S1 Table) .PLOS ONESpatial clustering and demographic characteristics of Salmonella infections in Toronto, Canada Scan statistic.", [["Salmonella infections", "DISEASE", 720, 741], ["S. Typhimurium", "ORGANISM", 26, 40], ["Low-Low IRs", "DNA", 90, 101], ["Low-Low IRs", "DNA", 315, 326], ["S. Typhimurium", "SPECIES", 26, 40], ["S. Typhimurium", "SPECIES", 26, 40], ["Salmonella", "SPECIES", 720, 730], ["Three FSAs", "TEST", 0, 10], ["four FSA", "TEST", 46, 54], ["High-Low IRs", "PROBLEM", 60, 72], ["Low-Low IRs", "PROBLEM", 90, 101], ["seven FSAs", "PROBLEM", 107, 117], ["FSAs", "TEST", 233, 237], ["four FSA", "TEST", 270, 278], ["twenty FSAs", "PROBLEM", 298, 309], ["Low-Low IRs", "PROBLEM", 315, 326], ["seven FSAs", "PROBLEM", 332, 342], ["Disease mapping", "TEST", 433, 448], ["Three FSAs", "TEST", 448, 458], ["two FSA", "TEST", 493, 500], ["High-Low IRs", "PROBLEM", 506, 518], ["four FSAs", "PROBLEM", 520, 529], ["Low-Low IRs", "PROBLEM", 535, 546], ["two FSAs", "PROBLEM", 552, 560], ["Fig", "TEST", 625, 628], ["Salmonella infections", "PROBLEM", 720, 741], ["High", "OBSERVATION_MODIFIER", 16, 20], ["Low IRs", "OBSERVATION_MODIFIER", 65, 72], ["Low IRs", "OBSERVATION_MODIFIER", 94, 101], ["Low IRs", "OBSERVATION_MODIFIER", 289, 296], ["Low IRs", "OBSERVATION_MODIFIER", 319, 326], ["High", "OBSERVATION_MODIFIER", 464, 468], ["Low IRs", "OBSERVATION_MODIFIER", 511, 518], ["Low IRs", "OBSERVATION_MODIFIER", 539, 546], ["Salmonella infections", "OBSERVATION", 720, 741]]], ["Three high rate purely spatial clusters were detected by using the discrete Poisson model (Fig 5, Table 1, S1 Fig, S1 Table) .PLOS ONESalmonella Typimurium infections (n = 48) cases clustered in the central part of Toronto.", [["Typimurium infections", "DISEASE", 145, 166], ["Three high rate purely spatial clusters", "PROBLEM", 0, 39], ["Typimurium infections", "PROBLEM", 145, 166], ["high", "OBSERVATION_MODIFIER", 6, 10], ["spatial clusters", "OBSERVATION", 23, 39], ["central", "ANATOMY_MODIFIER", 199, 206]]], ["Out of the 24 FSAs included in the cluster, 6 FSAs reported a relative risk of 0, one had a RR of 0.82, and one had a RR of 0.98.", [["a RR", "TEST", 90, 94], ["a RR", "TEST", 116, 120]]], ["On the other hand, 16 FSA had a relative risk greater than one, ranging from 1.17 to 6.2.PLOS ONESalmonella Thompson infections (n = 48) clustered in the north-central part of Toronto.", [["Thompson infections", "DISEASE", 108, 127], ["Thompson infections", "PROBLEM", 108, 127], ["central", "ANATOMY_MODIFIER", 160, 167]]], ["All the FSAs included in the cluster have a relative risk greater than one, ranging from 1.93 to 10.69.PLOS ONESalmonella Heidelberg infections (n = 68) clustered in the south-east part of Toronto.", [["infections", "DISEASE", 133, 143], ["FSAs", "DNA", 8, 12], ["All the FSAs", "TEST", 0, 12], ["relative", "OBSERVATION_MODIFIER", 44, 52], ["risk", "OBSERVATION_MODIFIER", 53, 57], ["greater", "OBSERVATION_MODIFIER", 58, 65]]], ["Out of the 35 FSAs included in the cluster, 5 FSAs reported a relative risk of 0, and 8 had a relative risk of one or less, which ranged from 0.51 to 1.", [["FSAs", "CANCER", 14, 18]]], ["On the other hand, 22 FSAs had a relative risk greater than one, ranging from 1.02 to 4.82.PLOS ONEThree significant (p \ufffd 0.05) high rate space-time clusters were detected (Table 1 , Fig 6, S1 Fig, S1 Table) .PLOS ONESpatial clustering and demographic characteristics of Salmonella infections in Toronto, CanadaPLOS ONEOne space-time cluster of S. Typhimurium infections (n = 26) occurred between July 2015 and October 2015 in the central part of Toronto (RR = 3.82).", [["Salmonella infections", "DISEASE", 271, 292], ["S. Typhimurium infections", "DISEASE", 345, 370], ["S. Typhimurium", "ORGANISM", 345, 359], ["S. Typhimurium", "SPECIES", 345, 359], ["Salmonella", "SPECIES", 271, 281], ["S. Typhimurium", "SPECIES", 345, 359], ["FSAs", "TEST", 22, 26], ["high rate space-time clusters", "PROBLEM", 128, 157], ["Salmonella infections", "PROBLEM", 271, 292], ["Toronto, CanadaPLOS ONEOne space", "TREATMENT", 296, 328], ["S. Typhimurium infections", "PROBLEM", 345, 370], ["RR", "TEST", 456, 458], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["Salmonella infections", "OBSERVATION", 271, 292]]], ["Out of the 52 FSAs included in the cluster, 32 FSAs had a relative risk of 0, and 20 FSAs had a relative risk greater than one, ranging from 3.48 to 55.32.", [["FSAs", "CANCER", 14, 18]]], ["A space-time cluster of S. Thompson infections (n = 30) occurred between September 2016 and December 2016 in the north-central part of Toronto (RR = 29.01).", [["Thompson infections", "DISEASE", 27, 46], ["S. Thompson", "ORGANISM", 24, 35], ["S. Thompson infections", "PROBLEM", 24, 46], ["RR", "TEST", 144, 146]]], ["Out of the 9 FSAs included in the cluster, one FSA had a relative risk of 0, and 9 FSAs had a relative risk greater than one, ranging from 11.67 to 52.86.PLOS ONEA space-time cluster of S. Heidelberg infections (n = 11) occurred between April 2017 and May 2017 in the south-east part of Toronto (RR = 11.43).", [["FSAs", "DISEASE", 83, 87], ["infections", "DISEASE", 200, 210], ["FSAs", "CANCER", 13, 17], ["FSAs", "TEST", 83, 87], ["S. Heidelberg infections", "PROBLEM", 186, 210], ["RR", "TEST", 296, 298]]], ["Out of the 12 FSAs included in the cluster, 4 FSAs have a relative risk of 0, and 8 FSAs have a relative risk greater than one, ranging from 9.89 to 39.29.PLOS ONENone of the 26 S. Typhimurium cases that were included in the space-time cluster were linked to an outbreak.", [["FSAs", "CANCER", 14, 18], ["S. Typhimurium", "ORGANISM", 178, 192], ["S. Typhimurium", "SPECIES", 178, 192], ["S. Typhimurium", "SPECIES", 178, 192], ["Typhimurium cases", "TEST", 181, 198], ["outbreak", "OBSERVATION", 262, 270]]], ["Of the 11 S. Heidelberg cases that were included in the space-time cluster, 8 cases (73%) were linked to an outbreak.PLOS ONEThe purely spatial multinomial scan statistic identified two clusters (Fig 7, Table 2 ).", [["S. Heidelberg", "ORGANISM", 10, 23], ["PLOS", "DNA", 117, 121], ["spatial multinomial scan statistic", "TEST", 136, 170]]], ["The primary spatial cluster was in the north-central part of Toronto, and included a relative risk greater than one for serotype Thompson and all the other serotypes had a smaller than one relative risk.", [["primary", "OBSERVATION_MODIFIER", 4, 11], ["spatial", "OBSERVATION_MODIFIER", 12, 19], ["cluster", "OBSERVATION_MODIFIER", 20, 27]]], ["The secondary spatial cluster was in the central and south-central part of Toronto and included a relative risk greater than one for serotypes Typhimurium and Heidelberg and had a relative risk smaller than one for serotypes Enteritidis and Thompson.PLOS ONEThe space-time multinomial scan statistic identified one cluster (Fig 7, Table 2 ).", [["Enteritidis", "ORGANISM", 225, 236], ["PLOS", "DNA", 250, 254], ["Typhimurium", "SPECIES", 143, 154], ["Enteritidis", "SPECIES", 225, 236], ["serotypes Typhimurium", "PROBLEM", 133, 154], ["multinomial scan statistic", "TEST", 273, 299], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["spatial", "OBSERVATION_MODIFIER", 14, 21], ["cluster", "OBSERVATION_MODIFIER", 22, 29], ["central", "ANATOMY_MODIFIER", 41, 48], ["smaller", "OBSERVATION_MODIFIER", 194, 201]]], ["The spacetime cluster occurred between August 2016 and December 2016 in the north-central and central part of Toronto and included a relative risk greater than one for serotype Thompson and all the other serotypes had a smaller than one relative risk.PLOS ONEThe primary cluster was in the north-central part of Toronto and included a relative risk greater than one for serotype Thompson and all the other serotypes have a smaller than onePLOS ONESpatial clustering and demographic characteristics of Salmonella infections in Toronto, Canada relative risk.", [["Salmonella infections", "DISEASE", 501, 522], ["Salmonella", "SPECIES", 501, 511], ["serotype Thompson", "TREATMENT", 370, 387], ["Salmonella infections", "PROBLEM", 501, 522], ["primary", "OBSERVATION_MODIFIER", 263, 270], ["cluster", "OBSERVATION_MODIFIER", 271, 278], ["smaller", "OBSERVATION_MODIFIER", 423, 430], ["Salmonella infections", "OBSERVATION", 501, 522]]], ["The secondary cluster was in the central and south-central part of Toronto and included a relative risk greater than one for serotypes Typhimurium and Heidelberg and have a relative risk smaller than one for serotypes Enteritidis and Thompson.Case-case multinomial logistic regression analysisThe results of the multinomial logistic regression model of serotype-specific NTS infections are shown in Table 3 .Case-case multinomial logistic regression analysisIn the multinomial model, S. Typhimurium infections compared to S. Enteritidis infections, given the other variables in the model were held constant, the relative risk ratio was significantly higher in the summer (RRR = 2.11, 95% CI 1.21-3.67) compared to the fall season.", [["infections", "DISEASE", 375, 385], ["S. Typhimurium infections", "DISEASE", 484, 509], ["S. Enteritidis infections", "DISEASE", 522, 547], ["serotypes Enteritidis", "ORGANISM", 208, 229], ["S. Typhimurium", "ORGANISM", 484, 498], ["S. Enteritidis", "ORGANISM", 522, 536], ["Typhimurium", "SPECIES", 135, 146], ["Enteritidis", "SPECIES", 218, 229], ["S. Typhimurium", "SPECIES", 484, 498], ["S. Enteritidis", "SPECIES", 522, 536], ["S. Typhimurium", "SPECIES", 484, 498], ["S. Enteritidis", "SPECIES", 522, 536], ["regression analysis", "TEST", 274, 293], ["the multinomial logistic regression", "TREATMENT", 308, 343], ["serotype-specific NTS infections", "PROBLEM", 353, 385], ["regression analysis", "TEST", 439, 458], ["S. Typhimurium infections", "PROBLEM", 484, 509], ["S. Enteritidis infections", "PROBLEM", 522, 547], ["the relative risk ratio", "TEST", 608, 631], ["RRR", "TEST", 672, 675], ["CI", "TEST", 688, 690], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["cluster", "OBSERVATION_MODIFIER", 14, 21], ["central", "ANATOMY_MODIFIER", 33, 40], ["smaller", "OBSERVATION_MODIFIER", 187, 194], ["Typhimurium", "OBSERVATION_MODIFIER", 487, 498], ["infections", "OBSERVATION", 499, 509], ["Enteritidis", "OBSERVATION_MODIFIER", 525, 536], ["infections", "OBSERVATION", 537, 547]]], ["Children 0-9 years of age (referent category), followed by individuals 20- Salmonella Heidelberg infections compared to S. Enteritidis infections, given the other variables in the model were held constant, the relative risk ratio was significantly lower in 2017 (RRR = 0.52, 95% CI 0.30-0.90) compared to 2015 (referent category).", [["infections", "DISEASE", 97, 107], ["S. Enteritidis infections", "DISEASE", 120, 145], ["Children", "ORGANISM", 0, 8], ["Salmonella Heidelberg", "ORGANISM", 75, 96], ["S. Enteritidis", "ORGANISM", 120, 134], ["Children", "SPECIES", 0, 8], ["S. Enteritidis", "SPECIES", 120, 134], ["S. Enteritidis", "SPECIES", 120, 134], ["Salmonella Heidelberg infections", "PROBLEM", 75, 107], ["S. Enteritidis infections", "PROBLEM", 120, 145], ["the relative risk ratio", "TEST", 206, 229], ["RRR", "TEST", 263, 266], ["CI", "TEST", 279, 281], ["infections", "OBSERVATION", 135, 145]]], ["Persons between 20 and 39 years of age (RRR = 1.93, 95% CI 1.03-3.61) had the highest risk of infection.", [["infection", "DISEASE", 94, 103], ["Persons", "ORGANISM", 0, 7], ["Persons", "SPECIES", 0, 7], ["RRR", "TEST", 40, 43], ["CI", "TEST", 56, 58], ["infection", "PROBLEM", 94, 103], ["infection", "OBSERVATION", 94, 103]]], ["Salmonella Heidelberg infections were significantly less likely to be travel related than S. Enteritidis infections (RRR = 0.06, 95% CI 0.02-0.14).", [["Salmonella Heidelberg infections", "DISEASE", 0, 32], ["S. Enteritidis infections", "DISEASE", 90, 115], ["Salmonella Heidelberg", "ORGANISM", 0, 21], ["S. Enteritidis", "ORGANISM", 90, 104], ["S. Enteritidis", "SPECIES", 90, 104], ["S. Enteritidis", "SPECIES", 90, 104], ["Salmonella Heidelberg infections", "PROBLEM", 0, 32], ["S. Enteritidis infections", "PROBLEM", 90, 115], ["RRR", "TEST", 117, 120], ["CI", "TEST", 133, 135]]], ["No significant differences were detected among years, seasons, or between sexes.DiscussionOur study applied a stepwise analytical framework that linked spatial exploratory and statistical methods with GIS to assess and compare the distribution and spatial clustering of NTS infections with different serotypes across the city of Toronto.", [["infections", "DISEASE", 274, 284], ["DiscussionOur study", "TEST", 80, 99], ["NTS infections", "PROBLEM", 270, 284], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26]]], ["As the first exploratory spatial analytical step, we visually assessed the geographic extent of NTS infections with major serotypes across Toronto's 95 FSAs by constructing disease choropleth maps.", [["infections", "DISEASE", 100, 110], ["NTS infections", "PROBLEM", 96, 110], ["constructing disease choropleth maps", "PROBLEM", 160, 196], ["NTS", "ANATOMY", 96, 99], ["infections", "OBSERVATION", 100, 110]]], ["In cities with several areal units with small populations, the estimated infection rates become unreliable and unstable if several cases were detected in these regions [13] .", [["infection", "DISEASE", 73, 82], ["several areal units", "TREATMENT", 15, 34], ["small populations", "PROBLEM", 40, 57], ["the estimated infection rates", "PROBLEM", 59, 88], ["small", "OBSERVATION_MODIFIER", 40, 45], ["populations", "OBSERVATION", 46, 57], ["infection", "OBSERVATION", 73, 82]]], ["To account for small area level unstable infection rates, we used spatial empirical Bayes method at the second step of our spatial exploratory analysis, which reduces the unbalanced infection rate estimates towards the local mean infection rate if local clustering is detected, and towards the global mean infection rate if no local clustering is found [47] .", [["infection", "DISEASE", 41, 50], ["infection", "DISEASE", 182, 191], ["infection", "DISEASE", 230, 239], ["infection", "DISEASE", 306, 315], ["small area level unstable infection rates", "PROBLEM", 15, 56], ["spatial empirical Bayes method", "TREATMENT", 66, 96], ["our spatial exploratory analysis", "TEST", 119, 151], ["the unbalanced infection rate estimates", "PROBLEM", 167, 206], ["small", "OBSERVATION_MODIFIER", 15, 20], ["area", "OBSERVATION_MODIFIER", 21, 25], ["unstable", "OBSERVATION_MODIFIER", 32, 40], ["infection", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 182, 191]]], ["This method in our study reduced the highest infection rate estimates for each of the four NTS serotypes and helped us to focus our attention toward the overall spatial disease trends to evaluate visually FSAs of high and low IRs.", [["infection", "DISEASE", 45, 54], ["our study", "TEST", 15, 24], ["the highest infection rate estimates", "PROBLEM", 33, 69], ["visually FSAs", "TEST", 196, 209], ["high and low IRs", "PROBLEM", 213, 229], ["highest", "OBSERVATION_MODIFIER", 37, 44], ["infection", "OBSERVATION", 45, 54], ["low IRs", "OBSERVATION_MODIFIER", 222, 229]]], ["Several high IR areas for each of the major NTS serotype infection were identified that were later recognized as statistically significant disease clusters.DiscussionWe identified three space-time clusters across the city of Toronto.", [["infection", "DISEASE", 57, 66], ["NTS serotype", "ORGANISM", 44, 56], ["Several high IR areas", "PROBLEM", 0, 21], ["the major NTS serotype infection", "PROBLEM", 34, 66], ["significant disease clusters", "PROBLEM", 127, 155], ["high IR", "OBSERVATION_MODIFIER", 8, 15], ["areas", "OBSERVATION_MODIFIER", 16, 21], ["serotype", "OBSERVATION_MODIFIER", 48, 56], ["infection", "OBSERVATION", 57, 66], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["disease", "OBSERVATION", 139, 146]]], ["In our analysis, spacetime clusters were defined as significantly higher than expected number of cases at a specific location and time period, which might or might not meet the definition of an outbreak [48] .", [["our analysis", "TEST", 3, 15], ["spacetime clusters", "PROBLEM", 17, 35]]], ["Our space-time scan statistics correctly identified the S. Thompson and S. Heidelberg outbreaks as many of the cases that were included in the space-time clusters were linked to an outbreak by public health staff.", [["Our space-time scan", "TEST", 0, 19]]], ["However, none of the S. Typhimurium cases that were included in the space-time cluster were linked to an outbreak, suggesting that these cases did not have a common exposure source.", [["S. Typhimurium", "ORGANISM", 21, 35], ["S. Typhimurium", "SPECIES", 21, 35], ["S. Typhimurium", "SPECIES", 21, 35], ["the S. Typhimurium cases", "TEST", 17, 41]]], ["At the first spatial statistical step, we evaluated differences in global clustering among serotype-specific NTS infection IRs.", [["infection", "DISEASE", 113, 122], ["global clustering among serotype-specific NTS infection IRs", "PROBLEM", 67, 126], ["infection", "OBSERVATION", 113, 122]]], ["The extent of global clustering of S. Thompson IRs ranged from 3.3 km to 13.3 km, with a maximum global clustering at 6.3 km, suggesting that S. Thompson infections were widespread and involved several areas across Toronto.", [["infections", "DISEASE", 154, 164], ["S. Thompson IRs", "TEST", 35, 50], ["a maximum global clustering", "PROBLEM", 87, 114], ["S. Thompson infections", "PROBLEM", 142, 164], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["global", "OBSERVATION_MODIFIER", 14, 20], ["clustering", "OBSERVATION_MODIFIER", 21, 31], ["Thompson infections", "OBSERVATION", 145, 164]]], ["The local cluster analysis later supported this finding, by identifying a large high-high infection rate area in the northwest region of Toronto.DiscussionAt the second spatial statistical step, we assessed and compared local clustering of serotypespecific NTS IRs by using the Moran's I method.", [["infection", "DISEASE", 90, 99], ["The local cluster analysis", "TEST", 0, 26], ["a large high-high infection rate area", "PROBLEM", 72, 109], ["large", "OBSERVATION_MODIFIER", 74, 79], ["high", "OBSERVATION_MODIFIER", 80, 84], ["high", "OBSERVATION_MODIFIER", 85, 89], ["infection", "OBSERVATION", 90, 99], ["northwest", "ANATOMY_MODIFIER", 117, 126], ["region", "ANATOMY_MODIFIER", 127, 133]]], ["This method is ideal in areas with dissimilar IRs, because it not only identifies areas with high-high or low-low IRs, but also detects outlier areas where low IR areas are surrounded by high IR areas or high IR areas are surrounded by low IR areas.", [["This method", "TREATMENT", 0, 11], ["dissimilar IRs", "TREATMENT", 35, 49], ["high-high or low-low IRs", "PROBLEM", 93, 117], ["outlier areas", "PROBLEM", 136, 149], ["low IR areas", "PROBLEM", 156, 168], ["high IR areas", "PROBLEM", 187, 200], ["high IR areas", "PROBLEM", 204, 217], ["high", "OBSERVATION_MODIFIER", 93, 97], ["high", "OBSERVATION_MODIFIER", 98, 102], ["low-low IRs", "OBSERVATION_MODIFIER", 106, 117], ["outlier", "OBSERVATION_MODIFIER", 136, 143], ["areas", "OBSERVATION_MODIFIER", 144, 149], ["low IR", "OBSERVATION_MODIFIER", 156, 162], ["high", "OBSERVATION_MODIFIER", 187, 191], ["high", "OBSERVATION_MODIFIER", 204, 208], ["IR", "OBSERVATION_MODIFIER", 209, 211], ["areas", "OBSERVATION_MODIFIER", 212, 217], ["low IR", "OBSERVATION_MODIFIER", 236, 242]]], ["Interestingly, when we compared FSA-level high-high IR clusters among major NTS serotypes they differed in their size and location.", [["FSA", "PROTEIN", 32, 35], ["FSA", "TEST", 32, 35], ["major NTS serotypes", "PROBLEM", 70, 89], ["size", "OBSERVATION_MODIFIER", 113, 117]]], ["The S. Thompson high-high IR cluster was the largest, including seventeen neighboring FSAs, in the northeast region of Toronto.", [["largest", "OBSERVATION_MODIFIER", 45, 52], ["neighboring FSAs", "OBSERVATION", 74, 90], ["northeast", "ANATOMY_MODIFIER", 99, 108], ["region", "ANATOMY_MODIFIER", 109, 115]]], ["The other NTS serotype clusters were small and included only three FSAs each, and were in the central region of Toronto for S. Enteritidis, in the northwest for S. Typhimurium, and the southeast for S. Heidelberg.", [["S. Enteritidis", "ORGANISM", 124, 138], ["S. Typhimurium", "ORGANISM", 161, 175], ["S. Enteritidis", "SPECIES", 124, 138], ["S. Typhimurium", "SPECIES", 161, 175], ["S. Enteritidis", "SPECIES", 124, 138], ["S. Typhimurium", "SPECIES", 161, 175], ["The other NTS serotype clusters", "PROBLEM", 0, 31], ["S. Enteritidis", "PROBLEM", 124, 138], ["NTS", "OBSERVATION_MODIFIER", 10, 13], ["serotype clusters", "OBSERVATION", 14, 31], ["small", "OBSERVATION_MODIFIER", 37, 42], ["Enteritidis", "OBSERVATION", 127, 138]]], ["The differences in serotype-specific geographical clustering among major NTS infections might be explained by differences related to their specific environmental, demographic, socioeconomic and host factors.", [["NTS infections", "DISEASE", 73, 87], ["major NTS infections", "PROBLEM", 67, 87], ["serotype-specific", "OBSERVATION_MODIFIER", 19, 36], ["geographical", "OBSERVATION_MODIFIER", 37, 49], ["clustering", "OBSERVATION_MODIFIER", 50, 60], ["infections", "OBSERVATION", 77, 87]]], ["Future targeted individual-level studies are needed in these areas to elucidate our study findings.DiscussionWhen we compared the spatial exploratory and spatial statistical methods for each NTS serotypes, the non-smoothed and smoothed maps visually identified areas with high and low rates, that were later identified by the local Moran's I method as statistically significant highhigh, low-low or outlier IR FSAs.", [["Future targeted individual-level studies", "TEST", 0, 40], ["our study findings", "TEST", 80, 98], ["each NTS serotypes", "PROBLEM", 186, 204], ["high and low rates", "PROBLEM", 272, 290], ["low-low or outlier IR FSAs", "PROBLEM", 388, 414], ["areas", "OBSERVATION_MODIFIER", 261, 266], ["high", "OBSERVATION_MODIFIER", 272, 276], ["low rates", "OBSERVATION_MODIFIER", 281, 290], ["significant", "OBSERVATION_MODIFIER", 366, 377], ["highhigh", "OBSERVATION_MODIFIER", 378, 386], ["low", "OBSERVATION_MODIFIER", 388, 391]]], ["The same high and low rate FSAs were consistently identified by each method, emphasizing the strength of our study methodology, and highlighting the consistency of FSA-level clustering of each NTS serotype.DiscussionWe built multinomial scan statistic models to identify purely spatial and space-time clusters of nontyphoidal Salmonella infections with major serotypes.", [["Salmonella infections", "DISEASE", 326, 347], ["Salmonella", "SPECIES", 326, 336], ["The same high and low rate FSAs", "PROBLEM", 0, 31], ["our study methodology", "TEST", 105, 126], ["each NTS serotype", "PROBLEM", 188, 205], ["multinomial scan statistic models", "TEST", 225, 258], ["nontyphoidal Salmonella infections", "PROBLEM", 313, 347], ["major serotypes", "PROBLEM", 353, 368], ["high", "OBSERVATION_MODIFIER", 9, 13], ["low rate", "OBSERVATION_MODIFIER", 18, 26], ["nontyphoidal Salmonella infections", "OBSERVATION", 313, 347]]], ["Multinomial scan statistic has some advantages over Poisson or binomial logistic regression models in that this model can investigate more than two outcomes (i.e. serotypes) concurrently in a single model.", [["Multinomial scan statistic", "TEST", 0, 26], ["binomial logistic regression models", "TREATMENT", 63, 98]]], ["This approach was useful in our purely spatial analysis in detecting simultaneous excess risk ratios for serotypes Heidelberg and Typhimurium that might suggest a common exposure source (Fig 7, Table 2 ).", [["Typhimurium", "ORGANISM", 130, 141], ["Typhimurium", "SPECIES", 130, 141], ["Typhimurium", "SPECIES", 130, 141], ["our purely spatial analysis", "TEST", 28, 55], ["simultaneous excess risk ratios", "PROBLEM", 69, 100], ["Typhimurium", "PROBLEM", 130, 141]]], ["The multinomial scan statistic is useful also in outbreak investigations, when a serotype compared to the \"other\" serotypes is strongly associated with a localized exposure source (i.e. local restaurant).", [["The multinomial scan statistic", "TEST", 0, 30], ["outbreak investigations", "TEST", 49, 72], ["a serotype", "PROBLEM", 79, 89], ["the \"other\" serotypes", "PROBLEM", 102, 123]]], ["This assumption was supported by our multinomial spatial and space-time scan statistic result that identified a cluster where only S. Thompson cases had an excess risk ratio (Fig 7, Table 2 ).DiscussionWe identified a high S. Thompson infection rate space-time cluster in the north-east region of Toronto between September 2016 and December 2016 (Table 1, Fig 6) , and 63% of cases that were included in this cluster were linked to an outbreak by public health enteric outbreak investigators.", [["infection", "DISEASE", 235, 244], ["a high S. Thompson infection rate space", "PROBLEM", 216, 255]]], ["The Quebec outbreak was linked to the consumption of chicken shawarma at a local restaurant chain in the city of Montreal and its neighboring regions.", [["chicken", "ORGANISM", 53, 60], ["chicken", "SPECIES", 53, 60], ["chicken", "SPECIES", 53, 60], ["chicken shawarma", "PROBLEM", 53, 69], ["chicken shawarma", "OBSERVATION", 53, 69]]], ["As our study did not have exposure history data, we cannot link the Montreal and Toronto outbreaks; however, it is possible that Toronto cases were exposed to the same food source, considering the probable inter-provincial poultry meat exchange through the supply chain, the identical time frame of illnesses, and the relatively rare serotype.DiscussionAt the final step of our study, we performed a retrospective case-case multinomial analysis to test whether a specific serotype compared to all the other serotypes had different seasonal and demographic factors.", [["meat", "ANATOMY", 231, 235], ["meat", "ORGANISM_SUBDIVISION", 231, 235], ["our study", "TEST", 3, 12], ["inter-provincial poultry meat exchange", "TREATMENT", 206, 244], ["the supply chain", "TREATMENT", 253, 269], ["illnesses", "PROBLEM", 299, 308], ["the relatively rare serotype", "PROBLEM", 314, 342], ["our study", "TEST", 374, 383], ["multinomial analysis", "TEST", 424, 444], ["a specific serotype", "PROBLEM", 461, 480], ["rare", "OBSERVATION_MODIFIER", 329, 333], ["serotype", "OBSERVATION", 334, 342]]], ["Differences in annual infections among major NTS serotypes were identified.", [["infections", "DISEASE", 22, 32], ["annual infections", "PROBLEM", 15, 32], ["major NTS serotypes", "PROBLEM", 39, 58], ["infections", "OBSERVATION", 22, 32], ["serotypes", "OBSERVATION", 49, 58]]], ["When compared to S. Enteritidis infections the relative risk ratio was higher in 2015 for S. Thompson and Heidelberg, and no differences among years were detected for S. Typhimurium.", [["S. Enteritidis infections", "DISEASE", 17, 42], ["S. Enteritidis", "ORGANISM", 17, 31], ["S. Typhimurium", "ORGANISM", 167, 181], ["S. Enteritidis", "SPECIES", 17, 31], ["S. Typhimurium", "SPECIES", 167, 181], ["S. Enteritidis", "SPECIES", 17, 31], ["S. Typhimurium", "SPECIES", 167, 181], ["S. Enteritidis infections", "PROBLEM", 17, 42], ["infections", "OBSERVATION", 32, 42]]], ["This finding is consistent with the results of previous Canadian [50] and US [51] studies that indicated an emergence in the number of S. Enteritidis infections during the last decade.DiscussionWhen we examined differences in cases' age among major NTS serotypes we identified that the relative risk ratio of infections were highest in children 0-9 years of age for S. Typhimurium, in persons between 20 and 39 years of age for S. Thompson, in persons greater than 60 years old for S. Heidelberg.", [["S. Enteritidis infections", "DISEASE", 135, 160], ["infections", "DISEASE", 309, 319], ["S. Enteritidis", "ORGANISM", 135, 149], ["children", "ORGANISM", 336, 344], ["S. Typhimurium", "ORGANISM", 366, 380], ["persons", "ORGANISM", 385, 392], ["S. Thompson", "ORGANISM", 428, 439], ["persons", "ORGANISM", 444, 451], ["S. Enteritidis", "SPECIES", 135, 149], ["children", "SPECIES", 336, 344], ["S. Typhimurium", "SPECIES", 366, 380], ["persons", "SPECIES", 385, 392], ["persons", "SPECIES", 444, 451], ["S. Enteritidis", "SPECIES", 135, 149], ["S. Typhimurium", "SPECIES", 366, 380], ["US", "TEST", 74, 76], ["S. Enteritidis infections", "PROBLEM", 135, 160], ["infections", "PROBLEM", 309, 319], ["consistent with", "UNCERTAINTY", 16, 31], ["Enteritidis", "OBSERVATION_MODIFIER", 138, 149], ["infections", "OBSERVATION", 150, 160], ["infections", "OBSERVATION", 309, 319]]], ["Differences in age predilection of various NTS serotypes might be explained by differences in their exposure sources and genetic determinants.DiscussionOur study detected a variation in NTS serotypes' seasonal predilection.", [["various NTS serotypes", "PROBLEM", 35, 56], ["DiscussionOur study", "TEST", 142, 161], ["a variation in NTS serotypes' seasonal predilection", "PROBLEM", 171, 222]]], ["The relative risk ratio of infections was highest in the summer for S. Typhimurium, in the fall for S. Thompson, and no seasonal effect was detected for S. Heidelberg.", [["infections", "DISEASE", 27, 37], ["S. Typhimurium", "ORGANISM", 68, 82], ["S. Typhimurium", "SPECIES", 68, 82], ["S. Typhimurium", "SPECIES", 68, 82], ["S. Thompson", "SPECIES", 100, 111], ["S. Heidelberg", "SPECIES", 153, 166], ["infections", "PROBLEM", 27, 37], ["S. Typhimurium", "PROBLEM", 68, 82], ["seasonal effect", "PROBLEM", 120, 135], ["infections", "OBSERVATION", 27, 37]]], ["Moreover, the relative risk ratio of cases who reported travel outside of Ontario was lowest among serotypes Typhimurium, Thompson, and Heidelberg when compared to S. Enteritidis infections.", [["S. Enteritidis infections", "DISEASE", 164, 189], ["serotypes Typhimurium", "ORGANISM", 99, 120], ["S. Enteritidis", "ORGANISM", 164, 178], ["Typhimurium", "SPECIES", 109, 120], ["S. Enteritidis", "SPECIES", 164, 178], ["serotypes Typhimurium", "SPECIES", 99, 120], ["S. Enteritidis", "SPECIES", 164, 178], ["S. Enteritidis infections", "PROBLEM", 164, 189], ["infections", "OBSERVATION", 179, 189]]], ["This finding agrees with previous studies conducted in Ontario, which showed that more than half of the S. Enteritidis infections detected in Ontario were travel-related [14, 52] , and were linked to cases who visited resorts in the Caribbean and Mexico region during the winter and spring months [52] .DiscussionBefore extrapolating our study results several limitations should be mentioned.", [["S. Enteritidis infections", "DISEASE", 104, 129], ["S. Enteritidis", "ORGANISM", 104, 118], ["S. Enteritidis", "SPECIES", 104, 118], ["S. Enteritidis", "SPECIES", 104, 118], ["previous studies", "TEST", 25, 41], ["the S. Enteritidis infections", "PROBLEM", 100, 129], ["our study", "TEST", 334, 343], ["Enteritidis", "OBSERVATION_MODIFIER", 107, 118], ["infections", "OBSERVATION", 119, 129]]], ["First, it is well documented that enteric surveillance systems commonly underestimate the true number of cases [53] and extrapolating our study results to the whole population requires caution.", [["enteric surveillance systems", "TEST", 34, 62], ["extrapolating our study", "TEST", 120, 143]]], ["Also, in spatial epidemiological studies the Modifiable Areal Unit Problem (MAUP) should be considered where the chosen case aggregation scale and area boundary might affect the results of the analysis.", [["the analysis", "TEST", 189, 201]]], ["Therefore, it is recommended to select an adequate scale that allows meaningful inferences about the spatial determinants of infectious diseases.", [["infectious diseases", "DISEASE", 125, 144], ["infectious diseases", "PROBLEM", 125, 144], ["infectious", "OBSERVATION", 125, 135]]], ["We chose the smallest scale that is readily available in surveillance systems, the FSA, and believe that FSAs are adequately small scale to define areas with distinctive features.", [["surveillance systems", "TEST", 57, 77], ["FSAs", "TEST", 105, 109], ["distinctive features", "PROBLEM", 158, 178], ["distinctive", "OBSERVATION_MODIFIER", 158, 169]]], ["Besides, to account for differences in FSA size and spatial characteristics, we used the \"zone of indifference\" conceptualization parameter in our spatial statistical analysis.DiscussionFor our scan statistic we used a circular scanning window that may miss irregularly shaped clusters.", [["differences in FSA size", "PROBLEM", 24, 47], ["our spatial statistical analysis", "TEST", 143, 175], ["our scan statistic", "TEST", 190, 208], ["a circular scanning window", "TREATMENT", 217, 243], ["irregularly shaped clusters", "PROBLEM", 258, 285], ["size", "OBSERVATION_MODIFIER", 43, 47], ["irregularly", "OBSERVATION_MODIFIER", 258, 269], ["shaped", "OBSERVATION_MODIFIER", 270, 276], ["clusters", "OBSERVATION_MODIFIER", 277, 285]]], ["However, Toronto's FSAs are compact, and irregularly shaped clusters are more common in elongated shaped areas (i.e. coastlines, rivers).", [["Toronto's FSAs", "TREATMENT", 9, 23], ["irregularly shaped clusters", "PROBLEM", 41, 68], ["irregularly", "OBSERVATION_MODIFIER", 41, 52], ["shaped", "OBSERVATION_MODIFIER", 53, 59], ["clusters", "OBSERVATION_MODIFIER", 60, 68], ["more common", "OBSERVATION_MODIFIER", 73, 84], ["elongated", "OBSERVATION_MODIFIER", 88, 97], ["shaped", "OBSERVATION_MODIFIER", 98, 104], ["areas", "OBSERVATION_MODIFIER", 105, 110]]], ["In addition, we chose a relatively large window size that may include a single large cluster with several low infection rate areas.", [["infection", "DISEASE", 110, 119], ["a relatively large window size", "PROBLEM", 22, 52], ["a single large cluster with several low infection rate areas", "PROBLEM", 70, 130], ["large", "OBSERVATION_MODIFIER", 35, 40], ["window", "OBSERVATION", 41, 47], ["size", "OBSERVATION_MODIFIER", 48, 52], ["may include", "UNCERTAINTY", 58, 69], ["large", "OBSERVATION_MODIFIER", 79, 84], ["cluster", "OBSERVATION_MODIFIER", 85, 92], ["several", "OBSERVATION_MODIFIER", 98, 105], ["low", "OBSERVATION_MODIFIER", 106, 109], ["infection", "OBSERVATION", 110, 119]]], ["To overcome this problem, we calculated and illustrated the relative risks of each FSA that were included in each significant cluster.DiscussionFinally, our study was a spatial exploratory study that aimed to identify areas with high infection rates and seek to understand host factors for disease and did not aim to identify environmental exposure sources for NTS infections.", [["infection", "DISEASE", 234, 243], ["NTS infections", "DISEASE", 361, 375], ["each FSA", "PROBLEM", 78, 86], ["our study", "TEST", 153, 162], ["a spatial exploratory study", "TEST", 167, 194], ["high infection rates", "PROBLEM", 229, 249], ["disease", "PROBLEM", 290, 297], ["NTS infections", "PROBLEM", 361, 375], ["high", "OBSERVATION_MODIFIER", 229, 233], ["infection", "OBSERVATION", 234, 243]]], ["Contamination of food products in retail stores and restaurants [54] , differences in microbial quality of food among various neighborhoods [55] , and food safety practices followed by food servers in local restaurants [56] have been described by previous studies as important factors for NTS infection outbreaks.", [["infection", "DISEASE", 293, 302], ["NTS infection outbreaks", "PROBLEM", 289, 312]]], ["Future studies should assess the role of local exposure sources, especially in high infection rate areas that were identified by our study.ConclusionsWe demonstrated the utility of integrating geographic exploratory data visualization and spatial statistics analysis with GIS to identify and compare serotype-specific NTS infection clusters across Toronto's FSAs.", [["infection", "DISEASE", 84, 93], ["infection", "DISEASE", 322, 331], ["Future studies", "TEST", 0, 14], ["local exposure sources", "PROBLEM", 41, 63], ["high infection rate areas", "PROBLEM", 79, 104], ["our study", "TEST", 129, 138], ["integrating geographic exploratory data visualization", "TEST", 181, 234], ["spatial statistics analysis", "TEST", 239, 266], ["GIS", "TEST", 272, 275], ["serotype-specific NTS infection clusters", "PROBLEM", 300, 340], ["high", "OBSERVATION_MODIFIER", 79, 83], ["infection", "OBSERVATION", 84, 93]]], ["To investigate differences in seasonal and demographic factors among major NTS serotypes a case-case multinomial analytical method was performed.", [["seasonal and demographic factors", "PROBLEM", 30, 62]]], ["Several FSAs with high serotype-specific NTS rates were identified.", [["FSAs", "CANCER", 8, 12], ["Several FSAs", "PROBLEM", 0, 12], ["high serotype-specific NTS rates", "PROBLEM", 18, 50], ["high", "OBSERVATION_MODIFIER", 18, 22], ["serotype-specific", "OBSERVATION_MODIFIER", 23, 40]]], ["Future studies in these FSAs should be conducted to identify local exposure sources and socioeconomic determinants for serotype specific NTS infections.", [["infections", "DISEASE", 141, 151], ["Future studies", "TEST", 0, 14], ["these FSAs", "TEST", 18, 28], ["local exposure sources", "PROBLEM", 61, 83], ["serotype specific NTS infections", "PROBLEM", 119, 151]]], ["A distinct seasonality of NTS infections were observed, the relative risk ratio of infections was highest in summer for S. Typhimurium and fall for S. Thompson.", [["NTS infections", "DISEASE", 26, 40], ["infections", "DISEASE", 83, 93], ["NTS", "ORGANISM", 26, 29], ["S. Typhimurium", "ORGANISM", 120, 134], ["S. Typhimurium", "SPECIES", 120, 134], ["S. Typhimurium", "SPECIES", 120, 134], ["S. Thompson", "SPECIES", 148, 159], ["NTS infections", "PROBLEM", 26, 40], ["infections", "PROBLEM", 83, 93], ["distinct", "OBSERVATION_MODIFIER", 2, 10], ["seasonality", "OBSERVATION_MODIFIER", 11, 22], ["NTS", "OBSERVATION_MODIFIER", 26, 29], ["infections", "OBSERVATION", 30, 40], ["infections", "OBSERVATION", 83, 93]]], ["The relative risk ratio of infections was highest in young children for S. Typhimurium, in adults between 20 and 39 years of age for S. Thompson, and older adults for S. Heidelberg.", [["infections", "DISEASE", 27, 37], ["children", "ORGANISM", 59, 67], ["S. Typhimurium", "ORGANISM", 72, 86], ["children", "SPECIES", 59, 67], ["S. Typhimurium", "SPECIES", 72, 86], ["S. Typhimurium", "SPECIES", 72, 86], ["infections", "PROBLEM", 27, 37], ["infections", "OBSERVATION", 27, 37]]], ["The relative risk ratio of infections in cases who reported travel was highest among S. Enteritidis infections.", [["infections", "DISEASE", 27, 37], ["S. Enteritidis infections", "DISEASE", 85, 110], ["S. Enteritidis", "ORGANISM", 85, 99], ["S. Enteritidis", "SPECIES", 85, 99], ["S. Enteritidis", "SPECIES", 85, 99], ["infections", "PROBLEM", 27, 37], ["Enteritidis infections", "PROBLEM", 88, 110], ["infections", "OBSERVATION", 27, 37], ["Enteritidis", "OBSERVATION_MODIFIER", 88, 99], ["infections", "OBSERVATION", 100, 110]]], ["Our research methodology could be applied to other enteric disease outbreak investigations across North America with a final goal to reduce the burden of NTS infections.", [["enteric disease", "DISEASE", 51, 66], ["infections", "DISEASE", 158, 168], ["NTS infections", "PROBLEM", 154, 168], ["infections", "OBSERVATION", 158, 168]]]], "72b3a417c2b1759b85d732cf070e13a965142e93": [["Climate Change & MedicineAnthropogenic global climate change spurred by fossil fuel consumption is a welldocumented phenomenon that has led to average global temperatures climbing to approximately 1\u00b0 C above pre-industrial (1850-1900) levels, with even higher regional deviations in some areas and significantly increased average warming in densely populated urban centers and in the Arctic.", [["MedicineAnthropogenic global climate change", "PROBLEM", 17, 60], ["fossil fuel consumption", "PROBLEM", 72, 95], ["a welldocumented phenomenon", "PROBLEM", 99, 126], ["average global temperatures", "PROBLEM", 143, 170], ["even higher regional deviations in some areas", "PROBLEM", 248, 293], ["global climate", "OBSERVATION", 39, 53], ["fossil fuel consumption", "OBSERVATION", 72, 95], ["higher", "OBSERVATION_MODIFIER", 253, 259], ["regional deviations", "OBSERVATION", 260, 279], ["some", "OBSERVATION_MODIFIER", 283, 287], ["areas", "OBSERVATION_MODIFIER", 288, 293], ["significantly", "OBSERVATION_MODIFIER", 298, 311], ["increased", "OBSERVATION_MODIFIER", 312, 321], ["average", "OBSERVATION_MODIFIER", 322, 329], ["warming", "OBSERVATION_MODIFIER", 330, 337], ["densely", "OBSERVATION_MODIFIER", 341, 348], ["populated", "OBSERVATION_MODIFIER", 349, 358], ["urban", "OBSERVATION_MODIFIER", 359, 364], ["Arctic", "ANATOMY_MODIFIER", 384, 390]]], ["17; 30 Although the scientific community has held the consensus for decades that climate change is human-caused, this was last year elevated to '5-sigma' certainty -the gold standard for level of scientific evidence.", [["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104]]], ["46 In 2018, the United Nations' Intergovernmental Panel on Climate Change set a threshold of 1.5\u00b0 C of average warming (above pre-industrial baseline levels), beyond which our planet will become significantly less hospitable to human life.", [["human", "ORGANISM", 228, 233], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 228, 233], ["average warming", "PROBLEM", 103, 118], ["average", "OBSERVATION_MODIFIER", 103, 110], ["warming", "OBSERVATION_MODIFIER", 111, 118]]], ["28; 30 Some impacts include extremes of temperature, powerfully destructive natural disasters, sea level rise rendering coastal areas uninhabitable, increased spread and emergence of disease, and severe food shortages as agricultural regions are changed.", [["powerfully destructive natural disasters", "PROBLEM", 53, 93], ["coastal areas uninhabitable", "PROBLEM", 120, 147], ["increased spread", "PROBLEM", 149, 165], ["disease", "PROBLEM", 183, 190], ["severe food shortages", "PROBLEM", 196, 217], ["destructive", "OBSERVATION_MODIFIER", 64, 75], ["coastal", "OBSERVATION_MODIFIER", 120, 127], ["areas", "OBSERVATION_MODIFIER", 128, 133], ["increased", "OBSERVATION_MODIFIER", 149, 158], ["spread", "OBSERVATION_MODIFIER", 159, 165], ["disease", "OBSERVATION", 183, 190], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["food shortages", "OBSERVATION", 203, 217]]], ["18 A 2020 Nature commentary by climate scientists posits that global policies are currently on track to lead to 3\u00b0 C of warming by 2100 -well above the best-case scenarios and \"still catastrophic\" -and reiterates our need to take more stringent action to avoid surpassing 1.5\u00b0 C. 18 The current Covid-19 pandemic has illustrated the fallacies of insufficient or laggardly responses to projected risks and scientific warnings and has revealed how such decision-making can lead to avoidable loss of lives and resources.", [["loss of lives", "DISEASE", 489, 502], ["still catastrophic\"", "PROBLEM", 177, 196], ["warming", "OBSERVATION", 120, 127]]], ["10 It is critical to take rapid action at this juncture to avoid surpassing 1.5\u00b0 of warming -the more we mitigate, the less extreme the consequences will be.", [["warming", "TREATMENT", 84, 91]]], ["However, adverse human health impacts are already occurring due to current levels of global climate change, as summarized by publications such as the The Lancet's annual \"Countdown on Health and Climate Change,\" initiated in 2016.", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["global climate change", "PROBLEM", 85, 106]]], ["7; 56; 57 The human health impacts of climate change are truly cross-disciplinary, with nearly every medical specialty either facing or set to face effects.", [["human", "ORGANISM", 14, 19], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["climate change", "TREATMENT", 38, 52]]], ["The medical profession in the US has recently begun to respond to climate change as a human health crisis: the American Medical Association signed the 2018 US Call to Action on Climate and Health Equity, and multiple specialty-specific national organizations have released position statements outlining health risks due to climate change.", [["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91]]], ["3; 13; 52 The field of dermatology is not immune to these impacts, as was recently acknowledged by the American Academy of Dermatology (AAD).", [["AAD", "DISEASE", 136, 139]]], ["2 This special issue of the International Journal of Women's Dermatology is dedicated to the cross section of dermatology and climate change.", [["Women", "SPECIES", 53, 58]]], ["We are delighted to work with the Women's Dermatological Society and welcome their support for this dedicated edition.", [["Women", "SPECIES", 34, 39]]], ["The articles in this issue will provide in-depth information on key topics relevant to the climate change-dermatology interface: infectious disease, the effect of air pollution on the skin, the impact of climate change on pediatric dermatology, heat-related illness and sweating, implications for skin cancer, sunscreens & the environment, skin issues related to flooding and extreme weather events, refugee health, and environmentally-friendly office practices and changes that dermatologists can incorporate into their professional lives.Overview of the Dermatologic Impacts of Climate ChangeThe ways in which our planet's climate is changing will influence the distribution and frequency of dermatologic conditions, particularly those associated with infectious etiologies, sun exposure, environmental irritants, and aquatic transmission.Overview of the Dermatologic Impacts of Climate ChangeThe incidence of infectious skin disease-viral, fungal, and vector-borne-is already shifting due to climatic conditions that favor microbe propagation, with a trend towards broadening geographic distributions of cases.", [["skin", "ANATOMY", 184, 188], ["skin cancer", "ANATOMY", 297, 308], ["skin", "ANATOMY", 340, 344], ["skin", "ANATOMY", 923, 927], ["infectious disease", "DISEASE", 129, 147], ["illness", "DISEASE", 258, 265], ["sweating", "DISEASE", 270, 278], ["skin cancer", "DISEASE", 297, 308], ["aquatic transmission", "DISEASE", 820, 840], ["infectious skin disease", "DISEASE", 912, 935], ["skin", "ORGAN", 184, 188], ["skin cancer", "CANCER", 297, 308], ["skin", "ORGAN", 340, 344], ["skin", "ORGAN", 923, 927], ["infectious disease", "PROBLEM", 129, 147], ["air pollution on the skin", "PROBLEM", 163, 188], ["related illness", "PROBLEM", 250, 265], ["sweating", "PROBLEM", 270, 278], ["skin cancer", "PROBLEM", 297, 308], ["sunscreens", "TREATMENT", 310, 320], ["skin issues", "PROBLEM", 340, 351], ["dermatologic conditions", "PROBLEM", 694, 717], ["infectious etiologies", "PROBLEM", 754, 775], ["environmental irritants", "PROBLEM", 791, 814], ["infectious skin disease", "PROBLEM", 912, 935], ["viral", "PROBLEM", 936, 941], ["fungal", "PROBLEM", 943, 949], ["climatic conditions", "PROBLEM", 995, 1014], ["microbe propagation", "PROBLEM", 1026, 1045], ["infectious", "OBSERVATION", 129, 139], ["air pollution", "OBSERVATION", 163, 176], ["skin", "ANATOMY", 184, 188], ["skin", "ANATOMY", 297, 301], ["cancer", "OBSERVATION", 302, 308], ["skin", "ANATOMY", 340, 344], ["environmental irritants", "OBSERVATION", 791, 814], ["aquatic transmission", "OBSERVATION", 820, 840], ["infectious", "OBSERVATION_MODIFIER", 912, 922], ["skin", "ANATOMY", 923, 927], ["disease", "OBSERVATION", 928, 935]]], ["9; 20 For example, studies have found demonstrable weather-related relationships for both incidence and severity of hand, foot, and mouth disease, an enteroviral-associated skin disease.", [["hand", "ANATOMY", 116, 120], ["foot", "ANATOMY", 122, 126], ["mouth", "ANATOMY", 132, 137], ["skin", "ANATOMY", 173, 177], ["hand, foot, and mouth disease", "DISEASE", 116, 145], ["skin disease", "DISEASE", 173, 185], ["hand", "ORGANISM_SUBDIVISION", 116, 120], ["foot", "ORGANISM_SUBDIVISION", 122, 126], ["mouth", "ORGAN", 132, 137], ["skin", "ORGAN", 173, 177], ["severity of hand, foot", "PROBLEM", 104, 126], ["mouth disease", "PROBLEM", 132, 145], ["an enteroviral-associated skin disease", "PROBLEM", 147, 185], ["hand", "ANATOMY", 116, 120], ["foot", "ANATOMY", 122, 126], ["mouth", "ANATOMY", 132, 137], ["enteroviral", "OBSERVATION", 150, 161], ["skin", "ANATOMY", 173, 177], ["disease", "OBSERVATION", 178, 185]]], ["8 Global populations are at a universally increased risk of skin cancer due to the earth's diminished atmospheric ozone layer, a results of the anthropogenic activities leading to climate change.", [["skin cancer", "ANATOMY", 60, 71], ["skin cancer", "DISEASE", 60, 71], ["ozone", "CHEMICAL", 114, 119], ["ozone", "CHEMICAL", 114, 119], ["skin cancer", "CANCER", 60, 71], ["Global populations", "PROBLEM", 2, 20], ["skin cancer", "PROBLEM", 60, 71], ["the earth's diminished atmospheric ozone layer", "PROBLEM", 79, 125], ["Global", "OBSERVATION_MODIFIER", 2, 8], ["populations", "OBSERVATION", 9, 20], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["skin", "ANATOMY", 60, 64], ["cancer", "OBSERVATION", 65, 71], ["atmospheric ozone", "OBSERVATION", 102, 119], ["layer", "OBSERVATION_MODIFIER", 120, 125]]], ["54 We are doubly-exposed to elevated ultraviolet (UV) radiation, both from the depleted protective ozone layer and from higher temperatures, which lead to increased UV damage at the same dose.", [["ozone", "CHEMICAL", 99, 104], ["ozone", "CHEMICAL", 99, 104], ["elevated ultraviolet (UV) radiation", "TREATMENT", 28, 63], ["the depleted protective ozone layer", "TREATMENT", 75, 110], ["higher temperatures", "PROBLEM", 120, 139], ["increased UV damage", "PROBLEM", 155, 174], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["ultraviolet", "OBSERVATION", 37, 48], ["depleted", "OBSERVATION_MODIFIER", 79, 87], ["protective ozone", "OBSERVATION", 88, 104], ["layer", "OBSERVATION_MODIFIER", 105, 110], ["higher temperatures", "OBSERVATION_MODIFIER", 120, 139], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["UV damage", "OBSERVATION", 165, 174]]], ["14 Warming climates in temperate zones also encourage more outdoor activity in the general population, compounding the extra UV exposure.", [["UV", "CHEMICAL", 125, 127], ["the extra UV exposure", "TREATMENT", 115, 136]]], ["Not only does this contribute to melanoma and nonmelanoma skin cancer incidence, which will be covered by Parker in this Importantly, the AAD position statement also calls attention to the fact that certain populations are especially vulnerable to the health impacts of climate change; these include children, the elderly, and individuals in low-income and minority communities.", [["melanoma", "ANATOMY", 33, 41], ["nonmelanoma skin cancer", "ANATOMY", 46, 69], ["melanoma", "DISEASE", 33, 41], ["nonmelanoma skin cancer", "DISEASE", 46, 69], ["melanoma", "CANCER", 33, 41], ["nonmelanoma skin cancer", "CANCER", 46, 69], ["children", "ORGANISM", 300, 308], ["children", "SPECIES", 300, 308], ["melanoma", "PROBLEM", 33, 41], ["nonmelanoma skin cancer", "PROBLEM", 46, 69], ["melanoma", "OBSERVATION", 33, 41], ["nonmelanoma", "OBSERVATION_MODIFIER", 46, 57], ["skin", "ANATOMY", 58, 62], ["cancer", "OBSERVATION", 63, 69]]], ["These populations are simultaneously more likely to experience the adverse health impacts of climate change and less likely to be able to adapt to and mitigate those impacts-broadly and in the context of the dermatologic risks of climate change.Overview of the Dermatologic Impacts of Climate ChangeBoth children and the elderly are at greater risk for many of the dermatologic risks discussed.", [["children", "ORGANISM", 304, 312], ["children", "SPECIES", 304, 312]]], ["47 Children's full dependency on adult caregivers compounds the challenges inherent in avoiding deleterious environmental surroundings; this is mirrored in the geriatric population.", [["Children", "SPECIES", 3, 11]]], ["1 The elderly are also at elevated risk for contracting dermatologic disease due to the natural weakening of the immune system with age, which includes reduced resiliency and functionality of the skin's cutaneous barrier.", [["immune system", "ANATOMY", 113, 126], ["skin", "ANATOMY", 196, 200], ["cutaneous barrier", "ANATOMY", 203, 220], ["dermatologic disease", "DISEASE", 56, 76], ["immune system", "ANATOMICAL_SYSTEM", 113, 126], ["skin", "ORGAN", 196, 200], ["cutaneous barrier", "TISSUE", 203, 220], ["contracting dermatologic disease", "PROBLEM", 44, 76], ["the natural weakening of the immune system", "PROBLEM", 84, 126], ["reduced resiliency", "PROBLEM", 152, 170], ["the skin's cutaneous barrier", "TREATMENT", 192, 220], ["weakening", "OBSERVATION", 96, 105], ["reduced", "OBSERVATION_MODIFIER", 152, 159], ["resiliency", "OBSERVATION", 160, 170], ["skin", "ANATOMY", 196, 200]]], ["19; 41 A variety of circumstances and risk factors combine to make low-resourced communities particularly susceptible to the dermatologic impacts of climate change.", [["risk factors", "PROBLEM", 38, 50]]], ["The individuals most exposed to air pollution are typically minority communities and/or those living in low-income, densely-populated urban areas adjacent to industrial activities and lacking green spaces; this compounds this compounds health impacts like chronic dermatitis exacerbations and carcinogenic skin damage.", [["skin", "ANATOMY", 306, 310], ["chronic dermatitis", "DISEASE", 256, 274], ["carcinogenic skin damage", "DISEASE", 293, 317], ["skin", "ORGAN", 306, 310], ["lacking green spaces", "PROBLEM", 184, 204], ["chronic dermatitis exacerbations", "PROBLEM", 256, 288], ["carcinogenic skin damage", "PROBLEM", 293, 317], ["air pollution", "OBSERVATION", 32, 45], ["industrial activities", "OBSERVATION", 158, 179], ["green spaces", "OBSERVATION", 192, 204], ["chronic", "OBSERVATION_MODIFIER", 256, 263], ["dermatitis", "OBSERVATION", 264, 274], ["carcinogenic", "OBSERVATION_MODIFIER", 293, 305], ["skin", "ANATOMY", 306, 310], ["damage", "OBSERVATION", 311, 317]]], ["5; 27; 32 For example, a study of pemphigus flares in a representative US sample found an association between ultraviolet index and hospital admissions only in the subset of Hispanic/Latino patients.", [["pemphigus flares", "DISEASE", 34, 50], ["pemphigus", "PATHOLOGICAL_FORMATION", 34, 43], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["a study", "TEST", 23, 30], ["pemphigus flares", "PROBLEM", 34, 50], ["a representative US sample", "TEST", 54, 80], ["ultraviolet index", "TEST", 110, 127], ["pemphigus", "OBSERVATION", 34, 43]]], ["43 Additionally, low-income outdoor laborers must often face prolonged periods in extreme sunlight and heat due to their occupational environment.", [["low", "OBSERVATION_MODIFIER", 17, 20]]], ["Indeed, heat is the leading cause of death worldwide from extreme weather events related to climate change.", [["death", "DISEASE", 37, 42], ["death", "PROBLEM", 37, 42], ["extreme weather events", "PROBLEM", 58, 80]]], ["Sweating, the body's natural cooling response, is impaired in certain dermatological conditions and in individuals with preexisting chronic disease like diabetes and renal failure.", [["body", "ANATOMY", 14, 18], ["renal", "ANATOMY", 166, 171], ["Sweating", "DISEASE", 0, 8], ["chronic disease", "DISEASE", 132, 147], ["diabetes", "DISEASE", 153, 161], ["renal failure", "DISEASE", 166, 179], ["body", "ORGANISM_SUBDIVISION", 14, 18], ["renal", "ORGAN", 166, 171], ["Sweating", "PROBLEM", 0, 8], ["impaired in certain dermatological conditions", "PROBLEM", 50, 95], ["preexisting chronic disease", "PROBLEM", 120, 147], ["diabetes", "PROBLEM", 153, 161], ["renal failure", "PROBLEM", 166, 179], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["disease", "OBSERVATION", 140, 147], ["diabetes", "OBSERVATION", 153, 161], ["renal", "ANATOMY", 166, 171], ["failure", "OBSERVATION", 172, 179]]], ["9 Williams elaborates upon the themes of hypohidrosis and overheating in this issue (Ed: add ref to article in this issue).", [["hypohidrosis", "DISEASE", 41, 53], ["hypohidrosis", "PROBLEM", 41, 53]]], ["Certain at-risk individuals may still accept elevated occupational exposure, despite predisposing conditions, due to economic necessity; this disproportionate risk to outdoor workers will only escalate with increasing climate change.Overview of the Dermatologic Impacts of Climate ChangeClimate change is also projected to increase the incidence of extreme weather events and associated displacement of populations.", [["individuals", "ORGANISM", 16, 27], ["elevated occupational exposure", "PROBLEM", 45, 75], ["predisposing conditions", "PROBLEM", 85, 108], ["Climate ChangeClimate change", "TREATMENT", 273, 301], ["extreme weather events", "PROBLEM", 349, 371], ["associated displacement of populations", "PROBLEM", 376, 414], ["displacement", "OBSERVATION_MODIFIER", 387, 399]]], ["The populations uprooted by weather-related destruction are often low income and/or minority communities in neighborhoods without preexisting disaster-response infrastructure and without the economic resiliency to quickly adapt or rebuild.Overview of the Dermatologic Impacts of Climate ChangeDisaster-related migration often leads to overcrowding in temporary shelters and subsequent outbreaks of skin disease, such as scabies and dermatophytosis, or stress-induced flares of conditions like psoriasis, alopecia areata, and vitiligo.", [["skin", "ANATOMY", 398, 402], ["ChangeDisaster", "CHEMICAL", 287, 301], ["skin disease", "DISEASE", 398, 410], ["scabies", "DISEASE", 420, 427], ["dermatophytosis", "DISEASE", 432, 447], ["psoriasis", "DISEASE", 493, 502], ["alopecia areata", "DISEASE", 504, 519], ["vitiligo", "DISEASE", 525, 533], ["skin", "ORGAN", 398, 402], ["destruction", "PROBLEM", 44, 55], ["Climate ChangeDisaster", "TREATMENT", 279, 301], ["skin disease", "PROBLEM", 398, 410], ["scabies", "PROBLEM", 420, 427], ["dermatophytosis", "PROBLEM", 432, 447], ["stress-induced flares of conditions", "PROBLEM", 452, 487], ["psoriasis", "PROBLEM", 493, 502], ["alopecia areata", "PROBLEM", 504, 519], ["vitiligo", "PROBLEM", 525, 533], ["destruction", "OBSERVATION", 44, 55], ["temporary shelters", "OBSERVATION", 351, 369], ["outbreaks", "OBSERVATION_MODIFIER", 385, 394], ["skin", "ANATOMY", 398, 402], ["disease", "OBSERVATION", 403, 410], ["dermatophytosis", "OBSERVATION", 432, 447], ["psoriasis", "OBSERVATION", 493, 502]]], ["47 Environmental injustice remains an issue globally, with populations in the lowest-income and lowest-emitting countries likely to bear the most significant burdens of cutaneous disease associated with escalating climate change.", [["cutaneous", "ANATOMY", 169, 178], ["cutaneous disease", "DISEASE", 169, 186], ["cutaneous", "ORGANISM_SUBDIVISION", 169, 178], ["cutaneous disease", "PROBLEM", 169, 186], ["injustice", "OBSERVATION", 17, 26], ["most significant", "OBSERVATION_MODIFIER", 141, 157], ["cutaneous", "ANATOMY", 169, 178], ["disease", "OBSERVATION", 179, 186], ["escalating", "OBSERVATION_MODIFIER", 203, 213], ["climate", "OBSERVATION", 214, 221]]], ["11 Specific impacts include cutaneous manifestations of severe nutrient deficiencywhich will likely be further exacerbated by drought-induced crop shortages due to climate change-and increased rates of skin-manifesting neglected tropical diseases, often due to environment-related shifts in parasitic and vectoral activity.", [["cutaneous", "ANATOMY", 28, 37], ["skin", "ANATOMY", 202, 206], ["skin", "ORGAN", 202, 206], ["severe nutrient deficiencywhich", "PROBLEM", 56, 87], ["climate change", "PROBLEM", 164, 178], ["increased rates of skin", "PROBLEM", 183, 206], ["neglected tropical diseases", "PROBLEM", 219, 246], ["shifts in parasitic and vectoral activity", "PROBLEM", 281, 322], ["cutaneous manifestations", "OBSERVATION_MODIFIER", 28, 52], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["nutrient deficiencywhich", "OBSERVATION", 63, 87], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["skin", "ANATOMY", 202, 206], ["tropical diseases", "OBSERVATION", 229, 246], ["parasitic", "OBSERVATION_MODIFIER", 291, 300], ["vectoral activity", "OBSERVATION", 305, 322]]], ["11ConclusionMoving forward, education around care for high-risk populations and prioritization of environmental justice are essential components in addressing the dermatologic health risks associated with climate change.", [["high-risk populations", "PROBLEM", 54, 75]]], ["Many of the subjects discussed by the authors in this special issue, such as eliminating unsustainable medical practices and uncovering the dermatologic consequences of environmental contamination, deserve additional research to elucidate future interventions and best practices.", [["environmental contamination", "PROBLEM", 169, 196], ["future interventions", "TREATMENT", 239, 259]]], ["We can also devote further attention to how physicians and medical societies can use their voices to advocate for policy action that protects patient health by promoting safe environments and addressing climate change.ConclusionIn the wake of the AAD's Position Statement on Climate and Health, and with the growing body of literature elucidating the links between skin disease and climate change, now is the time for the dermatology community to become a leader in advocating for healthy skin in the era of global climate change.", [["skin", "ANATOMY", 365, 369], ["skin", "ANATOMY", 489, 493], ["AAD", "DISEASE", 247, 250], ["skin disease", "DISEASE", 365, 377], ["patient", "ORGANISM", 142, 149], ["skin", "ORGAN", 365, 369], ["skin", "ORGAN", 489, 493], ["patient", "SPECIES", 142, 149], ["the AAD's", "TREATMENT", 243, 252], ["skin disease", "PROBLEM", 365, 377], ["healthy skin", "PROBLEM", 481, 493], ["skin", "ANATOMY", 365, 369], ["disease", "OBSERVATION", 370, 377], ["skin", "ANATOMY", 489, 493], ["global", "OBSERVATION_MODIFIER", 508, 514], ["climate", "OBSERVATION", 515, 522]]], ["Although there is more yet to be done, we hope the articles included in this special issue of the International Journal of Women's Dermatology help draw attention to the critical issue of climate change and the impacts that it has on dermatologic disease, our patients, our field, and our future.", [["patients", "ORGANISM", 260, 268], ["Women", "SPECIES", 123, 128], ["patients", "SPECIES", 260, 268], ["dermatologic disease", "PROBLEM", 234, 254]]]], "PMC7348130": [["BackgroundOn December 8, 2019, the first case of unexplained pneumonia was officially reported in Wuhan, the capital of Hubei Province in China [1].", [["pneumonia", "DISEASE", 61, 70], ["unexplained pneumonia", "PROBLEM", 49, 70], ["pneumonia", "OBSERVATION", 61, 70]]], ["There have been reports of the new coronavirus disease (coronavirus disease 2019, COVID-19, named by the World Health Organization on February 11, 2020) since December 2019 [1, 2].", [["coronavirus disease", "DISEASE", 35, 54], ["coronavirus disease", "DISEASE", 56, 75], ["coronavirus", "ORGANISM", 35, 46], ["the new coronavirus disease (coronavirus disease", "PROBLEM", 27, 75], ["COVID", "TEST", 82, 87], ["new", "OBSERVATION_MODIFIER", 31, 34], ["coronavirus disease", "OBSERVATION", 35, 54], ["coronavirus disease", "OBSERVATION", 56, 75]]], ["As was reported by the National Health Commission of the People\u2019s Republic of China, the number of confirmed cases had reached 63 851 by February 13, 2020 in China, including 1380 deaths.", [["deaths", "DISEASE", 180, 186]]], ["On the same day, Hubei Province alone totally had 51 986 confirmed cases including 1318 deaths, accounting for 81.4% and 95.5% of the whole country respectively.", [["deaths", "DISEASE", 88, 94]]], ["Among them there were 35 991 confirmed cases and 1016 deaths in Wuhan, accounting for 69.2% and 77.1% of the number in Hubei Province respectively [3].", [["deaths", "DISEASE", 54, 60]]], ["The cumulative number of confirmed cases keeps rising, indicating the strong transmissibility of COVID-19, especially in Wuhan, Hubei Province.", [["COVID-19", "CHEMICAL", 97, 105], ["COVID", "TEST", 97, 102]]], ["Therefore, it is of great importance to adopt reasonable indicators to assess the transmission ability of the disease, based on which effective intervention and control measures could be put forward [4, 5].BackgroundThe basic reproduction number (R0) refers to the expected number of cases generated from a single case when all people are susceptible to infection [6].", [["infection", "DISEASE", 354, 363], ["people", "ORGANISM", 328, 334], ["people", "SPECIES", 328, 334], ["the disease", "PROBLEM", 106, 117], ["effective intervention", "TREATMENT", 134, 156], ["control measures", "TREATMENT", 161, 177], ["infection", "PROBLEM", 354, 363], ["disease", "OBSERVATION", 110, 117], ["infection", "OBSERVATION", 354, 363]]], ["It is widely used to evaluate the transmission ability of an emerging infectious disease and determine what degree of control measures should be taken to eradicate the disease [7\u201310].", [["infectious disease", "DISEASE", 70, 88], ["an emerging infectious disease", "PROBLEM", 58, 88], ["control measures", "TREATMENT", 118, 134], ["the disease", "PROBLEM", 164, 175], ["infectious", "OBSERVATION", 70, 80]]], ["When R0>1, the disease starts to spread; and when R0<1, the disease is effectively controlled [11].", [["the disease", "PROBLEM", 11, 22], ["the disease", "PROBLEM", 56, 67], ["disease", "OBSERVATION", 15, 22], ["disease", "OBSERVATION", 60, 67]]], ["R0 is influenced by many other factors except for the characteristics of the disease itself, such as conditions of the environment, policies of the government, people\u2019s awareness of infectious diseases, and social behavior.", [["infectious diseases", "DISEASE", 182, 201], ["people", "SPECIES", 160, 166], ["the disease itself", "PROBLEM", 73, 91], ["infectious diseases", "PROBLEM", 182, 201], ["disease", "OBSERVATION", 77, 84], ["infectious", "OBSERVATION", 182, 192]]], ["Therefore, we can use R0 to measure the transmissibility of COVID-19 and analyze its influencing factors, which provides data support for suggestion-proposing and decision-making.BackgroundResearch on transmissible diseases like influenza [12], severe acute respiratory syndrome (SARS) [13] and Middle East respiratory syndrome (MERS) [14] has found that disease transmission is associated with temperature and humidity of the environment [15\u201320].", [["transmissible diseases", "DISEASE", 201, 223], ["influenza", "DISEASE", 229, 238], ["acute respiratory syndrome", "DISEASE", 252, 278], ["SARS", "DISEASE", 280, 284], ["Middle East respiratory syndrome", "DISEASE", 295, 327], ["MERS", "DISEASE", 329, 333], ["Middle East respiratory syndrome (MERS)", "SPECIES", 295, 334], ["R0", "TREATMENT", 22, 24], ["COVID", "TEST", 60, 65], ["transmissible diseases", "PROBLEM", 201, 223], ["influenza", "PROBLEM", 229, 238], ["severe acute respiratory syndrome (SARS)", "PROBLEM", 245, 285], ["Middle East respiratory syndrome", "PROBLEM", 295, 327], ["disease transmission", "PROBLEM", 355, 375], ["severe", "OBSERVATION_MODIFIER", 245, 251], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["respiratory syndrome", "OBSERVATION", 258, 278], ["Middle", "ANATOMY_MODIFIER", 295, 301], ["respiratory syndrome", "OBSERVATION", 307, 327], ["disease", "OBSERVATION", 355, 362]]], ["In terms of biological methods, influenza virus spread was found to be promoted by cold temperature and low relative humidity with the guinea pig as a model host [21]; besides, an experiment on the SARS coronavirus indicated that high temperature and high humidity suppressed the spread of the virus [22]; similarly, MERS coronavirus was more stable when temperature or humidity was lower [23].", [["SARS", "DISEASE", 198, 202], ["influenza virus", "ORGANISM", 32, 47], ["guinea pig", "ORGANISM", 135, 145], ["SARS coronavirus", "ORGANISM", 198, 214], ["MERS coronavirus", "ORGANISM", 317, 333], ["guinea pig", "SPECIES", 135, 145], ["pig", "SPECIES", 142, 145], ["SARS coronavirus", "SPECIES", 198, 214], ["MERS coronavirus", "SPECIES", 317, 333], ["biological methods", "TREATMENT", 12, 30], ["influenza virus spread", "PROBLEM", 32, 54], ["the guinea pig", "TREATMENT", 131, 145], ["the SARS coronavirus", "PROBLEM", 194, 214], ["high temperature", "PROBLEM", 230, 246], ["high humidity", "PROBLEM", 251, 264], ["the virus", "PROBLEM", 290, 299], ["MERS coronavirus", "PROBLEM", 317, 333], ["humidity", "TEST", 370, 378], ["stable", "OBSERVATION_MODIFIER", 343, 349]]], ["In terms of statistical methods, case studies of SARS in four major cities in China suggested that the transmissibility had a close relationship with temperature and its variation [24]; and a regression equation was derived to show how temperature, relative humidity, and wind velocity affected the transmission of SARS [25].", [["SARS", "DISEASE", 49, 53], ["SARS", "DISEASE", 315, 319], ["case studies", "TEST", 33, 45], ["SARS", "PROBLEM", 49, 53], ["a regression equation", "TEST", 190, 211], ["wind velocity", "TEST", 272, 285], ["SARS", "PROBLEM", 315, 319]]], ["Thus we wonder if the spread of COVID-19 follows a similar pattern.", [["COVID-19", "CHEMICAL", 32, 40], ["COVID-19", "DNA", 32, 40], ["COVID", "TEST", 32, 37]]], ["Considering that R0 is useful for measuring the transmission ability of infectious diseases, we conducted association analyses between R0 and temperature, relative humidity, and absolute humidity respectively.", [["infectious diseases", "DISEASE", 72, 91], ["infectious diseases", "PROBLEM", 72, 91], ["infectious", "OBSERVATION", 72, 82]]], ["Statistical methods such as correlation and regression were adopted for the analysis.BackgroundThis paper measured the transmissibility of COVID-19 with R0 and analyzed its correlation with temperature and humidity.", [["COVID-19", "CHEMICAL", 139, 147], ["the analysis", "TEST", 72, 84], ["COVID", "TEST", 139, 144], ["R0", "TREATMENT", 153, 155]]], ["Second, we calculated R0 and compared the average value and developing trend of R0 in 11 cities including Wuhan.", [["trend", "OBSERVATION_MODIFIER", 71, 76]]], ["Third, we conducted correlation and regression analysis between R0 and temperature and humidity to see the association between R0 and weather.Data acquisition and preprocessing ::: MethodsThe daily accumulative number of confirmed cases and new additions are reported by the National Health Commission of the People\u2019s Republic of China as well as the health commission of each province on the official website.", [["regression analysis", "TEST", 36, 55], ["R0 and temperature", "TREATMENT", 64, 82], ["humidity", "TREATMENT", 87, 95], ["Data acquisition", "TEST", 142, 158], ["Methods", "TREATMENT", 181, 188]]], ["An R package has been developed to access the epidemiological data directly [26].", [["An R package", "TREATMENT", 0, 12]]], ["Besides, we also collected the daily-reported accumulative number of confirmed cases from January 24, 2020 to February 13, 2020 in 10 Chinese major cities outside Hubei Province including Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Shenzhen, and Zhengzhou (listed by initials) for further calculation, estimation, and analysis.", [["further calculation", "TEST", 313, 332]]], ["Those cities could well represent the process status of the disease based on which disposal measures could be put forward.Data acquisition and preprocessing ::: MethodsAs for Wuhan, it was estimated by Imperial College London, UK that the total number of confirmed diagnoses had reached 4000 by January 18, 2020 [27], which was much higher than the officially reported number.", [["the disease", "PROBLEM", 56, 67], ["disposal measures", "TREATMENT", 83, 100], ["Data acquisition", "TEST", 122, 138], ["disease", "OBSERVATION", 60, 67]]], ["So we attempted to revise the data in Wuhan to infer the actual transmissibility of the new coronavirus.", [["coronavirus", "DISEASE", 92, 103], ["coronavirus", "ORGANISM", 92, 103], ["the new coronavirus", "PROBLEM", 84, 103], ["new", "OBSERVATION_MODIFIER", 88, 91], ["coronavirus", "OBSERVATION", 92, 103]]], ["With the substantial enhancement of case detection and reporting, the differences between the official numbers and the estimates are predicted to be fewer and fewer.", [["case detection", "TEST", 36, 50], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["enhancement", "OBSERVATION_MODIFIER", 21, 32]]], ["There are several assumptions for the data-preprocessing procedure:The first case appeared on December 8, 2019 in Wuhan and transmission started from that day on [1, 28].The cumulative number of cases Y(t) by day t since the first single case followed the exponential function Y(t)=e\u03bbt in early development [29].The cumulative number of cases on January 18, 2020 was 4000, that was, Y(41)=4000 [27].From February 13, 2020 on, all cases in Wuhan can be confirmed and the number of daily new cases is correct, given that the number of newly confirmed diagnoses on February 12, 2020 in Wuhan increased significantly, exceeding 10 000.Data acquisition and preprocessing ::: MethodsBased on those assumptions, the data-revising procedure in Wuhan is as follows:According to assumption 2 and 3, the exponential growth rate is estimated as \u03bb=ln[Y(41)]/41.According to assumption 2 and 3, the number of new additions on January 18, 2020 equals Y(41)\u2212Y(40)=4000\u2212e\u03bb\u221740=733.According to assumption 4, the number of new additions on February 13, 2020 is 2997, which is consistent with the officially reported number.According to assumption 2, the daily number of new additions y(t) can be calculated by1", [["the data", "TEST", 34, 42], ["preprocessing procedure", "TREATMENT", 43, 66], ["Data acquisition", "TEST", 631, 647], ["the data", "TEST", 705, 713], ["procedure", "TREATMENT", 723, 732], ["the exponential growth rate", "TEST", 789, 816], ["cumulative", "OBSERVATION_MODIFIER", 316, 326], ["number", "OBSERVATION_MODIFIER", 327, 333], ["consistent with", "UNCERTAINTY", 1057, 1072]]]]}